



University of Groningen

#### Towards better fall prevention -

De Groot, Maartje

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Final author's version (accepted by publisher, after peer review)

Publication date: 2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): De Groot, M. (2017). Towards better fall prevention -: Examining the interplay between factors that influence gait in older patients. Utrecht.

Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# TOWARDS BETTER FALL PREVENTION

Examining the interplay between factors that influence gait in older patients

Maartje de Groot

#### TOWARDS BETTER FALL PREVENTION

Examining the interplay between factors that influence gait in older patients

PhD-thesis, Utrecht University, The Netherlands

ISBN:978-94-6295-634-6Cover and layout:Maartje de GrootPrinted by:ProefschriftMaken || Vianen

© M.H. de Groot, Amsterdam, The Netherlands, 2017

All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means, without written permission of the author or the publisher holding the copyright of the published articles.

### TOWARDS BETTER FALL PREVENTION

# Examining the interplay between factors that influence gait in older patients

Op weg naar betere valpreventie – Een onderzoek naar de samenhang tussen factoren die het looppatroon van oudere patiënten beïnvloeden (met een samenvatting in het Nederlands)

### Proefschrift

ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op woensdag 10 mei 2017 des middags te 4.15 uur

door

Maartje Helena de Groot

geboren op 20 november 1986 te Aduard Promotor: Prof. dr. J.H. Beijnen

Copromotor: Dr. C.J.C. Lamoth

The research described in this thesis was carried out at the Department of Geriatric Medicine of the MC Slotervaart Hospital in Amsterdam in close collaboration with the Center for Human Movement Sciences of the University Medical Centre Groningen and the University of Groningen, Groningen, the Netherlands.

### Contents

#### INTRODUCTION

1	.1	L
	1	11

#### PART I: OSTEOPOROSIS-RELATED FACTORS

Chapter 2	Testing postural control among various osteoporotic patient groups: a literature review	25
	Geriatrics & Gerontology International 2012; 12 (4): 573-585	
Chapter 3	A flexed posture in elderly patients is associated with impairments in postural control during walking <i>Gait &amp; Posture</i> 2014; 39 (2): 767-772	57
Chapter 4	Associations between vertebral fractures, increased thoracic kyphosis, a flexed posture and falls in older adults: a prospective cohort study <i>BMC Geriatrics</i> 2015; 15: 34	73

#### PART II: MEDICATION-USE

Chapter 5A	The effects of fall-risk-increasing drugs on postural control: a literature review	91
	Drugs & Aging 2013; 30 (11): 901-920	
Chapter 5B	Authors' reply to dr. Toda: "The effects of fall-risk-increasing drugs on postural control: a literature review" <i>Drugs &amp; Aging</i> 2013; 30 (12): 1041-1042	133
Chapter 6	The association of medication-use and frailty-related factors with gait performance in older patients	139
	<i>PLoS ONE</i> 2016; 11 (2): e1049888	

#### PART III: CLASSIFICATION OF FALLERS

Chapter 7	Gait dynamics to optimize fall risk assessment in geriatric patients	175
	Submitted	
DISCUSSION		
Chapter 8	Conclusions & Future Perspectives	195
APPENDICES		
	Summary	215
	Samenvatting (Summary in Dutch)	223
	Dankwoord (Acknowledgments in Dutch)	233
	Curriculum Vitae	241
	Publications & Presentations	245

# INTRODUCTION

# CHAPTER 1

**General Introduction** 

Introduction

#### General introduction

Older patients visiting a geriatric outpatient clinic often suffer from multiple chronic conditions, e.g., physical, psychological and social problems, and use consequently multiple medications. These patients have a high risk of falling, hospitalization, institutionalization, and ultimately death [1, 2]. Falls are a major problem among older adults. About one third of the people aged 65 years and over fall annually, with approximately 5% of all fall incidents resulting in an injury that requires a visit to the emergency room or hospital admission, such as hip and wrist fractures or head injury [3]. The risk of falls and injuries increases when people become older and have more comorbidities [4]. Furthermore, recovery from a fall injury is often delayed in these old persons due to their decreased physical reserve, which consequently increases the risk of subsequent falls through deconditioning [5].

Most falls do not have a single cause, but are the result of the interaction between someone's physical functions (e.g., the ability to walk and maintain balance, muscle strength, visual and cognitive functioning), environmental hazards (e.g., wet floors and unsafe staircases), and medical factors (e.g., delirium, orthostasis, or medication-use) [6, 7]. In the past decades, numerous epidemiologic studies have investigated a wide variety of risk factors for falls [8–12], which can be classified as either intrinsic or environmental [7]. Intrinsic fall-related factors are physical and psychological characteristics that affect the ability of a person to maintain balance and prevent falling, such as gait and balance problems, muscle weakness, visual disability, or cognitive impairment [7]. Of these intrinsic risk factors, postural instability during daily activities, such as walking, is suggested to be the most consistent predictor for future falls [13], because it is related to many comorbidities, medication-use, muscle weakness, and cognitive impairment [14–20].

Walking is one of the cornerstones of independent living in the community, and an important factor for the quality of life in older adults [21, 22]. It is a multifactorial motor skill that requires a complex integration of, and cooperation between the sensory, neural, musculoskeletal, and cardiorespiratory systems in relation to the environment [23]. Due to advanced age a progressive loss of these systems occurs, which may cause impairments in postural control during walking. These problems can be induced by medical disorders, medication and alcohol-use [24].

Effects of age-related neurophysiological changes and medical conditions on the gait pattern can be quantified by a variety of measures, each characterizing a different aspect

Introduction

of the gait pattern [25]. Walking speed can be easily measured and is therefore often used in clinical practice to reflect the functional status of older patients [26, 27]. However, it lacks specificity since gait speed is slower in many different pathologies, and does not reveal information about the quality of the walking pattern [28]. Analyzing stride-to-stride variability during walking provides additional information about gait performance, i.e., the ability of a person to adapt one's gait smoothly, and the variability and regularity of the gait pattern.

In the present thesis, gait parameters were used that assess time-dependent fluctuations throughout the gait cycle, such as detrended fluctuations analyses [29], sample entropy [30], and index of harmonicity [31]. Several studies among relatively young and healthy older adults have shown that gait characteristics, including gait speed, stride-to-stride variability, gait asymmetry, harmonic ratios, and sample entropy, can differentiate fallers from non-fallers [32, 33]. However, these results cannot be easily extrapolated to geriatric patients. In the geriatric population there are, besides the normal age-related neurophysiological changes, multiple other conditions present that might affect the walking pattern and consequently increase fall risk, such as comorbid diseases, the use of multiple medications, cognitive impairment and/or frailty [14–20].

Geriatric patients are different from other older adults due to their vulnerability and multi-morbidity (the presence of more than one chronic illness). They can be considered as frail, which is defined as "a geriatric syndrome of decreased reserve and resistance to stressors, resulting from cumulative declines across multiple physiologic systems, causing vulnerability to adverse health outcomes including falls and fractures, disabilities, hospitalization, institutionalization and mortality" [34]. Frailty does not become evident in all elderly. It is estimated that about one third of the people aged 85 years and over are frail [1], because frailty may remain undetected, and only comes to clinical attention when illness occurs.

There are many tools to assess frailty in older adults [35], whereof the frailty criteria of Fried *et al.* [1] are widely used. According to Fried's described phenotype, an older person can be considered frail when three or more of the following criteria are present: unintentional weight loss, slow walking speed, exhaustion, low daily activity, or low muscle strength. Sarcopenia (i.e., the loss of muscle mass) and reduction of bone strength due to little physical activity seem to be the main cause of frailty [36, 37]. Besides the association with frailty, muscle strength is also an important factor in relation to walking [38], as muscle strength is necessary to maintain postural control,

which is the capacity to maintain the center of mass within the support base [39], in order to avoid falling.

Since falling is a complex problem, a multifactorial fall risk assessment followed by individualized interventions tailored to the identified intrinsic and extrinsic risk factors, seem to be the most attractive approach for preventing falls and functional decline in the older population. Because in the older patient population many comorbid factors are prevalent, fall risk assessments for geriatric patients should thus include multiple elements such as medication-use and the presence of fall-risk-influencing comorbidities, but should also include a gait and/or balance assessment, since gait and balance problems are the major risk factor for falls [13]. Indeed, a recent study [40] among older adults has shown that the ability to identify those at risk for falling based on questionnaires, grip strength, and a cognitive functioning test (sensitivity: 58%; specificity: 72%; area under the curve (AUC): 0.68) improved when accelerometer-derived parameters about the amount and quality of the gait pattern were added to the model (sensitivity: 70%; specificity: 81%; AUC: 0.82).

Because geriatric patients can be characterized by a unique set of variables that increases their risk of falling, it was aimed in this thesis to examine the association between characteristics that are common present in the geriatric population, including osteoporosis-related factors, medication-use, and frailty-related factors, with postural control during walking in older patients visiting a geriatric outpatient clinic. This multifactorial approach could provide insight in the interplay between all factors and gait performance, which can be used for future classification models of potential fallers, and subsequently could be used for the development of personalized intervention strategies to modify for example medication [41, 42], cognition [43], and physical activity levels [44] in order to reduce the number of falls and resultant injuries in older patients.

#### Outline of the thesis

In the first part of this thesis, it was investigated whether osteoporosis-related factors, e.g., vertebral fractures, increased thoracic kyphosis, and a flexed posture, are associated with postural control and fall incidence. Bone strength is an important factor in relation to falls and mobility [37], since deterioration of bone strength leads to bone fragility and increases the risk of fractures [45, 46]. The most prevalent type of fracture that is associated with osteoporosis, is the vertebral fracture [47]. In a population of patients who visited a geriatric outpatient clinic 51% were diagnosed with one or more

vertebral fractures [48]. Over time, thoracic vertebral fractures might increase the spinal thoracic kyphotic curvature, and might lead to a flexed posture [49]. These impairments could affect motor function and balance, and therefore increase the risk of falling and further fractures [50]. Since the exact cause and magnitude of balance problems in osteoporotic patients is not clear, **chapter 2** provides a literature review describing impairments in postural control among patients with osteoporosis, vertebral fractures, increased thoracic kyphosis, and/or flexed posture. This chapter also includes an evaluation of instruments to measure postural control among osteoporotic patients in a clinical setting. In **chapter 3**, the association between a flexed posture and impairments in postural control during walking in older patients is studied. Additionally, geriatric phenomena that may cause a flexed posture, e.g., increased thoracic kyphosis, the presence of vertebral fractures, frailty, polypharmacy and cognitive impairments, are investigated. In the next chapter, **chapter 4**, the association of these clinical entities with fall incidents within the next year is described.

In the second part of this thesis, the focus is on the association between medicationuse and postural control during walking. Because older patients often have multiple chronic diseases, they are copious medication users. Most drugs are used on a long-term basis to treat or prevent chronic disorders [51], such as anti-diabetic drugs, gastrointestinal drugs, diuretics, analgesics, sedatives and other psychotropic drugs. Some of these drugs are potential causes for unfavorable outcomes: meta-analyses have shown that medication affecting the central nervous system (e.g., antidepressants, neuroleptics, benzodiazepines, and antiepileptic drugs), and some cardiac drugs (digoxin, type IA anti-arrhythmics, and diuretics) are associated with an increased risk of falling [19, 52–55]. Falls due to these so-called fall-risk-increasing drugs (FRIDs) might be partly caused by impairments in postural control induced by these drugs due to their sedative side-effects [56]. Therefore, this hypothesis was investigated in chapter 5 describing a literature review that focuses on the effects of psychotropic and cardiac FRIDs on postural control. In addition, the effect of withdrawal of FRIDS on postural control is reviewed. In chapter 6, the association of medication-use and frailty-related factors with gait performance is described for a cohort of older patients with multiple comorbid diseases and polypharmacy.

In the last part of this thesis, in **chapter 7**, a model of the investigated factors in this thesis in relation to fall-status is presented. Since falling is a multifactorial problem, and walking is both influenced by factors that might be simultaneously present in the investigated population, e.g., the presence of frailty, comorbid diseases, cognitive impairment, and/or the use of different medications [14–16], a model was built

consisting of frailty-related parameters complemented with cognitive functioning and gait performance to discriminate fallers from non-fallers. This multifactorial approach could provide insight in the interplay between all factors and gait performance, which can be used for future classification models of potential fallers.

Finally, in **chapter 8**, the main results of the previous chapters are summarized and discussed, and recommendations for future research and clinical practice are presented.

#### References

**1.** Fried LP, Tangen CM, Walston J, *et al.* (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156.

**2.** de Vries OJ, Peeters GMEE, Lips P, Deeg DJH (2013) Does frailty predict increased risk of falls and fractures? A prospective population-based study. Osteoporos Int 24:2397–2403.

**3.** Rubenstein LZ (2006) Falls in older people: epidemiology, risk factors and strategies for prevention. Age Ageing 35:ii37-41.

**4.** Tinetti ME, Speechley M, Ginter SF (1988) Risk factors for falls among elderly persons living in the community. N Engl J Med 319:1701–1707.

**5.** Voermans NC, Snijders AH, Schoon Y, Bloem BR (2007) Why old people fall (and how to stop them). Pract Neurol 7:158–171.

**6.** Berry SD, Miller RR (2008) Falls: Epidemiology, pathophysiology, and relationship to fracture. Curr Osteoporos Rep 6:149–54.

**7.** American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons Panel on Falls Prevention (2001) Guideline for the prevention of falls in older persons. J Am Geriatr Soc 49:664–672.

**8.** Pluijm SMF, Smit JH, Tromp EAM, *et al.* (2006) A risk profile for identifying community-dwelling elderly with a high risk of recurrent falling: results of a 3-year prospective study. Osteoporos Int 17:417–425.

**9.** Graafmans WC, Ooms ME, Hofstee HMA, *et al.* (1996) Falls in the elderly: a prospective study of risk factors and risk profiles. Am J Epidemiol 143:1129–1136.

**10.** Masud T, Morris RO (2001) Epidemiology of falls. Age Ageing 30:3–7.

**11.** Holtzer R, Friedman R, Lipton RB, *et al.* (2007) The relationship between specific cognitive functions and falls in aging. Neuropsychology 21:540–8.

**12.** Ambrose AF, Paul G, Hausdorff JM (2013) Risk factors for falls among older adults: a review of the literature. Maturitas 75:51–61.

**13.** Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ (2007) Will my patient fall? JAMA 297:77–86.

**14.** IJmker T, Lamoth CJC (2012) Gait and cognition: the relationship between gait stability and variability with executive function in persons with and without dementia. Gait Posture 35:126–130.

**15.** Lamoth CJC, van Deudekom FJ, van Campen JPCM, *et al.* (2011) Gait stability and variability measures show effects of impaired cognition and dual tasking in frail people. J Neuroeng Rehabil 8:2.

**16.** Montero-Odasso M, Muir SW, Hall M, *et al.* (2011) Gait variability is associated with frailty in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 66A:568–576.

**17.** Landi F, Liperoti R, Russo A, *et al.* (2012) Sarcopenia as a risk factor for falls in elderly individuals: Results from the ilSIRENTE study. Clin Nutr 31:652–658.

**18.** van Schoor NM, Smit JH, Pluijm SMF, *et al.* (2002) Different cognitive functions in relation to falls among older persons: immediate memory as an independent risk factor for falls. J Clin Epidemiol 55:855–862.

**19.** Bloch F, Thibaud M, Dugué B, *et al.* (2011) Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 23:329–346.

**20.** van der Velde N, Stricker BHC, Pols HAP, van der Cammen TJM (2007) Withdrawal of fall-risk-increasing drugs in older persons: Effect on mobility test outcomes. Drugs Aging 24:691–699.

**21.** Viljanen A, Kulmala J, Rantakokko M, *et al.* (2012) Fear of falling and coexisting sensory difficulties as predictors of mobility decline in older women. J Gerontol A Biol Sci Med Sci 67:1230–1237.

**22.** Rantakokko M, Iwarsson S, Kauppinen M, *et al.* (2010) Quality of life and barriers in the urban outdoor environment in old age. J Am Geriatr Soc 58:2154–2159.

**23.** Frank JS, Patla AE (2003) Balance and mobility challenges in older adults: Implications for preserving community mobility. Am J Prev Med 25:157–163.

**24.** Sturnieks DL, St George R, Lord SR (2008) Balance disorders in the elderly. Clin Neurophysiol 38:467–478. **25.** Kaptein RG, Wezenberg D, IJmker T, *et al.* (2014) Shotgun approaches to gait analysis: insights & limitations. J Neuroeng Rehabil 11:120.

**26.** Bohannon RW (1997) Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing 26:15–19.

**27.** Abellan van Kan G, Rolland Y, Andrieu S, *et al.* (2009) Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people. An International Academy on Nutrition and Aging (IANA) task force. J Nutr Heal Aging 13:881–889.

**28.** Lamoth CJC, Daffertshofer A, Meijer OG, Beek PJ (2006) How do persons with chronic low back pain speed up and slow down? Trunk-pelvis coordination and lumbar erector spinae activity during gait. Gait Posture 23:230–9.

**29.** Hausdorff JM, Purdon PL, Peng CK, *et al.* (1996) Fractal dynamics of human gait: stability of long-range correlations in stride interval fluctuations. J Appl Physiol 80:1448–1457.

**30.** Pincus SM (1991) Approximate entropy as a measure of system complexity. Proc Natl Acad Sci 88:2297–2301.

**31.** Lamoth CJC, Beek PJ, Meijer OG (2002) Pelvisthorax coordination in the transverse plane during gait. Gait Posture 16:101–14.

**32.** Hamacher D, Singh NB, Van Dieen JH, *et al.* (2011) Kinematic measures for assessing gait stability in elderly individuals: a systematic review. J R Soc Interface 8:1682–1698.

**33.** Howcroft J, Kofman J, Lemaire ED (2013) Review of fall risk assessment in geriatric populations using inertial sensors. J Neuroeng Rehabil 10:91.

**34.** Fried LP, Ferrucci L, Darer J, *et al.* (2004) Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59:255– 263.

**35.** de Vries NM, Staal JB, van Ravensberg CD, *et al.* (2011) Outcome instruments to measure frailty: A systematic review. Ageing Res Rev 10:104–114.

**36.** Heuberger RA (2011) The frailty syndrome: a comprehensive review. J Nutr Gerontol Geriatr 30:315–68.

**37.** Pel-Littel RE, Schuurmans MJ, Emmelot-Vonk MH, Verhaar HJJ (2009) Frailty: Defining and measuring of a concept. J Nutr Heal Aging 13:390–394.

**38.** Wolfson L, Judge J, Whipple R, King M (1995) Strength is a major factor in balance, gait, and the occurrence of falls. J Gerontol A Biol Sci Med Sci 50 Spec No:64–7.

**39.** Alexander NB (1994) Postural control in older adults. J Am Geriatr Soc 42:93–108.

**40.** van Schooten KS, Pijnappels M, Rispens SM, *et al.* (2015) Ambulatory fall-risk assessment: amount and quality of daily-life gait predict falls in older adults. J Gerontol A Biol Sci Med Sci 70:608–615.

**41.** The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60:616–31.

**42.** Gallagher P, Ryan C, Byrne S, *et al.* (2008) STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 46:72–83.

**43.** Verghese J, Mahoney J, Ambrose AF, *et al.* (2010) Effect of cognitive remediation on gait in sedentary seniors. J Gerontol A Biol Sci Med Sci 65A:1338–1343.

**44.** Hortobágyi T, Lesinski M, Gäbler M, *et al.* (2015) Effects of three types of exercise interventions on healthy old adults' gait speed: A systematic review and meta-analysis. Sport Med 45:1627–1643.

**45.** Consensus development conference (1993) Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650.

**46.** Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018.

**47.** O'Neill TW, Felsenberg D, Varlow J, *et al.* (1996) The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J bone Miner Res 11:1010–8.

**48.** van der Jagt-Willems HC, van Hengel M, Vis M, *et al.* (2012) Why do geriatric outpatients have so many moderate and severe vertebral fractures? Exploring prevalence and risk factors. Age Ageing 41:200–206

Chapter 1

**49.** Katzman WB, Wanek L, Shepherd JA, Sellmeyer DE (2010) Age-related hyperkyphosis: its causes, consequences, and management. J Orthop Sports Phys Ther 40:352–60.

**50.** Cook DJ, Guyatt GH, Adachi JD, *et al.* (1993) Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 36:750–756.

**51.** Beers MH, Baran RW, Frenia K (2000) Drugs and the elderly, Part 1: The problems facing managed care. Am J Manag Care 6:1313–20.

**52.** Woolcott JC, Richardson KJ, Wiens MO, *et al.* (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960.

**53.** Hartikainen S, Lönnroos E, Louhivuori K (2007) Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 62:1172–1181.

**54.** Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 47:30–39.

**55.** Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 47:40–50.

**56.** Lord SR, Anstey KJ, Williams P, Ward JA (1995) Psychoactive medication use, sensori-motor function and falls in older women. Br J Clin Pharmacol 39:227–34.

# PART I

## OSTEOPOROSIS-RELATED FACTORS

## **CHAPTER 2**

# Testing postural control among various osteoporotic patient groups: A literature review

Maartje H. de Groot Hanna C. van der Jagt-Willems Jos P. C. M. van Campen Willem F. Lems Claudine J. C. Lamoth

Geriatrics & Gerontology International 2012; 12 (4): 573-585

#### Abstract

**Aim** Osteoporosis can cause vertebral fractures, which may lead to a flexed posture, impaired postural control and consequently increased fall risk. Therefore, the aim of the present review, was to examine whether postural control of patients with osteoporosis, vertebral fractures, thoracic kyphosis and flexed posture is affected. Furthermore, instruments measuring postural control are evaluated and examined for sensitivity and easy clinical use.

**Methods** Until February 2011 electronic databases were systematically searched for cross-sectional studies. Methodological quality was assessed with a modified Downs & Black scale.

**Results** Of the 518 found studies, 18 studies were included. Postural control was generally affected for patients with vertebral fractures, thoracic kyphosis and flexed posture. Patients with osteoporosis had impaired postural control when assessed with computerized instruments. Easy performance based tests did not show any impairments.

**Conclusions** There is evidence for an impaired postural control in all included patient groups. Impaired postural control is an important risk factor for falls. Functional performance tests are not sensitive and specific enough to detect affected postural control in patients with osteoporosis. To detect impaired postural control among osteoporotic patients and to get more insight into the underlying mechanisms of postural control, computerized instruments are recommended, such as easy-to-use ambulant motion-sensing (accelerometry) technology.

#### Introduction

Osteoporosis is one of the major public health problems facing postmenopausal women and aging individuals of both sexes [1]. Currently, it is estimated that over 200 million people worldwide suffer from this disease [2]; approximately 30% of all postmenopausal women in Europe and the USA have osteoporosis. The risk of fractures in the osteoporotic population is higher as a result of an increased bone fragility [3]: the lifetime fracture risk for a 50-year-old woman is 40% [4]. Where peripheral osteoporotic fractures (e.g. wrist or hip) occur frequently after a fall, vertebral fractures result mostly from substantial loads during daily activity, such as bending forward, lifting objects and climbing stairs [5]. Peripheral osteoporotic fractures are easily diagnosed in a hospital because of pain and loss of function. In contrast, vertebral fractures do not immediately result in functional limitations or pain. Therefore, it might be assumed that only onethird of all vertebral fractures are coming to medical attention [5].

In a population of patients who visited a geriatric outpatient clinic, 51% were diagnosed with 31 vertebral fractures [6]. Vertebral fractures are associated with pain [7–9], impaired trunk muscle control, fear of falling [7] and poor physical function when compared with individuals without a history of vertebral fractures [3, 10, 11]. Over time, thoracic vertebral fractures and/or intervertebral disc deformities and/or muscle weakness might increase thoracic kyphotic curvature [12, 13]. In turn, a flexed posture is characterized by an increased thoracic kyphosis, protrusion of the head and, in severe cases, knee flexion [14]. These impairments can affect motor function and balance, and increase the risk of falling [7, 15], and therefore the risk for further fractures [16]. Where an increased thoracic kyphosis is an anatomical nonreversible phenomenon, a training program for patients with flexed posture can improve posture and musculoskeletal impairment [17].

Balance is a multidimensional concept, referring to the ability of a person not to fall. The ability to maintain, achieve or restore a state of balance during any posture or activity is called "postural control" [18]. Adequate postural control is essential for daily activities, and requires integration of visual, proprioceptive and vestibular information [19]. The degree to which individuals rely on this information depends on task difficulty, cognitive load [20], motor skills [21, 22], age [23, 24] and pathology [25, 26]. A wide variety of instruments and outcome variables has been used to examine postural control and assess its relationship with fall risk in different patient populations [27–29]. These instruments include both clinical tests, such as the Timed Up & Go test or the Berg Balance Scale, as well as computerized instruments; for example, force plates, balance

platforms and sway meter systems that measure postural control more objectively. Consequently, it is hard to derive from these studies what the exact cause and magnitude of the balance problems are in osteoporotic patients. Therefore, the aim of the present literature review was to examine whether postural control of patients with (i) osteoporosis; (ii) vertebral fractures; (iii) thoracic kyphosis; and (iv) flexed posture is affected. Furthermore, instruments measuring postural control were evaluated for clinical use, and which instruments are most sensitive in the osteoporotic population was examined.

#### Methods

#### Search strategy and selection criteria

Electronic databases (PubMed, Web of Science) were searched until February 2011 (see Appendix I for details of the search strategy for PubMed). Furthermore, reference lists from the included studies were checked and author's names were searched for additional studies.

Studies were included when written in English, and with an available abstract online. Only studies with a cross-sectional design or baseline characteristics of an intervention study were used. Patients in the included studies were diagnosed with osteoporosis, vertebral fractures thoracic kyphosis or flexed posture, and carried out one or more balance tests. Studies were excluded if patients had other physical problems not related to their osteoporosis (e.g. Parkinson's disease, obesity or stroke), or when the study did not have a control group.

#### Quality assessment and data abstraction

The methodological quality of the included studies was assessed with the Downs & Black instrument [30]. The original checklist was adapted, ruling out the criteria related exclusively to intervention and follow-up studies. A total of 17 items were evaluated, allowing a maximum score of 18 points (see Appendix II for the evaluated items). Each included study was evaluated separately by two authors of this literature review (MdG and HvdJ). In case of disagreement between the two investigators, the assessments were discussed to achieve consensus.

Descriptive data of the studies included study design, a description of the study subjects (mean age and characteristics of osteoporosis, vertebral fractures, thoracic kyphosis or flexed posture) and the results of the balance outcome variables. The included studies are discussed by the various clinical entities: osteoporosis, vertebral fractures, thoracic kyphosis and flexed posture. In addition, the different balance outcome variables are discussed. These include clinical functional performance tests, measuring balance performance indirectly at a functional level (e.g. the Timed Up & Go test [TUG] and the Berg Balance Scale) [31, 32] and instrumental measurements of balance while standing and walking (e.g. force plates or an electronic walkway). The different balance outcome variables are discussed separately, because they all quantify different aspects of postural control.

#### Results


The search strategy resulted in 518 articles (Fig. 2.1). Based on the inclusion criteria, 16 studies were included. Two more studies were included after searching reference lists, author names and related articles. The median score for methodological quality among the reviewed studies was 14 points (range 9–17), where a maximum of 18 points was possible (Fig. 2.2). The scores for external validity were low, because just seven studies reported the population from which the research population was recruited. Study power was not described well in the reviewed studies. However, important effects were overall detected with a 5% significance level, although some studies had small sample sizes (Fig. 2.2). In the 18 reviewed studies, 27 different instruments with different balance outcome variables were used to assess balance performance among patients with osteoporosis, vertebral fractures, thoracic kyphosis and flexed posture. An overview of the used instruments and balance outcome variables is given in Table 2.1.

#### Influence of osteoporosis on various balance outcome variables

Ten studies compared various balance outcome variables among elderly with and without osteoporosis (Table 2.2) [33–42]. In eight studies, osteoporosis was diagnosed according to the patient's bone mineral density (BMD; t-score  $\leq$ 2.5) [33, 34, 36–40, 42], two studies did not describe the BMD in their population [35, 41]. One study described the degree of thoracic kyphosis [40]. Whether the patients had vertebral fractures and/or flexed posture was not described in all 10 studies. Nine studies controlled for visual, vestibular and proprioceptive dysfunctions [33–36, 38–42].

Among these 10 studies, six studies investigated the influence of osteoporosis on functional performance tests among elderly [33–38]. In the study by Abreu *et al.* [34], elderly osteoporotic women scored significantly lower on the TUG that healthy elderly

women, although all women scored within the normal range. All other functional performance tests used in these studies did not show any significant differences between patients with and without osteoporosis [33–38].



**Fig. 2.1.** Study selection: the flow chart shows the inclusion and exclusion of the studies used in this literature review.




Fig. 2.2. Methodological scores and population size (n) of reviewed studies.

Seven of the reviewed studies examined balance while standing still using instrumental measurements [33, 36, 38-42]. All seven studies used a different test protocol and different terms for "standing balance." Among them were postural sway [38, 41], balance [36], postural control [40], and static balance [35, 39, 42]. No significant differences between patients with and without osteoporosis were found in the studies of Tan et al. [38] and Gunendi et al. [35] In contrast, other studies found a significant difference in standing balance in women with and without osteoporosis [38-42]. De Abreu et al. [39] showed that women with osteoporosis had significantly more body displacement in the medio-lateral and anterior-posterior direction than their healthy controls. Liu-Ambrose et al. [36] found that women with osteoporosis performed worse than healthy controls for all six subtests in which the Sensory Organization Test was examined. In contrast with the former studies [36, 39], in the study by Lynn et al. [41] women with osteoporosis had significantly less postural sway than healthy controls. In the study by Da Silva et al. [42], osteoporotic women had only greater mean sway amplitude in the anterior-posterior direction than non-osteoporotic women when they had their eyes open. Burke et al. [40] found that the osteoporotic group had only larger center of pressure (COP) velocity in normal conditions (standing with eyes open on a firm surface) than the healthy controls.

Instrument	Outcome variable(s)	Used in reviewed studies
Functional performance tests		
Backward Tandem Walk test [43]	Time (s)	Palombaro <i>et al.</i> [33]
Berg Balance Scale [32]	Score: max. 45 points (= best performance)	De Abreu <i>et al.</i> [34]; Gunendi <i>et al.</i> [35]
Figure-of-8 test [44]	Speed (s <sup>-1</sup> )	Liu-Ambrose <i>et al.</i> [36]
Four Square Step test [45]	Time (s)	Gunendi <i>et al.</i> [35]
Functional Reach test [46]	Reached distance (cm)	Lyles et al. [47]
Mobility Skills protocol [47]	Score: max. 25 points (= best performance)	Lyles <i>et al.</i> [47]
Performance Oriented Mobility Assessment	Score: max. unknown (higher score = better	Balzini <i>et al.</i> [14]
[48]	performance)	
Repeated Chair Stands [49]	Score: range 0-1 (1 = best performance)	Antonelli-Incalzi <i>et al.</i> [49]
Romberg test [50]	Score: max. 150 points (= best performance)	Gerdhem <i>et al.</i> [51]
Short Physical Performance Battery [52, 53]	Score: max. 12 points (= best performance)	Balzini <i>et al.</i> [14]; Antonelli-Incalzi <i>et al.</i> [49]
Standing Balance in 3 conditions (feet side-by-	Score: range 0-1 (1 = best performance)	Antonelli-Incalzi <i>et al.</i> [49]
side, semi-tandem and tandem position for 10-		
seconds each) [49]		
Timed Up & Go test [31]	Time (s)	Hall <i>et al.</i> [11]; De Abreu <i>et al.</i> [34]; Berkemeyer <i>et al.</i> [37]; Gunendi <i>et al.</i> [35];
		lan et al. [38]; Katzman et al. [54]
Standing balance		
Polhemus system – detection of magnetic fields [39]	Anterior-posterior and medio-lateral displacement (cm)	De Abreu <i>et al.</i> [39]
Force platform – modified Clinical Test of Sensory Interaction and Balance (CTSIBm) [40]	Mean COP sway velocity (°/s)	Burke <i>et al.</i> [40]
Force platform - 100% LOS test [40]	% of theoretical Limits of Stability of anterior- posterior and medio-lateral sway	Burke <i>et al.</i> [40]

Table 2.1. Instruments and outcome variables used in the reviewed studies

Balance platform [35]	Static Balance Index indicating standing as	Gunendi <i>et al.</i> [35]
	motioniess as possible on the balance platform for 30-seconds with visual feedback. Score: max.	
	unknown (higher score = better performance)	
Force plate - Sensory Organization Test (SOT)	Composite Balance Score (average of all six	Liu-Ambrose <i>et al.</i> [36]; Sinaki <i>et al.</i> [56]
(existing of 6 subtests) [55]	conditions of SOT) based on postural sway. Score:	
	range 0-100 (0 = fall; 100 = no sway)	
	Postural sway (score) on SOT subtests 5 (eyes closed	Lynn <i>et al.</i> [41]
	and sway referencing on platform) and 6 (inaccurate	
	vision and sway referencing on platform). Score:	
	range 0-100 (0 = fall; 100 = no sway)	
	Balance Strategy Score = ratio of sway amplitude to	Lynn <i>et al.</i> [41]
	horizontal forces. Quantifying the use of hip (= low	
	score) or ankle strategy (= high score). Score: max.	
	unknown	
Force platform - COP sway in anterior-posterior and medio-lateral direction [57]	Mean COP amplitude and mean COP velocity (cm/s)	Greig <i>et al.</i> [3]; Da Silva <i>et al.</i> [42]
Sway-meter system [58] – tracing the sway	Total sway (defined as the total number of 1-mm	Tan <i>et al.</i> [38]
path on graph paper	squares traversed by the pen over a 30-second	
	period). Low score = better performance (less sway)	
Outcome variables related to walking	:	
10-feet Walking test [47]	Time (s)	Lyles et al. [47]
4-meter walking speed test [49]	score: range u-1 (1 = best performance)	AntoneIII-Incalzi <i>et al.</i> [49]
30-meter Gait Speed (including a turn after 15- m) [51]	Time (s)	Gerdhem <i>et al.</i> [51]
6-minute Walking test [59]	Distance (m)	Lyles <i>et al.</i> [47]

Instrument	Outcome variable(s)	Used in reviewed studies
Gait analysis		
Gait Mat II (a 3.87-m walkway containing	Free Gait Speed (m/s) and Coefficient of Variation of	Palombaro <i>et al.</i> [33]
pressure-sensitive switches) [60]	Step Length, Step Width, Stride Length, Step Time,	
	and Stance Time	
Reflective markers on bony landmarks of the	Right and left Step Length (cm), Stride Length (cm),	Sinaki <i>et al.</i> [56]
subject to collect three-dimensional marker	Forward Velocity (m/s), Cadence (steps/minute),	
trajectory data with a camera on a 10-meter	right and left Single Support Time (%), and Step	
walkway [61]	Width (cm)	
Electronic walkway GAITRite [62, 63]	Base-of-Support (cm), Cadence (steps/minute); Step	Balzini <i>et al.</i> [14]
	Length (cm), Single Support Duration (% gait cycle),	
	and Walking Speed (m/s)	

Table 2.1. Continued

Table 2.2. Characteristics of controlled studies with osteoporotic (OP) patients, patients with vertebral fractures (VF), thoracic kyphosis
(TK), and flexed posture (FP), included in this review. The abbreviations of the balance outcome variables are described in the footnote of
the table.

Study	Study	Subjects	n (mean age	Patient	Balance	Results
	design		± SD)	characteristics	outcome variables	
Studies with o	Studies with osteoporotic patients (OP)	tients (OP)				
de Abreu <i>et</i>	Cross-	1. Elderly	15 (65 ±	BMD: t-score >	BBS; TUG	BBS: Elderly women with and without
<i>al.</i> [34]	sectional	women with	4.11)	Ļ		osteoporosis had similar performance
	study	normal BMD				TUG: Elderly women with normal BMD
		2. Elderly	15 (72 ±	BMD: t-score ≤		performed significantly better than osteoporotic
		women with	5.54)	-2.5		women. Both groups scored within the normal
		osteoporosis				range.
De Abreu <i>et</i>	Cross-	Women with			BD in AP- &	Osteoporotic women had significantly more BD
<i>al.</i> [39]	sectional	1. normal BMD	20 (66.2 ±	BMD: t-score >	ML-dir (SS-	in AP-direction in all conditions than control
	study		4.7)	-1	OE, SS-CE,	group.
		2. osteopenia	20 (67.5 ±	BMD: t-score: <	US-OE, US-	Osteoporotic women had significantly more BD
			4.6)	-1 & > -2.5	CE)	in ML-direction in all conditions than control
		3. osteoporosis	20 (70.0 ±	BMD: t-score ≤		group and osteopenic group.
			5.4)	-2.5		
Berkemeyer	Cross-	440 elderly (men/female: 243/197	female: 243/19 <sup>-</sup>	7)	TUG	No significant differences between three groups:
<i>et al.</i> [37]	sectional	1. Healthy	196 (mean:	BMD: t-score:		Mean: 9.8 (Cl 95%: 91-10.4)
	study		79,8)	0.13		
		2. Osteopenia	201 (mean:	BMD: t-score:		Mean: 11.1 (Cl 95%: 10.1-12.1)
			79.9)	-1.64		
		3. Osteoporosis	43 (mean:	BMD: t-score:		Mean: 12.7 (Cl 95%: 9.2-16.2)
			81.6)	-3.06		

Study	Study	Subjects	n (mean age	Patient	Balance	Results
	design		± SD)	characteristics	outcome variables	
Burke <i>et al.</i>	Cross-	Women			COP velocity	COP velocity: $p = 0.03$ for SS-OE condition
[40]	sectional	1. with	46 (73.0 ±	BMD: t-score:	(SS-OE, SS-	between OP and NOP. For all other conditions,
	study	osteoporosis	4.2)	-3.5	CE, US-OE,	no significant differences between groups were
		(OP)		Kyphosis: 53.1°	US-CE);	found.
				±13.8°	%LOS (AP,	%LOS: $p = 0.04$ for %LOS in AP-direction between
		2. without	20 (71.9±	BMD: t-score:	ML)	groups. For ML-direction, no significant
		osteoporosis	3.2)	-1.0		difference was found between OP and NOP.
		(NOP)		Kyphosis: 45.9° ± 10.1°		
Gunendi <i>et</i>	Intervention	Postmenopausal women	vomen		SBI; TUG;	SBI: OP: 285.5 ± 113.4; NOP: 273.2 ± 111.6 ( <i>p</i> >
<i>al.</i> [35]	study	1. with	28 (56.3 ±	t-score	FSS; BBS	0.05)
		osteoporosis	6.4)	unknown		TUG: OP: 7.1 ± 0.7; NOP: 6.9 ± 1.2 ( <i>p</i> > 0.05)
		(OP)				FSS: OP: 9.3 ± 1.0; NOP: 8.9 ± 1.1 ( <i>p</i> > 0.05)
		2. without	25 (53.1±	t-score		BBS: OP: 53.8 ± 1.6; NOP: 54.1 ± 1.5 ( <i>p</i> > 0.05)
		osteoporosis	7.6)	unknown		
		(NOP)				
Lynn <i>et al.</i>	Case-control	Women with			PS on SOT-5	PS on SOT-5: <i>p</i> = 0.044
[41]	study	1. "normal"	5 (69 yrs)	None	and SOT-6;	PS on SOT-6: <i>p</i> = 0.002
		2. osteoporosis	10 (64 yrs)	Osteoporosis	BSS	BSS: The osteoporosis group had greater reliance
						on hip strategies to maintain balance.
Liu-Ambrose	Cross-	Women			CBS; Fo8	CBS: OP 70.9 ± 13.6; NOP: 79.4 ± 4.3 (p = 0.009)
<i>et al.</i> [36]	sectional	1. with	21 (68.3 ±	BMD: t-score: <		Fo8: OP: 2.34 ± 0.46; NOP: 2.41 ± 0.41 (p =
	study	osteoporosis (OP)	2.9)	-2.5		0.648)
		2. without	21 (68.6±	BMD: t-score: >		
		osteoporosis (NOP)	3.1)	-1.0		

Part I: Osteoporosis-related factors

2

Palombaro	Observation	Women in early menopause with	menopause with	:	BTWL; FGS;	BIWL: IOW BMD: 10.04 ± 3.65; normal BIMD: 8.76
<i>et al.</i> [33]	al	1. low BMD	31 (59.19 ±	BMD: t-score <	CV of StL,	$\pm 3.89 \ (p = 0.221)$
	cohort study		3.30)	-2	SW, StrL, ST,	Coefficient of Variation of.
		2. normal BMD	23 (58.13 ±	BMD: t-score >	StT	FGS: low BMD: 1.35 ± 0.17; normal BMD: 1.38 ±
			1000	Ŧ,		0.20 (p = 0.200) 2+1 : [o BMD: 0.03 ± 0.016: sorrool BMD: 0.03 ±
						StL: IOW BINIU: U.U3 ± U.U1b; NOTMAI BINIU: U.U3 ±
						0.012 ( <i>p</i> = 0.53/)
						SW: IOW BINU: U.1/ ± U.224; hormal BINU: U.12 ± ののが / - のつの /
						$0.084 \ (p = 0.293)$
						StrL: low BMD: 0.02 ± 0.013; normal BMD: 0.02 ±
						$0.013 \ (p = 0.156)$
						ST: low BMD: 0.09 ± 0.13; normal BMD: 0.03 ±
						$0.02 \ (p = 0.043)$
						StT: low BMD: 0.07 ± 0.09: normal BMD: 0.03 ±
						$0.02 \ (p = 0.049)$
Da Silva <i>et</i>	Cross-	Postmenopausal women	women		COPamp &	OP group had increased sway (greater COPamp)
<i>al.</i> [42]	sectional	1. with	133 (66.0 ±	BMD: 0.8 ± 0.1	COPvel	in AP-direction than NOP group.
	study	osteoporosis	4.5)	g/cm <sup>2</sup>		No statistically differences were found in ML
		(OP)		j		COPamp, COPvel, and ellipse area in the tests
		2. without	133 (64.9 +	BMD: 1.2 + 0.1		with eves open and closed, and in COPamp in AP-
				a/cm2		direction with ever cloced
		(NOP) 4.4)	4.4)	g/ cm -		all ection with eyes closed.
Tan <i>et al.</i>	Cross-	Postmenopausal	women		TUG; TS (SS-	TUG: OP: 8.4 ± 1.4; NOP: 7.8 ± 1.2 ( <i>p</i> = 0.20)
[38]	sectional	1. with	49 (72.8 ±	BMD: t-score <	OE, SS-CE,	SB-EO: no significant difference between OP and
	study	osteoporosis	6.6)	-2.5	US-OE, US-	NOP $(p = 0.58)$
		(OP)			CE)	SB-EC: no significant difference between OP and
		2. without	55 (70.1 ±	BMD: t-score		NOP $(p = 0.47)$
		osteoporosis	4.8)	unknown		SB-FEO: no significant difference between OP
		(NOP)				and NOP ( $p = 0.43$ )
						SB-FEC: no significant difference between OP and
						NOP $(p = 0.20)$

Study	Study	Subjects	n (mean age	Patient	Balance	Results
	design		± SD)	characteristics	outcome variables	
Patients with	and without ver	Patients with and without vertebral fractures (VF)				
Gerdhem <i>et</i>	Population-	All 75 yrs old women with	ien with		Romberg;	
<i>al.</i> [51]	based	1. No fractures	505 for	No VF	30m-GS	Romberg: Median: 94 (range: 0-159)
	retrospectiv	(NF)	Romberg			30-m GS: Mean: 24 ± 9 s
	e study		487 for			
			30m-WS			
		2. Vertebral	56 for	≥1 VF		Romberg: Median: 81 (range: 0-135); <i>p</i> = 0.012
		fractures	Romberg			compared to NF
			49 for 30m-			30-m GS: Mean: 29 ± 14 s; <i>p</i> < 0.001 compared
			WS			to NF
Greig <i>et al.</i>	Cross-	Women with osteoporosis and	oporosis and		COPx; COPy;	COPx: <i>p</i> = 0.049
[3]	sectional	1. with vertebral	10 (68.3 ±	t-score < -2 and	COPvx;	COPy: p = 0.421
	study	fracture(s) (VF)	7.1)	≥1 VF	COPvy	COPvx: p = 0.531
		2. without	12 (63.5 ±	t-score < -2 and		COPvy: <i>p</i> = 0.163
		vertebral	9.4)	no VF		
		fractures (NVF)				
Hall <i>et al.</i>	Cross-	Women			TUG	TUG: VF: 13.8 ± 7.3; NVF: 10.1 ± 4.1 ( <i>p</i> < 0.001)
[11]	sectional	1. with vertebral	100 (74.4 ±	VF per patient:		
	study	fractures (VF)	7.2)	$2.9 \pm 1.6$		
		2. without	100 (74.3 ±	No VFs		
		vertebral	7.2)			
		fractures (NVF)				

Part I: Osteoporosis-related factors

Table 2.2. Continued

Lyles <i>et al.</i>	Cross-	Women			FR, MS,	FR: VF: 26.9 ± 5.8; NVF: 34.5 ± 5.3 ( <i>p</i> = 0.007)
[47]	sectional	1. without VF	10 (79.6±	No VF	10ftW,	MS: VF: $21.2 \pm 2.6$ ; NVF: $24.9 \pm 1.7$ ( $p = 0.002$ )
	stuay	(NVF)	(c.o		amw	LUTTW: VF: 4.0 ± 1.5; NVF: 3.0 ± 0.5 (ク = 0.068)
		2. with ≥2 VF	10 (81.9 ±	Average VF: 4.2		6mW: VF: 353.5 ± 91; NVF: 453.6 ± 113 ( <i>p</i> =
		(VF)	5.9)	± 2.6		0.042)
				Range VF: 2 - 10		
<sup>p</sup> atients with	and without incr	Patients with and without increased thoracic kyphosis	hosis			
Greig <i>et al.</i>	Cross-	Women with osteoporosis and	eoporosis and		COPx; COPy;	COPx: p = 0.361
[3]	sectional	1. with low	11 (64.4 ±	TK (centroid):	COPvx;	COPy: <i>p</i> = 0.981
	study	kyphosis	7.3)	26.6° ± 4.9°	COPvy	COPvx: $p = 0.973$
				TK (Cobb): 35.3° ± 6.0°		COPvy: <i>p</i> = 0.790
		2. with high	12 (66.6±	TK (centroid):		
		kyphosis	10.4)	39.7° ± 4.5°		
				TK (Cobb): 46.6° ± 7.9°		
Katzman <i>et</i>	Prospective	Women with	3.108	Thoracic	TUG	For each SD (11.9°) increase in kyphosis angle,
<i>al.</i> [54]	cohort study	kyphosis	$(68.2 \pm 6.1)$	kyphosis		there was an increase in average performance on
				(mean ± SD		TUG time of 0.2 s ( $p < .001$ ).
				angle = 47.6° ± 11.9°)		

Study	Study design	Subjects	n (mean age ± SD)	Patient characteristics	Balance outcome	Results
Lynn et al. [41]	Case-control study	Women with 1. "normal" 2. osteoporosis 3. osteoporosis & kyphosis	5 (69 yrs) 10 (64 yrs) 6 (69 yrs)	None Osteoporosis Osteoporosis & kyphosis (Cobb angle > 54°)	Ps on SOT-5 & SOT-6; BSS	<ul> <li>SOT-5 - group comparisons</li> <li>kyphosis/osteoporosis: p &lt; 0.001</li> <li>kyphosis/"normal": p = 0.186</li> <li>osteoporosis/"normal": p = 0.044</li> <li>SOT-6 - group comparisons</li> <li>kyphosis/osteoporosis: p = 0.008</li> <li>kyphosis/"normal": p = 0.194</li> <li>osteoporosis/"normal": p = 0.194</li> <li>osteoporosis/"normal": p = 0.002</li> <li>BSS: Both osteoporosis groups had a significantly greater reliance on hip strategies to maintain balance. The kyphosis group showed the greatest reliance on hip strategies to maintain</li> </ul>
Sinaki <i>et al.</i> [56]	Cross- sectional study	<ol> <li>Women with osteoporosis &amp; hyperkyphosis (O-K)</li> <li>Healthy women (control)</li> </ol>	12 (76.5 ± 5) 13 (71 ± 5)	Osteoporosis (t- score < -2.5 SD) Hyperkyphosis (Cobb-angle T2- T12 is 50°-65°) None	Gait analysis (Cad; right & left StL; StrL; SW; WS; right & left SST); CBS	R StL: O-K: 57.4 $\pm$ 3.3; control: 61.83 $\pm$ 2.9 ( $p =$ 0.005) L StL: O-K: 58.0 $\pm$ 3.2; control: 60.87 $\pm$ 2.8 ( $p =$ 0.03) StrL: O-K: 115.4 $\pm$ 5.1; control: 122.70 $\pm$ 5.0 ( $p =$ 0.03) StrL: O-K: 115.4 $\pm$ 5.1; control: 1122.70 $\pm$ 5.0 ( $p =$ 0.003) WS: O-K: 0.99 $\pm$ 0.15; control: 1.18 $\pm$ 0.09 ( $p =$ 0.004) Cad: O-K: 103.9 $\pm$ 13.6; control: 115.79 $\pm$ 7.2 ( $p =$ 0.03) R SST: O-K: 36.1 $\pm$ 1.4; control: 37.39 $\pm$ 2.2 ( $p =$ 0.15) L SST: O-K: 35.97 $\pm$ 1.8; control: 36.47 $\pm$ 1.7 ( $p =$ 0.37) L SST: O-K: 35.21 $\pm$ 5.000001; 36.47 $\pm$ 1.7 ( $p =$ 0.37)

Part I: Osteoporosis-related factors

Table 2.2. Continued

Patients with	and without fl	Patients with and without flexed posture (FP)				
Antonelli-	Cross-	Men with	352 (73.8±		SB; RCC;	SB: $p = 0.009$ between groups; men with long
Incalzi <i>et al</i> .	sectional		6.34)		4mWS;	OWD performed worse
[49]	study	1. Short OWD	87 (19.5% ≥	OWD < 2.39% of	SPPB	RCS: $p = 0.790$ between groups; no differences
			75 yrs)	body height		between groups
		2. Medium	175 (36.6%	OWD ≥ 2.39%		4mWS: $p < 0.001$ between groups; men with long
		OWD	≥ 75 yrs)	and ≤ 3.55% of		OWD performed worse
				body height		SPPB: p < 0.001 between groups, men with long
		3. Long OWD	90 (54.4% ≥	OWD > 3.55% of		OWD performed worse
			75 yrs)	body height		
		Women with	431 (75.0±			SB: $p < 0.001$ between groups; women with long
			6.85)			OWD performed worse
		1. Short OWD	107 (22.4%	OWD < 2.58% of		RCS: $p = 0.001$ between groups: women with
			≥ 75 yrs)	body height		long OWD performed worse
		2. Medium	217 (44.7%	OWD ≥ 2.58%		4mWS: <i>p</i> < 0.001 between groups; women with
		OWD	≥ 75 yrs)	and ≤ 3.90% of		long OWD performed worse
				body height		SPPB: p < 0.001 between groups; women with
		3. Long OWD	107 (64.5%	OWD > 3.90% of		long OWD performed worse
			≥ 75 yrs)	body height		
3alzini <i>et al</i> .	Cross-	Elderly women with	ith		SPPB;	SPPB: <i>p</i> > 0.05 between groups
[14]	sectional	1. Mild FP	11 (74.8±	OWD ≤ 5.0 cm	POMA; Gait	POMA: $p < 0.05$ for severe FP group versus mild
	study		1.6)		analysis	FP
		2. Moderate FP	28 (77.0 ±	OWD 5.1-8.0 cm	(BoS; Cad;	Gait analysis: $p < 0.05$ for moderate and severe
			1.1)		SL; SSD; WS)	group versus control group for all variables; $p < $
		3. Severe FP	21 (78.0 ± 1.2)	OWD > 8.0 cm		0.05 for severe versus mild group for WS and BoS

42

olatform); RCS = Repeated Chair Stands (score); SB = Standing Balance in 3 conditions (feet stand side-by-side, semi-tandem and tandem position for 10second each); SBI = Static Balance Index (score); TS (SS-OE, SS-CE, US-OE, US-CE) = Total sway (defined as the total number of 1-mm squares traversed by Walk Line (seconds); CBS = Composite Balance Score; COPamp & COPvel = mean amplitude (COPamp) of COP-movements (cm) in anterior-posterior and (cm), Cadence (steps/minute); Step Length (cm), Single Support Duration (% gait cycle), and Walking Speed (m/s); Gait analysis (Cad; right & left Sway (score) on Sensory Organization Test, Subtests 5 (eyes closed and sway referencing on platform) and 6 (inaccurate vision and sway referencing on COP velocity in anterior-posterior (COPvx) and medio-lateral direction (COPvy); CV of StL, SW, StrL, ST, ST = Coefficient of Variation of Step Length (StL), StL; StrL; SW; WS; right & left SST) = Gait analysis, measuring Cadence (Cad); right and left Step (StL) and Stride Length (StrL); Step Width (SW); right and step Width (SW), Stride Length (StrL), Step Time (ST), and Stance Time (StT); FGS = Free Gait Speed (m/s); FOB = Figure-of-8 test, speed adjusted for leg (DftW = 10-ft walk (s); 30m-GS = Gait Speed over 30 meters (s); 4mWS = Walking Speed over 4-m distance (m/s calculated as best performance score); medio-lateral directions and mean velocity (COPvel) (cm/s), with eyes opened and closed; COP velocity (SS-OE, SS-CE, US-OE, US-CE) = Sway velocity of DE) and Eyes Closed (US-CE); COPX, COPX, COPX, & COPXy = COP displacement in the anterior-posterior (COPX) and medio-lateral direction (COPY) and ength (s<sup>-1</sup>); FR = Functional Reach (cm); FSS = Four Square Step test (seconds); Gait analysis (BoS; Cad; SL; SSD; WS) = Gait analysis, measuring Base-of-Centre of Pressure (degrees/second) on a Stable Surface with Eyes Open (SS-OE), Eyes Closed (SS-CE) and on an Unstable Surface with Eyes Open (USeft Single Support Time (SST); and Walking Speed (WS); **%LOS (AP, ML)** = Percentage of theoretical Limits of Stability in anterior-posterior and mediothe pen over a 30-second period) for standing on a Stable Surface with Eyes Opened (SS-OE) and Eyes Closed (SS-CE), and on a Unstable Surface with 6mW = 6-minute walk (m); BBS = Berg Balance Scale (score); BD = Body Displacement (cm); BSS = Balance Strategy Score; BTWL = Backward Tandem ateral direction; MS = Mobility Skills (tasks completed); POMA = Performance Oriented Mobility Assessment (score); PS on SOT-5 & SOT-6 = Postural Eves Opened (US-OE) and Eves Closed (US-CE); SPPB = Short Physical Performance Battery (score); TUG = Timed Up & Go test (seconds) Only one study examined walking characteristics of women with and without osteoporosis. Palombaro *et al.* [33] found significant increased step and stance time variability for women with osteoporosis compared with healthy women. Furthermore, they found a tendency toward increased variability in step width in the osteoporotic group.

#### Influence of vertebral fractures on various balance outcome measures

In four studies, balance was examined among patients with and without vertebral fractures (Table 2.2) [3, 11, 47, 51]. One study also assessed thoracic kyphosis and scored t-score for BMD [3]. Two studies controlled for visual, vestibular and proprioceptive dysfunctions [3, 47].

Three studies investigated the performance of these patients on clinically used functional performance tests [11, 47, 51]. Walking speed, measured by the 10-ft walk test, did not significantly differ between women with and without vertebral fractures in the study of Lyles *et al.* [47], but did significantly differ between these groups when measured with the 30-m walking speed test in a study by Gerdhem *et al.* [51]. Other tests measuring functional mobility were all carried out significantly worse by women with vertebral fractures: the Functional Reach test, the Mobility Scale protocol [47], and the TUG test [11].

Two studies investigated balance while standing still. Gerdhem *et al.* [51] measured balance during the Romberg test, finding a significantly worse performance of women with vertebral fractures. Greig *et al.* [3] found a significant difference between women with and without vertebral fractures in the mean anterior-posterior COP-displacement.

Walking characteristics are not yet evaluated between elderly with and without vertebral fractures.

#### Influence of thoracic kyphosis on various balance outcome measures

Table 2.2 shows furthermore the results of four studies that investigated the influence of thoracic kyphosis on various balance performance tests [3, 41, 54, 56]. Two studies registered the BMD [3, 56], and one study the amount of vertebral fractures as well [3]. Three studies controlled for visual, vestibular and proprioceptive dysfunctions [3, 41, 56].

Katzman *et al.* [54] concluded in their study that for each SD (11.9°) increase in thoracic kyphosis angle, there is an increase in average performance on the TUG time of 0.2 seconds.

Balance when standing still was recorded in three studies, with different results. Greig *et al.* [3] did not find any difference between patients with thoracic kyphosis and with normal posture for the mean COP displacement and velocity in anterior-posterior and medio-lateral direction. Likewise, Lynn *et al.* [41] did not find a significant difference between women with normal posture and with thoracic kyphosis for postural sway score. Contrary results were found by Sinaki *et al.* [56], who concluded that women with hyperkyphosis had significantly more postural sway than healthy women.

Furthermore, Sinaki *et al.* [56] carried out a gait analysis on a 10-meter walkway with 3-D marker trajectory data and a camera [61]. They found that women with hyperkyphosis had significant smaller step and stride lengths, a significantly lower walking speed and they performed significantly fewer steps per minute (cadence).

#### Influence of a flexed posture on various balance outcome measures

Two studies measured a variety of balance measurement among patients with flexed posture (Table 2.2) [14, 49]. Both studies measured the amount of flexed posture with the Occiput-to-Wall-Distance (OWD), and both studies were subdivided into three categories. Antonelli-Incalzi *et al.* [49] categorized men and women with short, medium and long OWD according to their body height. Balzini *et al.* [14] subdivided OWD into mild ( $\leq$ 5.0 cm), moderate (5.1–8.0 cm), and severe (>8.0 cm) flexed posture among women. Balzini *et al.* [14] mentioned the amount of vertebral fractures in their study; Antonelli-Incalzi *et al.* [49] did not assess the presence of osteoporosis, vertebral fractures or the degree of thoracic kyphosis. One study controlled for visual, vestibular and proprioceptive dysfunctions [14].

Balzini *et al.* [14] found significant differences between women with severe and mild flexed posture on the Performance Oriented Mobility Assessment [64]. However, they did not find a significant difference between the three groups for the Short Physical Performance Battery (SPPB). Contrary results were found by Antonelli-Incalzi *et al.* [49], where both men and women with increased OWD scored significantly lower on the SPPB than their healthy controls.

In the study of Antonelli-Incalzi *et al.* [49], standing balance was measured by asking patients to attempt to maintain their feet in a side-by-side, semi-tandem and tandem position for 10 s each. Both men and women with long OWD performed significantly worse than the other groups. Walking speed was evaluated over a 4-m distance. For both men and women, the long OWD groups performed significantly worse than the medium and short OWD groups.

Balzini *et al.* [14] analyzed gait, measuring cadence, step length, walking speed, base of support width and single support duration. For all variables, women with moderate or severe flexed posture performed significantly worse than women with mild flexed posture. Women with severe flexed posture had significantly lower walking speed and significantly wider base-of-support than women with moderate flexed posture.

## Discussion

The aim of the present literature review was to examine whether postural control of patients with osteoporosis, vertebral fractures, thoracic kyphosis and flexed posture is affected, and which instruments measuring postural control are most sensitive in this population. A total of 18 eligible studies were included, assessing postural control with 27 different instruments. Postural control was generally affected for patients with vertebral fractures, thoracic kyphosis and flexed posture. For patients with osteoporosis alone, the results were more nuanced. These patients showed affected postural control when tested with instrumental tests under various conditions. In contrast, functional performance tests did not show significant differences in postural control for osteoporotic patients compared with their healthy controls. Apparently, functional performance tests are less sensitive than computerized tests in the osteoporotic population.

These functional performance tests are easy to assess, but measure more than postural control alone. The TUG test is a good example: this is a commonly-used test to examine functional mobility in older frail adults, and is validated to detect patients at risk of falling [31, 65]. The term "functional mobility" reflects the balance and gait maneuvers used in everyday life; for example, getting out of a chair, walking, turning and sitting down. In fact, the TUG measures postural control indirectly by timing a set of different actions, but provide no direct quantification of impaired postural control. In the present review article, three studies were included assessing only the TUG in their patient population [11, 37, 54]. All three studies had large sample sizes, and two of them showed an affected functional mobility for patients with vertebral fractures and thoracic kyphosis [11, 54], but not for osteoporotic patients [37]. An explanation might be that women with vertebral fractures, thoracic kyphosis or flexed posture have more functional loss than women with only osteoporosis. However, when a TUG performance is within the normal range, there still might be an impaired postural control, resulting in an increased risk of falling. This means that the performance on the TUG is not specific for (impaired) postural control in the osteoporotic population.

For the osteoporotic group, we therefore recommend instrumental tests to detect whether these patients have impaired postural control and to obtain more insight into the underlying mechanisms of (impaired) postural control. Eight studies carried out more refined analyses under various conditions (e.g. eyes open or closed, standing on a stable or unstable surface) using objective outcome measures derived from computerized instruments; for example, detection of magnetic fields [39], force plate [36, 40, 41], balance platform [35, 42], sway meter system [38] and electronic walkway [33]. Significant different outcome variables for standing balance were the body displacement [39], velocity and amplitude of center of pressure [40, 42], percentage of theoretical limits of stability of sway [40], postural sway score [41], composite balance score of the sensory organization test [36], and for gait analysis: step and stance time [33]. However, not all instruments are very useful in clinical practice, because not all are easily and quickly assessable during consultation with a patient, as a result of large instrument sizes and advanced technical aspects. Other drawbacks of these computerized instruments could be the need to carry out off-line data-analysis, preprocess the data, and the translation to clinically applicable outcome measures. However, these processes are being automated and simplified more and more for clinical use.

A relatively new instrument that is useful in clinical practice is ambulant motionsensing (accelerometry) technology. This is an ambulatory instrument attached over the clothes on the body of the patient close to the center of body mass. These devices are light, compact and easy-to-use, with minimal awareness of the measuring process by the subject. The acceleration device records trunk acceleration in three dimensions, which can be used to assess postural control during walking and standing under various conditions, and for various patient groups [19, 27, 66–69]. From the accelerometer data, a variety of outcome variables can be calculated; for instance, to quantify amplitude of postural sway, stability and variability measures during standing and walking tasks [19, 22, 27, 66, 68, 69]. However, none of the included studies in the present review used an accelerometer to assess balance. Therefore, further research is required to investigate which outcome variables of accelerometry detect best the effect of postural changes on postural control and predict future falls in the osteoporotic population.

A limitation of the present literature review was the small amount of studies carried out to assess postural control in this population of elderly with osteoporosis, vertebral fractures, thoracic kyphosis or flexed posture. Also, the definition of osteoporosis was not clear in all studies [33, 35–42], particularly whether there were vertebral fractures and/or thoracic kyphosis and/or flexed posture in the osteoporotic group was not mentioned, which could interfere with the results. Furthermore, as a result of small sample sizes and low scores for external validity, the results of the included studies cannot be easily extrapolated to larger groups. Nevertheless, despite the small groups, significant differences in postural control were found between patients with vertebral fractures, thoracic kyphosis and flexed posture, and their healthy controls in all nine studies. In four studies, there were some non-significant test-results [3, 14, 41, 47]. This was probably caused by methodological choices in the studies. For example, Lyles *et al.* [47] used a test that was probably not sensitive enough, Greig *et al.* [3] determined high and low kyphosis arbitrarily, Lynn *et al.* [41] assessed postural control under very challenging conditions, possibly causing a ceiling effect, and Balzini *et al.* [14] used a much smaller patient population compared with Antonelli-Incalzi *et al.* [49]

In conclusion, based on the reviewed studies, there is evidence for impaired postural control in patients with osteoporosis, vertebral fractures, thoracic kyphosis and flexed posture. An impaired postural control is a risk factor for falls and further fractures among the elderly [16, 70]. An early diagnosis of balance disorders is of great importance to prevent osteoporotic patients from falling by offering them an early intervention, for instance Tai Chi or vitamin D supplementation [71, 72]. Therefore, we recommend that physicians assess postural control in osteoporotic patients. Because functional performance tests are not sensitive and specific enough for all patients, we recommend easily clinically usable ambulant technology, for instance the accelerometer, to detect impairments in postural control during various standing and walking tasks.

## Appendix I

## Search strategy for PubMed

(("osteoporosis" [mesh] OR "osteoporosis" [tiab]) OR ("osteoporosis postmenopausal" [mesh] OR "osteoporosis postmenopausal" [tiab]) OR ("bone mass" [mesh] OR "bone mass" [tiab]) OR ("bone density" [mesh] OR "bone density" [tiab]) OR ("bone mineral density" [mesh] OR "bone mineral density" [tiab]) OR ("BMD" [mesh] OR "BMD" [tiab]) OR ("osteopenia" [mesh] OR "osteopenia" [tiab]) OR ("vertebral fractur\*" [mesh] OR "vertebral fractur\*" [tiab]) OR ("osteoporotic fractur\*" [mesh] OR "osteoporotic fractur\*" [tiab]) OR ("compression fractur\*" [mesh] OR "compression fractur\*" [tiab]) OR ("spinal fractur\*" [mesh] OR "spinal fractur\*" [tiab]) OR ("kyphosis" [mesh] OR "kyphosis" [tiab]) OR ("thoracic kyphosis" [mesh] OR "thoracic kyphosis" [tiab]) OR ("cobb angle" [mesh] OR "cobb angle" [tiab]) OR ("flexed posture" [mesh] OR "flexed posture" [tiab]) OR ("occiput-to-wall distance" [mesh] OR "occiput-to-wall distance" [tiab])) AND (("gait" [mesh] OR "gait" [tiab]) OR ("gait analysis" [mesh] OR "gait analysis" [tiab]) OR ("gait speed" [mesh] OR "gait speed" [tiab]) OR ("walking speed" [mesh] OR "walking speed" [tiab]) OR ("balance measuremen\*" [mesh] OR "balance measuremen\*" [tiab]) OR ("balance tests" [mesh] OR "balance tests" [tiab]) OR ("balance testing" [mesh] OR "balance testing" [tiab]) OR ("balance test" [mesh] OR "balance test" [tiab]) OR ("dynamic balance" [mesh] OR "dynamic balance" [tiab]) OR ("static balance" [mesh] OR "static balance" [tiab]) OR ("functional mobility" [mesh] OR "functional mobility" [tiab]) OR ("motor skills" [mesh] OR "motor skills" [tiab]) OR ("gait disorders" [mesh] OR "gait disorders" [tiab]) OR ("force platform" [mesh] OR "force platform" [tiab]) OR ("timed up and go" [mesh] OR "timed up and go" [tiab]) OR ("TUG" [mesh] OR "TUG" [tiab]) OR ("berg balance scale" [mesh] OR "berg balance scale" [tiab]) OR ("BBS" [mesh] OR "BBS" [tiab]) OR ("center of pressure" [mesh] OR "center of pressure" [tiab]) OR ("COP" [mesh] OR "COP" [tiab]))

# Appendix II

## Downs & Black criteria used for methodological quality evaluation

Downs & Black [30] criteria used for the methodological quality evaluation of the reviewed studies. All items are scored 1 or 0 (yes or no), except item 4, which is scored 2, 1 or 0 (yes, partially or no).

Item	Score
Reporting	
Clear description of study's hypothesis, aim(s) or objective(s).	Yes(1)/No(0)
Definition of the main outcomes in the introduction or methods section.	Yes(1)/No(0)
Clear description of the individuals included in the study.	Yes(1)/No(0)
Description of the principal confounders.	Yes(2)/Partially
	(1)/No(0)
Clear description of the study's main findings.	Yes(1)/No(0)
Information on random data variability for the main outcomes.	Yes(1)/No(0)
Information on the real probability values for the main outcomes.	Yes(1)/No(0)
External validity	
Representativeness of the planned sample.	Yes(1)/No(0)
Representativeness of the individuals actually included in the final sample.	Yes(1)/No(0)
Internal validity – bias	
Blinding of those measuring the main outcomes.	Yes(1)/No(0)
Clear description of results not based on a priori hypothesis ('data dredging').	Yes(1)/No(0)
Adequacy of the statistical tests used to evaluate the main outcomes.	Yes(1)/No(0)
Accuracy of the main outcome measures.	Yes(1)/No(0)
Internal validity – confounding	
Comparability of the individuals included in all comparison groups in relation to the population they were recruited from.	Yes(1)/No(0)
Comparability of the individuals included in all comparison groups in relation to the period of time when they were recruited.	Yes(1)/No(0)
Adequate adjustment for principal confounders in the analysis from which the main findings were drawn.	Yes(1)/No(0)
Power	
Sufficient study power to detect an important effect, with a 5% significance level.	Yes(1)/No(0)

## References

**1.** Riggs BL, Melton  $\sqcup$  (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17:5055–115.

**2.** Cooper C, Campion G, Melton ⊔ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–9.

**3.** Greig AM, Bennell KL, Briggs AM, *et al.* (2007) Balance impairment is related to vertebral fracture rather than thoracic kyphosis in individuals with osteoporosis. Osteoporos Int 18:543–51.

**4.** Melton LJ, Chrischilles EA, Cooper C, *et al.* (1992) How many women have osteoporosis? J Bone Miner Res 7:1005–10.

**5.** Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221–7.

**6.** Van der Jagt-Willems HC, van Hengel M, Vis M, *et al.* (2012) Why do geriatric outpatients have so many moderate and severe vertebral fractures? Exploring prevalence and risk factors. Age Ageing 41:200–6.

**7.** Cook DJ, Guyatt GH, Adachi JD, *et al.* (1993) Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 36:750–6.

**8.** Silverman SL (1992) The clinical consequences of vertebral compression fracture. Bone 13:S27–S31.

**9.** Nevitt MC, Ettinger B, Black DM, *et al.* (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800.

**10.** Greendale GA, Barrett-Connor E, Ingles S, Haile R (1995) Late physical and functional effects of osteoporotic fracture in women: the Rancho Benardo Study. J Am Geriatr Soc 43:955–61.

**11.** Hall SE, Criddle RA, Comito TL, Prince RL (1999) A case-control study of quality of life and functional impairment in women with longstanding vertebral osteoporotic fracture. Osteoporos Int 9:508–15.

**12.** Cortet B, Roches E, Logier R, *et al.* (2002) Evaluation of spinal curvatures after a recent osteoporotic vertebral fracture. Jt Bone Spine 69:201–8.

**13.** Katzman WB, Wanek L, Shepherd JA, Sellmeyer DE (2010) Age-related hyperkyphosis: its causes, consequences, and management. J Orthop Sports Phys Ther 40:352–60.

**14.** Balzini L, Vannucchi L, Benvenuti F, *et al.* (2003) Clinical characteristics of flexed posture in elderly women. J Am Geriatr Soc 51:1419–26.

**15.** Huang C, Ross PD, Wasnich RD (1996) Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 156:2469–75.

**16.** Wagner H, Melhus H, Gedeborg R, *et al.* (2009) Simply ask them about their balance--future fracture risk in a nationwide cohort study of twins. Am J Epidemiol 169:143–9.

**17.** Benedetti MG, Berti L, Presti C, *et al.* (2008) Effects of an adapted physical activity program in a group of elderly subjects with flexed posture: clinical and instrumental assessment. J Neuroeng Rehabil 5:32.

**18.** Pollock AS, Durward BR, Rowe PJ, Paul JP (2000) What is balance? Clin Rehabil 14:402–6.

**19.** Lamoth CJC, van Heuvelen MJG (2012) Sports activities are reflected in the local stability and regularity of body sway: older ice-skaters have better postural control than inactive elderly. Gait Posture 35:489–93.

**20.** Vuillerme N, Nafati G (2007) How attentional focus on body sway affects postural control during quiet standing. Psychol Res 71:192–200.

**21.** Schmit JM, Regis DI, Riley MA (2005) Dynamic patterns of postural sway in ballet dancers and track athletes. Exp Brain Res 163:370–8.

**22.** Lamoth CJC, van Lummel RC, Beek PJ (2009) Athletic skill level is reflected in body sway: a test case for accelometry in combination with stochastic dynamics. Gait Posture 29:546–51.

**23.** Sturnieks DL, St George R, Lord SR (2008) Balance disorders in the elderly. Clin Neurophysiol 36:467–78.

**24.** Howe TE, Rochester L, Jackson A, *et al.* (2008) Exercise for improving balance in older people. Cochrane Database Syst Rev 4:CD004963.

**25.** Schmit JM, Riley MA, Dalvi A, *et al.* (2006) Deterministic center of pressure patterns characterize postural instability in Parkinson's disease. Exp Brain Res 168:357–67.

**26.** Houdijk H, Nooijen C, Rijntjes D, *et al.* (2010) Energy expenditure of stroke patients during postural control tasks. Gait Posture 32:321–6.

**27.** Lamoth CJC, van Deudekom FJ, van Campen JPCM, *et al.* (2011) Gait stability and variability measures show effects of impaired cognition and dual tasking in frail people. J Neuroeng Rehabil 8:2.

**28.** Kiyota Y, Hase K, Nagashima H, *et al.* (2011) Adaptation process for standing postural control in individuals with hemiparesis. Disabil Rehabil 33:2567–73.

**29.** Kouzaki M, Masani K (2012) Postural sway during quiet standing is related to physiological tremor and muscle volume in young and elderly adults. Gait Posture 35:11–7.

**30.** Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–84.

**31.** Podsiadlo D, Richardson S (1991) The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39:142–8.

**32.** Berg KO, Maki BE, Williams JI, *et al.* (1992) Clinical and laboratory measures of postural balance in an elderly population. Arch Phys Med Rehabil 73:1073–80.

**33.** Palombaro KM, Hack LM, Mangione KK, *et al.* (2009) Gait variability detects women in early postmenopause with low bone mineral density. Phys Ther 89:1315–26.

**34.** De Abreu DCC, Trevisan DC, Reis JG, *et al.* (2009) Body balance evaluation in osteoporotic elderly women. Arch Osteoporos 4:25–9.

**35.** Gunendi Z, Ozyemisci-Taskiran O, Demirsoy N (2008) The effect of a 4-week aerobic exercise program on postural balance in postmenopausal women with osteoporosis. Rheumatol Int 28:1217–22.

**36.** Liu-Ambrose T, Eng JJ, Khan KM, *et al.* (2003) Older women with osteoporosis have increased postural sway and weaker quadriceps strength than counterparts with normal bone mass: overlooked determinants of fracture risk? J Gerontol A Biol Sci Med Sci 58:M862–6.

**37.** Berkemeyer S, Schumacher J, Thiem U, Pientka L (2009) Bone T-scores and functional status: a cross-sectional study on German elderly. PLoS ONE 4:e8216.

**38.** Tan B-K, Price RI, Briffa NK, *et al.* (2008) Assessment of osteoporotic fracture risk in community settings: a study of post-menopausal women in Australia. Health Soc Care Community 16:621–8.

**39.** De Abreu DCC, Trevisan DC, da Costa G de C, *et al.* (2010) The association between osteoporosis and static balance in elderly women. Osteoporos Int 21:1487–91.

**40.** Burke TN, França FJR, Meneses SRF de, *et al.* (2010) Postural control among elderly women with and without osteoporosis: is there a difference? São Paulo Med J 128:219–24.

**41.** Lynn SG, Sinaki M, Westerlind KC (1997) Balance characteristics of persons with osteoporosis. Arch Phys Med Rehabil 78:273–7.

**42.** Da Silva RB, Costa-Paiva L, Morais SS, *et al.* (2010) Predictors of falls in women with and without osteoporosis. J Orthop Sports Phys Ther 40:582–8.

**43.** Topp R, Mikesky A, Wigglesworth J, *et al.* (1993) The effect of a 12-week dynamic resistance strength training-program on gait velocity and balance of older adults. Gerontologist 33:501–6.

**44.** Carter ND, Khan KM, McKay HA, *et al.* (2002) Community-based exercise program reduces risk factors for falls in 65- to 75-year-old women with osteoporosis: randomized controlled trial. Can Med Assoc J 167:997–1004.

**45.** Dite W, Temple VA (2002) A clinical test of stepping and change of direction to identify multiple falling older adults. Arch Phys Med Rehabil 83:1566–71.

**46.** Duncan PW, Weiner DK, Chandler JM, Studenski SA (1990) Functional reach - a new clinical measure of balance. J Gerontol 45:M192–7.

**47.** Lyles KW, Gold DT, Shipp KM, *et al.* (1993) Association of osteoporotic vertebral compression fractures with impaired functional status. Am J Med 94:595–601.

**48.** Tinetti ME, Ginter SF (1988) Identifying mobility dysfunctions in elderly patients. Standard neuromuscular examination or direct assessment? JAMA 259:1190–3.

**49.** Antonelli-Incalzi R, Pedone C, Cesari M, *et al.* (2007) Relationship between occiput-to-wall distance and physical performance in the elderly: a cross sectional study. Aging Clin Exp Res 19:207–12.

**50.** Franchignoni F, Tesio L, Martino MT, Ricupero C (1998) Reliability of four simple, quantitative tests of balance and mobility in healthy elderly females. Aging 10:26–31.

**51.** Gerdhem P, Ringsberg K a, Akesson K (2006) The relation between previous fractures and physical performance in elderly women. Arch Phys Med Rehabil 87:914–7.

**52.** Guralnik JM, Simonsick EM, Ferrucci L, *et al.* (1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49:M85–94.

**53.** Guralnik JM, Seeman TE, Tinetti ME, *et al.* (1994) Validation and use of performance measures of functioning in a non-disabled older population: MacArthur studies of successful aging. Aging 6:410–9.

**54.** Katzman WB, Vittinghoff E, Kado DM (2011) Age-related hyperkyphosis, independent of spinal osteoporosis, is associated with impaired mobility in older community-dwelling women. Osteoporos Int 22:85–90.

**55.** Wallmann HW (2001) Comparison of elderly nonfallers and fallers on performance measures of functional reach, sensory organization, and limits of stability. J Gerontol A Biol Sci Med Sci 56:M580–3.

**56.** Sinaki M, Brey RH, Hughes CA, *et al.* (2005) Balance disorder and increased risk of falls in osteoporosis and kyphosis: significance of kyphotic posture and muscle strength. Osteoporos Int 16:1004–10. **57.** Swanenburg J, de Bruin ED, Favero K, *et al.* (2008) The reliability of postural balance measures in single and dual tasking in elderly fallers and non-fallers. BMC Musculoskelet Disord 9:162.

**58.** Lord SR, Clark RD, Webster IW (1991) Physiological factors associated with falls in an elderly population. J Am Geriatr Soc 39:1194–1200.

**59.** Guyatt GH, Sullivan MJ, Thompson PJ, *et al.* (1985) The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132:919–23.

**60.** Barker S, Craik R, Freedman W, *et al.* (2006) Accuracy, reliability, and validity of a spatiotemporal gait analysis system. Med Eng Phys 28:460–7.

**61.** Kadaba MP, Ramakrishnan HK, Wootten ME, *et al.* (1989) Repeatability of kinematic, kinetic, and electromyographic data in normal adult gait. J Orthop Res 7:849–60.

**62.** Cutlip RG, Mancinelli C, Huber F, DiPasquale J (2000) Evaluation of an instrumented walkway for measurement of the kinematic parameters of gait. Gait Posture 12:134–8.

**63.** McDonough AL, Batavia M, Chen FC, *et al.* (2001) The validity and reliability of the GAITRite system's measurements: a preliminary evaluation. Arch Phys Med Rehabil 82:419–25.

**64.** Tinetti ME (1986) Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34:119–26.

**65.** Shumway-Cook A, Brauer S, Woollacott MH (2000) Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go test. Phys Ther 80:896–903.

**66.** Martinez-Mendez R, Sekine M, Tamura T (2012) Postural sway parameters using a triaxial accelerometer: comparing elderly and young healthy adults. Comput Methods Biomech Biomech Eng 15:899–910.

**67.** Dijkstra B, Kamsma YPT, Zijlstra W (2010) Detection of gait and postures using a miniaturized triaxial accelerometer-based system: accuracy in patients with mild to moderate Parkinson's disease. Arch Phys Med Rehabil 91:1272–7.

**68.** Lamoth CJC, Ainsworth E, Polomski W, Houdijk H (2010) Variability and stability analysis of walking of transfemoral amputees. Med Eng Phys 32:1009–14. **69.** IJmker T, Lamoth CJC (2012) Gait and cognition: the relationship between gait stability and variability with executive function in persons with and without dementia. Gait Posture 35:126–30.

**70.** Melzer I, Benjuya N, Kaplanski J (2004) Postural stability in the elderly: a comparison between fallers and non-fallers. Age Ageing 33:602–7.

**71.** Kalyani RR, Stein B, Valiyil R, *et al.* (2010) Vitamin D treatment for the prevention of falls in older adults: systematic review and meta-analysis. J Am Geriatr Soc 58:1299–1310.

**72.** Leung DP, Chan CK, Tsang HW, *et al.* (2011) Tai chi as an intervention to improve balance and reduce falls in older adults: a systematic and meta-analytical review. Altern Ther Health Med 17:40–8.

# **CHAPTER 3**

# A flexed posture in elderly patients is associated with impairments in postural control during walking

Maartje H. de Groot Hanna C. van der Jagt-Willems Jos P. C. M. van Campen Willem F. Lems Jos H. Beijnen Claudine J. C. Lamoth

Gait & Posture 2014; 39 (2): 767-772

## Abstract

A flexed posture (FP) is characterized by protrusion of the head and an increased thoracic kyphosis (TK), which may be caused by osteoporotic vertebral fractures (VFs). These impairments may affect motor function, and consequently increase the risk of falling and fractures. The aim of the current study was therefore to examine postural control during walking in elderly patients with FP, and to investigate the relationship with geriatric phenomena that may cause FP, such as increased TK, VFs, frailty, polypharmacy and cognitive impairments. Fifty-six elderly patients (aged 80 ± 5.2 years; 70% female) walked 160 m at self-selected speed while trunk accelerations were recorded. Walking speed, mean stride time and coefficient of variation (CV) of stride time were recorded. In addition, postural control during walking was quantified by time-dependent variability measures derived from the theory of stochastic dynamics, indicating smoothness, degree of predictability, and local stability of trunk acceleration patterns. Twenty-five patients (45%) had FP and demonstrated a more variable and less structured gait pattern, and a more irregular trunk acceleration pattern than patients with normal posture. FP was significantly associated with an increased TK, but not with other geriatric phenomena. An increased TK may bring the body's center of mass forward, which requires correcting responses, and reduces the ability to respond on perturbation, which was reflected by higher variation in the gait pattern in FP-patients. Impairments in postural control during walking are a major risk factor for falling: the results indicate that patients with FP have impaired postural control during walking and might therefore be at increased risk of falling.

## Introduction

A flexed posture (FP) is characterized by an increased thoracic kyphosis (TK), protrusion of the head and, in severe cases, knee flexion [1], which is a postural correction to the increased TK [2]. In the elderly, TK is likely to increase over time [3] because of intervertebral disc deformities and/or spinal extensor muscle weakness [4, 5]. Vertebral fractures (VFs) are characteristic of osteoporosis: VFs in the thoracic vertebral column may also increase TK. These impairments may affect motor function, thus increasing the risk of falling [6] and fractures.

A recent review showed significant differences in postural control during standing and walking between patients with osteoporosis and healthy controls, particularly when variables indicating postural stability were calculated from objective measurements using instrumented devices like force plates and accelerometers [7]. In the majority of studies reviewed, however, the presence and severity of FP, TK and/or VFs in the osteoporotic group were not specified, and the relationship between these clinical entities is not yet clear.

Impaired postural control during walking is a major risk factor for falls and new fractures in the elderly [8]; therefore, early recognition and quantification of balance disorders is important in osteoporotic patients. Analyses of time-dependent variability, using measures derived from the theory of stochastic dynamics [9], enable differences in postural control during walking to be detected between young and old patients, fallers and non-fallers, and those with and without cognitive impairments [9–11]. Measures to quantify time-dependent variations of postural control during walking, such as the detrended fluctuations analyses [12], sample entropy [13] and maximal Lyapunov exponents [11], were used in the current study as well as more conventional gait parameters (e.g. average gait speed, and stride times). In conventional measures, each gait cycle is treated as an independent event unrelated to previous or subsequent strides, whereas the methods used in the current study assess fluctuations throughout the gait cycle, thereby providing greater insight into movement behavior.

The primary aim of the present study was to examine postural control during walking in elderly patients with FP, and the secondary aim was to examine the relationship with TK, VFs and grip strength (as an indicator for overall limb strength) as possible causes of FP [1, 4, 5]. Comorbid diseases, frailty, polypharmacy and cognitive impairments are often present in the elderly, so the association of these geriatric phenomena with FP was also examined. Patients with FP are hypothesized to have increased variability of gait parameters compared with patients with normal posture. Also, the presence of increased TK, VFs, muscle weakness and other geriatric phenomena might further worsen FP, and consequently worsen postural control during walking.

## Methods

### Participants

Patients were recruited among the elderly who visited the Diagnostic Geriatric Day Clinic at the Slotervaart Hospital in Amsterdam. Patients aged at least 70 years who could walk safely for 3 minutes without assistance were included in the study. Patients who had any asymmetric mobility problems and/or did not understand the researcher's instructions were excluded from the study.

The study was approved by the Medical Ethical Committee of the Slotervaart Hospital. All included patients gave their informed consent.

#### Gait analysis

Patients walked about 160 m at a self-selected speed in a well-lit, 80-m-long hallway. Walking time was recorded to determine gait speed. Trunk accelerations were measured with a tri-axial accelerometer (DynaPort Minimod Hybrid, McRoberts BV, The Hague, the Netherlands; sample frequency 100 Hz) attached with a band at the level of the lumbar vertebral column.

#### Stride-related parameters

Medio-lateral (ML) and anterior-posterior (AP) trunk acceleration signals were analyzed using custom-made software in MATLAB (The MathWorks, Inc., Natick, MA, USA). Signals were corrected for horizontal tilt, and high-pass filtered using a Butterworth filter (4<sup>th</sup> order; cut-off frequency 0.25 Hz). Foot contacts were determined from the peaks of the AP-acceleration time-series. A median filter was used to exclude outliers in the data due to turning points in the gait assessment. Foot contact data were used to calculate stride times, which were defined as the time interval between two ipsilateral foot contacts. Mean stride time, coefficient of variation (CV) of stride time, and stride frequency were calculated for each patient.

Further parameters were calculated to assess variations throughout the gait cycle. Temporal variability was quantified by the variance of the relative timing between sequential ipsilateral foot contacts using the point estimate of the relative phase:  $\varphi_i = (FCR_{t(i)} - FCL_{t(i)}) / (FCL_{t(i+1)} - FCL_{t(i)}) \times 360^{\circ}$  [14], where FCL and FCR are the left and right

Chapter 3

foot contacts at time t(i), respectively. The relative phase is a circular measure; therefore, circular statistics were applied to calculate the mean and variance of the relative phase over strides [15]. A temporally symmetrical gait pattern is denoted by  $\varphi_i$  = 180°; a higher variance indicates a more variable gait pattern.

In addition, long-range correlations in stride time intervals were quantified by calculating scaling exponent a using the detrended fluctuation analysis (DFA) [12]. When  $0.5 \ge \alpha \ge 1$ , this indicates the presence of long-term correlations in the signal, which means future fluctuations are better predicted by past fluctuations. Therefore,  $\alpha$  values closer to 1 represent a more structured pattern.

## Trunk movement patterns

The magnitude of ML and AP trunk acceleration patterns was quantified by calculating the root mean square (RMS). The harmonic ratio (Hratio), sample entropy (SEn) [13], and maximal Lyapunov exponent ( $\lambda_{max}$ ) [16] were calculated using open source software (UPMOVE version 0.2a; http://www.upmove.org), indexing the smoothness, degree of predictability, and local stability of the trunk acceleration patterns, respectively.

The Hratio was calculated using spectral dynamics to quantify the smoothness of the ML and AP trunk movements, with a higher Hratio representing a smoother trunk acceleration pattern. A discrete Fourier transform was used to estimate the power spectral density of the fundamental oscillatory frequency and of the six consecutive harmonics. The Hratio was defined by dividing the power spectral density of the fundamental oscillatory frequency and normality of the fundamental oscillatory frequency by that of the first seven harmonics (the first seven harmonics were chosen because no additional information was obtained from spectral analysis of higher frequencies after low-pass filtering the data at 10 Hz).

The degree of predictability in ML and AP acceleration time-series was assessed by calculating the SEn, which is defined as the negative natural logarithm of an estimate of the conditional probability of epochs of length m (m = 3 in this study) that match pointwise within a tolerance r and repeats itself for m + 1 points. An optimization approach [17] was used to determine the tolerance parameter r and m, since the choice of r for given m is decisive. Smaller SEn values indicate greater regularity; larger SEn values are associated with a small chance of similar data being repeated. The ML and AP acceleration data were normalized to unit variance, so the outcome was scale-independent.

Local stability of the ML and AP trunk acceleration patterns was expressed by the  $\lambda_{max}$ , which was calculated by applying the Wolf algorithm [16]: this algorithm is most

appropriate to evaluate local dynamic stability from relatively small data sets. The timeseries was first low-pass filtered using a least squares finite impulse response filter (6th order; cut-off frequency 10 Hz) [11]. All stride-cycles were then resampled to 100 samples to enable comparison of trials between patients with FP and those with normal posture on the same time scale. The estimated time interval was 10% of the stride cycle for all reconstructed state spaces. An embedded dimension of 5 was chosen, following previous studies [9]. Larger  $\lambda_{max}$  indicates greater sensitivity to local perturbations.

#### Additional measurements

Age, gender, body mass index (BMI) and number of prescriptions were recorded for each patient. FP was defined as an occiput-to-wall distance (OWD) of 5.0 cm or more [1]; OWD was measured while subjects stood with their head in a natural position with heels and back touching the wall and knees extended.

Lateral X-rays of the thoracic and lumbar spine were assessed to determine the degree of TK and the presence of VFs. TK was measured by the Cobb angle between the superior endplate of the second thoracic vertebra and the inferior endplate of the twelfth thoracic vertebra. The Cobb angle was measured independently by two observers and the mean value was used. An abnormal increased TK was defined as a Cobb angle of  $\geq$ 50° [18], and a TK of <50° was considered normal. VFs were independently scored by two observers using Genant's semi-quantitative method [19]. When conclusions differed, final consensus was reached by discussion.

Grip strength (in kg) of the dominant hand was assessed with a Jamar hand-held dynamometer (average of three measurements; corrected for body height) and this was used as an indicator for overall limb strength [20]. Other geriatric phenomena were also recorded, including the presence of co-morbid diseases, using the Charlson comorbidity index (CCI) [21], cognitive functioning, using the mini mental state examination (MMSE) [22], risk of falling, using Pluijm's assessment [23] and the presence of frailty, according to the presence of three or more criteria of Fried *et al.* [24].

#### Statistical analyses

PASW Statistics 18 (SPSS, Inc., Chicago, IL, USA) was used for statistical analyses (level of significance p < 0.05). Non-parametric tests (Mann–Whitney U and  $\chi^2$ ) were used to test group differences between patients with normal posture and those with FP.

**Table 3.1.** Characteristics of patients with normal (NP; OWD <5.0 cm) and flexed posture (FP;  $OWD \ge 5.0$  cm).

Patient characteristics	NP (n = 31)	FP (n = 25)	<i>p</i> -value
Age (years), mean (SD)	79.7 (5.50)	79.6 (4.92)	0.85
Female, n (%)	22 (71%)	17 (68%)	0.81
BMI (kg/m2), mean (SD)	26.8 (4.40)	27.1 (3.47)	0.70
Vertebral fractures			
Presence of VFs, n (%)	11 (36%)	11 (44%)	0.52
Thoracic VFs (T2-T8), n (%)	9 (29%)	8 (32%)	0.81
Thoracolumbar VFs (T9-L1), n (%)	4 (13%)	5 (20%)	0.47
Lumbar VFs, n (%)	2 (7%)	1 (4%)	0.69
Thoracic kyphosis			
Cobb angle T2-T12 (°), mean (SD)	44.5 (12.1)	58.6 (11.9)	< 0.01
Increased thoracic kyphosis (Cobb angle $\geq$ 50°), n (%)	9 (29%)	20 (80%)	<0.01
Grip strength			
Grip strength (kg), mean (SD)	24.2 (8.76)	26.0 (8.45)	0.50
Comorbidities			
CCI score, median (range)	1 (0-4)	1 (0-5)	0.74
≥2 co-morbid diseases, n (%)	12 (39%)	11 (44%)	0.70
Dementia, n (%)	8 (26%)	7 (28%)	0.85
Myocardial infarct, n (%)	7 (23%)	7 (28%)	0.64
Chronic pulmonary disease, n (%)	2 (6%)	6 (24%)	0.06
Peripheral vascular disease, n (%)	5 (16%)	1 (4%)	0.15
Diabetes type II, n (%)	5 (16%)	2 (8%)	0.36
Cerebrovascular disease, n (%)	2 (6%)	3 (12%)	0.47
Prescriptions			
Number of prescriptions, median (range)	5 (0-15)	5 (0-15)	0.82
Polypharmacy (≥4 prescriptions), n (%)	21 (68%)	16 (64%)	0.77
Frailty			
Fried's frailty score, median (range)	1 (0-4)	1 (0-5)	0.30
Frail, n (%)	5 (16%)	3 (12%)	0.66
Cognitive functioning			
MMSE score, median (range)	24 (13-30)	25 (15-30)	0.24
Fall risk			
Pluijm score, median (range)	4 (0-19)	4 (0-20)	0.73
Increased fall risk (Pluijm score ≥7), n (%)	7 (23%)	4 (16%)	0.54

BMI Body Mass Index; CCI Charlson Comorbidity Index; MMSE Mini-Mental State Examination; OWD Occiput-to-Wall Distance; VF vertebral fracture; SD standard deviation

To test factors associated with FP, simple linear regressions were first calculated with the OWD as dependent variable, and patient characteristics, such as extent of TK, VFs and frailty, as independent variables. Three multiple linear regression models were then calculated: (A) a model based on the literature [1, 4, 5] (the independent variables included were the Cobb angle, presence of VFs, and grip strength corrected for body height); (B) a model with geriatric phenomena (CCI, number of prescriptions, Fried's frailty score, Pluijm's fall risk assessment score, and MMSE); and (C) a model based on the simple regression analyses (independent variables were included when p < 0.30).

## Results

Fifty-six patients (aged 80 ± 5.2 years; 70% female) were included in the present study. Twenty-five patients (45%) were classified as having FP (OWD  $\geq$ 5.0 cm). The characteristics of patients with normal posture and FP are presented in Table 3.1. Patients with FP had a significantly higher Cobb angle than patients with normal posture. Consequently, significantly more patients in the FP-group were classified as having an increased TK (Cobb angle  $\geq$ 50°) compared with patients with normal posture (80% vs. 29%; p < 0.01). There were no differences between groups in the presence of VFs, an indicator for severe osteoporosis, or in other characteristics.

## Effects of flexed posture on gait


Walking speed did not differ significantly between the two patient groups (p = 0.26). Variability (CV) of stride time was significantly higher (p = 0.03) and the scaling exponent  $\alpha$  was significantly lower (p < 0.01) in patients with FP compared with those with normal posture, which implies less correlated stride time intervals (Table 3.2). In addition, patients with FP had a significantly less symmetrical gait pattern than patients with normal posture, i.e. there was greater variability of the relative phase between foot contacts (p = 0.02). There were no statistically significant differences in other gait parameters between the two groups.

Variables quantifying trunk acceleration patterns for both groups are presented in Fig. 3.1. Patients with FP had significantly lower ML RMS (z = -2.18; p = 0.03) and AP RMS (z = -3.12; p < 0.01), and significantly higher AP SEn values (z = 1.99; p < 0.05) compared with patients with normal posture. ML SEn values and ML and AP Hratio and  $\lambda_{max}$  did not differ significantly between groups.

**Table 3.2.** Group differences of patients with normal (NP) and flexed posture (FP) for gait variables. Values are presented as mean (SD). Statistical differences between patient groups are indicated by *z*- and *p*-values (based on Mann-Whitney U tests).

Gait parameters	NP (n=31)	FP (n=25)	z-value (p-value)
Walking speed (m/s)	0.90 (0.22)	0.81 (0.29)	-1.13 (0.26)
Mean stride time (s)	1.16 (0.15)	1.17 (0.12)	0.95 (0.34)
CV of stride time (%)	3.56 (1.68)	4.27 (1.53)	2.22 (0.03)
Stride frequency (strides/s)	0.88 (0.10)	0.85 (0.09)	-1.39 (0.16)
SD of relative phase (°)	4.11 (1.22)	4.98 (1.38)	2.37 (0.02)
α stride times	0.81 (0.16)	0.67 (0.19)	-2.65 (0.01)

CV Coefficient of Variation; SD Standard Deviation



**Fig. 3.1.** Effects of normal (NP; n = 31) and flexed posture (FP; n = 25) on medio-lateral (ML) and anterior-posterior (AP) trunk movement pattern parameters, namely Root Mean Square (RMS), Harmonic Ratio (Hratio), Sample Entropy (SEn), and maximal Lyapunov exponent ( $\lambda_{max}$ ), presented as boxplots. A significant difference between the patient groups is marked as  $\star$  (p < 0.05, based on Mann-Whitney *U* tests).

					Mu	Multiple linear regression analyses	ession analys	es	
	Simple linear regression analyses	egression and	alyses	Model A		Model B	B	Model C	0
Patient characteristics	B (SE)	<i>p</i> -value	R <sup>2</sup>	B (SE)	<i>p</i> -value	B (SE)	<i>p</i> -value	B (SE)	<i>p</i> -value
Age (years)	0.03 (0.12)	0.82	<0.01						
Female	-1.76 (1.27)	0.17	0.04					-0.54 (1.74)	0.76
BMI (kg/m <sup>2</sup> )	-0.03 (0.12)	0.83	<0.01						
Osteoporosis-related parameters	ters								
Presence of VFs	0.55 (1.21)	0.65	<0.01	-0.83 (1.09)	0.45				
Cobb angle T2-T12 (°)	0.17 (0.04)	<0.01	0.27	0.18 (0.04)	<0.01			0.17 (0.04)	<0.01
Grip strength (kg) <sup>a</sup>	0.04 (0.04)	0.28	0.02	0.07 (0.03)	0.04			0.07 (0.05)	0.20
co-morpiaities									
CCI score	0.04 (0.46)	0.93	<0.01			0.23 (0.45)	0.64		
Number of prescriptions	-0.02 (0.15)	06.0	<0.01			-0.19 (0.18)	0.30		
Fried's frailty score	0.69 (0.50)	0.17	0.04			1.26 (0.59)	0.04	0.50 (0.47)	0:30
MMSE score	0.11 (0.14)	0.42	0.01			0.15 (0.15)	0.30		
Pluijm score	-0.08 (0.12)	0.47	0.01			-0.16 (0.13)	0.30		
R <sup>2</sup> :				0.34		0.10		0.35	
B regression coefficient; BMI Body Mass Index; CCI Charlson Comorbidity Index; MMSE Mini-Mental State Examination; R <sup>2</sup> Coefficient of Determination;	3ody Mass Index;	ccl Charlson	Comorbidi	ty Index; MMSE	Mini-Mental	State Examinati	on; <b>R</b> <sup>2</sup> Coeffi	icient of Determi	nation;
SD Standard deviation; SE Standard Error; VF Vertebral Fracture.	ndard Error; <b>VF</b> Ve	ertebral Fract	ure.						

<sup>a</sup> Grip strength was corrected for body height

Part I: Osteoprosis-related factors

Table 3.3. Results of simple and multiple linear regression analyses, examining the relationship between the Occiput-to-Wall Distance and (A) osteoporosis-related parameters, (B) comorbidities present in the population, and (C) a model based on the results of the simple linear

66


#### Factors associated with flexed posture

The results of simple linear regression analyses to examine the relationship between each variable independently with OWD are shown in the first column of Table 3.3. Only the degree of TK was significantly associated with OWD (p < 0.01). Fig. 3.2 illustrates the relationship between the Cobb angle and OWD. The other well-known risk factors for FP, namely VFs and grip strength, were not associated with FP in this cohort. The other characteristics examined in this study were not significantly associated with OWD in the simple linear regression analyses.

Multiple linear regression analyses were also performed (see the second column of Table 3.3). In model A, which was a model based on the literature [1, 4, 5], the relationship between osteoporosis-related parameters and OWD was examined: the Cobb angle and grip strength (corrected for body height) were both associated with OWD ( $R^2 = 34\%$ ). In model B, which included independent variables related to geriatric phenomena, frailty was the only variable significantly associated with the OWD ( $R^2 = 10\%$ ). Finally, in model C, which was based on the results of the simple linear regression analyses, Cobb angle was significantly associated with OWD, whereas the other included variables were not ( $R^2 = 35\%$ ).

## Discussion

The objective of the present study was to examine postural control during walking in elderly patients with FP, and to investigate factors that may influence this. The results of this study show that FP in elderly patients was associated with impairments in postural control during walking. Although walking speed did not differ significantly between the two patient groups, patients with FP showed a more variable and less structured gait pattern (higher CV of stride time), a less consistent gait pattern (greater variability of the relative phase), and less correlated stride times (lower  $\alpha$ ) than patients with normal posture. In addition, FP-patients exhibited a significantly decreased magnitude of trunk accelerations (lower values for ML RMS and AP RMS) compared with patients with normal posture. Trunk acceleration patterns were also significantly more irregular (higher AP SEn values), borderline significantly less smooth (lower Hratio values), and more unstable (higher AP  $\lambda_{max}$ ) in patients with FP compared with patients with normal posture.



**Fig. 3.2.** Relation between the Cobb angle T2-T12, the presence of vertebral fractures and the Occiput-to-Wall Distance. The black squares ( $\blacksquare$ ) represent patients without VFs and the white triangles ( $\Delta$ ) patients with prevalent VFs. The dotted line is the fit-line of the model based on the linear regression analysis.

FP, as defined by the OWD, was also associated with an increased TK. This forward curvature of the trunk shifts the body's center of mass forward from the center of rotation (the spine), causing an increased forward bending moment [2, 25]. As postural control can be defined as the capacity to maintain the center of mass within the support base [26], it can be argued that patients with FP need adaptations to maintain balance. Therefore, an increased posterior counterbalancing force is required from dorsal musculature and ligaments. This can be obtained by flexing the knees and contracting the dorsal musculature to tilt hips [27], which brings the head and shoulders back up, but also tightens the hamstrings [2]. In addition, trunk movements and rotation, and arm sway may be reduced due to the changed trunk alignment and altered functioning of muscles and ligaments. Since dynamics of head, arms, and trunk are important mechanisms to maintain balance during walking [28], it is likely that the ability to react on (small) perturbations during walking is diminished in FP-patients. This was expressed in our results by a more robust effect on variability of the stride-related parameters than effect on the trunk acceleration patterns.

Factors present in the elderly patient population that were potentially associated with FP were also investigated. According to the results of multiple linear regression analyses, FP, expressed by the OWD, was associated with an increased TK and increased grip strength, but was not associated with the presence of VFs. Other common phenomena in the geriatric population, such as frailty, cognitive impairments, increased

Chapter 3

fall risk, number of medications, and the presence of comorbid diseases, were weakly associated with the OWD ( $R^2 = 10\%$ ).

The hypothesis that the presence of VFs worsens the degree of TK and thus FP, was not confirmed in this study. Other known causes for an increased TK, and consequently FP, are degenerative disc diseases, or spinal extensor muscle weakness [1, 4, 5]; however, only grip strength was included in the present study. Grip strength is not a direct measure of spinal extensor muscle strength, but it was associated with the OWD in model A of the multiple linear regression analyses. Grip strength was higher in patients with FP compared with patients with normal posture; this may be explained by the increased posterior counterbalancing forces needed in FP-patients to maintain balance. However, this finding in the multiple regression analyses might be a coincidence since grip strength was not associated with OWD in the single linear regressions or in model C of the multiple linear regression.

The results of several outcome measures in the present study were borderline significant and the goodness-of-fit of the regression analyses was low-to-moderate (10–35%), which was probably caused by the large variation in patient data (see Figs. 3.1 and 3.2 presenting, respectively, boxplots of trunk movement pattern parameters, and the relationship between FP and TK). However, the heterogeneity in the present cohort is illustrative for the older population visiting a geriatric outpatient clinic. These patients are typically characterized by a combination of physiological, psychological and social problems, and comorbidities are often present [29]. In the present cohort, geriatric phenomena like frailty, cognitive impairment and polypharmacy were also present, and were equally distributed in patients with normal posture and FP; therefore, it can be concluded that these factors were not directly associated with the presence of FP. The patients of both groups were elderly with health issues: the comorbidities present in the included population might have impaired postural control during walking in both groups.

In summary, FP is characterized by an increased TK, which brings the body's center of mass forward and requires correcting responses of the body, such as counterbalancing force from posterior musculature to tilt the hips and flex the knees. These correcting responses may reduce the ability to respond on perturbations, which is reflected by the impaired postural control during walking in this study. Patients with FP demonstrated a more variable and less structured gait pattern, and a more irregular trunk acceleration pattern than patients with a normal posture. This may imply that patients with FP are at increased risk of falling compared with patients with normal posture, as impairments in postural control during walking are a major risk factor for falling.

## References

**1.** Balzini L, Vannucchi L, Benvenuti F, *et al.* (2003) Clinical characteristics of flexed posture in elderly women. J Am Geriatr Soc 51:1419–26.

**2.** Yuan HA, Brown CW, Phillips FM (2004) Osteoporotic spinal deformity - a biomechanical rationale for the clinical consequences and treatment of vertebral body compression fractures. J Spinal Disord Tech 17:236–42.

**3.** Cortet B, Roches E, Logier R, *et al.* (2002) Evaluation of spinal curvatures after a recent osteoporotic vertebral fracture. Jt Bone Spine 69:201–8.

**4.** Katzman WB, Wanek L, Shepherd JA, Sellmeyer DE (2010) Age-related hyperkyphosis: its causes, consequences, and management. J Orthop Sports Phys Ther 40:352–60.

**5.** Sinaki M, Itoi E, Rogers JW, *et al.* (1996) Correlation of back extensor strength with thoracic kyphosis and lumbar lordosis in estrogen-deficient women. Am J Phys Med Rehabil 75:370–74.

**6.** Huang C, Ross PD, Wasnich RD (1996) Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 156:2469–75.

**7.** De Groot MH, van der Jagt-Willems HC, van Campen JPCM, *et al.* (2012) Testing postural control among various osteoporotic patient groups: a literature review. Geriatr Gerontol Int 12:573–85.

**8.** Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ (2007) Will my patient fall? JAMA 297:77–86.

**9.** Lamoth CJC, van Deudekom FJ, van Campen JPC, *et al.* (2011) Gait stability and variability measures show effects of impaired cognition and dual tasking in frail people. J Neuroeng Rehabil 8:2.

**10.** Hamacher D, Singh NB, van Dieën JH, *et al.* (2011) Kinematic measures for assessing gait stability in elderly individuals: a systematic review. J R Soc Interface 8:1682–98.

**11.** Lockhart TE, Liu J (2008) Differentiating fallprone and healthy adults using local dynamic stability. Ergonomics 51:1860–72.

**12.** Hausdorff JM, Purdon PL, Peng C-K, *et al.* (1996) Fractal dynamics of human gait: stability of long-range correlations in stride interval fluctuations. J Appl Physiol 80:1446–57.

**13.** Pincus SM (1991) Approximate entropy as a measure of system complexity. Proc Natl Acad Sci U S A 88:2297–301.

**14.** Roerdink M, Lamoth CJC, Kwakkel G, *et al.* (2007) Gait coordination after stroke: Benefits of acoustically paced treadmill walking. Phys Ther 87:1009–22.

**15.** Lamoth CJC, Beek PJ, Meijer OG (2002) Pelvisthorax coordination in the transverse plane during gait. Gait Posture 16:101–14.

**16.** Stergiou N, Buzzi UH, Kurz MJ, Heidel J (2004) Nonlinear tools in human movement. In: Stergiou N (ed) Innovative Analyses in Human Movement. Human Kinetics Publishers, Champaign, IL, USA, pp. 63–90. **17.** Lake DE, Richman JS, Griffin MP, Moorman JR (2002) Sample entropy analysis of neonatal heart rate variability. Am J Physiol Regul Integr Comp Physiol 283:R789–97.

**18.** Sinaki M, Brey RH, Hughes CA, *et al.* (2005) Balance disorder and increased risk of falls in osteoporosis and kyphosis: significance of kyphotic posture and muscle strength. Osteoporos Int 16:1004–10.

**19.** Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–48.

**20.** Desrosiers J, Bravo G, Hébert R, Dutil E (1995) Normative data for grip strength of elderly men and women. Am J Occup Ther 49:637–44.

**21.** Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373–83.

**22.** Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–98. **23.** Pluijm SMF, Smit JH, Tromp EAM, *et al.* (2006) A risk profile for identifying community-dwelling elderly with a high risk of recurrent falling: Results of a 3-year prospective study. Osteoporos Int 17:417–25.

**24.** Fried LP, Tangen CM, Walston J, *et al.* (2001) Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–56.

**25.** Lyles KW, Gold DT, Shipp KM, *et al.* (1993) Association of osteoporotic vertebral compression fractures with impaired functional status. Am J Med 94:595–601.

**26.** Alexander NB (1994) Postural control in older adults. J Am Geriatr Soc 42:93–108.

**27.** Saha D, Gard SA, Fatone S (2008) The effect of trunk flexion on able-bodied gait. Gait Posture 27:653–60.

**28.** Winter DA (1995) Human balance and posture control during standing and walking. Gait Posture 3:193–214.

**29.** Ellis G, Langhorne P (2004) Comprehensive geriatric assessment for older hospital patients. Br Med Bull 71:45–59.

# **CHAPTER 4**

Associations between vertebral fractures, increased thoracic kyphosis, a flexed posture and falls in older adults: a prospective cohort study

> Hanna C. van der Jagt-Willems Maartje H. de Groot Jos P. C. M. van Campen Claudine J. C. Lamoth Willem F. Lems

BMC Geriatrics 2015; 15: 34

# Abstract

**Background** Vertebral fractures, an increased thoracic kyphosis and a flexed posture are associated with falls. However, this was not confirmed in prospective studies. We performed a prospective cohort study to investigate the association between vertebral fractures, increased thoracic kyphosis and/or flexed posture with future fall incidents in older adults within the next year.

**Methods** Patients were recruited at a geriatric outpatient clinic. Vertebral fractures were evaluated on lateral radiographs of the spine with the semi-quantitative method of Genant; the degree of thoracic kyphosis was assessed with the Cobb angle. The occiput-to-wall distance was used to determine a flexed posture. Self-reported falls were prospectively registered by monthly phone contact for the duration of 12 months.

**Results** Fifty-one older adults were included; mean age was 79 years (SD = 4.8). An increased thoracic kyphosis was independently associated with future falls (OR 2.13; 95% CI 1.10-4.51). Prevalent vertebral fractures had a trend towards significancy (OR 3.67; 95% CI 0.85-15.9). A flexed posture was not significantly associated with future falls.

**Conclusion** Older adults with an increased thoracic kyphosis are more likely to fall within the next year. We suggest clinical attention for underlying causes. Because patients with increased thoracic curvature of the spine might have underlying osteoporotic vertebral fractures, clinicians should be aware of the risk of a new fracture.

### Background

Among older adults the prevalence of falls is high: at least 30-40% of patients aged over 65 experience one or more fall accidents annually [1]. Falls in the older population are generally caused by a combination of risk factors, such as balance and gait disorders, poor vision, polypharmacy and environmental factors, and could lead to serious injuries such as fractures [2]. In addition, diminished bone quality due to osteoporosis increases the risk of fall-related fractures, especially in women [3, 4]. However, typical osteoporotic fractures of the vertebrae are commonly not the result of a fall incident, but occur usually during normal activities of daily living, such as climbing stairs, lifting groceries, or bending forward [5]. The prevalence of vertebral fractures increases with age, and is up to 50% among geriatric outpatients [6]. Vertebral fractures could cause pain and may lead to postural changes, restrictive respiratory disease, poor physical condition, and loss of quality of life [7], and are independently associated with increased mortality [8, 9]. Furthermore, it was recently found that a prevalent vertebral fracture on a chest computed tomography (CT) was associated with a threefold increased risk of a future hip fracture [10].

Over time, thoracic vertebral fractures could increase the kyphotic curvature of the thoracic spine [11], and may therefore cause a flexed posture [12]. A flexed posture is characterized by an increased thoracic kyphosis, protrusion of the head, and in more severe cases also hip and knee flexion. A flexed posture is the more extreme expression of an increased thoracic kyphosis, when the compensatory mechanisms to correct the kyphosis fail [12].

Previous studies showed that the presence of both vertebral fractures and an increased thoracic kyphosis are related with increased fall risk [13–15]. Recently, we showed that vertebral fractures, increased thoracic kyphosis and a flexed posture are associated with an impaired postural control [16, 17]. Patients that have one or more of these entities present might fall more often, since impairments in balance and gait are the primary cause of falls [18]. Until now, this association has not been prospectively investigated. Therefore, we performed a prospective cohort study to investigate the association between prevalent vertebral fractures, increased thoracic kyphosis and a flexed posture with future fall incidents in older adults.

### Methods

#### Patient characteristics

The study population comprised visitors of the geriatric outpatient clinic of the Slotervaart Hospital in Amsterdam between October 2010 and April 2012. They were referred to the clinic for various reasons, including memory complaints, mobility problems, or reducing polypharmacy. Eligible patients should be 70 years or older; should be able to walk safely for 3 minutes without using any assistive device (e.g. walking stick or wheeler); and should be able to understand and speak Dutch or English. Patients were excluded if they had any mobility problems due to (lateral) neurological or orthopedic disorders with function limitations of one or both legs; or if they were unable to understand the instructions of the researcher due to severe cognitive or hearing impairments.

All patients received a comprehensive geriatric assessment [19], being standard procedure at the geriatric outpatient clinic. Depending on the conclusions of the geriatrician, work up treatment was started. If the patient was referred to this clinic for fall-related problems, or reported falls in the last year, the Dutch national guidelines for the prevention of falls were followed [20]. The present study was approved by the Medical Ethical Committee of the Slotervaart Hospital and Reade. All patients (or their legal representatives) gave their informed consent.

### Data collection

Gender, age, Body Mass Index (BMI), number of prescriptions, hip replacement in history, and self-reported falls in the last year were recorded. The presence of comorbid diseases was scored using the Charlson Comorbidity Index (CCI) [21]. Cognitive functioning was examined by the Mini Mental State Examination (MMSE) [22].

The prevalence of vertebral fractures was assessed on standing upright lateral X-rays of the thoracic and lumbar vertebral spine. Vertebral fractures were scored by the semiquantitative technique of Genant [23, 24]. All radiographs were scored by two observers (MG and HJ). Their conclusions were compared, and if they differed, final consensus was reached by discussion.


The kyphosis of the thoracic vertebral column was determined by the Cobb angle, the angle between the superior endplate of the second, and the inferior endplate of the twelfth thoracic vertebra, as measured on the same lateral X-ray of the thoracic spine as was used for the judgment of vertebral fractures. In the present study, hyperkyphosis was defined as a Cobb angle of  $\geq$ 50° [25], a Cobb angle <50° was considered normal. Two

Chapter 4

observers (MG and HJ) measured the Cobb angle twice, and the mean value of the four measurements was used.

The severity of flexed posture was evaluated by measuring the occiput-to-wall distance (OWD), see Fig. 4.1. While subjects stood with their head in a natural position, their heels and back touching the wall and their knees as extended as possible, the distance between their occiput and the wall was measured [12]. A flexed posture was defined as an OWD >5.0 cm.

Fall incidents were prospectively registered for six months using a monthly calendar. A fall was defined as "an unexpected event where a person comes to rest on the ground from an upper level or the same level" [26]. During follow-up, patients (or their caregivers) were contacted by phone every month to report any fall incidents and/or injuries. When patients had a MMSE-score <24 points, caregivers who lived with the patient were asked to fill in the falls-and-fracture calendar. Since very few fall incidents were reported in the six-month follow-up period, we extended the falls-and fracture calendar with another six months. Main outcome of the study was the first fall during follow-up.



**Fig. 4.1.** Various postures among geriatric patients: (A) Normal posture; (B) Hyperkyphosis, defined as a Cobb angle  $\geq$ 50 ° between T2 and T12 as measured on the X-ray of the vertebral column; (C) Flexed posture, defined as an occiput-to-wall distance >5.0 cm.

#### Statistical analysis

The associations among vertebral fractures, hyperkyphosis (Cobb angle  $\geq$ 50°) and flexed posture (OWD >5.0 cm) were estimated using Chi-square tests. Then, to test which variables were associated with prospective falls, first univariate binary logistic analyses were performed for all patient characteristics. Secondly, a multivariate binary logistic regression analysis was computed (method: backward conditional), including all characteristics with P values < .20 in univariate analyses. Odds Ratio's (OR) with 95% Confidence Intervals (CI) and P values were calculated. In order to better compare the ORs of the variables, we standardized all continuous variables to unit variance, i.e., means were set to zero, and standard deviations to one (z-transformation). In addition, to test for multicollineartiy, we calculated the variance inflation factor (VIF) for the multivariate model. Since all VIF-values were around 1, we can assume that multicollinearity was not present in the model. For all statistical analyses, the level of significance was set on P < .05. SPSS Statistics version 21 was used.

### Results

During the inclusion period, 139 possibly eligible patients visited the geriatric, whereof 60 persons gave their consent to participate in the present study. In nine cases, the fallsand-fracture calendar was not completed, due to lost to follow-up within the first month. Finally, 51 patients were included in the present study. The mean age of the included patients was 79 years, and 77% were female (Table 4.1). Seventeen patients (33%) reported  $\geq$ 2 falls in the year previous to the baseline measurements. The mean follow-up for falls registration was 10.6 months. Thirty-eight patients (75%) had follow-up of twelve months with phone contact every month; the other thirteen patients had a mean follow-up of 6.2 months. After the first six months, eight patients refused further follow-up. Other reasons for lost to follow-up were: moving to a nursing home (n = 3); and being tired of registering high fall incidence (n = 2). Thirteen patients (25%) had at least one fall during follow-up; of these, eight patients were recurrent fallers ( $\geq$ 2 falls). Four patients had serious injury after the fall and had to visit a doctor, of whom one had a new non-vertebral fracture.

Population Characteristics	
Patient characteristics	
Age (years), mean (SD)	79.3 (4.8)
Female <i>, n</i> (%)	39 (77%)
BMI (kg/m²), mean (SD)	27.4 (4.0)
CCI score, mean (SD)	1.4 (1.3)
Number of prescriptions, mean (SD)	5.8 (3.9)
MMSE score, median (range)	24 (13-30)
Hip replacement in history, <i>n</i> (%)	7 (14%)
Osteoporosis-related factors	
Presence of vertebral fractures, n (%)	20 (39%)
Thoracic kyphosis, Cobb angle (°), mean (SD)	51.2 (14.5)
OWD (cm), median (range)	4.0 (0-16)
Falls during follow-up	
- no falls, <i>n</i> (%)	38 (74%)
- 1 fall, n (%)	5 (10%)
- $\geq 2$ falls during follow-up (range 2-9), n (%)	8 (16%)
CCI = Charlson Comorbidity Index: MMSE = Mini-Mental State Exam	ination:

**Table 4.1**. Population characteristics (*n* = 51)

**CCI** = Charlson Comorbidity Index; **MMSE** = Mini-Mental State Examination; **OWD** = Occiput-to-Wall Distance

### Relation between vertebral fractures, hyperkyphosis and flexed posture


Fig. 4.2 shows the distribution of vertebral fractures, hyperkyphosis (Cobb angle  $\geq$ 50°), and flexed posture (OWD >5.0 cm) in the study population. Twelve patients (24%) had none of the three entities. Nine patients (18%) were diagnosed with all three entities. The remaining thirty patients (59%) had one, or a combination of the entities.

Of the twenty patients with one or more vertebral fractures, thirteen (65%) had also a hyperkyphosis ( $\chi^2 = 1.36$ ; P = .24). Hyperkyphosis was significantly associated with the presence of a flexed posture ( $\chi^2 = 11.32$ ; P < .01). The association between flexed posture and vertebral fractures was not significant ( $\chi^2 = 0.47$ ; P = .83).

# Association of vertebral fractures, thoracic kyphosis and occiput-to-wall distance with future falls

In the univariate analyses (see Table 4.2), a significant association was found between the Cobb angle and future falls (OR 2.07; 95% CI 1.03-4.16). The presence of one or more vertebral fractures had a trend toward a significant association with future falls (OR 3.47; 95% CI 0.94- 12.8). The OWD was not significantly related with prospective fall incidents (OR 1.54; 95% CI 0.82-2.91).

In the multivariate analysis (Table 4.2), including all characteristics with P < .20 in the univariate analysis, only the Cobb angle was independently associated with falls during follow-up (OR 2.13; 95% CI: 1.10- 4.51). This indicates that for every standard deviation increase in the Cobb angle, the probability of a future fall doubles. Furthermore, the presence of vertebral fractures, and the number of prescriptions showed a trend towards significance for future falls in our study population.



**Fig. 4.2.** Illustration of the distribution of patients in the study according to the presence of vertebral fractures, hyperkyphosis and flexed posture in relation to future falls. The large white rectangle represents all patients in the study (n = 51), whereof in the blue rectangle patients with vertebral fractures (n = 20; 39%); in the grey rectangle patients with a hyperkyphosis (Cobb angle  $\geq 50^\circ$ ; n = 28; 55%); and in the pink rectangle patients with a flexed posture (OWD >5.0 cm; n = 22; 44%). Patients with combinations of these entities are represented by the overlapping areas of the colored rectangles, with n noted in each box. Twelve patients (24%) had none of the entities present (white rectangle).

\* 9 patients had all entities present.

\*\* The red oval represents all fallers (*n* = 13); all fallers had at least one of the three entities present. In nine fallers all entities were present.

	Non-fallers	Fallers	Univariate analyses	lyses	Multivariate analysis <sup>a</sup>	alysis <sup>a</sup>
Patient characteristics	(n=38)	(n=13)	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Age (years), mean (SD)	79.7 (4.7)	78.0 (5.0)	0.70 (0.37-1.32)	0.27		
Female, n (%)	28 (74%)	11 (85%)	1.96 (0.37-10.4)	0.43		
BMI (kg/m²), mean (SD)	27.3 (3.9)	27.7 (4.3)	1.12 (0.58-2.16)	0.73		
CCI (score), median (SD)	1 (0-4)	1 (0-5)	1.26 (0.68-2.34)	0.47		
Number of prescriptions, median (range)	4.5 (0-15)	7 (0-13)	1.51 (0.81-2.80)	0.19	1.86 (0.91-3.79)	0.09
MMSE (score), median (range)	24 (15-30)	23 (13-28)	0.82 (0.44-1.52)	0.53		
Hip replacement in history, n (%)	5 (13%)	2 (15%)	1.20 (0.20-1.09)	0.84		
Vertebral fractures, n (%)	12 (32%)	8 (62%)	3.47 (0.94-12.8)	0.06	3.67 (0.85-15.9)	0.08
Cobb angle (°), mean (SD)	49 (13)	59 (16)	2.07 (1.03-4.16)	0.04	2.13 (1.10-4.51)	0.04
OWD (cm), mean (SD)	4.2 (4.5)	6.2 (4.1)	1.54 (0.82-2.91)	0.18		
= C C	idity Index; <b>CI</b> = O	Confidence Interva	l; MMSE = Mini-Menta	al State Examin	Charlson Comorbidity Index; CI = Confidence Interval; MMSE = Mini-Mental State Examination; OR = Odds Ratio;	

Table 4.2. Univariate and multivariate associations of the patient characteristics with future falls. All continuous variables were first z-

<sup>a</sup> Adjusted for vertebral fractures, the Cobb angle, the OWD, and the number of prescriptions. After step 1, the OWD was excluded.

Chapter 4

### Discussion

We showed that in this population an increased thoracic kyphosis, as measured by the Cobb angle, was independently associated with future fall incidents (standardized OR: 2.13; 95% CI: 1.10-4.51). We did not find a significant association between a flexed posture, as indicated by the OWD, and falls. In the multivariate analysis, the presence of one or more vertebral fractures and future falls had a trend towards a significant association (P = .08).

It is remarkable that the presence of an increased thoracic kyphosis had such a clear association with future falls, even in this small study sample. This is in coincidence with previous retrospective studies [13–15]. The Rancho-Bernardo study (n = 1883) [14, 15], for instance, showed that men with hyperkyphotic posture had an independent age-adjusted association with self-reported falls in the past year. In women, this association appeared to be age-dependent. In addition, a smaller study (n = 92) showed that kyphosis of the total spine was independently associated with self-reported falls [13].

An increased thoracic kyphosis can originate from many causes, such as vertebral fractures, degenerative disc diseases, muscle weakness, and genetic disorders such as Scheuermanns disease [12, 27]. The prevalence of vertebral fractures in patients with hyperkyphosis (39%) in our study was equal compared to other studies [28–30]. In these studies also no relation was found between vertebral fractures and hyperkyphosis [28–30]. However, the consequences of hyperkyphosis in the long term may be severe, even without vertebral fractures. One study showed that older women with greater degrees of kyphosis are at increased risk of non-spinal fractures, independent of bone mineral density and vertebral fractures [11]. In addition, patients with more severe kyphosis experienced more decline in functioning occurs during a long-term follow-up [31]. Therefore, clinicians should be alert of the presence of vertebral fractures in patients with hyperkyphosis and provide adequate treatment to prevent subsequent fractures. In addition, several studies have shown promising improvements in kyphosis with, amongst others, 6-month spinal bracing intervention [32], 12-week yoga intervention [33], and 12 weeks of multidimensional group exercise [34].

In the present study, fall incidence was lower than expected, namely 26% where at least 30% was expected based on the literature [2]. This low fall rate was remarkable, because our participants were relatively old (mean age: 79 years) and had many fall risk factors such as a history of falls in the past year, substantial co–morbidity. The low fall incidence in our cohort might be the result of a successful visit to our geriatric outpatient clinic, where fall risk was analyzed, and various advices were given to minimize the

Chapter 4

chance of a fall accident according to the Dutch guidelines [20]. Otherwise, although we gave a calendar and called patients every month, there might be underreporting: it is known that falls, even in healthy older adults, are easily forgotten [35].

Some limitations of this study should be addressed. Because of the small sample size and the low fall incidence during follow-up, we might have overestimated the independent association between the Cobb angle and future falls. Our standardized OR of 2.13 is larger than reported OR's in studies with more participants [14, 15]. Moreover, the association between vertebral fractures and prospective falls was quite strong, but not significant (P = .08). This might be a type II error, namely the failure to reject the false null hypothesis, caused by the low sample size, and therefore the large confidence interval. The relatively high OR of 3.67 shows the importance of vertebral fractures in relation to future falls. Future larger studies between older adults should investigate the association between vertebral fractures and falls, since this was not investigated before.

However, despite these limitations, we can conclude that there is a clear independent association between an increased thoracic curvature of the spine and future falls. An explanation might be that due to the forward curvature of the upper body, the center of mass shifts forward and requires correcting responses of the body. These correcting responses may reduce the patient's ability to respond on perturbations, which is reflected by an impaired postural control during walking as found in previous studies [16, 17].

# Conclusions

Since older adults with a hyperkyphosis may thus have an increased fall risk, as we show in this study, we suggest clinical attention for these patients to search for underlying causes. In almost 40% of the patients with hyperkyphosis in our cohort, one or more vertebral fractures were present. For these patients, we therefore should not forget to prescribe anti-osteoporosis medication. Future research should further evaluate whether hyperkyphosis is an important risk factor for falls and which therapies may prevent, improve or delay its progression.

## References

**1.** Rubenstein LZ (2006) Falls in older people: epidemiology, risk factors and strategies for prevention. Age Ageing 35:ii37–41.

**2.** American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons Panel on Falls Prevention (2001) Guideline for the prevention of falls in older persons. J Am Geriatr Soc 49:664–72.

**3.** Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–8.

**4.** Lin MR, Hwang HF, Lin PS, Chen CY (2014) Relations of osteoporosis and follow-up duration to recurrent falls in older men and women. Osteoporos Int 25:863–71.

**5.** Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221–7.

**6.** Van der Jagt-Willems HC, van Hengel M, Vis M, *et al.* (2012) Why do geriatric outpatients have so many moderate and severe vertebral fractures? Exploring prevalence and risk factors. Age Ageing 41:200–6.

**7.** Ross PD (1997) Clinical consequences of vertebral fractures. Am J Med 103:30S–42S; discussion 42S–43S.

**8.** Van der Jagt-Willems HC, Vis M, Tulner CR, *et al.* (2013) Mortality and incident vertebral fractures after 3 years of follow-up among geriatric patients. Osteoporos Int 24:1713–9.

**9.** Cummings SR, Melton ⊔ (2002) Osteoporosis I: Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–7.

**10.** Buckens CF, de Jong PA, Mali WP, *et al.* (2014) Prevalent vertebral fractures on chest CT: higher risk for future hip fracture. J Bone Miner Res 29:392–8.

**11.** Kado DM, Miller-Martinez D, Lui L-Y, *et al.* (2014) Hyperkyphosis, kyphosis progression, and risk of non-spine fractures in older community dwelling women: the Study of Osteoporotic Fractures (SOF). J Bone Miner Res 29:1–22.

**12.** Balzini L, Vannucchi L, Benvenuti F, *et al.* (2003) Clinical characteristics of flexed posture in elderly women. J Am Geriatr Soc 51:1419–26.

**13.** Kasukawa Y, Miyakoshi N, Hongo M, *et al.* (2010) Relationships between falls, spinal curvature, spinal mobility and back extensor strength in elderly people. J Bone Miner Metab 28:82–7.

**14.** Huang M-H, Barrett-Connor E, Greendale GA, Kado DM (2006) Hyperkyphotic posture and risk of future osteoporotic fractures: the Rancho Bernardo Study. J Bone Miner Res 21:419–23.

**15.** Kado DM, Huang M-H, Nguyen CB, *et al.* (2007) Hyperkyphotic posture and risk of injurious falls in older persons: the Rancho Bernardo Study. J Gerontol A Biol Sci Med Sci 62:652–7.

**16.** De Groot MH, van der Jagt-Willems HC, van Campen JPCM, *et al.* (2012) Testing postural control among various osteoporotic patient groups: A literature review. Geriatr Gerontol Int 12:573–85.

**17.** De Groot MH, van der Jagt-Willems HC, van Campen JPCM, *et al.* (2014) A flexed posture in elderly patients is associated with impairments in postural control during walking. Gait Posture 39:767–72.

**18.** Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ (2007) Will my patient fall? JAMA 297:77–86.

**19.** Ellis G, Langhorne P (2004) Comprehensive geriatric assessment for older hospital patients. Br Med Bull 71:45–59.

**20.** CBO (2004) Guideline for the prevention of fall incidents in elderly. Van Zuiden, Alphen aan den Rijn, the Netherlands

**21.** Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–83.

**22.** Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–98.

**23.** Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–48.

**24.** Van der Jagt-Willems HC, van Munster BC, Leeflang M, *et al.* (2014) Diagnosis of vertebral fractures on lateral chest X-ray: intraobserver agreement of semi-quantitative vertebral fracture assessment. Eur J Radiol 83:2177–80.

**25.** Lynn SG, Sinaki M, Westerlind KC (1997) Balance characteristics of persons with osteoporosis. Arch Phys Med Rehabil 78:273–7.

**26.** WHO (1977) Manual of the international statistical classification of diseases, injuries, and causes of death. Geneva, Switserland.

**27.** Kado DM, Prenovost K, Crandall C (2007) Narrative review: hyperkyphosis in older persons. Ann Intern Med 147:330–8.

**28.** Schneider DL, Von Mühlen DG, Barrett-Connor E, Sartoris DJ (2004) Kyphosis does not equal vertebral fractures: The Rancho Bernardo Study. J Rheumatol 31:747–52.

**29.** Kado DM, Browner WS, Palmero L, *et al.* (1999) Vertebral fractures and mortality in older women. A prospective study. Arch Intern Med 159:1215–20.

**30.** Ribom EL, Kindmark A, Ljunggren Ö (2015) Hyperkyphosis and back pain are not associated with prevalent vertebral fractures in women with osteoporosis. Physiother Theory Pract 31:182-5.

**31.** Katzman WB, Huang M-H, Lane NE, *et al.* (2013) Kyphosis and decline in physical function over 15 years in older community-dwelling women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 68:976–83.

**32.** Pfeifer M, Begerow B, Minne HW (2004) Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil 83:177–86.

**33.** Greendale GA, McDivit A, Carpenter A, *et al.* (2002) Yoga for women with hyperkyphosis: results of a pilot study. Am J Public Health 92:1611–4.

**34.** Pawlowsky SB, Hamel KA, Katzman WB (2009) Stability of kyphosis, strength, and physical performance gains 1 year after a group exercise program in community-dwelling hyperkyphotic older women. Arch Phys Med Rehabil 90:358–61.

**35.** Cummings SR, Nevitt MC, Kidd S (1988) Forgetting falls. The limited accuracy of recall of falls in the elderly. J Am Geriatr Soc 36:613–6.

# PART II

MEDICATION-USE

# **CHAPTER 5A**

# The effects of fall-risk-increasing drugs on postural control: A literature review

Maartje H. de Groot Jos P. C. M. van Campen Marije A. Moek Linda R. Tulner Jos H. Beijnen Claudine J. C. Lamoth

Drugs & Aging 2013; 30 (11): 901-920

# Abstract

Meta-analyses showed that psychotropic drugs (antidepressants, neuroleptics, benzodiazepines, antiepileptic drugs) and some cardiac drugs (digoxin, type IA antiarrhythmics, diuretics) are associated with increased fall risk. Because balance and gait disorders are the most consistent predictors of future falls, falls due to use of these so-called fall-risk-increasing drugs (FRIDs) might be partly caused by impairments of postural control that these drugs can induce. Therefore, the effects of FRIDs on postural control were examined by reviewing literature. Electronic databases and reference lists of identified papers were searched until June 2013. Only controlled research papers examining the effects of FRIDs on postural control were included. FRIDs were defined according to meta-analyses as antidepressants, neuroleptics, benzodiazepines, antiepileptic drugs, digoxin, type IA antiarrhythmics, and diuretics. Ninety-four papers were included, of which study methods for quantifying postural control, and the effects of FRIDs on postural control were abstracted. Postural control was assessed with a variety of instruments, mainly evaluating aspects of body sway during quiet standing. In general, postural control was impaired, indicated by an increase in parameters quantifying body sway, when using psychotropic FRIDs. The effects were more pronounced when people were of a higher age, used psychotropics at higher daily doses, with longer half-lives, and administered for a longer period. From the present literature review, it can be concluded that psychotropic drugs cause impairments in postural control, which is probably one of the mediating factors for the increased fall risk these FRIDs are associated with. The sedative effects of these drugs on postural control are reversible, as was proven in intervention studies where FRIDs were withdrawn. The findings of the present literature review highlight the importance of using psychotropic drugs in the older population only at the lowest effective dose and for a limited period of time.

### Introduction

Drugs play a fundamental role in treating and preventing disorders that frequently occur in elderly patients. Appropriate use of drugs may reduce mortality and morbidity and improve quality of life. As a result of multi-morbidity, older people are extensive drug users: in a population-based cohort of community-dwelling older people, almost 72% used one or more prescribed drugs, of whom 20% used four or more drugs [1]. In contrast to younger adults, who mainly use medications for a short duration to treat acute illness, older people tend to use drugs on a long-term basis for chronic diseases [2], e.g., analgesics, diuretics, other cardiovascular drugs, sedatives, gastrointestinal drugs, and anti-diabetic drugs. Psychotropic drugs are also extensively used by older people [3]. In Finland, for example, more than one-third of the community-dwelling people aged 75 years or over use at least one psychotropic drug [4]. In nursing homes, this rate is even higher: 66% of the Dutch nursing home inhabitants use psychoactive medication [5]. These frequently used drugs in the older population are potential causes of unfavorable outcomes: meta-analyses showed that medication affecting the central nervous system (CNS; antidepressants, neuroleptics, benzodiazepines, antiepileptic drugs (AEDs)) and some cardiac drugs (digoxin, type IA antiarrhythmics, diuretics) are associated with an increased risk of falling (odds ratios of 1.1-6.0) [6–10]. These so-called fall-risk-increasing drugs (FRIDs) are often used among older people: about one third of the older patients taking prescribed medicine use FRIDs [1].

The relationship between FRIDs and the risk of falling has been established in a number of studies [6–10], while withdrawal of FRIDs has been shown to decrease the incidence of falls in the older population [11–14]. However, less is known about the underlying mechanisms of fall accidents. Because a primary cause of falling is postural instability during daily activities, such as walking [15], falls due to the use of FRIDs might be partly caused by impairments of postural control induced by these drugs [16]. Therefore, the present review discusses studies examining the effects of both psychotropic and cardiac FRIDs on postural control. Furthermore, the effects of withdrawal of FRIDs on postural control are reviewed.

### Search methods

To examine the effects of FRIDs on postural control, the electronic databases of PubMed, Web of Science, CINAHL, EMBASE, and Cochrane were searched until June 2013. The search terms included ("postural control" OR "gait" OR "walking" OR "body sway") AND ("fall risk increasing drug" OR "psychotropic" OR "antidepressant" OR "neuroleptic" OR "benzodiazepine" OR "antiepileptic" OR "cardiac drug" OR "digoxin" OR "type IA antiarrhythmic" OR "diuretic"). Synonyms of these terms, and generic medication names of the various medication groups, were also used in the search. Furthermore, reference lists of relevant included and excluded research papers and literature reviews were reviewed for additional papers.

Studies were included for the present literature review if they (1) examined the effects of FRIDs (selected based on the results of meta-analyses [6–10], namely antidepressants, neuroleptics, benzodiazepines, AEDs, digoxin, type IA antiarrhythmics, diuretics) on postural control, and (2) were placebo controlled, had a control group, or a before-and-after design. Review articles and papers not written in English were excluded. There were no restrictions for inclusion regarding the instruments used for assessing postural control. Because postural control can be assessed with many different test protocols, we provide an overview of the various instruments used in the included studies.

The methodological quality of the included studies was assessed using the Downs and Black instrument [17]. A total of 27 items was evaluated, distributed between five subscales: reporting (10 items), external validity (3 items), internal validity—bias (7 items), internal validity—selection bias (6 items), and power (1 item). A maximum score of 28 points was allowed. Higher scores indicate better methodological quality.

## Testing postural control

Postural control can be defined as the act of maintaining, achieving, or restoring a state of balance during any posture or activity [18]. Adequate postural control is essential for daily activities, and requires the integration of visual, proprioceptive, and vestibular information [19]. The degree to which individuals rely on this information depends on task difficulty, cognitive load [20], motor skill [21, 22], age [23, 24], and pathology [25, 26]. Due to a more general age-related deterioration of sensory and neuromuscular control mechanisms, aging has a detrimental effect on postural control [27].

A large variety of test protocols, both in the motor laboratory and in clinical practice, exist to quantify postural control during different standing and walking tasks. Performance based tests, e.g., the Timed Up and Go (TUG) test [28], the Berg Balance Scale (BBS) [29], or Tinetti's Performance Oriented Mobility Assessment (POMA) [30], are frequently used in a clinical setting. These tests assess postural control indirectly by

Chapter 5A

scoring and/or timing different sets of actions, e.g., standing still, walking, turning, going from sit to stand, or standing on one leg.

More refined analyses of postural control can be obtained by using objective measures derived from computerized instruments, such as a force platform, an electronic walkway, or body-worn sensors like gyroscopes and accelerometers [31]. These instruments record data over time, e.g., force platforms and electronic walkways register ground reaction forces, and accelerometers record accelerations of the body segment it is fixed on. From these data, a wide variety of outcome parameters can be calculated that all quantify different aspects of postural control, for instance, linear spatial (e.g., step length, or length of displacement of the center of pressure [CoP]) or time-dependent (e.g., walking speed, stride times, or cadence) parameters may be computed [32–34].

For the present review, 94 studies were included [35–128]. Among these studies, only one study used a typical performance based test [114], the Romberg test: observing body sway while standing quiet with eyes opened and closed. More body sway during the Romberg test is associated with an increased chance of falling [129].

All other included studies used instruments to assess postural control during standing or walking. One of the instruments that was frequently used for assessing standing balance was an ataxia meter [35–54]. This instrument integrates the amplitude of bidirectional body movements in the anterior-posterior plane only, transferred through a string attached to the subject's waist. Body sway is measured in units of sway recorded as  $\frac{1}{3}^{\circ}$  of angle of arc [130]. The ataxia meter gives only a single reading at the end of the test of the total amount of sway in the forward-backward direction during the duration of the test.

For assessing standing balance in a more quantitative way, a force platform was the instrument used in the majority of the included studies [61–110]. The platform identifies the position on the base of support of the instantaneous center of feet pressure during quiet stance [131]. Under quiet stance, the CoP broadly reflects the position on the support base of the projection of the body's center of mass [132]. Measuring changes in CoP, e.g., the length or the area included within the path of the CoP, is mostly used as an indicator of the CoP in both the anterior-posterior and lateral directions, which can be processed at a later time. Among older people, greater CoP displacement measured with a force platform is typically used to indicate impaired postural control [133].

Other studies included in the present literature review used comparable methods, based on the same principles as an ataxia meter and/or force platform, to assess body sway, such as a stabilometer [116–120], a sway table [122–124], and a body sway meter [57–59]. Two of the included studies analyzed gait [112, 113]. Draganich *et al.* [112] used a three-dimensional optical system to analyze the effects of FRIDs on obstructed and unobstructed gait over a 9.5-m distance in healthy older people. Of the motion data, temporal-distance measures were calculated, consisting of stride length, walking velocity, and cadence (strides/minute). Paleacu *et al.* [113] used force-sensitive insoles placed in the subject's shoe to measure gait rhythm and timing of the gait cycle during a 2-min walk. Walking speed, stride length, stride time, stride time variability (i.e., the magnitude of the stride-to-stride variations) [134–136], swing time, and gait asymmetry (defined as 100 times the absolute value of the natural logarithm of the ratio between the left foot and right foot swing times) [137] were determined.

# Effects of FRIDs on postural control

### Psychotropic drugs

Generally, psychotropic medication can be defined as drugs that cross the blood-brain barrier and act directly on the CNS. Psychotropic drugs can be categorized into a number of groups. In the present review, only groups of psychotropic drugs associated with an increased fall risk, according to meta-analyses [6–9], are discussed: (1) antidepressant medications; (2) neuroleptic medications; (3) benzodiazepines; and (4) AEDs. These groups of medications are somewhat arbitrary [14], because many of these drugs are used in multiple conditions. For example, benzodiazepines are used as hypnotics, anxiolytics, muscle relaxants, and to treat or abort epileptic seizures. However, classifying drugs into different groups provides a framework for reviewing the effects of these drugs on postural control.

### Antidepressant medications

The main indication for prescribing antidepressants is moderate to severe depression, although a number of other indications exist. Mainly, there are three classes of antidepressants: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase A (MAO-A) inhibitors. TCAs and SSRIs (although SSRIs to a less extent than TCAs) have been associated with autonomic adverse effects, such as orthostatic hypotension [138, 139], and psychomotor impairment [140]. Their use has

Chapter 5A

also been related to an increased incidence of falls [6–9], and hip fractures in older patients [141, 142].

Twelve studies examined the effects of antidepressants on postural control among healthy young subjects [35, 42, 67, 68, 106, 109], healthy older people [35, 42, 90, 93, 112], and older patients with (major) depression [91–93, 113] (Table 5.1). The methodological quality score of these studies was in the range of 17-23 points. One study performed a power analysis to estimate the sample size [35].

Among healthy subjects, amitriptyline was the only antidepressant that impaired postural control during standing and walking: body sway was significantly increased in young subjects [42, 67, 106], and older people [42, 90], and gait velocity and cadence were significantly reduced [112]. This effect was only present when the daily dose was 50 mg or higher. Other antidepressants, such as the TCA desipramine [67, 112], the SSRIs femoxetine [68], paroxetine [112], and zimelidine [42, 67], and the MAO-A inhibitors befloxatone [90], and minaprine [35], did not affect postural control significantly among healthy young subjects and old people.

Antidepressants are generally prescribed in patients with a (major) depression, and it is known that depression itself is associated with alterations in locomotion and increased fall risk [143, 144]. However, the link between depression, falls, and postural control is not fully clear [145], because depression itself is among the most common risk factors for falls [144], and medication may cause confounding effects. Therefore, it was questioned what the isolated effects of antidepressants are on postural control among depressed older people.

Four studies examined the effects of antidepressants on postural control among older patients suffering a (major) depression [91–93, 113]. Both the TCA nortriptyline and the SSRI paroxetine did not have significant influence on postural control while standing with eyes opened and closed after 2 [93], or 6 weeks of treatment [91, 92]. On the other hand, sertraline, another SSRI, caused a significant increase in body sway in older depressed patients after 1 week of treatment, when standing with eyes opened and closed [93]. Opposite results were found by Paleacu *et al.* [113] They demonstrated in older people diagnosed with clinical depression that antidepressant pharmacological therapy with SSRIs or SNRIs (serotonin norepinephrine reuptake inhibitors) for 10 weeks brings significant improvements in gait (increased gait speed and stride length, and reduced stride time variability and gait asymmetry). Furthermore, significantly better cognitive functioning (higher scores on the Mini Mental State Examination (MMSE) and Instrumented Activities of Daily Living (IADL)), and an improved affective state (lower.

Table 5.1. The	effects of various a	antidepressant	Table 5.1. The effects of various antidepressants on postural control.			
Drug	Daily dose Subjects	Subjects	Method	Outcome variables	Effect Study	Study (
	(mg)					
Tricyclic antide	ricyclic antidepressants (TCA)					

Drug	Daily dose (mg)	Subjects	Method	Outcome variables	Effect	Study (quality score) <sup>a</sup>
Tricyclic antidepressants (TCA)	ants (TCA)					
Amitriptyline	75	12 HYS	Force platform	L, Ao, PSD	$\leftarrow$	Patat <i>et al.</i> [106] (21)
	50	12 HOS	Gait analysis with 3D	SL, WS, Cad	$\rightarrow$	Draganich <i>et al.</i> [112] (23)
			optical system			
		12 HOS	Force platform	L, Ao	$\leftarrow$	Rosenzweig <i>et al.</i> [90] (23)
		12 HYS	Force platform	Body sway	$\leftarrow$	Linnoila <i>et al.</i> [67] (19)
		4 HYS & 4 HOS	Ataxia meter	Body sway	$\leftarrow$	Swift <i>et al.</i> [42] (17)
		12 HYS	Force platform	Body sway	П	Strömberg & Mattila [68] (19)
	25	9 HYS & 9 HOS <sup>b</sup>	Ataxia meter	°AS in AP plane	П	Kinirons <i>et al.</i> [35] (22)
		5 HYS	Force platform	Sway index	II	Dorian <i>et al.</i> [109] (18)
Desipramine	100	12 HYS	Force platform	Body sway	11	Linnoila <i>et al.</i> [67] (19)
	50	12 HOS	Gait analysis with 3D	SL, WS, Cad	Ш	Draganich <i>et al.</i> [112] (23)
			optical system			
Nortriptyline	60	10 DOP	Force platform	L, Ao	11	Laghrissi-Thode <i>et al.</i> [91] (20)
	51 (mean)	17 DOP	Force platform	L, Ao	II	Mamo <i>et al.</i> [92] (21)
	52 (mean)	11 DOP	Force platform	L, Ao	II	Laghrissi-Thode <i>et al.</i> [93] (18)
Selective serotonin reuptake inhibitors (SSRI)	euptake inhibito	ors (SSRI)				
Femoxetine	200	12 HYS	Force platform	Body sway	II	Strömberg & Mattila [68] (19)
Paroxetine	23 (mean)	25 DOP	Force platform	L, Ao	П	Mamo <i>et al.</i> [92] (21)
	20	12 HOS	Gait analysis with 3D	SL, WS, Cad	11	Draganich <i>et al.</i> [112] (23)
			optical system			
		10 DOP	Force platform	L, Ao	Ш	Laghrissi-Thode <i>et al.</i> [91] (20)
Sertraline	67 (mean)	10 DOP	Force platform	L, Ao	$\leftarrow$	Laghrissi-Thode <i>et al.</i> [93] (18)
Zimelidine	200	12 HYS	Force platform	Body sway	Ш	Linnoila <i>et al.</i> [67] (19)
	100	4 HYS & 4 HOS	Ataxia meter	Body sway	II	Swift <i>et al.</i> [42] (17)
Various SSRIs	100	19 DOP	Gait analysis with force-	WS, SL	$\leftarrow$	Paleacu <i>et al.</i> [113] (20)
and SNRIs			sensitive insoles	Stvar, Gait asymmetry	$\rightarrow$	
				ST, SWT	Ш	

Monoamine oxidase A inhibitors	e A inhibitors					
Befloxatone	10	12 HOS	Force platform	L, Ao	Ш	Rosenzweig <i>et al.</i> [90] (23)
Minaprine	100	9 HYS & 9 HOS <sup>b</sup>	Ataxia meter	°AS in AP plane	П	Kinirons <i>et al.</i> [35] (22)
*AS degree of angle c	of sway (°); <b>Ao</b> a	area included within	the path of the center of	pressure (cm <sup>2</sup> ); <b>Cad</b> cadence	e (strides/r	AS degree of angle of sway (°); Ao area included within the path of the center of pressure (cm <sup>2</sup> ); Cad cadence (strides/minute); DOP depressed older
patients; HOS health	y older subject:	s; HYS healthy young	subjects; L total length of	displacement of the center	- of pressu	patients; HOS healthy older subjects; HYS healthy young subjects; L total length of displacement of the center of pressure (cm); PSD power spectral
density (total energy.	', energy less th	an 0.5 Hz, correspon	iding to the constant displ	acement of the center of gr	avity, and	density (total energy, energy less than 0.5 Hz, corresponding to the constant displacement of the center of gravity, and energies between 0.5 and 2 Hz,
corresponding to po:	stural readjustr	nent mechanisms of	an essentially muscular o	corresponding to postural readjustment mechanisms of an essentially muscular origin); SL stride length (m); ST stride time (ms); Stvar stride time	ST stride tii	me (ms); <b>Stvar</b> stride time
variability (ms); SwT :	swing time (%);	WS walking speed (I	m/s); $m h$ significant increa:	se in outcome variable; = no	significan	variability (ms); SwT swing time (%); WS walking speed (m/s); $\Lambda$ significant increase in outcome variable; = no significant change in outcome variable; $\downarrow$
significant decrease in outcome	in outcome var	variable				
(rthise OC minimum) and a leaf of here and a						

<sup>a</sup> Downs and Black score (maximum 28 points)

 $^{\rm b}$  A power analysis was performed to estimate the sample size

99

scores on the Hamilton Depression Rating Scale (HDS)) were found after the 10-week intervention

In summary, amitriptyline  $\geq$ 50 mg was the only antidepressant that impaired postural control in healthy subjects. In depressed older patients, sertraline was the only antidepressant that increased body sway significantly. However, this result was only found in one study where the methodological quality was moderate. One study found improvements in gait in this patient population after therapy with SSRIs or SNRIs. Thus, it seems that amitriptyline is the only antidepressant to cause impairments in postural control in the reviewed studies.

### Neuroleptic medications

Neuroleptic, or antipsychotic, medication is primarily used for the treatment of psychotic disorders. However, these drugs have a number of other indications, including the treatment of behavioral and psychiatric symptoms of dementia (BPSD). However, the use of neuroleptics other than risperidone to treat BPSD is off-label, and associated with various boxed warnings, e.g., metabolic syndrome and cardiovascular disorders such as stroke. Neuroleptics can be categorized into two groups: conventional (or first-generation) neuroleptics (CNLs) and atypical (second-generation) antipsychotics (AAPs). AAPs differ from CNLs with respect to their adverse effects profile (lower incidence of extra-pyramidal adverse effects and tardive dyskinesia) and their therapeutic properties [95].

Thirteen studies examined the effects of neuroleptics on postural control among healthy young subjects [37, 57–59, 69, 87, 94, 110, 125], and older subjects [36, 95, 96, 126] (Table 5.2). The methodological quality score of these studies was in the range of 18-24 points. Two studies performed a power analysis to estimate the sample size [57, 95].

Haloperidol 3 mg was found to be the only CNL causing deterioration in postural control, indicated by significantly more body sway in young subjects [57], and older subjects [126]. However, this effect was only found in two studies [57, 126], whereas two other, comparable studies did not find a significant effect with the same dose of haloperidol in young subjects [58, 125]. Lower daily doses of haloperidol and the use of chlorpromazine (another CNL) did not influence body sway significantly [36, 69, 125].

Drug	Daily dose (mg)	Subjects	Method	Outcome variables	Effect	Study (quality score) <sup>a</sup>
Conventional neuroleptics	oleptics (CNL)					
Chlorpromazine	50	12 HYS	Ultrasound ranging device	Body sway	11	McClelland <i>et al.</i> [125] (19)
		12 HYS	Force platform	Body sway	11	Mattila <i>et al</i> . [69] (21)
Haloperidol	£	14 HOS	Unknown	Body sway	$\leftarrow$	Beuzen <i>et al</i> . [126] (22)
		35 HYS <sup>b</sup>	Body Sway meter	Body sway	←	Liem-Moolenaar et al. [57] (24)
		12 HYS	Body Sway meter	Body sway	11	Liem-Moolenaar <i>et al.</i> [58] (22)
		12 HYS	Ultrasound ranging device	Body sway	Ш	McClelland <i>et al.</i> [125] (19)
	2	16 HOS	Ataxia meter	½°AS	П	Legangneux <i>et al.</i> [36] (22)
Atypical antipsychotics (AAP)	otics (AAP)					
Amisulpride	200	16 HOS	Ataxia meter	%°AS	II	Legangneux <i>et al.</i> [36] (22)
		18 HYS	Force platform		П	Mattila <i>et al</i> . [87] (18)
		18 HYS	Force platform	L, Ao	П	Perault <i>et al</i> . [94] (21)
	50	16 HOS	Ataxia meter	⅓°AS	Ш	Legangneux <i>et al.</i> [36] (22)
		18 HYS	Force platform	L, Ao	Ш	Perault <i>et al.</i> [94] (21)
Olanzapine	с	14 HOS	Unknown	Body sway	$\leftarrow$	Beuzen <i>et al.</i> [126] (22)
Remoxipride	120	11 HYS	Ataxia meter	⅓°AS	Ш	Fagan <i>et al.</i> [37] (19)
	60	11 HYS	Ataxia meter	)₃°AS	Ш	Fagan <i>et al.</i> [37] (19)
	30	11 HYS	Ataxia meter	⅓°AS	Ш	Fagan <i>et al.</i> [37] (19)
Risperidone	ſ	12 HYS	Force platform	Vel	$\leftarrow$	Corbeil <i>et al.</i> [110] (23)
	2	18 HYS	Body Sway meter	Body sway	$\leftarrow$	Liem-Moolenaar <i>et al.</i> [59] (23)
	1	12 HYS	Force platform	Vel	$\leftarrow$	Corbeil <i>et al.</i> [110] (23)
	0.5	12 HOS <sup>b</sup>	Force platform	L, Ao	П	Allain <i>et al</i> . [95] (24)
	0.25	12 HOS <sup>b</sup>	Force platform	L, Ao	Ш	Allain <i>et al</i> . [95] (24)
Sulpiride	400	12 HYS	Ultrasound ranging device	Body sway	Ш	McClelland <i>et al</i> . [125] (19)
Tiapride	100	12 HOS	Force platform	L, Ao	П	Patat <i>et al.</i> [96] (22)

Table 5.2. The effect of various neuroleptics on postural control.

101

estimate the sample size

Among the AAPs, olanzapine 3 mg [126], and risperidone  $\geq 1$  mg increased body sway significantly [59, 110], whereas other AAPs, such as amisulpride [36, 87, 94], remoxipride [37], sulpiride [125], tiapride [102], and daily doses smaller than 1 mg of risperidone [95], did not affect postural control significantly in healthy young and older subjects.

To summarize these results, we can conclude that olanzapine 3 mg and risperidone  $\geq 1$  mg impair postural control in quiet standing, whereas other neuroleptics did not show any significant effect on body sway. For haloperidol 3 mg, the results were not consistent: two studies found an effect on postural control in healthy young subjects and older adults, whereas two other studies did not. Because the two studies finding an effect had higher methodological quality and performed a power analysis, we tentatively conclude that haloperidol 3 mg has serious effects on postural control in both young and older subjects.

### Benzodiazepines

There is a number of indications for the use of benzodiazepines, and the appropriateness of their use depends on the actual indication and consideration of the risks and benefits for individual patients [14]. Indications include insomnia, anxiety, panic disorders, seizures/epilepsy, and acute alcohol withdrawal. Benzodiazepines are frequently used in the elderly community: between 16.6% [146] and 25.4% [147] of community-dwelling older people use one or more benzodiazepines. In nursing homes, this rate is even higher: 50-80% of the residents take one or more benzodiazepines [148]. The use of benzodiazepines has been associated with falls [6–9], hip fractures [149], and impaired cognitive function [150]. Therefore, benzodiazepine use in older people has been questioned, especially for benzodiazepines with long half-lives , because these are more likely to accumulate, remain longer in the body, and cause prolonged sedation [151].

Benzodiazepines have sedative effects, and may impair psychomotor function, which potentially causes falls. Especially among older adults who use benzodiazepines as a hypnotic, walking to the toilet in the night because of nocturia might increase the risk of falling. Another problem, associated with the use of benzodiazepines as a hypnotic, is the risk of 'hangover' effects, e.g. residual daytime sleepiness and impairment of psychomotor and cognitive functioning the day after bedtime administration [152]. These effects of benzodiazepines on postural control appear to be stronger with increasing half-lives, higher daily dosage, and longer duration of use of these drugs [152]. Enhanced receptor sensitivity to benzodiazepines with increasing age has also been

Chapter 5A

documented, which together with pharmacokinetic change probably contributes to an accentuated and prolonged sedative effect [39, 40, 49].

Therefore, in the present review, the effects of benzodiazepines were categorized into drugs with (a) long half-life (>24 h), (b) intermediate half-life (8-24 h), and (c) short half-life (<8 h). Furthermore, (d) benzodiazepine receptor agonists, e.g., zolpidem and zopiclone, are discussed. Then, the various benzodiazepines were categorized into (a) short effects (within 8 h after administration, the so-called "nightly effects"), (b) some longer effects (past 8 h after administration, the so-called "day after" or "hangover" effects), and (c) long-term effects, when using benzodiazepines for a longer period (at least 7 days). Among the psychotropics, the effects of benzodiazepines on postural control are the most extensively studied: 68 studies (Table 5.3) examined effects of benzodiazepines on postural control among healthy young subjects [38, 39, 41, 43–51, 54, 55, 62, 64–66, 69–82, 85, 86, 88, 89, 94, 96, 99–101, 103, 106–108, 111, 114, 116– 118, 120–124, 127, 128], and older people [39, 41, 49, 54, 61, 63, 64, 83, 95, 98, 102, 104, 115, 124], and older subjects with chronic insomnia [56]. All studies assessed postural control during quiet standing, none analyzed gait. The methodological quality score of these studies ranged between 13 and 25 points. Nine studies performed a power analysis to estimate the sample size [46, 48, 63, 66, 74, 95, 97, 98, 105].

#### Benzodiazepines with a long half-life (>24 h)

Diazepam has been the most extensively studied individual benzodiazepine in 14 studies among young subjects [38, 39, 43–45, 70, 71, 73, 82, 108, 121, 122, 127], and older subjects [39, 61]. Generally, significant more body sway was found as nightly effect for daily doses of diazepam  $\geq 0.2 \text{ mg/kg}$  or  $\geq 10 \text{ mg}$  [38, 39, 43, 82, 106, 108, 121, 122, 127], except for two studies [70, 71]. For lower daily doses of diazepam, the results were more nuanced [44, 45, 61, 73, 108, 122, 127]. Three studies examined hangover effects of diazepam [38, 39, 106], of which one study found significant effects after >8 h for diazepam 10 mg [38]. The other two studies did not find any significant effects for body sway for the same daily dose of diazepam [42, 106]. Only one study examined the longterm effects of diazepam; Aranko *et al.* [73] did not find any significant effect for postural control during standing after 2 weeks of daily diazepam 15 mg administration.

Nightly, hangover, and long-term effects were also examined for other benzodiazepines with a long half-life, namely flurazepam [55, 56, 98, 114], nitrazepam [54, 72, 115–118, 120], and quazepam [123]. These effects were examined in 12 studies for healthy young subjects [54, 55, 72, 114, 116–118, 120, 123], and older persons [54, 98, 115], and for older subjects with chronic insomnia [56]. Increased postural sway

(LTE: >7 days of usage).         Drug       Daily dose       Subjects       Method       Outcome       NE       HE       Study (quality score)         Drug       Daily dose       Subjects       Method       Outcome       NE       HE       LTE       Study (quality score)         Benzoniazepine derivatives       0.21 mg/kg       120 HYS       Force platform       F       F       Renzoliazepine derivatives         Long half-life (>24 h)       0.21 mg/kg       120 HYS       Force platform       F       F       Ghoneim et al. [122]         Long half-life (>24 h)       0.21 mg/kg       13 HYS       Force platform       F       F       Nikaido et al. [122]         Long half-life (>24 h)       0.21 mg/kg       16 HYS       Sway table       FS       F       F       Schuckti et al. [122]         O.12 mg/kg       16 HYS       Sway table       FS       F       F       Inkaido et al. [122]         O.13 mg/kg       16 HYS       Sway table       FS       F       F       Analoo et al. [122]         O.14 mg/kg       16 HYS       Sway table       FS       F       F       Analoo et al. [122]         O.12 mg/kg       1	benzodiazepines on postural		ntrol were sub	divided in nightly (f	VE; <8 h post-dose	e), hang(	over (H	E; >8	control were subdivided in nightly (NE; <8 h post-dose), hangover (HE; >8 h post-dose), and long-term effects
✓ dose       Subjects       Method       Outcome       NE       HE       LTE         mg/kg       120 HYS       Force platform       SF       ↑       ↑         mg/kg       16 HYS       Sway table       TPS       =       =         mg/kg       12 HYS       Force platform       AO       =	-			)	-	)	•		-
Daily dose         Subjects         Method         Outcome         NE         HE         LTE           nh)         variables         variables         variables         Nariables         Nariables<	(LTE; >7 days of	usage).							
variables       tepire derivatives       tipe (>224 h)       0.3 mg/kg     120 HYS     Force platform     F       0.1 mg/kg     16 HYS     Sway table     TPS     T       0.21 mg/kg     120 HYS     Force platform     F     T       0.21 mg/kg     120 HYS     Force platform     F     T       0.21 mg/kg     120 HYS     Force platform     F     T       0.14 mg/kg     16 HYS     Sway table     TPS     T       0.12 mg/kg     16 HYS     Sway table     TPS     T       0.12 mg/kg     16 HYS     Sway table     TPS     T       0.11 mg/kg     12 HOS     Force platform     Ao     T       0.11 mg/kg     12 HYS     Force platform     Ao     T       0.11 mg/kg     12 HYS     Force platform     S     T       0.07 mg/kg     16 HYS     Sway table     TPS     T       0.07 mg/kg     16 HYS     Sway table     TPS     T       10 mg     12 HYS     Force platform     Body sway     T       12 HYS     Force platform     Body sway     T     T       12 HYS     Force platform     Body sway     T     T       10 mg     <	Drug	Daily dose	Subjects	Method	Outcome	R	 <u>+</u>	E	Study (quality score) <sup>a</sup>
repine derivatives life (>24 h) 0.3 mg/kg 120 HYS Force platform SF ↑ 0.21 mg/kg 16 HYS Sway table TPS ↑ 0.21 mg/kg 16 HYS Force platform SF ↑ 48 HYS Unknown elec- Body sway ↑ 12 HYS Force platform CSV ↑ 12 HYS Force platform Ao 0.11 mg/kg 16 HYS Sway table TPS = 0.12 mg/kg 120 HYS Force platform Ao 12 HYS Force platform Ao 0.10 mg/kg 12 HYS Force platform SF = 0.07 mg/kg 16 HYS Sway table TPS = 0.07 mg/kg 16 HYS Sway table TPS = 12 HYS Force platform Body sway = 10 mg 12 HYS Ataxia meter 1V Amp P↑ 12 HYS Force platform Body sway = 11 HYS Ataxia meter 1V Amp P↑ 12 HYS Force platform Body sway = 12 HYS Ataxia meter 1V Amp P↑ 12 HYS Ataxia meter 1V Amp P↑ 12 HYS Force platform Body sway = 12 HYS Ataxia meter 1V Amp P↑ 12 HYS Ataxia meter 1V Amp P↑ 13 HYS Ataxia meter 1V Amp P↑ 14 HYS Ataxia meter 1V Amp P↑ 15 HYS Force platform Body sway P↑	(t <sub>1/2</sub> , in h)				variables				
<ul> <li>0.3 mg/kg 120 HYS Force platform SF</li> <li>0.21 mg/kg 16 HYS Sway table TPS</li> <li>0.21 mg/kg 16 HYS Sway table TPS</li> <li>0.21 mg/kg 120 HYS Force platform SF</li> <li>0.21 mg/kg 120 HYS Force platform CSV</li> <li>0.14 mg/kg 16 HYS Sway table TPS</li> <li>0.14 mg/kg 16 HYS Sway table TPS</li> <li>0.11 mg/kg 16 HYS Sway table TPS</li> <li>0.11 mg/kg 120 HYS Force platform Ao</li> <li>0.11 mg/kg 120 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter ½*AS</li> <li>12 HYS Ataxia meter ½*AS</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter ½*AS</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter ½*AS</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter ½*AS</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter ½*AS</li> <li>12 HYS Force platform Body sway</li> <li>13 HYS Ataxia meter ½*AS</li> <li>14 HYS Body sway</li> <li>15 HYS Force platform Body sway</li> <li>15 HYS Ataxia meter ½*AS</li> <li>14 HYS Body sway</li> <li>15 HYS Force platform Body sway</li> <li>15 HYS Ataxia meter ½*AS</li> <li>14 HYS Body sway</li> <li>15 HYS Force platform Body sway</li> <li>15 HYS Ataxia meter ½*AS</li> <li>14 HYS Body sway</li> <li>15 HYS Force platform Body sway</li> <li>15 HYS Ataxia meter ½*AS</li> <li>17 HYS Ataxia meter ½*AS</li> <li>18 HYS Body sway</li> <li>18 HYS Body sway</li> <li>18 HYS Body sway</li> <li>19 HYS Body sway</li> <li>10 mg 12 HYS Platometer IV</li> </ul>	Benzodiazepine c	derivatives							
0.3 mg/kg       120 HYS       Force platform       SF       7         0.21 mg/kg       16 HYS       Sway table       TPS       7         0.21 mg/kg       16 HYS       Sway table       TPS       7         0.21 mg/kg       16 HYS       Force platform       SF       7         0.21 mg/kg       120 HYS       Force platform       SF       7         21 HYS       Force platform       CSV       7         21 HYS       Unknown elec-       Body sway       7         12 HOS       Force platform       Ao       7         0.12 mg/kg       16 HYS       Sway table       TPS       =         0.12 mg/kg       16 HYS       Sway table       TPS       =         0.11 mg/kg       12 HOS       Force platform       Ao       7       7         0.11 mg/kg       16 HYS       Sway table       TPS       =       =         0.07 mg/kg       16 HYS       Statometer IV       Amp       7       7       7       1         15 mg       12 HYS       Force platform       Sody sway       1       7       1       1         10 mg       12 HYS       Force platform       Sody sway       7 <td< td=""><td>Long half-life (&gt;2</td><td>'4 h)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Long half-life (>2	'4 h)							
<ul> <li>0.21 mg/kg 16 HYS Sway table TPS</li> <li>0.2 mg/kg 120 HYS Force platform SF</li> <li>0.2 mg/kg 120 HYS Force platform SF</li> <li>0.14 mg/kg 120 HYS Unknown elec- Body sway</li> <li>21 HYS Unknown elec- Body sway</li> <li>0.14 mg/kg 16 HYS Sway table TPS</li> <li>0.12 mg/kg 16 HYS Sway table TPS</li> <li>0.12 mg/kg 120 HYS Force platform Ao</li> <li>0.12 mg/kg 120 HYS Force platform Ao</li> <li>0.12 mg/kg 120 HYS Force platform Ao</li> <li>12 HYS Force platform SF</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter % AS</li> <li>12 HYS Ataxia meter % AN</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter Body sway</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter Body sway</li> <li>12 HYS Force platform Body sway</li> <li>12 HYS Ataxia meter Body sway</li> <li>12 HYS Ataxia meter Body sway</li> <li>12 HYS Force platform Body sway</li> <li>13 HYS Ataxia meter Body sway</li> <li>14 HYS Ataxia meter Body sway</li> <li>15 HYS Force platform Body sway</li> <li>15 HYS Force platform Body sway</li> </ul>	Diazepam	0.3 mg/kg	120 HYS	Force platform	SF	$\leftarrow$			Ghoneim <i>et al.</i> [108] (14)
120 HYS       Force platform       SF       ↑         21 HYS       Force platform       SV       ↑         48 HYS       Unknown elec-       Body sway       ↑         48 HYS       Unknown elec-       Body sway       ↑         16 HYS       Sway table       TPS       =         12 HOS       Force platform       AO       =         12 HOS       Force platform       AO       =         12 HYS       Sway table       TPS       =         12 HYS       Force platform       SF       =         16 HYS       Sway table       TPS       =         16 HYS       Sway table       TPS       =         12 HYS       Force platform       Body sway       =         24 HYS       Force platform       Body sway       =         12 HYS       Force platform       L, Ao, PSD       ↑       ↑         12 HYS       Ataxia meter       ½ AS       ↑       ↑       ↑         12 HYS       Force platform       L, Ao, PSD       ↑       ↑       ↑         11 HYS & Ataxia meter       ½ AS       ↑       ↑       ↑       ↑         12 HYS       Force platform       L, Ao,	$(43 \pm 13)$	0.21 mg/kg	16 HYS	Sway table	TPS	$\leftarrow$			Nikaido <i>et al.</i> [122] (19)
21 HVS       Force platform       CSV       ↑         48 HYS       Unknown elec-       Body sway       ↑         48 HYS       Unknown elec-       Body sway       ↑         16 HYS       Sway table       TPS       =         12 HOS       Force platform       Ao       =         48 HYS       Unknown elec-       Body sway       ↑         12 HYS       Force platform       SF       =         14 HYS       Statometer IV       Amp       ↑         12 HYS       Force platform       Body sway       =         12 HYS       Force platform       L, Ao, PSD       ↑       ↑         12 HYS       Ataxia meter       ½*AS       ↑       ↑       ↑         12 HYS       Ataxia meter       ½*AS       ↑       ↑       ↑       ↑         12 HYS       Ataxia meter       ½*AS       ↑       ↑       ↑       ↑       ↑         12 HYS       Ataxia meter       ½*AS       ↑       ↑		0.2 mg/kg	120 HYS	Force platform	SF	$\leftarrow$			Ghoneim <i>et al.</i> [108] (14)
48 HYS Unknown elec- Body sway ↑ tronic device TPS = = = = = = = = = = = = = = = = = = =			21 HYS	Force platform	CSV	$\leftarrow$			Jansen <i>et al</i> . [82] (17)
g/kg       16 HYS       sway table       TPS       =         g/kg       16 HYS       sway table       TPS       =         g/kg       12 HOS       Force platform       Ao       =         g/kg       12 HOS       Force platform       Ao       =         g/kg       12 HYS       Unknown elec-       Body sway       =         g/kg       120 HYS       Force platform       SF       =         g/kg       120 HYS       Force platform       Body sway       =         g/kg       12 HYS       Force platform       Body sway       =       =         g/kg       12 HYS       Force platform       Body sway       =       =       =         g/kg       12 HYS       Ataxia meter       ½*AS       ↑       ↑       ↑       ↑       1         g/kg       11 HYS & Ataxia meter       ½*AS       ↑       ↑       =       1         g/kg       12 HYS       Ataxia meter       ½*AS       ↑       ↑       ↑       1         g/kg       12 HYS       Ataxia meter       ½*AS       ↑       ↑       1       1         g/f       12 HYS       Ataxia meter       ½*AS       ↑			48 HYS	Unknown elec-	Body sway	$\leftarrow$			Schuckit <i>et al.</i> [127] (23)
g/kg 16 HYS Sway table TPS = = = = = = = = = = = = = = = = = = =				tronic device					
12 HOS       Force platform       Ao       =         g/kg       48 HYS       Unknown elec-       Body sway       +         tronic device       Body sway       +       +         kg       120 HYS       Force platform       SF       =         g/kg       16 HYS       Sway table       TPS       =         12 HYS       Statometer IV       Amp       +       +         12 HYS       Force platform       Body sway       =       =         12 HYS       Force platform       Body sway       =       =         12 HYS       Ataxia meter       %*AS       +       +       =         12 HYS       Ataxia meter       %*AS       +       +       =         12 HYS       Ataxia meter       %*AS       +       +       =         12 HYS       Ataxia meter       %*AS       +       =       =         12 HYS       Ataxia meter       %*AS       +       =       =         12 HYS       Statometer IV       Amp       +       =       =         12 HYS       Statometer IV       Amp       +       =       =         12 HYS       Statometer IV       Amp		0.14 mg/kg	16 HYS	Sway table	TPS	П			Nikaido <i>et al</i> . [122] (19)
<ul> <li>g/kg 48 HYS Unknown elec- Body sway ↑</li> <li>kg 120 HYS Force platform SF = </li> <li>g/kg 120 HYS Force platform SF = </li> <li>g/kg 16 HYS Sway table</li> <li>TPS = </li> <li>g/kg 12 HYS Statometer IV Amp</li> <li>12 HYS Force platform Body sway = </li> <li>12 HYS A taxia meter % AS</li> <li>12 HYS A taxia meter % AS</li> <li>12 HYS A taxia meter % AS</li> <li>12 HYS A taxia meter % AN</li> <li>13 HYS A taxia meter % AN</li> <li>14 HYS A taxia meter % AN</li> <li>15 HYS A taxia meter % AN</li> <li>15 HYS A taxia meter % AN</li> <li>16 HYS A taxia meter % AN</li> <li>17 HYS A taxia meter % AN</li> </ul>			12 HOS	Force platform	Ao	II			Cutson <i>et al.</i> [61] (21)
Kgtronic device $S/kg$ 120 HYSForce platform $F$ $S/kg$ 16 HYSSway tableTPS= $S/kg$ 16 HYSSway tableTPS= $5$ HYSStatometer IVAmp $\uparrow$ $\uparrow$ $12$ HYSForce platformBody sway= $12$ HYSForce platformBody sway= $12$ HYSAtaxia meter $\chi^{*}_{*}AS$ $\uparrow$ $\uparrow$ $12$ HYSStatometer IVAmp $\uparrow$ $\uparrow$ $12$ HYSForce platformBody sway $\uparrow$ $\uparrow$ $12$ HYSForce platformBody sway $\uparrow$ $\uparrow$		0.12 mg/kg	48 HYS	Unknown elec-	Body sway	$\leftarrow$			Schuckit <i>et al.</i> [127] (23)
<ul> <li><sup>4</sup>/<sub>8</sub> 120 HYS Force platform SF</li> <li><sup>5</sup>/<sub>4</sub>/<sub>8</sub> 16 HYS Sway table TPS</li> <li><sup>5</sup> HYS Sway table TPS</li> <li><sup>5</sup> HYS Statometer IV Amp</li> <li><sup>6</sup> TPS</li> <li><sup>6</sup> HYS Statometer IV Amp</li> <li><sup>7</sup> 12 HYS Force platform Body sway</li> <li><sup>7</sup> 24 HYS Force platform Body sway</li> <li><sup>7</sup> 12 HYS Ataxia meter ½°AS</li> <li><sup>7</sup> ↑</li> <li><sup>7</sup> ↑</li> <li><sup>7</sup> ↑</li> <li><sup>8</sup> Ataxia meter ½°AS</li> <li><sup>7</sup> ↑</li> <li><sup>8</sup> Ataxia meter ½°AS</li> <li><sup>7</sup> ↑</li> <li><sup>12</sup> HYS Ataxia meter ½°AS</li> <li><sup>12</sup> HYS Ataxia meter ½°AS</li> <li><sup>12</sup> HYS Ataxia meter ½°AS</li> </ul>				tronic device					
<ul> <li>J/kg 16 HYS Sway table TPS = =</li> <li>5 HYS Statometer IV Amp ↑</li> <li>12 HYS Force platform Body sway =</li> <li>24 HYS Force platform Body sway =</li> <li>12 HYS Ataxia meter ½°AS ↑ ↑</li> <li>12 HYS Ataxia meter ½°AS ↑ =</li> <li>11 HYS &amp; Ataxia meter ½°AS ↑ =</li> <li>12 HYS Ataxia meter ½°AS ↑ =</li> <li>12 HYS Ataxia meter 1/ Amp ↑</li> <li>5 HYS Force platform Body sway ↑</li> <li>15 HYS Force platform Body sway 1</li> </ul>		0.1 mg/kg	120 HYS	Force platform	SF	Ш			Ghoneim <i>et al.</i> [108] (14)
5 HYS Statometer IV Amp $\uparrow$ 12 HYS Force platform Body sway = 24 HYS Force platform Body sway = 24 HYS Force platform Body sway $\uparrow$ $\uparrow$ $\uparrow$ 12 HYS Ataxia meter $\chi^{s}AS$ $\uparrow$ $\uparrow$ $\uparrow$ = 12 HYS Ataxia meter $\chi^{s}AS$ $\downarrow$ $\uparrow$ = 13 HYS Ataxia meter $\chi^{s}AS$ $\downarrow$ $\downarrow$ = 14 HYS $\chi^{s}AS$ $\chi^{s}AS$ $\downarrow$ $\downarrow$ = 15 HYS Ataxia meter $\chi^{s}AS$ $\downarrow$ $\chi^{s}AS$ $\downarrow$ $\downarrow$ = 15 HYS Ataxia meter $\chi^{s}AS$ $\downarrow$ $\downarrow$ = 15 HYS Force platform Body sway $\uparrow$ $\downarrow$ = 15 HYS Force platform $\chi^{s}AS$ $\downarrow$ $\downarrow$ $\downarrow$ = 15 HYS Force platform $\chi^{s}AS$ $\downarrow$ $\downarrow$ $\downarrow$ = 15 HYS Force platform $\chi^{s}AS$ $\downarrow$ $\downarrow$ $\downarrow$ $\downarrow$ = 15 HYS Force platform $\chi^{s}AS$ $\downarrow$ $\downarrow$ $\downarrow$ $\downarrow$ $\downarrow$ = 15 HYS Force platform $\chi^{s}AS$ $\downarrow$ $\downarrow$ $\downarrow$ $\downarrow$ $\downarrow$ = 15 HYS Force platform $\chi^{s}AS$ $\downarrow$		0.07 mg/kg	16 HYS	Sway table	TPS	Ш			Nikaido <i>et al.</i> [122] (19)
12 HYSForce platformBody sway=24 HYSForce platformBody sway=24 HYSForce platform $\chi^{*}$ AS $\uparrow$ $\uparrow$ 12 HYSAtaxia meter $\chi^{*}$ AS $\uparrow$ $\uparrow$ 12 HYSAtaxia meterBody sway $\uparrow$ $\uparrow$ 12 HYSStatometer IVAmp $\uparrow$ $\uparrow$ 15 HYSForce platformBody sway $=$		20 mg	5 HYS	Statometer IV	Amp	$\leftarrow$			Orr <i>et al.</i> [121] (18)
24 HYS Force platform Body sway 24 HYS Ataxia meter $3^{\circ}$ AS $\uparrow \uparrow$ $\uparrow$ 12 HYS Ataxia meter $3^{\circ}$ AS $\uparrow \uparrow$ $\uparrow$ 12 HYS Ataxia meter $3^{\circ}$ AS $\uparrow \uparrow$ = 11 HYS & Ataxia meter $3^{\circ}$ AS $\uparrow \uparrow$ = 12 HOS 12 HOS 12 HYS Ataxia meter Body sway $\uparrow$ 5 HYS Statometer IV Amp $\uparrow$ 156 HYS Force platform Body sway =		15 mg	12 HYS	Force platform	Body sway	Ш			Mattila <i>et al.</i> [70] (19)
12 HYSAtaxia meter $\%$ AS $\uparrow$ $\uparrow$ 12 HYSForce platformL, Ao, PSD $\uparrow$ =11 HYSAtaxia meter $\%$ AS $\uparrow$ =12 HOS12 HOSAtaxia meterBody sway $\uparrow$ 5 HYSStatometer IVAmp $\uparrow$ 156 HYSForce platformBody sway=			24 HYS	Force platform	Body sway			II	Aranko <i>et al.</i> [73] (19)
Force platform L, Ao, PSD ト = & Ataxia meter ½°AS ト = Ataxia meter Body sway ト Statometer IV Amp ト		10 mg	12 HYS	Ataxia meter	%°AS	$\leftarrow$	$\leftarrow$		Cohen <i>et al.</i> [38] (19)
& Ataxia meter ½。AS  Ataxia meter Body sway  Statometer IV Amp  Force platform Body sway =			12 HYS	Force platform	L, Ao, PSD	$\leftarrow$	Ш		Patat <i>et al.</i> [106] (21)
Ataxia meter Body sway Statometer IV Amp 5 Force platform Body sway =			11 HYS &	Ataxia meter	%°AS	$\leftarrow$	11		Swift <i>et al.</i> [39] (19)
Ataxia meter Body sway Statometer IV Amp S Force platform Body sway =			12 HOS						
Statometer IV Amp VS Force platform Body swav =			12 HYS	Ataxia meter	Body sway	$\leftarrow$			van Steveninck <i>et al.</i> [43] (21)
Force platform Body swav =			5 HYS	Statometer IV	Amp	$\leftarrow$			Orr <i>et al.</i> [121] (18)
			156 HYS	Force platform	Body sway	Ш			Palva [71] (16)

Benzodiazepines were categorized according to their half-life: long (>24 h), intermediate (8-24 h) and short half-life (<8 h). Effects of Table 5.3. The effects of various benzodiazepines on postural control.

$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		5 mg	12 HYS	Ataxia meter	Body sway	п			Gerrard <i>et al.</i> [44] (18)
<ul> <li>24 HYS Force platform Body sway</li> <li>30 mg 25 HOS<sup>b</sup> Force platform L, Ao</li> <li>15 mg 24 HYS Romberg test Score</li> <li>15 mg 14 HYS Balance platform Time</li> <li>5 mg 84 HYS Rabilometer Time</li> <li>5 mg 84 HYS Stabilometer Ao</li> <li>5 mg 84 HYS Stabilometer L, Ao, Vel, Acc</li> <li>24 HOS Stabilometer L, Ao, Vel, Acc</li> <li>21 HYS Svay table</li> <li>22 HYS Svay table</li> <li>22 HYS Svay table</li> <li>23 HYS Svay table</li> <li>24 HYS Force platform</li> <li>20 HYS Force platform</li> <li>20 HYS Force</li></ul>		I	12 HYS	Ataxia meter	Body sway	II			Gerrard <i>et al.</i> [45] (18)
an 30 mg 25 HOS <sup>b</sup> Force platform L, Ao 35 HOS <sup>b</sup> Romberg test Score = $(A + A)$ 14 HYS Ranner Station Time $(A + A)$ 5 mg 8 HYS Stabilometer Ao 5 mg 8 HYS Stabilometer Ao 5 mg 8 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Rabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 12 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 13 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 13 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 13 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 13 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 13 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 13 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 14 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 17 HOS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 17 HOS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 17 HOS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 18 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 19 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 10 HYS Stabilometer L, Ao, Vel, Acc = $(A + A)$ 10 HYS Force platform Body sway = $(A + A)$ 10 HYS Force platform SE = $(A + A)$ 10 HYS Force platform SE = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A + A)$ 10 HYS Force platform L, Ao = $(A +$			24 HYS	Force platform	Body sway	Ш			Aranko <i>et al.</i> [73] (19)
<ul> <li>(1) 48 HYS Romberg test Score = = = 14 HYS Balance platform Time ? 14 HYS Balance platform Body sway</li> <li>(14 HYS Balance platform Time ? 14 HYS Balance platform Time ? 14 HYS Balance platform Body sway</li> <li>(14 HYS Force platform Body sway</li> <li>(14 HYS Force platform Time ? 14 HYS Proventies</li> <li>(14 HYS Force platform Body sway</li> <li>(14 HYS Stabilometer L, Ao, Vel, Acc</li> <li>(12 HYS Stabilometer L, Ao, Vel, Acc</li> <li>(13 HYS Stabilometer L, Ao, Vel, Acc</li> <li>(14 HYS Stabilometer L, Ao, Vel, Acc</li> <li>(17 HOS Stabilometer L, Ao, Vel, Acc<!--</td--><td>Flurazepam</td><td>30 mg</td><td>25 HOS<sup>b</sup></td><td>Force platform</td><td>L, Ao</td><td></td><td><math>\leftarrow</math></td><td></td><td>Boyle <i>et al</i>. [98] (25)</td></li></ul>	Flurazepam	30 mg	25 HOS <sup>b</sup>	Force platform	L, Ao		$\leftarrow$		Boyle <i>et al</i> . [98] (25)
14 HYS       Balance platform       Time       1         15 mg       14 HYS       Balance platform       Time       1         36 OCI       Balance platform       Time       1         36 OCI       Balance platform       Time       1         36 OCI       Balance platform       Alow       1         36 OCI       Balance platform       Alow       1       1         36 OCI       Balance platform       Alow       1       1         20 HYS       Stabilometer       Time       1       1         21 HYS       Stabilometer       LAo, Vel, Acc       1       1         21 HYS       Stabilometer       L, Ao, Vel, Acc       1       1         am       30 mg       21 HYS       Svay table       7       1         am       30 mg       21 HYS       Svay table       7       1         am       30 mg       21 HYS       Svay table       7       1       1         am       30 mg       21 HYS       Svay table       7       1       1       1         am       1.5 mg       21 HYS       Svay table       7       1       1       1         am       <	$(74 \pm 24)$		48 HYS	Romberg test	Score	Ш	II		Hill <i>et al.</i> [114] (19)
15 mg14 HYSBalance platformTime $\uparrow$ Jam10 mg14 HYSForce platformTime $\uparrow$ $=$ Jam10 mg14 HYSForce platformBody sway $=$ $\uparrow$ Jam10 mg14 HYSForce platformBody sway $=$ $\uparrow$ Jam5 mg8 HYSStabilometerAo $\uparrow$ $=$ $\uparrow$ Jam20 HYSSelf-designed0.1° body sway $=$ $\uparrow$ $\uparrow$ Jam24 HOSSelf-designed0.1° body sway $=$ $\uparrow$ $\uparrow$ RHXSStabilometerLAo, Vel, Acc $=$ $\uparrow$ $\uparrow$ RHXSStabilometerL, Ao, Vel, Acc $=$ $\uparrow$ $\uparrow$ Jam30 mg21 HYSSway tableTPS $=$ $\uparrow$ $\uparrow$ Jam15 mg21 HYSSway tableTPS $\uparrow$ $\uparrow$ $\uparrow$ $\downarrow$ Jam1.5 mg21 HYSSway tableTPS $\uparrow$ $\uparrow$ $\downarrow$ $\downarrow$ $\downarrow$ Jam1.5 mg21 HYSSway tableTPS $\uparrow$ $\uparrow$ $\downarrow$ $\downarrow$ $\downarrow$ $\downarrow$ Jam1.5 mg21 HYSSway tableTPS $\uparrow$ $\uparrow$ $\downarrow$			14 HYS	Balance platform	Time	$\leftarrow$	II		Roth <i>et al.</i> [55] (20)
<ul> <li>36 OCI Balance platform Time</li> <li>36 OCI Balance platform Body sway</li> <li>5 mg 8 HYS Stabilometer Ao</li> <li>20 HYS Stabilometer Time</li> <li>20 HYS Stabilometer L, Ao, Vel, Acc</li> <li>8 HYS Stabilometer L, Ao, Vel, Acc</li> <li>12 HYS Stabilometer L, Ao, Vel, Acc</li> <li>13 HYS Stabilometer L, Ao, Vel, Acc</li> <li>17 HOS</li> <li>0.75 mg 21 HYS Sway table TPS</li> <li>0.75 mg 19 HYS &amp; Sway table TPS</li> <li>17 HOS</li> <li>0.75 mg 19 HYS &amp; Sway table TPS</li> <li>17 HOS</li> <li>0.75 mg 19 HYS &amp; Sway table TPS</li> <li>17 HOS</li> <li>0.75 mg 19 HYS &amp; Sway table TPS</li> <li>17 HOS</li> <li>0.75 mg 20 HYS Force platform Body sway</li> <li>17 HOS</li> <li>22 HYS Force platform SE</li> <li>17 HOS</li> <li>24 HYS Force platform SE</li> <li>17 HOS</li> <li>18 HYS Force platform SE</li> <li>18 HYS Force platform L, Ao</li> <li>19 HYS Force platform L, Ao</li> <li>10 HYS Force platform L, AO</li> </ul>		15 mg	14 HYS	Balance platform	Time	$\leftarrow$	II		Roth <i>et al.</i> [55] (20)
<ul> <li>Jam 10 mg 14 HYS Force platform Body sway</li> <li>5 mg 8 HYS Stabilometer Ao</li> <li>20 HYS Stabilometer Time</li> <li>24 HOS Self-designed 0.1° body sway</li> <li>24 HOS Self-designed 0.1° body sway</li> <li>24 HOS Stabilometer L, Ao, Vel, Acc</li> <li>12 HYS Ratai meter Cumulative sway</li> <li>12 HYS Ratai meter L, Ao, Vel, Acc</li> <li>12 HYS Stabilometer L, Ao, Vel, Acc</li> <li>12 HYS Sway table TPS</li> <li>17 HOS</li> <li>17 HOS</li> <li>0.75 mg 19 HYS &amp; Sway table TPS</li> <li>17 HOS</li> <li>0.75 mg 19 HYS &amp; Sway table TPS</li> <li>17 HOS</li> <li>17 HOS</li> <li>0.75 mg 19 HYS &amp; Sway table TPS</li> <li>17 HOS</li> <li>18 HYS Stabilometer L, Ao, Vel, Acc</li> <li>18 HYS Force platform Body sway</li> <li>19 HYS Force platform C, L</li> <li>17 HOS</li> <li>17 HOS</li> <li>18 HYS Force platform L, Ao</li> <li>17 HYS Force platform L, Ao</li> <li>17 HYS Force platform L, Ao</li> <li>17 HYS Force platform L, Ao</li> </ul>			36 OCI	Balance platform	Time			$\leftarrow$	Mamelak <i>et al.</i> [56] (19)
5 mg       8 HYS       Stabilometer       Ao       A         20 HYS       Stabilometer       Time       A         20 HYS       Stabilometer       Time       A         20 HYS       Stabilometer       Time       A         21 HOS       Self-designed       0.1° body sway       A         8 HYS       Stabilometer       L, Ao, Vel, Acc       =         12 HYS       Stabilometer       L, Ao, Vel, Acc       =       -         12 HYS       Stabilometer       L, Ao, Vel, Acc       =       -       -         ann       30 mg       21 HYS       Sway table       TPS       -       -       -         12 HYS       Sway table       TPS       -	Nitrazepam	10 mg	14 HYS	Force platform	Body sway		II	$\leftarrow$	Mattila <i>et al.</i> [72] (20)
20 HYS       Stabilometer       Time       Time         24 HOS       Self-designed       0.1° body sway       >         24 HOS       Self-designed       0.1° body sway       >         8 HYS       Stabilometer       L, Ao, Vel, Acc       =       >         12 HYS       Stabilometer       L, Ao, Vel, Acc       =       >         12 HYS       Stabilometer       L, Ao, Vel, Acc       =       >         12 HYS       Stabilometer       L, Ao, Vel, Acc       =       =       >         12 HYS       Stabilometer       L, Ao, Vel, Acc       =       =       >         12 HYS       Sway table       TPS       =       =       1         alm       30 mg       21 HYS       Sway table       TPS       =       =       1         almate half-life (8-24 h)       19 HYS       Sway table       TPS       =       1       1         almate 1.5 mg       19 HYS       Sway table       TPS       =       1       1         almate 1.5 mg       19 HYS       Sway table       TPS       =       1       1         almate 1.5 mg       19 HYS       Sway table       TPS       1       1       1 <td>(26±3)</td> <td>5 mg</td> <td>8 HYS</td> <td>Stabilometer</td> <td>Ao</td> <td><math>\leftarrow</math></td> <td>II</td> <td></td> <td>Tazaki <i>et al.</i> [116] (17)</td>	(26±3)	5 mg	8 HYS	Stabilometer	Ao	$\leftarrow$	II		Tazaki <i>et al.</i> [116] (17)
24 HOS       Self-designed       0.1° body sway         8 HYS       Stabilometer       L, Ao, Vel, Acc       =         12 HYS & Ataxia meter       Cumulative sway       =       -         12 HYS & Stabilometer       L, Ao, Vel, Acc       =       -         12 HYS & Stabilometer       L, Ao, Vel, Acc       =       =         12 HYS & Sway table       TPS       →       -       -         12 HYS & Sway table       TPS       →       -       -         aliate half-life (8-24 h)       19 HYS & Sway table       TPS       +       -       -         15 mg       21 HYS       Sway table       TPS       +       +       -       -         aliate half-life (8-24 h)       19 HYS & Sway table       TPS       + <td></td> <td></td> <td>20 HYS</td> <td>Stabilometer</td> <td>Time</td> <td></td> <td><math>\leftarrow</math></td> <td></td> <td>Hindmarch [120] (15)</td>			20 HYS	Stabilometer	Time		$\leftarrow$		Hindmarch [120] (15)
sway meter 8 HYS Stabilometer L, Ao, Vel, Acc = 12 HYS Rabilometer L, Ao, Vel, Acc = 12 HYS Stabilometer L, Ao, Vel, Acc = 8 HYS Stabilometer L, Ao, Vel, Acc = 8 HYS Sway table TPS + alone 1.5 mg 21 HYS Sway table TPS + alone 1.5 mg 21 HYS Sway table TPS + 17 HOS 5 way table TPS + 18 way table TPS + 19 way table TPS			24 HOS	Self-designed	0.1° body sway			$\leftarrow$	Campbell & Somerton [115] (18)
8 HYS       Stabilometer       L, Ao, Vel, Acc       =         12 HYS       Ataxia meter       Cumulative sway       =         12 HOS       8 HYS       Stabilometer       L, Ao, Vel, Acc       =         12 HOS       8 HYS       Stabilometer       L, Ao, Vel, Acc       =         12 HOS       8 HYS       Stabilometer       L, Ao, Vel, Acc       =         8 HYS       Stabilometer       L, Ao, Vel, Acc       =       =         12 HOS       Sway table       TPS       >       =       =         aliate half-life (8-24 h)       19 HYS       Sway table       TPS       >       = <td></td> <td></td> <td></td> <td>sway meter</td> <td></td> <td></td> <td></td> <td></td> <td></td>				sway meter					
am 30 mg 21 HYS & Ataxia meter Cumulative sway = 12 HOS Stabilometer L, Ao, Vel, Acc = 8 HYS Stabilometer L, Ao, Vel, Acc = 8 HYS Sway table TPS = 7 Ao, Vel, Acc = 15 mg 21 HYS Sway table TPS = 7 A = 17 HYS Sway table TPS = 7 A = 17 HOS = 24 HYS Force platform Body sway = 17 HYS = 24 HYS Force platform Body sway = 17 HYS = 20 HYS = 50			8 HYS	Stabilometer	L, Ao, Vel, Acc	II			Tada <i>et al.</i> [117] (20)
am 30 mg 12 HOS 8 HYS Stabilometer L, Ao, Vel, Acc = 8 HYS Sway table TPS + <i>diate half-life (8-24 h)</i> lam 1.5 mg 21 HYS Sway table TPS + 1.5 mg 1.5 mg 19 HYS & Sway table TPS + 1.7 HOS Sway table TPS + 0.75 mg 19 HYS & Sway table TPS + 1.7 HOS Force platform Body sway = 2.4 HYS Force platform Body sway = 2.4 HYS Force platform Body sway = 2.4 HYS Force platform SE + 2.4 HYS Force platform SE = 2.4 HYS Force platform SE = 2.4 HYS Force platform L + 2.5 mg 2.0 HYS Force platform L + 2.6 mg 16 HYS Force platform L + 2.6 mg 2.0 HYS Force platform L + 3.6 mg 2.0 HYS Force platform 2 mg 2.0 HYS Force platf			12 HYS &	Ataxia meter	Cumulative sway	Ш			Castleden <i>et al.</i> [54] (18)
am 30 mg 21 HYS Stabilometer L, Ao, Vel, Acc = 15 mg 21 HYS Sway table TPS + Ao, Vel, Acc = <i>diate half-life (8-24 h)</i> lam 1.5 mg 21 HYS Sway table TPS + A = 1.5 mg 19 HYS & Sway table TPS + A = 1.7 HOS = 0.75 mg 19 HYS & Sway table TPS + A = 1.7 HOS = 0.75 mg 24 HYS Force platform Body sway = 24 HYS Force platform Body sway = 24 HYS Force platform Body sway = 24 HYS Force platform SE = m 20 mg 16 HYS Force platform SE = 20 HYS Force platform L + Ao + A = 20 HYS Force platform L + Ao + A = 20 HYS Force platform L + Ao + A = 20 HYS Force platform L + Ao + A = 20 HYS Force platform L + Ao + A = 20 HYS Force platform L + Ao + A = 20 HYS Force platform L + A = 20 HYS Force platform H + A = 20 HYS Force platform L + A =			12 HOS						
am 30 mg 21 HYS Sway table TPS 7 15 mg 21 HYS Sway table TPS 7 <i>diate half-life (8-24 h)</i> 13 mg 19 HYS & Sway table TPS 7 17 HOS 0.75 mg 19 HYS & Sway table TPS 7 17 HOS 0.75 mg 24 HYS Force platform Body sway = 24 HYS Force platform Body sway = 24 HYS Force platform Body sway = 24 HYS Force platform SE 7 m 20 mg 16 HYS Force platform SE 7 20 HYS Force platform L 1 20 HYS Force platform L 1 20 HYS Force platform L 2 20 HYS Force platform L 1 20 HYS Force platform L 2 20 HYS Force platfor			8 HYS	Stabilometer	L, Ao, Vel, Acc		II	П	Muraoka <i>et al.</i> [118] (18)
15 mg 21 HYS Sway table TPS = 1 diate half-life (8-24 h) lam 1.5 mg 19 HYS & Sway table TPS $\uparrow$ $1.5 mg 19 HYS & Sway table TPS \uparrow1.7 HOS 0.75 mg 19 HYS & Sway table TPS \uparrow1.7 HOS 24 HYS Force platform Body sway = 124 HYS Force platform Body sway = 124 HYS Force platform SE = 1m 20 mg 16 HYS Force platform SE = 120 HYS Force platform L \uparrow \uparrow \uparrowzepam 2 mg 20 HYS Force platform L \downarrow Ao \uparrow \uparrow$	Quazepam	30 mg	21 HYS	Sway table	TPS	$\leftarrow$			Nikaido & Ellinwood [123] (19)
diate half-life (8-24 h) lam 1.5 mg 19 HYS & Sway table TPS $\uparrow$ 17 HOS 19 HYS & Sway table TPS $\uparrow$ 0.75 mg 19 HYS & Sway table TPS $\uparrow$ 17 HOS 24 HYS Force platform Body sway = 24 HYS Force platform Body sway = 24 HYS Force platform SE $\uparrow$ $\uparrow$ = m 20 mg 16 HYS Force platform SE = 20 HYS Force platform $\Sigma$ $\uparrow$ $\uparrow$ = 20 HYS Force platform $\Sigma$ $\downarrow$ $\downarrow$ $\uparrow$ = 20 HYS Force platform $L$ $\downarrow$	(±39)	15 mg	21 HYS	Sway table	TPS	Ш			Nikaido & Ellinwood [123] (19)
Iam       1.5 mg       19 HYS & Sway table       TPS       7         Iam       1.5 mg       19 HYS & Sway table       TPS       7         0.75 mg       19 HYS & Sway table       TPS       7         17 HOS       Sway table       TPS       7         0.75 mg       19 HYS & Sway table       TPS       7         17 HOS       Sway table       TPS       7         17 HOS       Sway table       TPS       7         17 HOS       24 HYS       Force platform       Body sway       =         24 HYS       Force platform       Body sway       =       =       1         epam       6 mg       16 HYS       Force platform       SE       7       =       1         m       20 mg       16 HYS       Force platform       SE       =       =       =       =       1         m       20 mg       16 HYS       Force platform       L       7       7       1       =       1         m       20 mg       16 HYS       Force platform       L       1       7       1       =       1       =       1       =       1       =       1       1       1       1 <td>Intermediate hal</td> <td>f life (2-21 h)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Intermediate hal	f life (2-21 h)							
lam 1.5 mg 19 HYS & Sway table TPS $\uparrow$ 17 HOS 17 HOS Sway table TPS $\uparrow$ 17 HOS Sway table TPS $\uparrow$ 17 HOS Force platform Body sway = 24 HYS Force platform Body sway = 24 HYS Force platform SE $\uparrow$ m 20 mg 16 HYS Force platform SE = 20 HYS Force platform SE = 20 HYS Force platform L $\uparrow$ 20 HYS Force platform L $\downarrow$ A0 $\uparrow$	ווורבו וובמומרב וומי	J-11Jc (0-24 11)							
0.75 mg 19 HYS & Sway table TPS ↑ 17 HOS 24 HYS Force platform Body sway = 24 HYS Force platform Body sway = 17 HYS Force platform Body sway = 16 HYS Force platform SE = 1 = 1 = 1 = 1 = 10 mg 16 HYS Force platform L Ao ↑ ↑ 00 mg 16 HYS Force platform L Ao ↑ ↑ 00 mg 16 HYS Force platform L Ao ↑ ↑ 00 mg 16 HYS Force platform L Ao ↑ ↑ 00 mg 16 HYS Force platform L Ao ↑ ↑ 00 mg 16 HYS Force platform L Ao ↑ ↑ 00 mg 16 HYS Force platform L Ao ↑ ↑ 00 mg 16 HYS Force platform L Ao ↑ ↑ 1 mg 16 HYS Force platform L Ao ↑ ↑ 00 mg 10 hYS Force platform L Ao ↑ ↑ ↑ 00 mg 10 hYS Force platform L Ao ↑ ↑ 00 mg 10 hYS Force platform L Ao ↑ ↑ 00 mg 10 hYS Force platform L Ao ↑ ↑ 00 mg 10 hYS Force platform L Ao ↑ ↑ 00 mg 10 hYS Force platform L Ao ↑ ↑ 00 mg 10 hYS Force platform L Ao ↑ ↑ ↓ 00 mg 10 hYS Force platform L Ao ↑ ↑ ↓ 00 mg 10 hYS Force platform L Ao ↑ ↑ ↓ 00 mg 10 hYS Force platform L Ao ↑ ↑ ↓ 00 mg 10 hYS Force platform L Ao ↑ ↑ ↓ 00 mg 10 hYS Force platform L Ao ↑	Alprazolam (12-15)	1.5 mg	19 HYS & 17 HOS	Sway table	TPS	$\leftarrow$			Nikaido <i>et al.</i> [124] (17)
17 HOS17 HOS $24 \text{ HYS}$ Force platformBody sway $6 \text{ mg}$ $16 \text{ HYS}$ Force platform $6 \text{ mg}$ $16 \text{ HYS}$ Force platform $86 \text{ mg}$ $16 \text{ HYS}$ Force platform $86 \text{ mg}$ $20 \text{ mg}$ $16 \text{ HYS}$ $20 \text{ HYS}$ Force platformL $20 \text{ HYS}$ Force platformL $1 \text{ mg}$ $16 \text{ HYS}$ Force platform $1 \text{ mg}$ $16 \text{ HYS}$ Force platform $1 \text{ mg}$ $16 \text{ HYS}$ Force platform		0.75 mg	19 HYS &	Sway table	TPS	$\leftarrow$			Nikaido <i>et al.</i> [124] (17)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			17 HOS						
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			24 HYS	Force platform	Body sway			П	Aranko <i>et al.</i> [73] (19)
epam 6 mg 16 HVS Force platform SE $\uparrow$ = 1 m 20 mg 16 HVS Force platform SE = 7 = 1 20 HVS Stabilometer Time $\uparrow$ = 7 zepam 2 mg 20 HVS Force platform L $\uparrow$ $\uparrow$ $\uparrow$ 1 1 mg 16 HVS Force platform L Ao $\uparrow$ $\uparrow$		0.25 mg	24 HYS	Force platform	Body sway	Ш			Aranko <i>et al.</i> [73] (19)
m 20 mg 16 HVS Force platform SE = $= 1$ 20 HVS Stabilometer Time $\uparrow$ 1 zepam 2 mg 20 HVS Force platform L $\uparrow$ $\uparrow$ 5 1 mg 16 HVS Force platform L, Ao $\uparrow$ $\uparrow$ 5	Bromazepam	6 mg	16 HYS	Force platform	SE	$\leftarrow$		П	Patat & Foulhoux [107] (20)
Im 20 mg 16 HVS Force platform SE = $= 1$ 20 HVS Stabilometer Time $\uparrow$ 1 zepam 2 mg 20 HVS Force platform L $\uparrow$ $\uparrow$ 3 1 mg 16 HVS Force platform L, Ao $\uparrow$ $\uparrow$ $\downarrow$	(16-24)								
20 HYS Stabilometer Time $\uparrow$ zepam 2 mg 20 HYS Force platform L $\uparrow$ $\uparrow$ 1 mg 16 HYS Force platform L, Ao $\uparrow$	Clobazam	20 mg	16 HYS	Force platform	SE	11		Ш	Patat & Foulhoux [107] (20)
2 mg 20 HYS Force platform L イート・1 1 mg 16 HYS Force platform L, Ao イ	(18-32)		20 HYS	Stabilometer	Time		$\leftarrow$		Hindmarch [120] (15)
1 mg 16 HVS Force platform L, Ao $\uparrow$	Flunitrazepam	2 mg	20 HYS	Force platform	_		$\leftarrow$		Seppälä <i>et al.</i> [88] (21)
	(18-26)	1 mg	16 HYS	Force platform	L, Ao	$\leftarrow$			Allain <i>et al.</i> [99] (22)

Drug	Daily dose	Subjects	Method	Outcome	Ш	Ħ	Ш	Study (quality score) <sup>a</sup>
(t <sub>1/2</sub> , in h)				variables				
Lorazepam (14 + 5)	2.5 mg	12 HYS	Unknown elec- tronic device	Body sway	÷			Seppälä <i>et al.</i> [128] (21)
	2 mg	16 HYS	Force platform	L. Ao	$\leftarrow$	$\leftarrow$		Patat <i>et al</i> . [100] (22)
	)	12 HYS	Force platform	L, Ao	~	$\leftarrow$		Norris <i>et al.</i> [101] (22)
		16 HYS	Force platform	Ao	$\leftarrow$	II		Patat <i>et al.</i> [96] (22)
		20 HYS <sup>b</sup>	Ataxia meter	Body sway	$\leftarrow$	II		de Haas <i>et al.</i> [46] (22)
		12 HYS	Ataxia meter	Body sway	$\leftarrow$	II		de Haas <i>et al.</i> [47] (21)
		$12 \text{ HYS}^{b}$	Ataxia meter	Body sway	$\leftarrow$	Ш		de Haas <i>et al.</i> [48] (22)
		16 HYS	Force platform	SE	$\leftarrow$		П	Patat & Foulhoux [107] (20)
		$12 \text{ HYS}^{b}$	Force platform	Body sway	$\leftarrow$		П	Vanakoski <i>et al.</i> [74] (23)
		27 HYS	Force platform	Body sway	$\leftarrow$			Hege <i>et al.</i> [75] (22)
		18 HYS	Force platform	L, Ao	$\leftarrow$			Perault <i>et al.</i> [94] (21)
	1 mg	12 HOS <sup>b</sup>	Force platform	L, Ao	$\leftarrow$			Allain <i>et al.</i> [95] (24)
		12 HOS	Force platform	L, Ao	$\leftarrow$			Patat <i>et al.</i> [102] (20)
	0.057 mg/kg	6 HYS	Force platform	FPS	$\leftarrow$			Gupta <i>et al.</i> [85] (16)
Lormetazepam (10 ± 2.5)	1 mg	48 HOS <sup>b</sup>	Force platform	L, Ao	$\leftarrow$	Ш		Allain <i>et al.</i> [97] (24)
Loprazolam (8-12)	1 mg	10 HYS & 9 HOS	Ataxia meter	%°AS	$\leftarrow$	$\leftarrow$		Swift <i>et al.</i> [40] (21)
	0.5 mg	10 HYS & 9 HOS	Ataxia meter	%°AS	$\leftarrow$	II		Swift <i>et al.</i> [40] (21)
Oxazepam	30 mg	12 HYS	Force platform	Body sway	Ш			Mattila <i>et al.</i> [70] (19)
$(8 \pm 2.4)$	15 mg	14 HYS	Force platform	Body sway	$\leftarrow$			McDevitt <i>et al.</i> [76] (19)
		12 HYS	Force platform	Body sway	$\leftarrow$			McDevitt <i>et al.</i> [77] (18)
		12 HYS	Force platform	Body sway	$\leftarrow$			Nicholson <i>et al.</i> [78] (13)
		14 HYS	Force platform	Body sway	Ш			Nicholson <i>et al.</i> [79] (14)
Temazepam (11 + 6)	30 mg	14 HYS	Balance platform	Time	$\leftarrow$	II		Roth <i>et al.</i> [55] (20)

Table 5.3. Continued

	20 mg	9 HYS & 9 HOS	Ataxia meter	Body sway	$\leftarrow$			Swift <i>et al.</i> [49] (13)
		16 HYS	Ataxia meter	Body sway	$\leftarrow$			van der Post <i>et al.</i> [50] (22)
		10 HYS & 10 HOS	Ataxia meter	%°AS	Ш	Ш		Briggs <i>et al.</i> [41] (20)
		14 HYS	Force platform	Body sway		Ш	Ш	Mattila <i>et al.</i> [72] (20)
	15 mg	14 HYS	Balance platform	Time	Ш	Ш		Roth <i>et al</i> . [55] (20)
Short half-life (<8 h)	(4							
Brotizolam (4.4)	0.25 mg	36 OCI	Balance platform	Time			$\leftarrow$	Mamelak <i>et al.</i> [56] (19)
Midazolam	0.080 mg/kg	12 HYS	Force platform	_	$\leftarrow$			Mattila <i>et al.</i> [89] (20)
$(1.9 \pm 0.6)$	15 mg	11 HYS	Force platform	L, Ao	$\leftarrow$			Patat <i>et al.</i> [103] (21)
		12 HYS &	Ataxia meter	Cumulative sway	II			Castleden <i>et al.</i> [54] (18)
		TT HUS						
	5 mg	8 HOS	Force platform	L, Ao	II			Krupka <i>et al</i> . [104] (19)
riazolam	1 mg	21 HYS	Sway table	TPS	$\leftarrow$			Nikaido & Ellinwood [123] (19)
$(2.9 \pm 1.0)$		10 HYS	Force platform	FPS	$\leftarrow$			Gupta <i>et al</i> . [86] (16)
	0.5 mg	19 HYS &	Sway table	TPS	$\leftarrow$			Nikaido <i>et al</i> . [124] (17)
		17 HOS						
		21 HYS	Sway table	TPS	$\leftarrow$			Nikaido & Ellinwood [123] (19)
	0.375 mg	6 HYS	Force platform	Ao	$\leftarrow$	II		Robin <i>et al.</i> [62] (20)
		16 HOS <sup>b</sup>	Force platform	Ao	$\leftarrow$			Kinirons <i>et al.</i> [63] (22)
		9 HYS &	Force platform	Ao	$\leftarrow$			Robin <i>et al.</i> [64] (21)
		SOH 6						
	0.25 mg	18 HYS	Force platform	Ao	$\leftarrow$	II		Berlin <i>et al.</i> [65] (22)
		19 HYS &	Sway table	TPS	$\leftarrow$			Nikaido <i>et al</i> . [124] (17)
		17 HOS						
		8 HYS	Stabilometer	L, Ao, Vel, Acc	$\leftarrow$			Tada <i>et al.</i> [117] (20)
		8 HYS	Force-sensitive	L, Ao	$\leftarrow$			Nakamura <i>et al.</i> [111] (19)
			insoles					
		12 HYS	Force platform	Body sway	II			Kuitunen <i>et al.</i> [80] (20)
			Ctabilomotor			I	I	110/ [110] / 2 - 10/ 110/

Drug (t <sub>1/2</sub> , in h)	Daily dose	Subjects	Method	Outcome variables	¥	뽀	Ë	Study (quality score) <sup>a</sup>
		24 HOS	Self-designed	0.1° body sway			←	Campbell & Somerton [115] (18)
		у НУС	Eorca platform	0	÷	I		Bohin <i>at al</i> [62] /30)
			Dombora toct	Scoro	-			1000111 51 41. [02] (20) Hill of al [111] (10)
		011.0		30016	_	I		
	0.125 mg	6 HYS	Force platform	Ao	II	II		Robin <i>et al.</i> [62] (20)
Benzodiazepine ı	Benzodiazepine receptor agonists							
Alpidem (18-20)	50 mg	16 HYS	Force platform	L, Ao	II	Ш		Patat <i>et al.</i> [96] (22)
Zaleplon (1-2)	10 mg	16 HYS <sup>b</sup>	Force platform	Ao	$\leftarrow$			Whitmore <i>et al.</i> [66] (23)
Zolpidem	15 mg	12 HYS	Force platform	Body sway	$\leftarrow$			Mattila <i>et al.</i> [70] (19)
$(1.9 \pm 0.2)$	10 mg	18 HYS	Force platform	Ao	$\leftarrow$	Ш		Berlin <i>et al.</i> [65] (22)
		14 HYS	Ataxia meter	Body sway	$\leftarrow$	II		de Haas <i>et al.</i> [51] (21)
		16 HYS	Force platform	L, Ao	$\leftarrow$			Allain <i>et al.</i> [99] (22)
		12 HOS	Force platform	ES	$\rightarrow$			Zammit <i>et al.</i> [83] (22)
		8 HYS	Force-sensitive	L, Ao	$\leftarrow$			Nakamura <i>et al.</i> [111] (19)
			insoles					
	5 mg	48 HOS <sup>b</sup>	Force platform	L, Ao	$\leftarrow$	П		Allain <i>et al.</i> [97] (24)
		24 HOS <sup>b</sup>	Force platform	L, Ao	$\leftarrow$	$\leftarrow$		Boyle <i>et al.</i> [105] (25)
Zopiclone	7.5 mg	8 HYS	Stabilometer	L, Ao, Vel, Acc	$\leftarrow$			Tada <i>et al.</i> [117] (20)
(3.5-6.5)		12 HYS	Force platform	Body sway	$\leftarrow$			Mattila <i>et al.</i> [70] (19)
		12 HYS	Force platform	Body sway	$\leftarrow$			Mattila <i>et al.</i> [69] (21)
		16 HYS	Force platform	L, Ao	$\leftarrow$			Allain <i>et al.</i> [99] (22)
		12 HYS	Force platform	Body sway	$\leftarrow$			Kuitunen <i>et al.</i> [81] (20)
		12 HYS	Force platform	Body sway	Ш			Kuitunen <i>et al.</i> [80] (20)
		20 HYS	Force platform	_		Ш		Seppälä <i>et al.</i> [88] (21)
	3.75 mg	48 HOS <sup>b</sup>	Force platform	L, Ao	$\leftarrow$	п		Allain <i>et al.</i> [97] (24)

108

Table 5.3. Continued

cadence (steps/min); CSV common sway vector (the areas between the mean positions of the center of pressure integrated and divided by the sampling 3.3 As 33 degree of angle of sway; Acc mean acceleration (m/s2); Amp amplitude; Ao area included within the path of the center of pressure (in cm2); Cad SE spectral energies (total energy, (0-0.5 HZ) energy band, (0.5-2 Hz) energy band; SL step length (cm); SF sway frequency (sway units per centimeter of older subjects; HYS healthy young subjects; LTE Long-term effects; NE Nightly effects; OCI older subjects with chronic insomnia; TPS total power score; scales below 2.5 Hz obtained from four directions; HE Hangover effects; L total length of displacement of the center of pressure (in cm); HOS healthy time; in cm x 0.01); ES equilibrium scores of the sensory organization test (higher score indicates better balance); FPS summarized frequency power displacement of the center of gravity); Stab length and amplitude of stabilogram; Vel mean velocity (cm/s); WS walking speed (m/s);  $\pi$  significant increase in outcome variable; = no significant change in outcome variable; ↓ significant decrease in outcome variable <sup>a</sup> Downs and Black score (max. 28 points)

<sup>b</sup> A power analysis was performed to estimate the sample size

during quiet standing was found as a nightly effect among healthy young subjects for flurazepam 15 and 30 mg [55], nitrazepam 5 mg [116], and quazepam 30 mg [123]; as a hangover effect for flurazepam 30 mg [98], and nitrazepam 5 mg [120]; and as a long-term effect for flurazepam 15 mg [56], and nitrazepam 10 and 5 mg [72, 115]. Other studies did not find any significant effects on standing steadiness for benzodiazepines with a long half-life [54, 114, 117, 118].

## Benzodiazepines with an intermediate half-life (8-24 h)

The effects of benzodiazepines with an intermediate half-life were examined in 31 studies for healthy young subjects [40, 41, 46–50, 55, 70, 72–79, 85, 88, 94, 96, 99–101, 107, 120, 124, 128], and older people [40, 41, 49, 95, 97, 102, 124]. Significant nightly effects on postural control, quantified by increased parameters indicating body sway, were found for alprazolam  $\geq$ 0.75 mg [124], bromazepam 6 mg [107], flunitrazepam 1 mg [99], lorazepam  $\geq$ 1 mg [46–48, 74, 75, 85, 94, 96, 100, 101, 107, 128], lormetazepam 1 mg [97], loprazolam  $\geq$ 0.5 mg [40], oxazepam 15 mg [76–78], and temazepam 20 mg [49, 50, 55]. Hangover effects were found for clobazam 20 mg [120], flunitrazepam 2 mg [88], lorazepam 2 mg [100, 101], and loprazolam 1 mg [40]. Other studies did not find any hangover effects on parameters indicating quiet standing abilities [40, 41, 46–48, 55, 72, 96, 97]. Long-term effects on postural control when using benzodiazepines with an intermediate half-life were not found [72–74, 107].

## Benzodiazepines with a short half-life (<8 h)

The effects of benzodiazepines with a short half-life on body sway were examined for 18 studies in healthy young subjects [54, 62, 64, 65, 80, 86, 89, 103, 111, 114, 117, 118, 123, 124], and older subjects [54, 63, 64, 104, 115, 124], and older persons with chronic insomnia [56]. Midazolam 15 mg [103], and 0.080 mg/kg [89], and triazolam  $\geq$ 0.25 mg [62–65, 86, 111, 114, 117, 123, 124] had significant nightly effects on postural control during standing, indicated by increased parameters of body sway. There were no hangover effects found for the benzodiazepines with a short half-life [62, 65, 114, 118]. Long-term effects were only investigated in two studies, whereof one study found that body sway was significantly greater after using 0.25 mg triazolam for one week [115]. The other study did not find any long-term effects for this drug on body sway [118].

## Benzodiazepine receptor agonists

Body sway has been investigated in 15 studies among healthy young subjects [51, 65, 66, 69, 70, 80, 81, 88, 96, 99, 111, 117], and older subjects [83, 97, 105] for four

Chapter 5A

benzodiazepine receptor agonists: alpidem [96], zopiclone (both intermediate half-life) [69, 70, 80, 81, 88, 97, 99, 117], zaleplon [66], and zolpidem (both short half-life) [51, 65, 70, 83, 97, 99, 105, 111]. Alpidem 50 mg did not have significant nightly or hangover effects among healthy young subjects [96]. Six studies found significant nightly impairments in standing steadiness for zopiclone 7.5 mg [69, 70, 81, 99, 117], and 3.75 mg [97]. There were no hangover effects found for benzodiazepine receptor agonists with an intermediate half-life on postural control [88, 97].

Nine studies found nightly effects, indicated by increased body sway parameters, for zaleplon 10 mg [66], and zolpidem  $\geq$ 5 mg [51, 65, 70, 83, 97, 99, 105, 111]. One study found a hangover effect for zolpidem 5 mg [105], whereas other studies did not [51, 65, 97].

## Summary

It can be concluded that benzodiazepines and benzodiazepine receptor agonists have effects on postural control within 8 h after administration (the so-called nightly effects). These effects are more pronounced when the dosage is higher, and when people are older. Hangover effects on postural control (more than 8 h after administration) are, as expected, more present in benzodiazepines with an intermediate or long half-life (half-life >8 h) than in drugs with a short half-life (<8 h). The long-term effects of these drugs on postural control are not fully clear, because results differed strongly between studies and the methodological quality of these studies was moderate. Therefore, we suggest that more research of higher quality is needed to investigate the long-term effects of benzodiazepines on postural control.

#### Antiepileptic drugs

AEDs are used in older patients, not only to treat epilepsy, but also as mood stabilizers and to treat a variety of other conditions, e.g., post-herpetic neuralgia, and other neuropathic pain. The frequency of AED use in nursing homes is in the range of 10-12% [153, 154]. In people with epilepsy, falls and skeletal fractures are significantly more frequent than in the general population, and less than half are directly related to seizures [155]. Therefore, it is suggested that some falls may be caused by medication effects [156], because dizziness, ataxia, and unsteady gait are known adverse effects of AEDs [157]. Furthermore, using AEDs is associated with a reduced bone mineral density and lower levels of vitamin D, and therefore increases the risk of fractures [158].

Drug	Daily dose (mg)	Subjects	Method	Outcome variables	Effect	Study (quality score) <sup>a</sup>
Carbamazepine	600	22 PTN	Force platform	ES	$\rightarrow$	Delcker <i>et al.</i> [84] (15)
		12 HYS	Ataxia meter	Body sway	$\leftarrow$	Hamilton <i>et al.</i> [52] (19)
		12 HYS	Force platform	Body sway	$\leftarrow$	Kuitunen <i>et al.</i> [81] (20)
	400	6 HYS	Ataxia meter	Body sway	$\leftarrow$	Hockings <i>et al</i> . [53] (19)
		5 HOS	Ataxia meter	Body sway	$\leftarrow$	Hockings <i>et al</i> . [53] (19)
		12 HYS	Stabilometer	RMS sway	$\leftarrow$	Noachtar <i>et al.</i> [119] (19)
		22 PTN	Force platform	ES	$\rightarrow$	Delcker <i>et al.</i> [84] (15)
		12 HYS	Ataxia meter	Body sway	Ш	Hamilton <i>et al.</i> [52] (19)
		12 HYS	Electronic sway meter	Amp	Ш	Wildin <i>et al.</i> [60] (22)
	200	22 PTN	Force platform	ES	Ш	Delcker <i>et al.</i> [84] (15)
		12 HYS	Ataxia meter	Body sway	Ш	Hamilton <i>et al.</i> [52] (19)
Gabapentin	600	12 HYS	Stabilometer	RMS sway	$\leftarrow$	Noachtar <i>et al.</i> [119] (19)

Hamilton *et al*. [52] (19)

 ${}^{\scriptscriptstyle \|} \leftarrow {}^{\scriptscriptstyle \|}$ 

Body sway

12 HYS **12 HYS** 

Gabapentin Lamotrigine

Ataxia meter Ataxia meter Ataxia meter Ataxia meter

Body sway Body sway Body sway Body sway

12 HYS **12 HYS 12 HYS** 

**12 HYS** 

300 240 150

%°AS

Hamilton *et al.* [52] (19) Cohen et al. [38] (19)

Cohen et al. [38] (19) Cohen et al. [38] (19) Cohen et al. [38] (19)

 $" \leftarrow$ П

Ataxia meter

Ataxia meter

**12 HYS** 

1000

Phenytoin

500

120

0
Ľ
U L
8
_
σ
E L
st
õ
Q
ō
S
Ö
÷
d
Ð
÷.
a d
· <u> </u>
Ц
an
пs
õ
·Ĕ
đ
>
4
0
S
Ч
ă
£
Ţ.
a)
ž
亡
۰.
4
പ്
<u>_</u>
Р
שי
F

Amp mean amplitude of sway; ES equilibrium score of the sensory organization test (higher score indicates better balance); HOS healthy older subjects; mean square of anterior-posterior and medio-lateral sway;  $\Lambda$  significant increase in outcome variable; = no significant change in outcome variable;  $\downarrow$ HYS healthy young subjects; L total length of displacement of the center of pressure (in cm); PTN patients with trigeminal neuralgia; RMS sway root

significant decrease in outcome variable; <sup>a</sup> Downs and Black score (max. 28 points)

Part II: Medication-use

The effects of AEDs on postural control have been investigated in seven studies among healthy young subjects [38, 52, 53, 60, 81, 119], and older subjects [53], and patients with trigeminal neuralgia [84] (Table 5.4). The methodological quality score of these studies was in the range of 15-22 points. None of these studies performed a power analysis to estimate the sample size.

Among healthy subjects, postural control was impaired, as quantified by more body sway, when using carbamazepine 600 mg [52, 81], and 400 mg [53, 119], although two studies did not find significantly increased body sway for carbamazepine 400 mg among healthy young subjects [52, 60]. Postural control was not significantly impaired by a lower dose of carbamazepine [52]. Body sway was significantly increased when using gabapentin 600 mg [119] and lamotrigine 240 mg [38]. Other dosages, including a higher dose of lamotrigine (300 mg), did not impair postural control [38, 52]. Furthermore, 1,000 mg of phenytoin increased body sway significantly, whereas a lower dosage of 500 mg did not [38].

Among patients with trigeminal neuralgia, postural stability was reduced when using >400 mg of carbamazepine [84]. A lower dose of carbamazepine did not impair postural control in this patient group [84].

AEDs seem to impair postural control when administered in relatively higher doses. It is therefore recommended, if appropriate, to administer AEDs only at the lowest effective dose.

## Cardiac drugs

Other than the already discussed psychotropic FRIDs, there are some cardiac drugs associated with an increased risk of falling: digoxin, type IA antiarrhythmics and diuretics [10]. However, these associations were weak since pooled odds ratios for these drugs were in the range of 1.08-1.59 [10]. It was therefore questioned by Leipzig *et al.* [10] whether these cardiac medications substantially increase the risk of falls. Because there is a (weak) association between these cardiac FRIDs and falling, it has been examined whether there is also an association with impaired postural control, as this is one of the primary causes of falling [15]. The effects of the known cardiac FRIDs on postural control are discussed below.

### Digoxin

Digoxin is a cardiac glycoside and is widely used in the treatment of heart conditions, namely rate control in atrial fibrillation and heart failure that cannot be controlled by other medication. As far as the authors know, the effects of digoxin use on postural control have not yet been investigated, although this drug may cause adverse effects that may impair postural control, for instance, dizziness, blurred vision, or cardiovascular adverse effects such as arrhythmias.

## Type IA antiarrhythmics

Type IA antiarrhythmics are typically used for supraventricular tachycardia and arrhythmias. This class of anti-arrhythmic agents includes disopyramide, procainamide, and quinidine. There were no studies found examining the effects of type IA antiarrhythmics on postural control. However, these drugs may cause adverse effects that may be associated with impairments in postural control, such as hypotension, arrhythmias (bradycardia), or blurred vision.

## Diuretics

Diuretics are used to treat hypertension, and as a therapy for heart failure, ascites in liver cirrhosis, and nephrotic syndrome. There are various types of diuretics, e.g., highceiling loop diuretics, thiazides, potassium-sparing diuretics, and osmotic diuretics. These drugs may cause adverse effects that may cause impairments in postural control, for example, orthostatic hypotension, arrhythmias, or hypokalemia, which may cause muscle weakness. Diuretics have been associated with an increased risk of falling [10]. However, thiazide diuretics appear to reduce the risk of hip fracture [159], perhaps because chronic ingestion of thiazides is associated with higher bone mineral density [160].

Two studies have examined the effects of a thiazide diuretic, bendroflumethiazide (formerly named bendrofluazide), on body sway among healthy young subjects [45, 77]. Gerrard *et al.* [45] did not find any significant effects of bendroflumethiazide 5 mg on the amount of body sway. On the other hand, McDevitt *et al.* [77] found increased amplitude of body sway for bendroflumethiazide 2.5 mg, where the increase in amplitude of body sway was not significantly affected in higher doses.

Study (quality score) <sup>a</sup>	Study design	Sample (n <sub>total</sub> ; age; gender; population)	CON and INT activities	Method	Outcome variables	Results
van der Velde <i>et al.</i> [161] (23)	Prospective cohort study	137 <sup>b</sup> ; 77.7±5.7 y; 72% F; patients visiting a geriatric outpatient clinic and using ≥1 FRIDs <sup>c</sup>	INT: fallers with FRID withdrawal in 1-month CON: non- fallers without FRID change	10m WT; TUG; FR; IQFMS; body sway with force platform	10m WT – time (s); TUG – time (s); FR – distance reaching forward (cm); IQFMS – strength (N); body sway – length of displacement of center of gravity (cm)	Fallers with FRID change: 10m WT -1.3 s ( $p$ = 0.021); TUG -3.0 s ( $p$ = 0.026); FR +0.5 cm (NS); IQFMS +7 N (NS); body sway -3.8 cm (NS) (NS) Fallers without FRID change: 10m WT +3.4 s ( $p$ = 0.004); TUG +3.8 s ( $p$ = 0.002); FR - 3.0 cm ( $p$ = 0.002); IQFMS +4 N (NS); body sway -2.6 cm (NS) Non-fallers without FRID change: 10 m WT +1.2 s ( $p$ < 0.001); TUG +1.6 s ( $p$ = 0.003); FR - 0.003); FR -4.3 cm ( $p$ < 0.001); IQFMS -2.7 N ( $p$ = 0.003); FR - 0.004); TUG +1.6 s ( $p$ = 0.003); FR -4.3 cm ( $p$ < 0.001); IQFMS -2.004)
Tsunoda <i>et</i> <i>al.</i> [162] (23)	Open-label study	30; 79.1±8.9 y; 43% F; nurs- ing home residents receiving BZD as hvonotic	INT: tapering off BZD over 3 weeks CON: NA	Clinical Stabilometric Platform	Range (cm <sup>2</sup> ) and total length (cm) of trunk motion during 30 s with eyes opened and closed	0.000), body sway $\pm 0.1011$ ( $p = 0.004$ ) Change: total length of trunk motion, eyes open -0.5 cm (NS), eyes closed -1.5 cm ( $p =$ 0.002); range of trunk motion, eyes open - 0.02 cm <sup>2</sup> ( $p = 0.046$ ), eyes closed -1.51 cm <sup>2</sup> ( $p = 0.010$ )
<b>BZD</b> benzodiazi quadriceps ferr <sup>a</sup> Downs and Bl. <sup>b</sup> A power analy <sup>c</sup> FRIDs in this si vasodilators, dij	<b>BZD</b> benzodiazepine; <b>CON</b> control group; quadriceps femoris muscle strength (N); N <sup>a</sup> Downs and Black score (max. 28 points); <sup>b</sup> A power analysis was performed to estin <sup>c</sup> FRIDs in this study were defined as anxio vasodilators, digoxin, β-adrenoceptor anti	<b>3ZD</b> benzodiazepine; <b>CON</b> control group; <b>F</b> female; <b>FR</b> function quadriceps femoris muscle strength (N); <b>NA</b> not available; <b>NS</b> n Downs and Black score (max. 28 points); A power analysis was performed to estimate the sample size; FRIDs in this study were defined as anxiolytics/hypnotics, anti asodilators, digoxin, β-adrenoceptor antagonist eye drops, an	F functional r vailable; NS not s vailable; S not s s sample size; ypnotics, antipsy eye drops, analg	each test (cm); <b>FR</b> significant; <b>TUG</b> tir chotics, antidepre esics (mainly opioi	<b>BZD</b> benzodiazepine; <b>CON</b> control group; <b>F</b> female; <b>FR</b> functional reach test (cm); <b>FRID</b> fall risk increasing drug; <b>INT</b> interventio quadriceps femoris muscle strength (N); <b>NA</b> not available; <b>NS</b> not significant; <b>TUG</b> timed up & go test (s); <b>WT</b> walking time (s); <sup>a</sup> Downs and Black score (max. 28 points); <sup>b</sup> A power analysis was performed to estimate the sample size; <sup>c</sup> FRIDs in this study were defined as anxiolytics/hypnotics, antipsychotics, antidepressants, antihypertensives, antihrsthmic vasodilators, digoxin, β-adrenoceptor antagonist eye drops, analgesics (mainly opioids), anticholinergic drugs, antihistamines,	BZD benzodiazepine; CON control group; F female; FR functional reach test (cm); FRID fall risk increasing drug; INT intervention group; IQFMS isometric quadriceps femoris muscle strength (N); NA not available; NS not significant; TUG timed up & go test (s); WT walking time (s); <sup>a</sup> Downs and Black score (max. 28 points); <sup>b</sup> A power analysis was performed to estimate the sample size; <sup>c</sup> FRIDs in this study were defined as anxiolytics/hypnotics, antidepressants, antihypertensives, antiarrhythmics, nitrates and other vasodilators, digoxin, β-adrenoceptor antagonist eve drops, analgesics (mainly opioids), anticholinergic drugs, antihytamines, antivertigo drugs and

Table 5.5. Effect of FRID withdrawal on postural control

antihyperglycaemics

# Effects of FRIDs withdrawal on postural control

Because psychotropic drugs have been associated with numerous deleterious effects, including impaired postural control and increased risk of falling, it could be argued that the use of psychotropic drugs in older people should be reduced to a minimum. Withdrawal of FRIDs, especially psychotropic drugs, reduces the risk of falling, as three intervention studies concluded [11–13]. It is questioned whether this effect is induced by an improved postural control.

We only found two studies examining the effects of discontinuation of FRIDs on postural control (see Table 5.5) [161, 162]. Van der Velde *et al.* [161] showed that among geriatric outpatients, withdrawal of FRIDs significantly improved walking time on the 10-m walking test and the TUG over a mean follow-up period of 6.7 months. The results of Tsunoda *et al.* [162] are in line with these results, that is, they found that discontinuation of benzodiazepine hypnotics was feasible in a majority of older persons. Benzodiazepine withdrawal resulted in a significant improvement in the stability of the body and a recovery of cognitive functions during the daytime.

## Discussion

Psychotropics and some cardiac drugs are associated with an increased risk of falling in older adults [6–10]. The aim of the present literature review was to examine the effects of these so-called FRIDs on postural control. Of the 94 included studies, there were 71 that found impairments in postural control after using FRIDs, all using objective measures to assess postural control during standing or walking. In the reviewed studies, affected postural control during standing was indicated by an increase in parameters quantifying body sway (e.g., greater CoP displacement, larger postural sway), while impairments in postural control during walking were quantified by, amongst others, slower walking speed, smaller step length, and lower cadence.

The present review showed that of the known FRIDs, especially psychotropic drugs affected postural control. Among the antidepressant, neuroleptic, and antiepileptic medications, there were specific drugs with specific daily dosages significantly affecting postural control in healthy young subjects and older subjects. Of the antidepressants, administering the TCA amitriptyline  $\geq$ 50 mg resulted in significantly impaired postural control. The CNL haloperidol  $\geq$ 3 mg, and the AAPs olanzapine 3 mg, and risperidone  $\geq$ 1 mg, were the drugs in the group of neuroleptics affecting postural control. In addition,

Chapter 5A

among the AEDs, carbamazepine  $\geq$ 400 mg, gabapentin 600 mg, lamotrigine 240 mg, and phenytoin 1,000 mg caused significant more body sway.

In particular, the effects of using benzodiazepines on postural control have been studied in a large number of studies. These studies showed that benzodiazepines had an effect on postural control within 8 h after administration, the so-called nightly effects. These effects were larger when people were older, and when the daily dose was higher. Hangover effects on postural control (after 8 h of administration) were mainly found for benzodiazepines with an intermediate and a long half-life. The long-term effects of benzodiazepines on postural control are not fully clear yet. Importantly, the effects of these psychotropic FRIDs on postural control were reversible after discontinuation, as two intervention studies concluded [161, 162].

In contrast to psychotropic FRIDs, we only found two studies of the possible effects of a cardiac FRID, bendroflumethiazide, a thiazide diuretic, on postural control during standing or walking [45, 77]. Although cardiac drugs have been reported to increase fall risk [10], the present review, with only two studies, did only find a significant effect of bendroflumethiazide 2.5 mg on body sway in healthy young subjects [77], whereas higher doses did not show any effect [45, 77]. Presumably, the increased fall risk these cardiac FRIDs are associated with is not caused by impairments in postural control, but is more likely a direct result of the underlying cardiovascular disease, e.g., arrhythmias, or the adverse effects these drugs may induce, such as orthostatic hypotension.

On the other hand, the effects of psychotropic drugs on postural control, and consequently on fall risk, are likely to be induced by the adverse effects of these drugs. All psychotropic FRIDs have sedative effects, inducing muscle relaxation and decreased grip strength [163], therefore impairing postural control [164]. In addition, TCAs and neuroleptics can cause orthostatic hypotension [138]. It is likely that an acute orthostatic drop in blood pressure may lead to diminished blood flow to the brain, causing acute and temporal difficulties in maintaining postural control, which may subsequently lead to falls [165]. CNLs, SSRIs, and some AEDs may cause extrapyramidal adverse effects, such as parkinsonism (tremor, bradykinesia, muscle rigidity), causing postural instability, and consequently increase the risk of falling [166].

Furthermore, the effects of psychotropic FRIDs on cognitive functioning [150] might indirectly influence postural control. Current evidence suggests that postural control, during both quiet standing and walking, is closely related to cognition, especially with executive functions, e.g., attention, planning, and working memory [32, 34, 167]. Especially among older persons, the age-related loss of visual, proprioceptive, and vestibular sensitivity requires more conscious attention for maintaining postural stability

during standing and walking [168]. Consequently, as results of the present review showed, effects of psychotropic drugs on postural control are more pronounced in older than younger subjects.

The quality of the listed evidence was moderate to good, as Downs and Black methodological quality scores were in the range of 13-25 points. Only 11 of the 94 reviewed studies estimated sample size by a priori power analysis, all other studies should have done this because the sample size was quite low. None of the studies reported any information regarding external validity, so it was not clear from which population subjects were recruited. The examined older subjects were healthy and relatively young (around 65 years of age), therefore it can be questioned what impact FRIDs would have on postural control in frailer older people with multiple co-morbidities and taking multiple medications. Further research should investigate this.

To conclude, the review shows that it has been underestimated that FRIDs have negative effects on postural control in older people due to their sedative adverse effects, which may consequently contribute to fall risk. Therefore, it is important that physicians take into account the adverse effects of psychotropic drugs on postural control, and consequently fall risk, when prescribing these types of drugs to older patients. Preferably, psychotropic drugs should only be administered after consideration of other pharmacological (with potentially less effect on postural control) or non-pharmacological interventions, and when administered, only at the lowest effective dose, with a short half-life, and for a limited period of time. Interestingly, the adverse effects of FRIDs have been reported to be reversible, for postural control [161, 162], cognition [169], and for fall incidents [11–14]. For older patients who are using psychotropic drugs on a regular basis, withdrawing or reducing the use FRIDs appears to be effective [170]. Patients who need psychotropic drugs, even on a reduced dose, may consider reducing their risk of falling by physical exercise involving gait, standing balance, or muscle strengthening [24].

To monitor the effects of (withdrawing) FRIDs on postural control, and adjust the intervention accordingly, refined analyses of postural control are needed, which can be obtained from computerized instruments, e.g., force platforms, electronic walkways, or body-worn sensors. Monitoring postural control among older persons who start or stop using psychotropic drugs may give relevant information about the effects of these drugs on the ability to maintain, achieve, or restore a state of balance during any posture or activity, and may therefore detect patients at risk for falling. Then, (preventive) interventions can be offered, for instance, withdrawing or reducing psychotropic drug

use, and/or exercise training, to prevent falls and possible adverse injuries, for instance, hip fractures or head trauma.

# Conclusion

Increased fall risk from the use of psychotropic drugs is associated with impairments in postural control these drugs can induce. The effects seem to be more pronounced in the older than the younger population, and when the daily dose is higher and the half-life and duration are longer. The effects on postural control, as well as the mediating sedative adverse effects such as impaired cognitive functioning and muscle relaxation, are reversible after withdrawing FRIDs as was proven in a small number of intervention studies. The findings of the present literature review highlight the importance of monitoring effects of psychotropic drugs on postural control, to detect patients at risk for falling, and offer them interventions, e.g., discontinuing or reducing the use of psychotropic drugs, or offering physical exercise training, to prevent them for possible adverse fall-related injuries, such as hip fractures.

# References

**1.** Ziere G, Dieleman JP, Hofman A, *et al.* (2006) Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 61:218– 23.

**2.** Beers MH, Baran RW, Frenia K (2000) Drugs and the elderly, Part 1: The problems facing managed care. Am J Manag Care 6:1313–20.

**3.** Aparasu RR, Mort JR, Brandt H (2003) Psychotropic prescription use by communitydwelling elderly in the United States. J Am Geriatr Soc 51:671–7.

**4.** Hartikainen S, Rahkonen T, Kautiainen H, Sulkava R (2003) Use of psychotropics among home-dwelling nondemented and demented elderly. Int J Geriatr Psychiatry 18:1135–41.

**5.** Zuidema SU, de Jonghe JFM, Verhey FRJ, Koopmans TCM (2011) Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians' prescription behavior. Int Psychogeriatrics 23:1632–9.

**6.** Bloch F, Thibaud M, Dugué B, *et al.* (2011) Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 23:329–46.

**7.** Woolcott JC, Richardson KJ, Wiens MO, *et al.* (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–60.

**8.** Hartikainen S, Lönnroos E, Louhivuori K (2007) Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 62A:1172–81. **9.** Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 47:30–9.

**10.** Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 47:40–50.

**11.** Van der Velde N, Stricker BHC, Pols HAP, van der Cammen TJM (2007) Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 63:232–7.

**12.** Campbell AJ, Robertson MC, Gardner MM, *et al.* (1999) Psychotropic medication withdrawal and a home-based exercise program to prevent falls, a RCT. J Am Geriatr Soc 47:850–3.

**13.** Salonoja M, Salminen M, Vahlberg T, Aarnio P (2012) Withdrawal of psychotropic drugs decreases the risk of falls requiring treatment. Arch Gerontol Geriatr 54:160–7.

**14.** Hill KD, Wee R (2012) Psychotropic druginduced falls in older people. A review of interventions aimed at reducing the problem. Drugs Aging 29:15–30.

**15.** Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ (2007) Will my patient fall? JAMA 297:77–86.

**16.** Lord SR, Anstey KJ, Williams P, Ward JA (1995) Psychoactive medication use, sensori-motor function and falls in older women. Br J Clin Pharmacol 39:227–34. **17.** Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–84.

**18.** Pollock AS, Durward BR, Rowe PJ, Paul JP (2000) What is balance? Clin Rehabil 14:402–6.

**19.** Lamoth CJC, van Heuvelen MJG (2012) Sports activities are reflected in the local stability and regularity of body sway: older ice-skaters have better postural control than inactive elderly. Gait Posture 35:489–93.

**20.** Vuillerme N, Nafati G (2007) How attentional focus on body sway affects postural control during quiet standing. Psychol Res 71:192–200.

**21.** Lamoth CJC, van Lummel RC, Beek PJ (2009) Athletic skill level is reflected in body sway: a test case for accelometry in combination with stochastic dynamics. Gait Posture 29:546–51.

**22.** Schmit JM, Regis DI, Riley MA (2005) Dynamic patterns of postural sway in ballet dancers and track athletes. Exp Brain Res 163:370–8.

**23.** Sturnieks DL, St George R, Lord SR (2008) Balance disorders in the elderly. Clin Neurophysiol 36:467–78.

**24.** Howe TE, Rochester L, Neil F, *et al.* (2011) Exercise for improving balance in older people. Cochrane Database Syst Rev 11:CD004963.

**25.** Schmit JM, Riley MA, Dalvi A, *et al.* (2006) Deterministic center of pressure patterns characterize postural instability in Parkinson's disease. Exp Brain Res 168:357–67. **26.** Houdijk H, Nooijen C, Rijntjes D, *et al.* (2010) Energy expenditure of stroke patients during postural control tasks. Gait Posture 32:321–6.

**27.** Street H, Menz HB, Lord SR, Fitzpatrick RC (2003) Age-related differences in walking stability. Age Ageing 32:137–142.

**28.** Podsiadlo D, Richardson S (1991) The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39:142–8.

**29.** Berg KO, Maki BE, Williams JI, *et al.* (1992) Clinical and laboratory measures of postural balance in an elderly population. Arch Phys Med Rehabil 73:1073–80.

**30.** Tinetti ME (1986) Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34:119–26.

**31.** Gil AWO, Oliveira MR, Coelho VA, *et al.* (2011) Relationship between force platform and two functional tests for measuring balance in the elderly. Rev Bras Fisioter 15:429–35.

**32.** Lamoth CJC, van Deudekom FJ, van Campen JPCM, *et al.* (2011) Gait stability and variability measures show effects of impaired cognition and dual tasking in frail people. J Neuroeng Rehabil 8:2.

**33.** Lamoth CJC, Ainsworth E, Polomski W, Houdijk H (2010) Variability and stability analysis of walking of transfemoral amputees. Med Eng Phys 32:1009–14.

**34.** IJmker T, Lamoth CJC (2012) Gait and cognition: the relationship between gait stability and variability with executive function in persons with and without dementia. Gait Posture 35:126–30.

**35.** Kinirons MT, Jackson SH, Kalra L, *et al.* (1993) Computerised psychomotor performance testing: A comparative study of the single dose pharmacodynamics of minaprine and amitriptyline in young and elderly subjects. Br J Clin Pharmacol 36:376–9.

**36.** Legangneux E, McEwen J, Wesnes KA, *et al.* (2000) The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol 14:164–71.

**37.** Fagan D, Scott DB, Mitchell M, Tiplady B (1991) Effects of remoxipride on measures of psychological performance in healthy volunteers. Psychopharmacology 105:225–9.

**38.** Cohen AF, Ashby L, Crowley D, *et al.* (1985) Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 20:619–29.

**39.** Swift CG, Ewen JM, Clarke P, Stevenson IH (1985) Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol 20:111–8.

**40.** Swift CG, Swift MR, Ankier SI, *et al.* (1985) Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly. Br J Clin Pharmacol 20:119–28.

**41.** Briggs RS, Castleden CM, Kraft CA (1980) Improved hypnotic treatment using chlormethiazole and temazepam. Br Med J 280:601–4. **42.** Swift CG, Haythorne JM, Clarke P, Stevenson IH (1981) Cardiovascular, sedative and anti-cholinergic effects of amitriptyline and zimelidine in young and elderly volunteers. Acta Psychiatr Scand Suppl 290:425–32.

**43.** Van Steveninck AL, Gieschke R, Schoemaker RC, *et al.* (1996) Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 41:565–73.

**44.** Gerrard L, Wheeldon NM, McDevitt DG (1995) Effect of combined atenolol and nifedipine administration on psychomotor performance in normal subjects. Eur J Clin Pharmacol 48:229–33.

**45.** Gerrard L, Wheeldon NM, McDevitt DG (1993) Central effects of combined bendro-fluazide and atenolol administration. A single dose study in normal subjects. Eur J Clin Pharmacol 45:539–43.

**46.** De Haas SL, Franson KL, Schmitt JAJ, *et al.* (2009) The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol 23:625–32.

**47.** De Haas SL, de Visser SJ, van der Post JP, *et al.* (2008) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 22:24–32.

**48.** De Haas SL, de Visser SJ, van der Post JP, *et al.* (2007) Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol 21:374–83.

**49.** Swift CG, Haythorne JM, Clarke P, Stevenson IH (1981) The effect of ageing on measured responses to single doses of oral temazepam. Br J Clin Pharmacol 11:413P–4P.

**50.** Van der Post JP, Schram MT, Schoemaker RC, *et al.* (2002) CNS effects of sumatriptan and rizatriptan in healthy female volunteers. Cephalalgia 22:271–81.

**51.** De Haas SL, Schoemaker RC, van Gerven JMA, *et al.* (2010) Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 24:1619–29.

**52.** Hamilton MJ, Cohen AF, Yuen AW, *et al.* (1993) Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 34:166–73.

**53.** Hockings N, Pall A, Moody J, *et al.* (1986) The effects of age on carbamazepine pharmaco-kinetics and adverse effects. Br J Clin Pharmacol 22:725–8.

**54.** Castleden CM, Allen JG, Altman J, St John-Smith P (1987) A comparison of oral midazolam, nitrazepam and placebo in young and elderly subjects. Eur J Clin Pharmacol 32:253–7.

**55.** Roth T, Piccione P, Salis P, *et al.* (1979) Effects of temazepam, flurazepam and quinalbarbitone on sleep: Psychomotor and cognitive function. Br J Clin Pharmacol 8:47S–54S.

**56.** Mamelak M, Csima A, Buck L, Price V (1989) A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 9:260–7.

**57.** Liem-Moolenaar M, te Beek ET, de Kam ML, *et al.* (2010) Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 24:1697–708.

**58.** Liem-Moolenaar M, Gray FA, de Visser SJ, *et al.* (2010) Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol 24:73–82.

**59.** Liem-Moolenaar M, Rad M, Zamuner S, *et al.* (2011) Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. Br J Clin Pharmacol 71:907–16.

**60.** Wildin JD, Pleuvry BJ, Mawer GE (1993) Impairment of psychomotor function at modest plasma concentrations of carbamazepine after administration of the liquid suspension to naive subjects. Br J Clin Pharmacol 35:14–9.

**61.** Cutson TM, Gray SL, Hughes MA, *et al.* (1997) Effect of a single dose of diazepam on balance measures in older people. J Am Geriatr Soc 45:435–40.

**62.** Robin DW, Hasan SS, Lichtenstein MJ, *et al.* (1991) Dose-related effect of triazolam on postural sway. Clin Pharmacol Ther 49:581–8.

**63.** Kinirons MT, Lang CC, He HB, *et al.* (1996) Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: Ethnicity and CYP3A activity. Br J Clin Pharmacol 41:69–72.

**64.** Robin DW, Hasan SS, Edeki T, *et al.* (1996) Increased baseline sway contributes to increased losses of balance in older people following triazolam. J Am Geriatr Soc 44:300–4.

**65.** Berlin I, Warot D, Hergueta T, *et al.* (1993) Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 13:100–6.

**66.** Whitmore JN, Fischer JR, Barton EC, Storm WF (2004) Performance following a sudden awakening from daytime nap induced by zaleplon. Aviat Space Environ Med 75:29–36.

**67.** Linnoila M, Johnson J, Dubyoski K, *et al.* (1984) Effects of antidepressants on skilled performance. Br J Clin Pharmacol 18:109S–20S.

**68.** Strömberg C, Mattila MJ (1985) Acute and subacute effects on psychomotor performance of femoxetine alone and with alcohol. Eur J Clin Pharmacol 28:641–7.

**69.** Mattila MJ, Vanakoski J, Mattila ME, Karonen S-L (1994) Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects. Eur J Clin Pharmacol 46:215–20.

**70.** Mattila MJ, Vanakoski J, Kalska H, Seppälä T (1998) Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav 59:917–23.

**71.** Palva ES (1985) Gender-related differences in diazepam effects on performance. Med Biol 63:92–5.

**72.** Mattila MJ, Aranko K, Mattila ME, Strömberg C (1984) Objective and subjective assessment of hangover during subacute administration of temazepam and nitrazepam to healthy subjects. Eur J Clin Pharmacol 26:375–80.

**73.** Aranko K, Mattila MJ, Bordignon D (1985) Psychomotor effects of alprazolam and diazepam during acute and subacute treatment, and during the follow-up phase. Acta Pharmacol Toxicol 56:364–72.

**74.** Vanakoski J, Seppälä T, Strömberg C, *et al.* (2001) Effects of ceronapril alone or in combination with alcohol on psychomotor performance in healthy volunteers: a placebo-controlled, crossover study. Curr Ther Res 62:699–708.

**75.** Hege SG, Ellinwood EH, Wilson WH, *et al.* (1997) Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam. Psychopharmacology 131:101–7.

**76.** McDevitt DG, Currie D, Nicholson AN, *et al.* (1991) Central effects of the calcium antagonist, nifedipine. Br J Clin Pharmacol 32:541–9.

**77.** McDevitt DG, Currie D, Nicholson AN, *et al.* (1994) Central effects of the diuretic, bendro-fluazide. Br J Clin Pharmacol 38:249–56.

**78.** Nicholson AN, Wright NA, Zetlein MB, *et al.* (1988) Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway. Br J Clin Pharmacol 26:129–41.

**79.** Nicholson AN, Wright NA, Zetlein MB, *et al.* (1990) Central effects of the angiotensinconverting enzyme inhibitor, captopril. II. Electroencephalogram and body sway. Br J Clin Pharmacol 30:537–46.

**80.** Kuitunen T, Mattila MJ, Seppälä T (1990) Actions and interactions of hypnotics on human performance: Single doses of zopiclone, triazolam, and alcohol. Int Clin Psychopharmacol 5:115–30.

**81.** Kuitunen T, Matrila MJ, Seppälä T, *et al.* (1990) Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests. Br J Clin Pharmacol 30:453–61.

**82.** Jansen EC, Wachowiak-Andersen G, Münster-Swendsen J, Valentin N (1985) Postural stability after oral premedication with diazepam. Anesthesiology 63:557–9.

**83.** Zammit G, Wang-Weigand S, Peng X (2008) Use of computerized dynamic posturography to assess balance in older adults after nighttime awakenings using zolpidem as a reference. BMC Geriatr 8:15. **84.** Delcker A, Wilhelm H, Timmann D, Diener HC (1997) Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans. Eur Neuropsychopharmacol 7:213–8.

**85.** Gupta SK, Ellinwood EH, Nikaido AM, Heatherly DG (1990) Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam. J Pharmacokinet Biopharm 18:89–102.

**86.** Gupta SK, Ellinwood EH, Nikaido AM, Heatherly DG (1990) Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam. Pharm Res 7:570–6.

**87.** Mattila MJ, Patat A, Seppälä T, *et al.* (1996) Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. Eur J Clin Pharmacol 51:161–6.

**88.** Seppälä T, Nuotto E, Dreyfus JF (1983) Drugalcohol interactions on psychomotor skills: Zopiclone and flunitrazepam. Pharmacology 27:127–35.

**89.** Mattila MJ, Mattila ME, Olkkola KT, Scheinin H (1991) Effect of dexmedetomidine and midazolam on human performance and mood. Eur J Clin Pharmacol 41:217–23.

**90.** Rosenzweig P, Patat A, Zieleniuk I, *et al.* (1998) Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor. Clin Pharmacol Ther 64:211–22. **91.** Laghrissi-Thode F, Pollock BG, Miller MC, *et al.* (1995) Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients. Psychopharmacol Bull 31:659–63.

**92.** Mamo DC, Pollock BG, Mulsant B, *et al.* (2002) Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. Am J Geriatr Psychiatry 10:199–205.

**93.** Laghrissi-Thode F, Pollock BG, Miller MC, *et al.* (1995) Comparative effects of sertraline and nortriptyline on body sway in older depressed patients. Am J Geriatr Psychiatry 3:217–28.

**94.** Perault M-C, Bergougnan L, Paillat A, *et al.* (1998) Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers. Hum Psychopharmacol 13:493–500.

**95.** Allain H, Tessier C, Bentué-Ferrer D, *et al.* (2003) Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers. Psychopharmacology 165:419–29.

**96.** Patat A, Perault M-C, Vandel B, *et al.* (1995) Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers. J Psychopharmacol 9:91–101.

**97.** Allain H, Bentué-Ferrer D, Tarral A, Gandon J-M (2003) Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, crossover, double-blind study versus placebo. Eur J Clin Pharmacol 59:179–88. **98.** Boyle J, Wolford D, Gargano C, *et al.* (2009) Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects. Hum Psychopharmacol 24:61–71.

**99.** Allain H, Patat A, Lieury A, *et al.* (1995) Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry 10:129s–35s.

**100.** Patat A, Perault M-C, Vandel B, *et al.* (1995) Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers. Br J Clin Pharmacol 39:31–8.

**101.** Norris V, Baisley KJ, Calder N, *et al.* (2005) Assessment of the AccuSwayPLUS system in measuring the effect of lorazepam on body sway in healthy volunteers. Int J Pharm Med 19:233–8.

**102.** Patat A, Alberini H, Bonhomme D, *et al.* (1999) Effects of tiapride on electroencephalograms and cognitive functions in the elderly. Int Clin Psychopharmacol 14:199–208.

**103.** Patat A, Molinier P, Hergueta T, *et al.* (1994) Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist. Int Clin Psychopharmacol 9:155–62.

**104.** Krupka E, Venisse N, Lafay C, *et al.* (2006) Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol 62:653–9. **105.** Boyle J, Danjou P, Alexander R, *et al.* (2009) Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. Br J Clin Pharmacol 67:180–90.

**106.** Patat A, Klein MJ, Hucher M, Granier J (1988) Acute effects of amitriptyline on human performance and interactions with diazepam. Eur J Clin Pharmacol 35:585–92.

**107.** Patat A, Foulhoux P (1985) Effect on postural sway of various benzodiazepine tranquillizers. Br J Clin Pharmacol 20:9–16.

**108.** Ghoneim MM, Mewaldt SP, Hinrichs J V (1984) Dose-response analysis of the behavioral effects of diazepam: II. Psychomotor performance, cognition and mood. Psychopharmacology 82:296–300.

**109.** Dorian P, Sellers EM, Reed KL, *et al.* (1983) Amitriptyline and ethanol: Pharmacokinetic and pharmacodynamic interaction. Eur J Clin Pharmacol 25:325–31.

**110.** Corbeil P, Rodrigue J, Simoneau M, *et al.* (2012) Influence of risperidone on balance control in young healthy individuals. Psychopharmacology 222:59–69.

**111.** Nakamura M, Ishii M, Niwa Y, *et al.* (2005) Temporal changes in postural sway caused by ultrashort-acting hypnotics: triazolam and zolpidem. ORL 67:106–12.

**112.** Draganich LF, Zacny J, Klafta J, Karrison T (2001) The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J Gerontol A Biol Sci Med Sci 56:M36–41.

**113.** Paleacu D, Shutzman A, Giladi N, *et al.* (2007) Effects of pharmacological therapy on gait and cognitive function in depressed patients. Clin Neuropharmacol 30:63–71.

**114.** Hill SY, Goodwin DW, Reichman JB, *et al.* (1982) A comparison of two benzodiazepine hypnotics administered with alcohol. J Clin Psychiatry 43:408–10.

**115.** Campbell AJ, Somerton DT (1982) Benzodiazepine drug effect on body sway in elderly subjects. J Clin Exp Gerontol 4:341–7.

**116.** Tazaki T, Tada K, Nogami Y, *et al.* (1989) Effects of butoctamide hydrogen succinate and nitrazepam on psychomotor function and EEG in healthy volunteers. Psychopharmacology 97:370–5.

**117.** Tada K, Sato Y, Sakai T, *et al.* (1994) Effects of zopiclone, triazolam, and nitrazepam on standing steadiness. Neuropsychobiology 29:17–22.

**118.** Muraoka M, Tada K, Nogami Y, *et al.* (1992) Residual effects of repeated administration of triazolam and nitrazepam in healthy volunteers. Pharmacopsychiatry 25:134–9.

**119.** Noachtar S, von Maydell B, Fuhry L, Büttner U (1998) Gabapentin and carbamazepine affect eye movements and posture control differently: A placebo-controlled investigation of acute CNS side effects in healthy volunteers. Epilepsy Res 31:47–7.

**120.** Hindmarch I (1979) Some aspects of the effects of clobazam on human psychomotor performance. Br J Clin Pharmacol 7:775–825.

**121.** Orr J, Dussault P, Chappel C, *et al.* (1976) Relation between drug-induced central nervous system effects and plasma levels of diazepam in man. Mod Probl Pharmacopsychiatry 11:57–67.

**122.** Nikaido AM, Ellinwood EH, Heatherly DG, Dubow D (1987) Differential CNS effects of diazepam in elderly adults. Pharmacol Biochem Behav 27:273–81.

**123.** Nikaido AM, Ellinwood EH (1987) Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance. Psychopharmacology 92:459–64.

**124.** Nikaido AM, Ellinwood EH, Heatherly DG, Gupta SK (1990) Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology 100:90–7.

**125.** McClelland GR, Cooper SM, Pilgrim AJ (1990) A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 30:795–803.

**126.** Beuzen JN, Taylor N, Wesnes KA, Wood A (1999) A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J Psychopharmacol 13:152–8.

**127.** Schuckit MA, Greenblatt D, Gold E, Irwin M (1991) Reactions to ethanol and diazepam in healthy young men. J Stud Alcohol 52:180–7.

**128.** Seppälä T, Aranko K, Mattila MJ, Shrotriya RC (1982) Effects of alcohol on buspirone and lorazepam actions. Clin Pharmacol Ther 32:201–7.

**129.** Van Vaerenbergh J, Broos P (1990) Positive Romberg test and the probability of falls in the aged. Tijdschr Gerontol Geriatr 21:71–4.

**130.** Wright BM (1971) A simple mechanical ataxia-meter. J Physiol 218:27P–8P.

**131.** Piirtola M, Era P (2006) Force platform measurements as predictors of falls among older people - a review. Gerontologia 52:1–16.

**132.** Caron O, Gelat T, Rougier P, Blanchi JP (2000) A comparative analysis of the center of gravity and center of pressure trajectory path lengths in standing posture: an estimation of active stiffness. J Appl Biomech 16:234–47.

**133.** Thapa PB, Gideon P, Brockman KG, *et al.* (1996) Clinical and biomechanical measures of balance as fall predictors in ambulatory nursing home residents. J Gerontol A Biol Sci Med Sci 51:M239–46.

**134.** Hausdorff JM, Rios DA, Edelberg HK (2001) Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch Phys Med Rehabil 82:1050–6.

**135.** Maki BE (1997) Gait changes in older adults: predictors of falls or indicators of fear. J Am Geriatr Soc 45:313–20.

**136.** Hausdorff JM, Edelberg HK, Cudkowicz ME, *et al.* (1997) The relationship between gait changes and falls. J Am Geriatr Soc 45:1406.

**137.** Plotnik M, Giladi N, Balash Y, *et al.* (2005) Is freezing of gait in Parkinson's disease related to asymmetric motor function? Ann Neurol 57:656–63.

**138.** Glassman AH, Bigger JT (1981) Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry 38:815–20.

**139.** Pacher P, Kecskemeti V (2004) Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 10:2463–2475.

**140.** Gill HS, DeVane CL, Risch SC (1997) Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 17:377–89.

**141.** Liu B, Anderson G, Mittmann N, *et al.* (1998) Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351:1303–7.

**142.** Thapa PB, Gideon P, Cost TW, *et al.* (1998) Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339:875– 82.

**143.** Tinetti ME (2003) Preventing falls in elderly persons. N Engl J Med 348:42–9.

**144.** Rubenstein LZ, Josephson KR (2002) The epidemiology of falls and syncope. Clin Geriatr Med 18:141–58.

**145.** Hausdorff JM, Yogev G, Springer S, *et al.* (2005) Walking is more like catching than tapping: gait in the elderly as a complex cognitive task. Exp Brain Res 164:541–8.

**146.** Jorm AF, Grayson DA, Creasey H, *et al.* (2000) Long-term benzodiazepine use by elderly people living in the community. Aust N Z J Public Health 24:7–10. **147.** Voyer P, Préville M, Cohen D, *et al.* (2010) The prevalence of benzodiazepine dependence among community-dwelling older adult users in Quebec according to typical and atypical criteria. Can J Aging 29:205–13.

**148.** Conn DK, Madan R (2006) Use of sleeppromoting medications in nursing home residents : risks versus benefits. Drugs Aging 23:271–87.

**149.** Ray WA (1992) Psychotropic drugs and injuries among the elderly: A review. J Clin Psychopharmacol 12:386–96.

**150.** Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Cognitive effects of long-term benzodiazepine use. CNS Drugs 18:37–48.

**151.** Madhusoodanan S, Bogunovic OJ (2004) Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 3:485–93.

**152.** Vermeeren A (2004) Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 18:297–328.

**153.** Cloyd JC, Lackner TE, Leppik IE (1994) Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med 3:589–98.

**154.** Garrard J, Cloyd JC, Gross C, *et al.* (2000) Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A Biol Sci Med Sci 55A:M384–92.

**155.** Persson HBI, Alberts KA, Farahmand BY, Tomson T (2002) Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 43:768–72.

**156.** Mattson RH, Gidal BE (2004) Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 5:S36–40.

**157.** Fife TD, Sirven J (2005) Antiepileptic drugs and their impact on balance. Aging health 1:147–55.

**158.** Nakken KO, Taubøll E (2010) Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf 9:561–71.

**159.** Aung K, Htay T (2011) Thiazide diuretics and the risk of hip fracture (Review). Cochrane Database Syst Rev 10:CD005185.

**160.** Morton DJ, Barrett-Connor E, Edelstein SL (1994) Thiazides and bone mineral density in elderly men and women. Am J Epidemiol 139:1107–15.

**161.** Van der Velde N, Stricker BHC, Pols HAP, van der Cammen TJM (2007) Withdrawal of fall-risk-increasing drugs in older persons: Effect on mobility test outcomes. Drugs Aging 24:691–9.

**162.** Tsunoda K, Uchida H, Suzuki T, *et al.* (2010) Effects of discontinuing benzodiazepinederivative hypnotics on postural sway and cognitive functions in the elderly. Int J Geriatr Psychiatry 25:1259–65.

**163.** Huang M-Y, Matsuura N, Kaneko Y, Ichinohe T (2012) Midazolam increases bite force during intravenous sedation. J Oral Maxillofac Surg 70:e458–63.

**164.** Alexander NB (1994) Postural control in older adults. J Am Geriatr Soc 42:93–108.

**165.** Gangavati A, Hajjar I, Quach L, *et al.* (2011) Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc 59:383– 9.

**166.** Louter M, Tromp SC (2009) Parkinsonism due to the medication [in Dutch]. Ned Tijdschr Geneeskd 153:A336.

**167.** Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM (2012) Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc 60:2127–36.

**168.** Massion J (1994) Postural control system. Curr Opin Neurobiol 4:877–87.

**169.** Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19:437–54.

**170.** Lader M, Tylee A, Donoghue J (2009) Withdrawing benzodiazepines in primary care. CNS Drugs 23:19–34.

# **CHAPTER 5B**

# Authors' reply to Toda: "The effects of fall-risk-increasing drugs on postural control: A literature review"

Maartje H. de Groot Jos P. C. M. van Campen Marije A. Moek Linda R. Tulner Jos H. Beijnen Claudine J. C. Lamoth

Drugs & Aging 2013; 30 (12): 1041-1042

Part II: Medication-use

## Letter to the Editor

We thank Dr. Toda [1] for his interesting question. Dr. Toda asked, in response to our literature review [2], whether psychotropic drugs with longer half-lives are more likely to increase fall risk than psychotropic drugs with shorter half-lives. In our paper [2], we concluded that psychotropic fall-risk-increasing drugs (FRIDs) cause impairments in postural control, which is probably one of the mediating factors for the increased fall risk with which these FRIDs are associated. The effects of psychotropic FRIDs on postural control are more pronounced when people are of higher age, use psychotropics at higher daily dosages, for a longer period of time, and when the half-life of the drug is longer. By the latter, we mean that the effects on postural control of benzodiazepines with intermediate to long half-lives (>8 h) sustain for a longer period of time after taking the drug (the so-called hangover effect).

Regrettably, since we only examined the effects of FRIDs on postural control [2]—not on fall risk—we cannot conclude whether psychotropic drugs with a longer half-life are more likely to increase the risk of falling than psychotropics with a shorter elimination time. However, an interesting study by De Vries *et al.* [3] has recently been published, examining prospectively whether long-acting benzodiazepines are associated with a higher fall risk than short-acting benzodiazepines. The findings of De Vries *et al.* [3] are in line with the meta-analysis of Leipzig *et al.* [4], namely that the use of short-acting benzodiazepines is not associated with a lower fall risk compared with long-acting benzodiazepines. Remarkably, it must be noted that the cut-off defining short and long half-life differs in studies: for instance, we defined short half-life as  $\leq 8$  h [2], De Vries *et al.* [3] defined it as  $\leq 10$  h, and Leipzig *et al.* [4] as  $\leq 24$  h.

Thus, it can be stated that both short- and long-acting psychotropics increase the risk of falling in older people, the former not more than the latter. However, we can speculate about the moment and location of fall incidents caused by psychotropic FRIDs. For example, it can be hypothesized that short-acting benzodiazepines (mainly hypnotics) increase the risk of falling during the night, for instance when walking to the toilet because of nocturia (the nightly effects); while long-acting benzodiazepines (mainly anxiolytics) may increase the risk of falling both during the night and daytime because of residual daytime sleepiness (the hangover effect).

Nevertheless, the use of psychotropic FRIDs, both with short and long half-lives, should be discouraged in the older population, and when administered, only at the lowest effective dose and for a limited period of time.

# References

**1.** Toda K (2013) Comment on: The effects of fallrisk-increasing drugs on postural control: A literature review. Drugs Aging 30:1040.

**2.** De Groot MH, van Campen JPCM, Moek MA, *et al.* (2013) The effects of fall-risk-increasing drugs on postural control: a literature review. Drugs Aging 30:901–20.

**3.** De Vries OJ, Peeters GMEE, Elders PJM, *et al.* (2013) The elimination half-life of benzodiazepines and fall risk: Two prospective observational studies. Age Ageing 42:764–70.

**4.** Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 47:30–9.

# **CHAPTER 6**

# The association of medication-use and frailty-related factors with gait performance in older patients

Maartje H. de Groot Jos P. C. M. van Campen Nienke M. Kosse Oscar J. de Vries Jos H. Beijnen Claudine J. C. Lamoth

PLoS ONE 2016; 11 (2): e0149888

# Abstract

The increased fall risk associated with the use of psychotropic drugs might be caused by underlying problems in postural control that are induced by sedative side-effects of these drugs. The current literature on the effects of psychotropics on postural control only examined acute single-drug effects, and included relatively healthy young elderly. Consequently, it is unclear what the impact of the long-term use of these drugs is on gait in frail older persons with polypharmacy. Therefore, it was aimed in the present study to explore the association between the use of psychotropics, multiple other medications, frailty-related parameters and gait performance in older patients. Eighty older persons (79±5.6 years) were recruited. Comorbid diseases, frailty-related parameters, and medication-use were registered. Trunk accelerations during a 3minute-walking-task were recorded, whereof walking speed, mean stride times, coefficient of variation (CV) of stride times, and step consistency were determined. Multivariate Partial Least Squares (PLS) regression analysis was used to examine the association between population characteristics and medication-use, versus gait parameters. A PLS-model existing of four latent variables was built, explaining 45% of the variance in four gait parameters. Frailty-related factors, being female, and laxativeuse were most strongly associated with lower walking speed, higher mean stride times, higher CV of stride times, and less consistent steps. In conclusion, frailty-related parameters were stronger associated with impaired gait performance than the use of psychotropic drugs. Possibly, at a certain frailty-level, the effect of the deterioration in physical functioning in frailty is so large, that the instability-provoking side-effects of psychotropic drugs have less impact on gait.

# Introduction

Older persons visiting a geriatric outpatient clinic are characterized by a combination of physical, psychological and social problems. They often have multiple chronic conditions, and use therefore multiple medications (polypharmacy). These frail old people have a high risk of adverse events, such as falling, hospital admissions, and ultimately death [1, 2].

The past decades, many risk factors for falls in elderly people have been identified, which can be classified as either intrinsic (e.g., age-related changes in the sensor-motor system leading to gait and balance deficits), extrinsic (e.g., polypharmacy), or environmental factors [3]. In addition, meta-analyses showed that specific medication classes, including psychotropics and some cardiac drugs, have been associated with an increased risk of falling [4-7]. In a recent literature review [8], we suggested that the increased fall risk with which these psychotropic drug classes are associated, is caused by underlying problems in postural control these drugs can induce. That is because postural instability during daily activities, such as walking, is a primary cause of falling [9]. Walking can be characterized by a wide variety of gait parameters, each characterizing different aspects of the gait pattern. Walking speed is easily assessable and often used in clinical practice to reflect the functional status in older patients [10]. However, it lacks specificity (gait speed is slower in many different pathologies), and does not reveal information about the quality of the walking pattern, i.e., the ability of a person to adapt his/her gait smoothly, and the variability and regularity of the gait pattern. Stride-to-stride variability during walking provides additional information about gait performance, since high variability in stride times in frail elderly can be considered as a marker of abnormal regulation of gait [11, 12]. Both walking speed and characteristics indicating the variability in the walking pattern are suggested to be associated with increased fall risk [13, 14].

The current literature about the effects of psychotropic drugs on postural control assessed postural control during quiet standing, described only acute single-drug effects, and included relatively healthy young elderly [8]. Thus, the impact of long-term psychotropic drug-use on gait performance in frail older people with multiple comorbid diseases and polypharmacy remains still unclear.

In the present study, we therefore aimed to explore the association between the use of psychotropic drugs and gait performance in a cohort of older patients. Because in this frail older population many factors may be simultaneously present that could influence gait (e.g., the use of multiple medications, the presence of comorbid diseases, cognitive impairment, and/or frailty [11, 12, 15, 16]), we included these factors in our analyses as well. The use of a cross-sectional study design, and a Partial Least Squares (PLS) regression analysis, enabled us to examine the association between the use of psychotropic drugs and gait parameters, in relation to other factors that might influence the walking pattern. We hypothesized that a deterioration in gait performance was not only explained by the use of psychotropics, but that in older patients frailty-related parameters, polypharmacy and comorbidity would also be associated.

## Methods

## Ethics statement

The study was approved by the local Medical Ethics Committee of the MC Slotervaart (registration number: NL33825.048.10). All participants or their legal representatives (when participants had cognitive impairment) gave their written informed consent.

## Participants

Eighty patients were recruited consecutively among the elderly that visited the geriatric outpatient clinic of the MC Slotervaart in Amsterdam between October 2010 and April 2013. They were referred to the clinic by their general practitioner for various reasons, including memory complaints, mobility problems, or for evaluating polypharmacy. Patients were eligible to participate in the study if they were at least 65 years or older, and could walk safely for at least 3-minutes without any assistive device. They were excluded when they had any mobility problems due to neurological or orthopedic disorders, or were not able to understand the instructions of the researcher due to severe cognitive or hearing impairment.

During the study period, 619 older adults visited the geriatric outpatient clinic. Thereof, 392 patients (63%) did not meet the in- and exclusion criteria. In total, 227 (37%) patients were eligible, whereof 80 patients (13% of all visitors of the geriatric outpatient clinic) were willing to cooperate in the present study. The other 147 patients refused to cooperate because they felt too tired after the day in the hospital or did not want to cooperate (without giving reason).

## Measurements

#### Population characteristics

All participants underwent extensive physical and cognitive examination, as part of a Comprehensive Geriatric Assessment (CGA) [17]. General information was obtained from their patient file. All population characteristics were binary coded for statistical analyses. Age was coded as being  $\geq$ 80 or <80 years, because this was the mean age of the included participants). Cognitive functioning was assessed using the Mini Mental State Examination (MMSE) [18]. Participants scoring  $\leq$ 23 points were categorized as being cognitive impaired [19]. Fall risk was examined using the LASA fall risk assessment [20]. When participants scored  $\geq$ 8 points, they were identified as having an increased risk of recurrent falling. Four frailty criteria were registered [1], namely: unintentional weight loss, self-reported exhaustion, low physical activity, and low hand grip strength. Walking speed was a dependent variable in the statistical analyses. Comorbid diseases were registered using the Charlson's Comorbidity Index (CCI) [21]. Table 6.1 lists the registered comorbid diseases.

## Medication-use

Medication-use was systematically reviewed by the participant's physician as part of the CGA. Prior to their visit to the Geriatric Outpatient Clinic, patients were requested to bring the packaging of their medications or a list of their pharmacist with the drugs they use. The physician went through the list with the patients and/or their caregivers to check if the patients used all medications appropriately and/or used other non-prescribed drugs or supplements. The actual medication-use was then registered in the patients' file, which was used in the present study.

All generic names of the drugs (trade names) were manually looked up and subsequently linked with the corresponding code of Anatomical Therapeutic Chemical (ATC) classification system [22] (see Appendix I for an overview of the prevalence of all drugs in the study population). The medications were clustered into ATC-drug classes (see Table 6.1 for an overview of the 37 included ATC-drug classes in the present study). For each participant it was binary scored whether the participant used a drug in a specific ATC-drug class or not. Furthermore, the total number of drugs used per participant was registered. Polypharmacy was present when the participant used ≥4 drugs.

Table 6.1. Prevalence of the independent variables (population characteristics, comorbid diseases, and medication-use per ATC-drug class)
is presented in the left column as $n$ (%) in the population (N=80). In the right column, the captured variance (%) in every independent
variable per latent variable (LV) of the PLS-model, and the total variance is presented. Values with high modeling power (>6.90%) <sup>a</sup> are
relevant to the LVs.

	Prevalence		Captu	Captured Variance (%)	ice (%)	
Independent variables	n (%)	LV1	LV 2	LV 3	LV 4	TOTAL
Population characteristics						
Female	50 (63%)	13.26	3.20	24.72	2.37	43.55
280 years	41 (51%)	9.65	0.75	1.94	3.41	15.76
≥2 comorbid diseases		13.21	16.63	4.86	6.84	41.55
Cognitive impairment (MMSE ≤23 points)	35 (44%)	0.55	2.70	0.24	3.22	6.71
Increased fall risk (Pluijm score ≥8 points)		15.90	1.09	21.45	0.82	39.26
Polypharmacy (≥4 medications)	52 (65%)	35.52	20.44	5.44	1.26	62.66
Frailty-criteria						
- Unintentional weight loss		14.09	3.30	1.78	1.83	20.99
- Self-reported exhaustion		24.77	0.00	0.44	1.67	26.87
- Low physical activity	12 (15%)	24.92	0.23	0.05	2.18	27.38
- Low hand grip strength	20 (25%)	10.85	1.33	24.00	5.71	41.89
Comorbid diseases (CCI)						
Myocardial infarct	21 (26%)	9.51	11.14	0.12	19.40	40.17
Peripheral vascular disease	8 (10%)	2.39	6.85	2.03	0.05	11.32
Cerebrovascular disease	5 (6%)	0.39	0.02	00.0	0.21	0.62
Dementia	22 (28%)	0.37	2.90	10.44	1.74	15.45
Chronic pulmonary disease	8 (10%)	7.45	0.45	19.96	2.32	30.17
Connective tissue disease	2 (3%)	00.0	0.65	1.28	0.06	1.99
Ulcer disease	4 (5%)	3.96	0.31	0.37	6.39	11.02
Diabetes	11 (14%)	2.92	4.67	0.69	0.36	8.65
Moderate or severe renal disease	6 (8%)	2.81	11.53	1.22	1.96	17.52
Diabetes with end organ damage	2 (3%)	3.35	0.48	0.50	3.51	7.84
Any tumor	10 (13%)	0.81	8.31	0.74	6 66	16 52

		Η	(1%)	0.49	0.22	1.11	0.01	1.83
Medication-us	Medication-use (per ATC-drug class)							
Agents for alin	Agents for alimentary tract & metabolism (group A)							
A02A	Antacids	2	(3%)	2.01	0.55	4.25	0.13	6.93
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	31	(39%)	39.46	7.92	0.21	0.66	48.24
A03	Drugs for functional gastrointestinal disorders	m	(4%)	4.76	0.00	3.24	2.15	10.15
A06	Drugs for constipation	12	(15%)	11.13	4.29	6.06	0.65	22.13
A07	Antidiarrheals, intestinal anti-inflammatory/anti-infective	2	(3%)	4.33	0.08	1.79	0.04	6.24
	agents							
A09	Digestives, incl. enzymes	1	(1%)	2.25	0.17	3.91	0.38	6.71
A10	Drugs used in diabetes	11	(14%)	5.63	8.89	1.40	0.01	15.92
A11 & A12	Vitamins & mineral supplements	25	(31%)	9.07	0.63	18.18	2.43	30.30
Drugs acting o	Drugs acting on the cardiovascular system (group C)							
C01AA05a	Digoxin	4	(2%)	0.03	1.26	0.13	0.98	2.41
C01B	Antiarrhythmics (class I and III), excl. type IA	2	(3%)	0.61	0.37	3.46	0.76	5.20
C01BA	Type IA antiarrhythmicsb	0	q(%0)					
C01D	Vasodilators used in cardiac diseases	10	(13%)	6.79	16.39	0.96	2.50	26.65
C01E	Other cardiac preparations	2	(3%)	1.03	3.91	0.84	1.59	7.37
C03	Diuretics	30	(38%)	2.01	27.48	6.21	1.61	37.31
C07	Beta blocking agents	25	(31%)	1.55	18.13	3.25	10.40	33.33
C08	Calcium channel blockers	13	(16%)	4.52	9.03	0.00	1.76	15.31
C09	Agents acting on the renin-angiotensin system	31	(39%)	0.56	35.73	4.91	13.54	54.74
C10	Lipid modifying agents	38	(48%)	3.98	20.24	7.59	4.82	36.64
Drugs acting o	Drugs acting on the nervous system (group N)							
N02	Analgesics (no paracetamol)	9	(8%)	12.15	0.26	7.85	2.06	22.33
NO2BE	Paracetamol/acetaminophen	Ŋ	(%9)	9.95	0.10	15.57	2.74	28.37
NO3A	Antiepileptics	9	(8%)	1.12	1.81	7.29	4.23	14.46
NO5A	Antipsychotics	2	(3%)	1.61	0.68	0.01	0.21	2.52
NOSRA	Anxiolytics (henzodiazenine-derivatives)	00	(10%)	0.47	0 1 1		0 83	1 1 1

		Prev	Prevalence		Captu	Captured Variance (%)	ce (%)	
Independent variables	variables	u	(%)	LV 1	LV 2	LV 3	LV 4	TOTAL
NO5C	Hypnotics, excl. benzodiazepine-derivatives	7	(%6)	15.58	1.61	5.70	2.91	25.80
NO5CD	Hypnotics & sedatives (benzodiazepine-derivatives)	5	(%9)	0.37	0.44	4.20	0.00	5.02
NO6A	Antidepressants	12	(15%)	7.93	7.15	0.01	2.07	17.15
NO7	Other nervous system drugs	2	(3%)	0.24	0.47	6.05	0.03	6.80
Other ATC-drua classes	ug classes							
B01	Antithrombotic agents	34	(43%)	12.48	22.64	7.16	2.30	44.59
B03	Anti-anemic preparations	4	(2%)	3.67	1.56	0.41	6.58	12.22
D	Antifungals for dermatological use	1	(1%)	2.76	2.46	2.35	0.04	7.61
IJ	Genito-urinary system and sex hormones	11	(14%)	12.63	1.39	0.73	2.04	16.78
т	Systemic hormonal preparations, excl. sex hormones and	5	(%9)	7.85	0.61	1.03	1.51	10.99
	insulins							
_	Anti-infectives for systemic use	4	(2%)	5.15	0.38	0.07	2.77	8.37
Ţ	Antineoplastic and immunomodulating agents	1	(1%)	0.01	2.78	0.83	6.49	10.11
Σ	Musculo-skeletal system	10	(13%)	5.88	1.59	0.61	6.38	14.46
Ж	Respiratory system	13	(16%)	7.71	0.02	5.77	0.82	14.32
S	Sensory organs	∞	(10%)	3.41	17.45	5.68	5.63	32.18
<sup>a</sup> Variables wit	<sup>a</sup> Variables with low modeling power, i.e., around A/K, are of little relevance (A = number of LVs = 4; and K = number of independent variables = 58)	number o	of LVs = 4; ar	id K = numb€	er of indep	endent va	iriables = 5	58).
Thus variables	Thus variables with less variance captured than 4/58=6.90% are not important to the LV [23].	the LV [2						

umber of LVs = 4; and K = number of independent	he LV [23].
.e., around A/K, are of little relevance (A = numbe	ired than 4/58=6.90% are not important to th
<sup>a</sup> Variables with low modeling power, i.	Thus variables with less variance captu
a)	$\vdash$

Thus variables with less variance נשעיני אי איידי אי דאיט איז because n=0. <sup>b</sup> This item was excluded from further PLS-analyses, because n=0.

Table 6.1. Continued

#### Gait parameters

Participants walked 3-minutes in a 80-meter long hallway at a self-selected speed while trunk accelerations were recorded using an accelerometer (DynaPort Minimod Hybrid; McRoberts BV; sample frequency 100 Hz), which was attached with a band at the level of the lumbar spine. Walking distance was recorded to determine gait speed. Trunk acceleration signals were analyzed using custom-made software in MATLAB (version 2011b; The MathWorks Inc.). Foot contact moments were determined from the peaks of the anterior-posterior-acceleration time-series. From the foot contact moments, stride times were calculated defined as the time interval between two ipsilateral foot contacts. For each participant, mean and CV of stride times were computed. The variability between left and right steps within the strides was quantified by the standard deviation (SD) of the relative timing between ipsilateral foot contact moments, with larger values indicating less consistent steps [24, 25]. See De Groot *et al.* [16] for a detailed description of the calculated gait parameters.

## Statistical analyses

To test the association between the various drug classes, the population characteristics, and the comorbid diseases in relation to stride variability, a multivariate PLS regression analysis was computed using the PLS\_toolbox for Matlab (version 3.7.1; Eigenvector Research Inc.). PLS-regression is a technique that combines features from principal component analysis and multiple regression, and is not impeded by collinearity among variables [26–28]. PLS has particularly been applied in studies in which a set of dependent variables is predicted from a relatively large set of independent variables with relatively few observations [29–31]. In these studies, similar to our study, continuous, ordinal and binary data were included. It is well known that their exists an interdependency among different gait variables, such as walking speed, mean stride times, and variability in stride times [32–34]. When using PLS, a model can be constructed wherein the dependency among these gait variables is taken into account. That makes the PLS-regression analysis more favorable over the more conventional multiple regression analysis.

In the PLS-regression analysis, 58 independent variables (the population characteristics, comorbid diseases, and medication-use) and four dependent gait parameters were included. In order to give the variables the same scale, i.e., the same importance in the analysis, all independent (binary coded) variables were mean-centered (i.e., means of each column were set to zero), and the dependent gait

parameters were scaled to unit variance by dividing each variable by their SD's and centering them by subtracting their averages [23, 35].

PLS-regression analysis searches for a set of latent variables (LVs) explaining as much as possible of the covariance between the independent (the population characteristics, comorbid diseases, and medication-use per ATC-class), and dependent variables (the four gait parameters). With numerous and correlated variables, there is a substantial risk for "over-fitting", i.e., getting a well-fitting model with little or no predictive power. Cross-validation is a practical and reliable way to test the predictive significance of the model [35]. Cross-validation was performed by dividing the data into eight groups (method: Venetian Blinds), and then developing eight parallel models from reduced data with one of the groups deleted. Then, differences between the actual and the predicted values for the gait parameters were calculated for the deleted data. The sums of squares of these differences were computed and collected from all the parallel models to form the predictive residual sum of squares (PRESS), which estimates the predictive ability of the model. The optimal number of LVs was determined by stop adding LVs as soon as the Predicted REsidual Sum of Squares (PRESS) decreased [36]. From the PRESS-values of the final model, the predictive ability of the model was indicted by the parameter Q<sup>2</sup>, the predicted variation, or: the goodness of prediction. This value can be compared to  $R^2$ , the explained variation, which is the capacity of the population characteristics, comorbid diseases and medication-use to explain the variance among the gait variables, or: the goodness of fit.

From the PLS model, a set of model parameters was computed (see Table 6.2). A downside of using PLS is that it is relatively difficult to interpret model parameters, since these are biased and *p*-values and confidence intervals are lacking. By interpreting the model parameters simultaneously, the associations between the independent variables (the population characteristics, comorbid diseases, and medication-use) were examined in relation to the gait parameters. The relevance of each independent variable to the LVs was indicated by the percentage variance that was captured by the LV [23]. Variables with low modeling power, i.e., around A/K (in our study, A = number of LVs = 4; and K = number of independent variables = 58), were of little relevance. Thus variables with variance below 4/58=6.90% are not important to the LV [23, 29]. Therefore, variables with high captured variance for the same LV were clustered in the same LV.

Abbreviation	Outcome variable	Indicator of	Interpretation
	Independent variables		Population characteristics, comorbid diseases, medication-use in
			various ATC-drug classes
	Dependent variables		Gait parameters: walking speed, mean stride times, CV of stride
			times, and step consistency
$Q^2$	Predicted variance	Goodness of prediction	Higher $Q^2$ means better predictive ability of the model. $Q^2 > 50\%$
			is regarded good [23].
R <sup>2</sup>	Explained variance	Goodness of fit	Higher R <sup>2</sup> means better capacity of the independent variables to
			explain the variance among the gait parameters
RC	Regression Coefficient	Association between	Higher positive or negative RC means that the independent
		independent and dependent	variable is stronger related to gait parameter
		variable in the model	
	Variance Captured	Relevance of the independent	Variance>6.9% means that independent variable is relevant to
		variable to the LV	the LV. Higher captured variance means more relevant
VIP	Variable Importance on	Importance of each	VIP>1.0 means that independent variable is influential to the gait
	Projection	independent variable for the	parameters. Higher VIP means more influence
		gait parameters	

Table 6.2. List of abbreviations and explanations of outcome variables of the PLS-analysis.

The association between each independent variable and the gait parameters was indicated by regression coefficients. A higher positive or negative regression coefficient means that the independent variable is stronger related to the gait parameter. The importance of each variable in explaining the variation among gait parameters was given by the variable importance in projection (VIP) value. A VIP-value higher than 1 means that the independent variable is influential to the gait parameters. At last, score and weight plots illustrate and summarize the relationship between observations (the participants) and independent variables (population characteristics, comorbid diseases and medication-use), respectively, with respect to the latent variables.

Since the model parameters are biased, the important variables in relation to the gait parameters have overall higher modeling power (high captured variance), have higher positive or lower negative regression coefficients, and have a VIP-value higher than one. Moreover, these important variables have higher positive or lower negative weightvalues, and are therefore clustered in the upper right or lower left quadrant of the weight plot. Based on the scores and weights of the model, predicted values for the gait parameters were calculated to illustrate the fit of the model [23, 28, 36]. See for a more detailed mathematical description of the PLS regression analysis the Supplementary Information (Appendix II).

# Results

#### Descriptive characteristics of the study population

Eighty older persons were included in the present study (aged 79±5.6 years). Cognitive impairment was present in 35 participants (44%); the median MMSE score was 24 points (range: 11-30). Fourteen participants (18%) scored  $\geq$ 8 points on the LASA fall risk assessment, indicating an increased risk for recurrent falls. Considering the frailty-related indicators, 13 participants (16%) reported  $\geq$ 5kg unintentional weight loss, 21 participants (26%) had self-reported exhaustion, 12 participants (15%) had low physical activity, and 20 participants (25%) had low grip strength. Twenty-nine participants (36%) had  $\geq$ 2 comorbid diseases on the CCI. Dementia, myocardial infarct, and diabetes were most present in the included population (respectively 27%, 26%, and 14%). See Table 6.1 for the prevalence of other comorbid diseases.

The participants used 5.5 $\pm$ 3.9 drugs; 52 participants (65%) were categorized as having polypharmacy, because they used  $\geq$ 4 drugs. Twenty-nine participants (36%) used one or more psychotropic medications that are known to be associated with increased fall risk, e.g. antiepileptics (N03A), antipsychotics (N05A), anxiolytics (N05BA), hypnotics

Chapter 6

(N05C), and antidepressants (N06A). Medication-use per ATC-class is presented in Table 6.1.

Mean walking speed was  $0.90\pm0.24$  m/s, mean stride time was  $1.16\pm0.13$  seconds, the variation (CV) of stride times was  $3.81\pm1.61\%$ , and step consistency was  $4.67\pm1.68^\circ$ .


# Association between population characteristics, comorbid diseases, and medication-use in relation to gait parameters

The PLS-regression testing the association between population characteristics, comorbid diseases and medication-use in relation to gait parameters yielded a model of four LVs (see Table 6.3), explaining 27.6% of the variance between the population characteristics, comorbid diseases, and medication-use, and 45.4% of the variance in gait parameters ( $R^2$ ). Adding more LVs to the model did not improve  $R^2$ , as indicated by the PRESS.

The variable most relevant to the model, i.e., with the most variance captured by the model, was the presence of polypharmacy (63%). The first LV captured most variance of the following variables: using drugs for ulcer and reflux disease (A02B; 39%), polypharmacy (36%), and two frailty criteria: low physical activity (25%), and self-reported exhaustion (25%). The second LV captured most variance in polypharmacy (20%), and in using drugs acting on the cardiovascular system (ATC-drug classes C09, C10, C03, C07, and C01D). Most variance by the third LV was captured in being female (25%), having low hand grip strength (24%), and increased fall risk (21%). By the fourth LV, most variance was captured in having myocardial infarction in medical history (19%), and using agents acting on the renin-angiotensin system (C09; 14%), and beta-blocking agents (C07; 10%). The variance captured by the model for all variables per LV are presented in Table 6.1.

**Table 6.3.** Explained variance (%) in the population characteristics, comorbid diseases and medication-use (independent variables) and gait parameters (dependent variables) by the PLS-model existing of four latent variables (LVs).

	LV 1	LV 2	LV 3	LV 4	TOTAL
Explained variance in the independent variables (%)	9.62	8.57	5.76	3.67	27.61
Explained variance in the dependent variables (%)	20.71	9.33	5.70	9.69	45.43







Fig. 6.1. VIP-values and regression coefficients.

VIP-values (gray bars; left Y-axis) and regression coefficients (black dots ( $\bullet$ ); right Y-axis) of all population characteristics, comorbid diseases and medications used are presented for (A) walking speed, (B) mean stride times, (C) CV of stride times, and (D) step consistency. The variables are placed on the horizontal axis and sorted according to the height of the regression coefficient. Variables placed at the outer left and right side of the graph have a stronger association with the gait parameter than the variables in the middle of the graph. Variables with a VIP-value of >1 are important to the model. Note that right of the vertical dotted line the variables are presented that are associated with impaired gait ability, that is negative regression coefficients for walking speed, and positive regression coefficients for mean stride times, CV of stride times and step consistency. See Table 1 for a description of the ATC-drug classes.

In Fig. 6.1, the VIP-values and regression coefficients of all population characteristics, comorbid diseases and medication-use for the gait parameters are presented. The most important variables to the model (highest VIP-values) were unintentional weight loss, self-reported exhaustion, being female, and the use of drugs for constipation (A06). These variables were associated with lower walking speed (negative regression coefficients), and higher mean and CV of stride times and less consistent steps (positive regression coefficients).

The association between the participants and the independent variables (population characteristics, comorbid diseases, and medication-use) in relation to the gait parameters is revealed in Fig. 6.2. The position of the participants in a given direction in the score plot (Fig. 6.2A) is influenced by the independent variables lying in the same direction in the weight plot (Fig. 6.2B). Participants in the upper right quadrant of the score plot had overall higher stride variability, whereas persons clustered in the lower left quadrant had lower stride variability. Furthermore, in the weight plot, the relations between the independent variables are visualized. Variables with high regression coefficients and high VIP-scores, e.g., unintentional weight loss, self-reported exhaustion, and being female (see Fig. 6.1), are situated in the upper right quadrant of the weight plot, illustrating that they are associated with each other (as can be also seen by the captured variance of LV1 as presented in Table 6.1), and are associated with higher values for the gait parameters (higher regression coefficients; see Fig. 6.1).



quartile 1 (Q1; lowest variability; < 2.6%), quartile 2 (Q2; 2.7-3.4%), quartile 3 (Q3; 3.4-4.4%), and quartile 4 (highest variability in stride he weight plot can be considered as a coordinate system, where the underlying structure between the variables in relation to stride variability is revealed. The most influential variables are situated far from origo, with the variables at upper right quadrant associated The score-plot (A) shows the relationship between the participants. The participants are categorized according to their CV of stride times: times; >4.4%). Coupled to the weight plot (B), the inter-relatedness among the patient characteristics and stride variability is revealed. with higher stride variability, and those situated in the lower left quadrant are associated with lower variability.

6

The fit and predictive ability of the model are illustrated in Fig. 6.3. The observed versus predicted values of the PLS model for walking speed ( $R^2$ =60%;  $Q^2$ =92%), mean stride times ( $R^2$ =56%;  $Q^2$ =98%), CV of stride times ( $R^2$ =39%;  $Q^2$ =88%), and for step consistency ( $R^2$ =26%;  $Q^2$ =87%) are presented in this figure.




Fig. 6.3. Observed versus predicted values.

For (A) walking speed, (B) mean stride times, (C) CV of stride times, and (D) step consistency the observed and predicted values are presented. The striped line represents the fit-line, and the dotted line is the 1:1-line.

In summary, the results show that impairments in gait performance are strongest associated with unintentional weight loss, self-reported exhaustion, being female and the use of laxatives (A06). These variables had overall most variance captured by the model, and the highest VIP-values and regression coefficients.

# Discussion

In the present cross-sectional study, we aimed to determine the association between population characteristics, comorbid diseases, medication-use and gait parameters in a population of older patients visiting a geriatric outpatient clinic. Therefore, a PLS-regression model was created testing the association between the use of medications in various ATC-drug classes, comorbid diseases, and common factors in a geriatric population, versus gait parameters. In total, 58 variables were included, explaining 45% of the total variance in four gait parameters, namely walking speed, mean stride times, variation in stride times, and step consistency. R<sup>2</sup>- and Q<sup>2</sup>-values showed that the model had an appropriate fit and a good predictive ability (see Fig. 6.3).

We created a statistical model including characteristics common in a population of older patients visiting a geriatric outpatient clinic. 45% of the variance in four gait parameters was explained by this model. Gait is a complex motor behavior requiring adequate integration of sensor-motor information. With aging, there is an age-related deterioration of postural control due to progressive loss of functioning of the neurophysiological system, resulting in, amongst others, visual problems, vestibular impairment, affected proprioception, changes in central processing mechanisms, reduced muscle strength, and slower reaction times [37, 38]. These factors are also present in our geriatric study population, but were not as such included in our model. Therefore, these not included aging-related factors presumably account for the unexplained variance in gait parameters in our model.

Nevertheless, most variance in the gait variables was explained by the first LV, and the clustered variables in this LV were therefore strongest related with the gait parameters. In particular, frailty-related criteria were clustered in this first LV, such as unintended weight loss, self-reported exhaustion, low physical activity, and low hand grip strength (see Table 6.1 and Fig. 6.2), and these were associated with lower walking speed, and higher mean stride times, increased variability of stride times, and less consistent steps. The identified association between these frailty-related indicators and gait parameters is in line with previous research [15, 39]. Montero-Odasso *et al.* [15] suggested that frailty reflects a general deterioration in the neurophysiological system.

6

At the same time, gait can be considered as a complex task that is highly regulated by neurophysiological systems. Consequently, the decreased walking speed, increased stride variability, and worse step consistency that was seen in frail elderly and was found to be related with frailty-related parameters as found in the present study, may reflect the multisystem reduction in neurophysiological capacity.

Based on a previous literature review [8], we anticipated a strong association between the use of psychotropic drugs and gait performance. However, the association of the use of antiepileptics (N03A) and antidepressants (N06A) with impaired gait ability was moderate, while hardly any association with other psychotropic drug classes was observed. We suggest that the effect of the deterioration in physical functioning in the frailest elderly is so large, that the added impact of the side-effects of psychotropics on gait regulation is relatively small. What also may have contributed to the weak associations between gait performance and psychotropic drugs is that the dosages of drugs that were taken by our study population (see Appendix I) was much lower than reported in the aforementioned literature review [8]. This underpins the recommendation of Lader *et al.* [40] that psychotropic drugs – when administered – should only be prescribed at the lowest effective dose and for a restricted period of time to limit the side-effects of these drugs.

Beside the strong association between frailty-related characteristics and gait parameters, and the moderate association of psychotropic drugs with gait, in the present study also other medication classes were found to be associated with impaired gait ability. The use of laxatives (A06), agents acting on sensory organs (ATC-class S), and drugs for peptic ulcer and reflux disease (A02B) were strongly associated with lower walking speed and higher stride variability as was indicated by high VIP-values and regression coefficients (Fig. 6.1), and illustrated in the score and weight plots (Fig. 6.2). These medication-classes are among the most prescribed medications, and are much more commonly used in individuals with indicators of frailty. For instance, laxatives are used for constipation that, in turn, may be caused by inactivity (one of the indicators of frailty) or the use of constipation-associated medications (e.g., opioid analgesics) [41]. Therefore, these kind of drugs may act as frailty markers [42, 43].

The results of the present study correspond with a study of Askari *et al.* [43] who reported that besides known "fall-risk-increasing drugs", such as analgesics (NO2), anti-Parkinson drugs (NO4) and psychoanaleptics (NO6), also relatively new classes showed significant association with recurrent falls in elderly, namely nasal preparations (RO1), ophthalmologicals (SO1), and drugs for acid-related disorders (AO2). Especially the finding that drugs for acid-related disorders were associated with recurrent falling and

increased stride variability is interesting, because these drugs are commonly used in our study population (see Appendix I) and in the older population in general [44]. Protonpump inhibitors (PPIs; A02BC), a subclass of drugs for acid-related disorders (A02), have been associated with an increased risk of fractures [45]. It is assumed that PPIs reduce calcium absorption, possibly leading to reduced bone mineral density that would lead to increased fracture risk [46]. Another explanation could be that PPI-use may lead to muscle weakness and gait disorders [46]. This might explain our finding that these drugs were associated with impaired gait ability, and with recurrent falling as Askari *et al.* [43] found. However, further longitudinal research is necessary to confirm this suggestion.

# Conclusion

In the present study, we found an association between frailty-related parameters and impaired walking ability, as was expressed by lower walking speed and increased stride variability. The absence of a strong association between the use of psychotropic drugs and gait parameters is in accordance to our hypothesis that results from studies in healthy and relatively young elderly cannot be extrapolated to a frail population, because comorbid diseases and the use of many medications are complicating factors in this population leading to multisystem reduction in the neurophysiological system. Therefore, in future studies among frail elderly we recommend to develop models which include frailty-related parameters.

ATC-code	Description	u	(%)	Dosage	Dosage range
<i>A02A</i>	Antacids	2	(3%)		
A02AA02	magnesium oxide	2	(3%)	724-1448	шg
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	31	(39%)		
A02BA02	ranitidine	£	(4%)	150-300	mg
A02BC01	omeprazole	12	(15%)	20-80	mg
A02BC02	pantoprazole	11	(14%)	20-40	mg
A02BC03	lansoprazole	1	(1%)	15	mg
A02BC04	rabeprazole	1	(1%)	20	mg
A02BC05	esomeprazole	ŝ	(4%)	40-80	тg
<i>A03</i>	Drugs for functional gastrointestinal disorders	m	(4%)		
A03AA04	mebeverine	1	(1%)	400	mg
A03FA01	metoclopramide	1	(1%)	10	mg
A03FA03	domperidone	1	(1%)	30	тg
<i>A06</i>	Drugs for constipation	12	(15%)		
A06AC01	ispaghula (psylla seeds)	£	(4%)	1-3	dose/day
A06AD65	macrogol, combinations	6	(11%)	1-2	mg
A06AD11	lactulose	2	(3%)	15	ml
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	2	(3%)		
A07DA03	loperamide	1	(1%)	2	mg
A07EC02	mesalazine	Ξ	(1%)	1000	тg
<i>A09</i>	Digestives, incl enzymes	1	(1%)		
A09AA02	multienzymes (libase, protease, etc.)	1	(1%)	C.	dose/dav

Prevalence of the medications used by the study's participants and the dosage range.

Part II: Medication-use

Appendix I

A10	Druas used in diabetes	11	(14%)		
A10AD05	insulin aspar	Ч	(1%)	32	units
A10BB01	glibenclamide	-	(1%)	7.5	mg
A10BB03	tolbutamide	2	(3%)	1000	тg
A10BB12	glimepiride	£	(4%)	0.5-2	mg
A10BD02	metformin and sulfonylureas	9	(%8)	1000-2550	mg
A11&A12	Vitamins & mineral supplements	25	(31%)		
A11BA	multivitamins, plain	4	(5%)		
A11CC03	alfacalcidol	ŝ	(4%)	0.25	bп
A11CC05	colecalciferol	16	(20%)	400-880	IE
A11DA01	thiamine (vit B1)	2	(3%)	100	mg
A12AA02	calcium glubionate	-	(1%)	500	mg
A12AA04	calcium carbonate	15	(19%)	500	mg
<i>B01</i>	Antithrombotic agents	34	(43%)		
B01AA07	acenocoumarol	6	(11%)	1	g
B01AC04	clopidogrel	4	(5%)	75	mg
B01AC06	acetylsalicylic acid	m	(4%)	80	mg
B01AC07	dipyridamole	4	(5%)	200-400	mg
B01AC08	carbasalate calcium	22	(28%)	38-100	mg
B03	Antianemic preparations	4	(5%)		
B03AA02	ferrous fumarate	Η	(1%)	600	
B03AA07	ferrous sulfate	Ч	(1%)	325	mg
B03BA03	hydroxocobalamin	Ч	(1%)	1	dose/day
B03BB01	folic acid	ŝ	(4%)	5	mg
C01AA05*	Digoxin	4	(2%)		
C01AA05	digoxin	4	(5%)	0.0625-0.25	mg
CO1B	Antiarrhythmics (class I and III), excl. type IA	2	(3%)		
C01BC04	flecainide	2	(3%)	100	mg

	arrhythmics* 0 arrhythmics* 0 tused in cardiac diseases 10 trate 2 initrate 2 nononitraat 1 trate 2 tc preparations 2	(0%) (13%) (3%) (10%) (1%) (3%)		
Vasodilators ( IDA02 glyceryl triniti IDA14 isosorbide dir IDX16 nicorandil IDX16 nicorandil <i>Diuretics</i> AA03 hydrochlorotl 3BA04 chlortalidone 3CA01 burnetanide 3CA01 burnetanide sDA01 spironolactor BDB02 triamterene 3BD02 triamterene gEA03 sotalol 7AB02 metoprolol 7AB03 atenolol	in cardiac diseases te itraat barations	(13%) (3%) (3%) (10%) (1%) (3%)		
IDA08 isosorbide dir IDA14 isosorbide mo IDX16 nicorandil <i>Other cardiac</i> IEB17 ivabradine <i>Diuretics</i> AA03 hydrochlorotl BA04 chlortalidone furosemide 3CA01 furosemide bumetanide spironolactor BB02 triamterene 3CA07 sotalol 7AB07 sotalol 7AB03 atenolol	te itraat oarations	(3%) (10%) (1%) (3%)		
<ul> <li>IDA14 isosorbide mc</li> <li>IDX16 nicorandil</li> <li>IEB17 ivabradine</li> <li>0ther cardiac</li> <li>IEB17 ivabradine</li> <li>BA03 hydrochlorotl</li> <li>BA03 hydrochlorotl</li> <li>BBA04 chlortalidone</li> <li>BCA01 furosemide</li> <li>BCA01 spironolactor</li> <li>Beta blocking</li> <li>7AB02 metoprolol</li> <li>7AB03 atenolol</li> </ul>		(10%) (1%) (3%)	2.5-5	mg
1DX16 nicorandil 1EB17 ivabradine 0ther cardiac Diuretics AA03 hydrochlorotl 3BA04 chlortalidone 3CA01 burnesemide 3CA01 burnesemide 3CA01 spironolactor 3DA01 spironolactor 3DB02 triamterene 3EA03 epitizide and <i>Beta blocking</i> 7AB07 sotalol 7AB03 atenolol		(1%) (3%)	30-100	mg
1EB17Other cardiac1EB17ivabradine3A03hydrochlorotl3BA04chlortalidone3BA04chlortalidone3CA01furosemide3CA02bumetanide3DB02triamterene3EA03epitizide and3EA07sotalol7AB02metoprolol7AB03atenolol		(3%)	10	mg
1EB17ivabradineDiureticsBA03hydrochlorotl3BA04chlortalidone3BA01furosemide3CA01bumetanide3DA01spironolactor3DB02triamterene3DB02epitizide andBeta blocking7AB077AB03atenolol7AB03atenolol	2			
Diuretics3AA03hydrochlorotl3BA04chlortalidone3CA01furosemide3CA02bumetanide3DA01spironolactor3DB02triamterene3DB02triamterene3EA03epitizide and7AB02sotalol7AB03atenolol		(3%)	10-70	mg
C03AA03 hydrochlorotl C03BA04 chlortalidone C03CA01 furosemide C03CA02 bumetanide C03CA02 bumetanide C03CA02 primetene C03EA03 epitizide and <i>Beta blocking</i> C07AA07 sotalol C07AB03 atenolol	30	(38%)		
C03BA04 chlortalidone C03CA01 furosemide C03CA02 bumetanide C03DA01 spironolactor C03BB02 triamterene C03EA03 epitizide and <i>Beta blocking</i> C07AB02 metoprolol C07AB03 atenolol	thiazide 17	(21%)	12.5-25	mg
C03CA01 furosemide C03CA02 bumetanide C03DA01 spironolactor C03BB02 triamterene C03EA03 epitizide and <i>Beta blocking</i> C07AB02 metoprolol C07AB03 atenolol	e 1	(1%)	12.5	mg
C03CA02 burnetanide C03DA01 spironolactor C03DB02 triamterene C03EA03 epitizide and <i>Beta blocking</i> C07AB07 sotalol C07AB03 atenolol	8	(10%)	20-40	mg
C03DA01 spironolactor C03DB02 triamterene C03EA03 epitizide and <i>Beta blocking</i> C07AB02 metoprolol C07AB03 atenolol	2	(3%)	1	mg
C03DB02 triamterene C03EA03 epitizide and <i>Beta blocking</i> C07AB02 metoprolol C07AB03 atenolol		(2%)	25-50	mg
CO3EAO3 epitizide and Beta blocking CO7ABO2 metoprolol CO7ABO3 atenolol		(%8)	50	mg
Beta blocking C07AA07 sotalol C07AB02 metoprolol C07AB03 atenolol		(3%)	4	mg
	g agents 25	(31%)		
	1	(1%)	240	mg
	21	(26%)	25-200	mg
	2	(3%)	25-100	mg
C07AB04 acebutolol	1	(1%)	100	mg
C07AG02 carvedilol	1	(1%)	12.5	mg
CO8 Calcium channel blockers	1	(16%)		
C08CA01 amlodipine	L	(%6)	5-10	mg
C08CA02 felodipine	1	(1%)	S	mg

Appendix I. Continued

CUBCAUS	niredipine	4	(%2)	30-240	mg
C08DA01	verapamil	1	(1%)	120	mg
<i>C09</i>	Agents acting on the renin-angiotensin system	31	(39%)		
C09AA02	enalapril	Ŋ	(%9)	5-40	mg
C09AA03	lisinopril	ъ	(%9)	10-20	mg
C09AA04	perindopril	7	(%6)	2-8	mg
C09AA06	quinapril	Ч	(1%)	20	mg
C09CA01	losartan	4	(5%)	50-100	mg
C09CA03	valsartan	Η	(1%)	80	mg
C09CA04	irbesartan	4	(5%)	150-300	mg
C09CA06	candesartan	4	(5%)	16-20	mg
C10	Lipid modifying agents	38	(48%)		
C10AA01	simvastatin	26	(33%)	10-40	mg
C10AA03	pravastatin	4	(5%)	20-40	mg
C10AA04	fluvastatin	1	(1%)	80	mg
C10AA05	atorvastatin	4	(5%)	20-40	mg
C10AA07	rosuvastatin	2	(3%)	5-40	mg
C10AB04	gemfibrozil	1	(1%)	1200	mg
C10AX09	ezetimibe	1	(1%)	10	шg
D	Antifungals for dermatological use	Ч	(1%)		
D02AB	zink products	Ч	(1%)	1	
G	Genito urinary system and sex hormones	11	(14%)		
G01AF04	miconazole	1	(1%)	1	dose/day
G01AF15	butoconazole	Η	(1%)		
G03CA04	estriol	2	(3%)	0.5	mg
G03HA01	cyproterone	-	(1%)	50	mg
G04BD08	solifenacin	2	(3%)	D	mg
G04BD10	darifenacin	-	(1%)	7.5	mg
G04CA01	alfuzosin		(1%)	10	mg

604CA02     tamsulosin       604CB01     finasteride       604CB02     dutasteride       604CB02     dutasteride       604CB02     dutasteride       604CB01     systemic hormonal preprarations, excl. Sex hormones and insulins       1     JU1XE01       1     Antiinfectives for systemic use       J01XE01     introfurantoin       J04BA02     dapsone       L     Antiinfectives for systemic use       J01XE01     introfurantoin       J04BA02     dapsone       L     Antiineoplastic and immunomodulating agents       L     LU1BC02       fluorouracil     M04AA01       M     Musculo-skeletal system       M04AA01     allopurinol       M01AB05     diclofenac       M05BA06     ibandronic acid       M05BA06     ibandronic acid       M02BA01     hydroquinine       N02     Analgesics (no paracetamol)       N02BA01     octylsalicylic acid       N02BA01     acetylsalicylic acid       N02BA01     acetylsalicylic acid       N02BE01     buspirone       N02BE01     buspirone       N02BE01     buspirone		(%) <i>u</i>	Dosage	Dosage range
04.04.001 04.002 03.4.01 01.01.01 04.8.02 04.8.02 04.8.02 01.8.02 05.8.04 05.8.04 05.8.04 05.8.04 05.8.00 05.8.01 02.8.01 00.8.51 00.8.51 00.8.51 00.8.51 00.0000 00.0000 00.0000 00.0000 00.0000 00.0000 00.0000 00.0000 00.0000 00.00000 00.000000		5 (6%)	0.4-0.5	шg
04CB02 03AA01 0101XE01 04BA02 04AA01 01AB05 05BA04 05BA04 05BA06 09AA01 02BA01 02BA01 02BA01 02BA01 02BA01 02BA01 02BA01 002BA01		1 (1%)	5	тg
03AA01 01XE01 04BA02 04BA02 04AA01 01AB05 05BA06 05BA06 05BA06 05BA06 05BA01 02BA01 02BA01 02BA01 02BA01 02BA01 02BA01		2 (3%)	0.4-0.5	mg
03A401 001XE01 04BA02 04BA02 01BC02 01AA01 01AB05 05BA04 05BA04 05BA06 09AA01 02BA01 02BA01 02BA01 02BA01 02BA01 02BA01 02BA01		5 (6%)		
Antiinfectives       J01XE01     nitrofurantoi       04BA02     dapsone       04BA02     dapsone       Antineoplasti     Antineoplasti       01BC02     fluorouracil       Antineoplasti     Musculo-skel       01AB05     diclofenac       01AB05     diclofenac       05BA04     alendronic ac       05BA04     alendronic ac       05BA01     hydroquinine       02BA01     aralgesics (n       02BA01     acetylsalicylic       02BA01     acetylsalicylic       8E     Paracetamol       102BE01     buspirone       102BE01     buspirone		5 (6%)	50-150	рц
J01XE01 nitrofurantoi 04BA02 dapsone Antineoplasti Antineoplasti 04AA01 fluorouracil Musculo-skel 04AA01 allopurinol 01AB05 diclofenac 05BA06 ibandronic ac 05BA06 ibandronic ac 05BA06 ibandronic ac 09AA01 hydroquinine 002A01 tramadol 02BA01 acetylsalicylic 8 <sup>E</sup> Paracetamol 102BE01 buspirone		4 (5%)		
04BA02 dapsone Antineoplasti Antineoplasti Musculo-skel 04AA01 allopurinol 01AB05 diclofenac 01AB05 diclofenac 01AB05 alendronic ac 05BA06 ibandronic ac 05BA06 ibandronic ac 09AA01 hydroquinine 002A01 acetylsalicylic 8E Paracetamol 102BE01 buspirone		3 (4%)	50-100	тg
01BC02 fluorouracil 01BC02 fluorouracil <i>Musculo-skel</i> 04AA01 allopurinol 01AB05 diclofenac 05BA04 alendronic ac 05BA06 ibandronic ac 05BA01 hydroquinine 09AA01 hydroquinine 002A01 acetylsalicylic 8E Paracetamol 102BE01 buspirone		1 (1%)	100	mg
01BC02 fluorouracil Musculo-skel 04AA01 allopurinol 01AB05 diclofenac 05BA04 alendronic ac 05BA06 ibandronic ac 09AA01 hydroquinine 102AX02 tramadol 02BA01 acetylsalicylic 8E Paracetamol 102BE01 buspirone	c and immunomodulating agents	1 (1%)		
Musculo-skel 04AA01 allopurinol 01AB05 diclofenac 05BA06 alendronic ac 05AA01 hydroquinine 09AA01 hydroquinine 02AX02 tramadol 02BA01 acetylsalicylic 8E Paracetamol 102BE01 buspirone		1 (1%)		
04AA01 allopurinol 01AB05 diclofenac 05BA06 alendronic ac 05BA06 ibandronic ac 09AA01 hydroquinine 002AX02 tramadol 02BA01 acetylsalicylic <i>8E Paracetamol</i> 102BE01 buspirone	etal system 10	-		
01AB05 diclofenac 05BA04 alendronic ac 05BA06 ibandronic ac 09AA01 hydroquinine <i>Analgesics (n</i> 102AX02 tramadol 02BA01 acetylsalicylic <i>BE Paracetamol</i> 102BE01 buspirone	7	4 (5%)	100-200	mg
05BA04 alendronic ac 05BA06 ibandronic ac 09AA01 hydroquinine Analgesics (n 02BA01 acetylsalicylic 8E Paracetamol, 102BE01 buspirone 002B51 paracetamol		1 (1%)	100	mg
05BA06 ibandronic ac 09AA01 hydroquinine 02AX02 tramadol 02BA01 acetylsalicylic <i>8E Paracetamol</i> 102BE01 buspirone		4 (5%)	70	mg/week
09AA01 hydroquinine Analgesics (n 102AX02 tramadol 02BA01 acetylsalicylic 8E Paracetamol 102BE01 buspirone 102BE51 naracetamol	bid	1 (1%)	150	mg/month
Analgesics (n 102AX02 tramadol 02BA01 acetylsalicylic 8E Paracetamol 102BE01 buspirone 102RE51 naracetamol		2 (3%)	200	mg
AX02 tramadol BA01 acetylsalicylic <i>Paracetamol</i> BE51 buspirone		5 (6%)		
BA01 acetylsalicylic <i>Paracetamol</i> BE01 buspirone BE51 naracetamol		2 (3%)	37.5-50	mg
<i>Paracetamol,</i> 2BE01 buspirone 2BE51 paracetamol	acid	3 (4%)	80	mg
buspirone		9 (11%)		
naracetamol		5 (6%)	500-1500	тg
	combinations excl. psycholeptics	1 (1%)	65	mg
N02BE71 paracetamol, combinations with psycholeptics		3 (4%)	10-30	mg

Part II: Medication-use

Appendix I. Continued

	Antiepileptics	9 (8	3%)			
N03AE01	clonazepam	2 ()	3%)	0.5-1	mg	
N03AF01	carbamazepine		1%)	400	mg	
N03AG01	valproic acid		(3%)	600-1600	тg	
N03AX12	gabapentin	1 ()	1%)	600	тg	
N03AX16	pregabalin		1%)	150	mg	
* 750N	Antinsuchatics	() ()	1%)			
	haloneridol		(%) (%)	-	b m d	
N05AX12	aripiprazole	+	(1%)	ιŪ	вш	
NO5BA*	Anxiolytics (benzodiazepine-derivatives)	0	10%)			
N05BA01	diazepam		1%)	9	mg	
N05BA04	oxazepam	5 ((	(%9)	10-30	mg	
N05BA12	alprazolam		1%)	1.5	тg	
NO5BAXX	mexazolam	1 ()	1%)	0.5	mg	
NOSC	Other hypnotics, excl. benzodiazepine-derivatives	5) 2	(%6			
N05CH01	melatonin		1%)	1-2	тg	
N05CM09	valerianae radix		1%)	45-350	тg	
N05CX04	clomethiazole, combinations	1 ()	(1%)	20	тg	
N05CD*	Hypnotics & sedatives (benzodiazepine-derivatives)	5 (6	5%)			
N05CD02	nitrazepam		(1%)	2.5	mg	
N05CD07	temazepam	3 (7	1%)	5-10	mg	
N05CF01	zopiclone	1 ()	1%)	7.5	mg	
N06A *	Antidepressants	12 ()	(15%)			
N06AB04	citalopram	3 (7	1%)	20	mg	
N06AB05	paroxetine		3%)	20	mg	
N06AB06	sertraline		3%)	50-100	mg	
N06AX11	mirtazapine	3 (7	(4%)	30-45	тg	
N06AX16	venlafaxine	_	(3%	75-450	mg	

ATC-code	Description	n (%)	Dosag	Dosage range
N07	Other nervous system drugs	2 (3%)		
N07CA01	N07CA01 betahistine	2 (3%)	8-16	тд
R	Respiratory system	13 (16%)		
R01AD08	R01AD08 fluticasone	2 (3%)	100	bп
R03AC13	formoterol	3 (4%)	200-400	тд
R03AK06	salmeterol and fluticason	4 (5%)	1-2	dose/day
R03AL01	fenoterol and ipratropium bromide	1 (1%)	4	
R03BA02	budesonide	4 (5%)	2-12	
R03BB04	tiotropium bromide	(%6) 2	1	dose/day
R05CB01	acetylcysteine	1 (1%)	1200	тg
R06AE09	levocetirizine	1 (1%)	5	mg
R06AX15	mebhydrolin	1 (1%)	1	dose/day
R06AX27	desloratadine	2 (3%)	5	тg
10	Sensory organs	8 (10%)		
S01ED02	betaxolol	1 (1%)	1	dose/day
S01ED51	timolol, combinations	1 (1%)	1	dose/day
S01EE04	travoprost	2 (3%)	1	dose/day
S01XA20	artificial tears and other indifferent preparations	4 (5%)	1	dose/day
S02CA03	S02CA03 hvdrocortisone and antiinfectives	1 (1%)	1	dose/dav

Part II: Medication-use

Appendix I. Continued

# Appendix II

# Detailed mathematical description of the PLS regression analysis

# PLS – Analysis [23, 28, 36]

The X and Y-matrices represent respectively, the independent variables (population characteristics, co-morbidities and medication-use) and the dependent variables (gait parameters):

$$X = \begin{pmatrix} x_{11} & \cdots & x_{1j} \\ \vdots & \ddots & \vdots \\ x_{i1} & \cdots & x_{ij} \end{pmatrix} \qquad Y = \begin{pmatrix} y_{11} & \cdots & y_{1j} \\ \vdots & \ddots & \vdots \\ y_{i1} & \cdots & y_{ij} \end{pmatrix}$$
(1)

with *i* is the *i*<sup>th</sup> participant and *j* the *j*<sup>th</sup> variable. The relationship between the X and Y is defined by the function *F*: Y = F \* X + e, where *F* is modelled with the PLS analysis.

Number of latent variables (LVs) based the goodness of prediction (Q2)

$$Q2_k = 1 - \frac{PRESS_k}{RSS_{k-1}} \tag{2}$$

$$PRESS = \sum (y_{k-1,m} - \hat{y}_{k-1,-m})^2$$
(3)

where *PRESS* is the predictive sum of squares of the model containing *k* components and *RSS* is the residual sum of squares of the model. The *PRESS* depends on the  $y_{k-1,m}$  the residual of observation *m* when *k*-1 components are fitted in the model and  $\hat{y}_{k-1,-m}$  the predicted *y* when the latest observation of *m* is removed. When Q2 decreases after reaching a plateau, this is considered the optimal number of latent variables.

## Goodness of fit

The R2 explains how well the model fits the data and is defined by te residual sum of squares (RSS) of the  $k^{th}$  LV and the total sum of squares (TSS):

$$R2_k = 1 - \frac{RSS_k}{TSS} \tag{4}$$

#### The scores

Scores of the PLS reflect the individual participants contribution/position on the LVs as follows:

$$X = T * P' + xres \text{ and } Y = U * Q' + yres$$
(5)

X represents the independent variables (population characteristics, co-morbidities and medication-use), with T are the X-scores, P the X-loadings, U the Y-scores, and Q as Y-loadings.

# X-weights (W)

Weights describe the importance of the variables on the model for individual latent factors, if they are for all identified LVs near zero than they add little to the model. Weights are defined by the X-loadings (P) and the matrix of weights from the model (see eq. 6). They represent the correlation between the X-variables and U, whereas Q represents the correlation between the Y-variables and T (see eq. 5). Note that the X-loadings P and the X-weights W are very similar.

$$W^* = (P * w)^{-1} \tag{6}$$

## The Variable Importance of Projection (VIP)

The VIP-values are based on the explained sum of squares and the weights as follow:

$$VIP_{j} = \sqrt{p \sum_{k=1}^{N} \left[ SS_{k} \left( w_{kj} / \|w_{k}\|^{2} \right) \right] / \sum_{k=1}^{N} (SS)_{k}}$$
(7)

with  $SS_k$  is the explained sum of squares of the  $k^{th}$  LV, N the number of LVs in the model. The  $VIP_j$  weights  $w_{kj}$  quantify the contribution of each variable *j* according to the variance explained by each  $k^{th}$  LV.

# References

**1.** Fried LP, Tangen CM, Walston J, *et al.* (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–56.

**2.** de Vries OJ, Peeters GMEE, Lips P, Deeg DJH (2013) Does frailty predict increased risk of falls and fractures? A prospective population-based study. Osteoporos Int 24:2397–403.

**3.** American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons Panel on Falls Prevention (2001) Guideline for the prevention of falls in older persons. J Am Geriatr Soc 49:664–72.

**4.** Ham AC, Swart KMA, Enneman AW, *et al.* (2014) Medication-related fall incidents in an older, ambulant population: The B-PROOF study. Drugs Aging 31:917–27.

**5.** Bloch F, Thibaud M, Dugué B, *et al.* (2011) Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 23:329–46.

**6.** Woolcott JC, Richardson KJ, Wiens MO, *et al.* (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–60.

**7.** Hartikainen S, Lönnroos E, Louhivuori K (2007) Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 62:1172–81.

**8.** de Groot MH, van Campen JPCM, Moek MA, *et al.* (2013) The effects of fall-risk-increasing drugs on postural control: a literature review. Drugs Aging 30:901–20.

**9.** Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ (2007) Will my patient fall? JAMA 297:77–86.

**10.** Abellan van Kan G, Rolland Y, Andrieu S, *et al.* (2009) Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people. An International Academy on Nutrition and Aging (IANA) task force. J Nutr Heal Aging 13:881–9.

**11.** Lamoth CJC, van Deudekom FJ, van Campen JPCM, *et al.* (2011) Gait stability and variability measures show effects of impaired cognition and dual tasking in frail people. J Neuroeng Rehabil 8:2.

**12.** IJmker T, Lamoth CJC (2012) Gait and cognition: the relationship between gait stability and variability with executive function in persons with and without dementia. Gait Posture 35:126–30.

**13.** Hamacher D, Singh NB, Van Dieen JH, *et al.* (2011) Kinematic measures for assessing gait stability in elderly individuals: a systematic review. J R Soc Interface 8:1682–98.

**14.** Menant JC, Schoene D, Lord SR (2014) Single and dual task tests of gait speed are equivalent in the prediction of falls in older people: A systematic review and meta-analysis. Ageing Res Rev 16:83–104.

**15.** Montero-Odasso M, Muir SW, Hall M, *et al.* (2011) Gait variability is associated with frailty in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 66A:568–76.

**16.** de Groot MH, van der Jagt-Willems HC, van Campen JPCM, *et al.* (2014) A flexed posture in elderly patients is associated with impairments in postural control during walking. Gait Posture 39:767–72.

**17.** Ellis G, Langhorne P (2004) Comprehensive geriatric assessment for older hospital patients. Br Med Bull 71:45–59.

**18.** Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–98.

**19.** Tombaugh TN, McIntyre NJ (1992) The Mini-Mental State Examination: A comprehensive review. J Am Geriatr Soc 40:922–35.

**20.** Pluijm SMF, Smit JH, Tromp EAM, *et al.* (2006) A risk profile for identifying community-dwelling elderly with a high risk of recurrent falling: results of a 3-year prospective study. Osteoporos Int 17:417–25.

**21.** Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–83.

**22.** WHO Collaborating Centre for Drug Statistics Methodology (2012) Guidelines for ATC classification and DDD assignment 2013. Norwegian Institute of Public Health, Oslo, Norway

**23.** Eriksson L, Johansson E, Kettaneh-Wold N, *et al.* (2006) Multi- and megavariate data analysis. Part I - Basic principles and applications. Umetrics, Umea, Sweden **24.** Roerdink M, Lamoth CJC, Kwakkel G, *et al.* (2007) Gait coordination after stroke: benefits of acoustically paced treadmill walking. Phys Ther 87:1009–22.

**25.** Plotnik M, Giladi N, Hausdorff JM (2007) A new measure for quantifying the bilateral coordination of human gait: effects of aging and Parkinson's disease. Exp Brain Res 181:561–70.

**26.** Wold H (1966) Estimation of principal components and related models by iterative least squares. In: Krishnaiah PR (ed) Multivariate Analysis. Academic Press, New York, NY, USA, pp 391–420.

**27.** Haenlein M, Kaplan AM (2004) A beginner's guide to Partial Least Squares Analysis. Underst Stat 3:283–97.

**28.** Boulesteix A-L, Strimmer K (2007) Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform 8:32–44.

**29.** Kosse NM, de Groot MH, Vuillerme N, *et al.* (2015) Factors related to the high fall rate in long-term care residents with dementia. Int Psychogeriatrics 27:803–14.

**30.** Marzetti E, Lees HA, Manini TM, *et al.* (2012) Skeletal muscle apoptotic signaling predicts thigh muscle volume and gait speed in communitydwelling older persons: an exploratory study. PLoS ONE 7:e32829.

**31.** Eriksson S, Gustafson Y, Lundin-Olsson L (2008) Risk factors for falls in people with and without a diagnose of dementia living in residential care facilities: a prospective study. Arch Gerontol Geriatr 46:293–306.

**32.** Beauchet O, Annweiler C, Lecordroch Y, *et al.* (2009) Walking speed-related changes in stride time variability: effects of decreased speed. J Neuroeng Rehabil 6:32.

**33.** Kang HG, Dingwell JB (2008) Separating the effects of age and walking speed on gait variability. Gait Posture 27:572–7.

**34.** Allali G, Ayers EI, Verghese J (2015) Multiple modes of assessment of gait are better than one to predict incident falls. Arch Gerontol Geriatr 60:389–93.

**35.** Wold S, Sjöström M, Eriksson L (2001) PLSregression: a basic tool of chemometrics. Chemom Intell Lab Syst 58:109–30.

**36.** Abdi H (2010) Partial least squares regression and projection on latent structure regression (PLS regression). WIREs Comp Stat 2:97–106.

**37.** Sturnieks DL, St George R, Lord SR (2008) Balance disorders in the elderly. Clin Neurophysiol 38:467–78.

**38.** Papegaaij S, Taube W, Baudry S, *et al.* (2014) Aging causes a reorganization of cortical and spinal control of posture. Front Aging Neurosci 6:28.

**39.** Schwenk M, Howe C, Saleh A, *et al.* (2014) Frailty and technology: a systematic review of gait analysis in those with frailty. Gerontology 60:79– 89. **40.** Lader M, Tylee A, Donoghue J (2009) Withdrawing benzodiazepines in primary care. CNS Drugs 23:19–34.

**41.** Wald A (1993) Constipation in elderly patients. Pathogenesis and management. Drugs Aging 3:220–231.

**42.** Teramura-Grönblad M, Hosia-Randell H, Muurinen S, Pitkala K (2010) Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care 28:154–9.

**43.** Askari M, Eslami S, Scheffer AC, *et al.* (2013) Different risk-increasing drugs in recurrent versus single fallers: are recurrent fallers a distinct population? Drugs Aging 30:845–51.

**44.** Mouli VP, Ahuja V (2011) Proton pump inhibitors: concerns over prolonged use. Trop Gastroenterol 32:175–84.

**45.** Kwok CS, Yeong JK-Y, Loke YK (2011) Metaanalysis: risk of fractures with acid-suppressing medication. Bone 48:768–76.

**46.** Lewis JR, Barre D, Zhu K, *et al.* (2014) Longterm proton-pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 29:2489–97.

# PART III

# CLASSIFICATION OF FALLERS

# CHAPTER 7

# Gait dynamics to optimize fall risk assessment in geriatric patients

Lisette H. J. Kikkert Maartje H. de Groot Jos P. C. M. van Campen Jos H. Beijnen Tibor Hortobágyi Nicolas Vuillerme Claudine J. C. Lamoth

Submitted

# Abstract

The development of interventions that aim to decrease fall risk in old adults requires knowledge about modifiable fall risk factors. Fall prediction in geriatric patients remains challenging because the increased fall risk in this population involves multiple, interrelated factors caused by natural age and/or pathology. Therefore, we used a multifactorial statistical approach to model categories of modifiable fall risk factors among geriatric patients to identify fallers with highest sensitivity and specificity. We particularly focused on gait performance. Sixty-one patients (mean age 79 ± 5.0; 41% fallers) underwent extensive screening in three categories: (1) patient characteristics (e.g., handgrip strength, medication use, osteoporosis-related factors), (2) cognitive function (global cognition, memory, executive function), and (3) gait performance (speed-related and dynamic outcomes assessed by tri-axial trunk accelerometry). Falls were registered prospectively (mean follow-up 8.6 months) and one year retrospectively. Principal Component Analysis (PCA) on 11 gait variables was performed to determine underlying gait properties. Three fall-classification models were then built using Partial Least Squares–Discriminant Analysis (PLS-DA), with separate and combined analyses of the fall risk factors. PCA identified 'pace', 'variability', and 'coordination' as key properties of gait. The best PLS-DA model produced a fall classification accuracy of AUC=0.93. The specificity of the model using patient characteristics was 60% but reached 80% when cognitive and gait outcomes were added. The inclusion of cognition and gait dynamics in fall classification models reduced misclassification. We therefore recommend assessing geriatric patients' fall risk using a multi-factorial approach that incorporates patient characteristics, cognition, and gait dynamics.

# Introduction

Approximately 30% of all old adults aged 65 or older experience a fall at least once a year. Falls are associated with pain, functional impairments, morbidity, devastating psychological impacts, and even mortality [1]. Preventing falls therefore remains a health care priority and early identification of individuals at risk is the first step in fall prevention. Older compared with younger adults are more likely to fall due to age-related declines in sensory, cognitive, and neuromuscular function, leading to an impaired gait [2]. Consequently, impaired gait and balance, in addition to personal characteristics (e.g., gender, age, anthropometry, polypharmacy), are related to falls in community dwelling adults [3].

Age-related slowing of gait is the most documented gait outcome, with habitual gait speed slowing by 16% per decade after age 60 [4–6]. A gait speed below 1.0 m/s signifies potential clinical or sub-clinical impairment, such as mobility impairments, recurrent falling, loss of independence and institutionalization [4]. In addition to gait speed, a variety of measures can quantify the dynamic nature (time dependent variations in time) of gait, such as detrended fluctuation analysis [7], sample entropy [8], and index of harmonicity [9]. Each of these gait dynamics reflect a unique characteristic of gait (e.g. speed, coordination, variability) and can be considered as complementary to each other. However, some gait measures are not independent but inter-related [10]. For instance, the coefficient of variation of stride time increases when gait speed decreases [11]. Factor analysis takes these inter-relations into account and reduces the dimensionality of the gait data by identifying underlying clusters of gait characteristics [12–15].

With respect to falling, prediction models become more accurate when characteristics of gait are included [16, 17]. For example, gait smoothness prospectively discriminated fallers from non-fallers in community dwelling old adults with a sensitivity of 68.8 % and a specificity of 84.2% [17]. In addition, the accuracy of fall prediction models based on clinical tests commonly used in fall risk assessments such as questionnaires, handgrip strength, and neuropsychological tests, increased by 0.14 when comprehensive gait analysis was added (AUC from 0.68 to 0.82, sensitivity: 70%; specificity: 81% [16]).

The accuracy of fall prediction models may be population-dependent and may not be generalizable to patients admitted to geriatric outpatient clinics. Geriatric patients do not only walk slower than the clinical threshold of 1.0 m/s [4, 18], but pathological conditions also modify gait dynamics. For example, 50% of geriatric patients use polypharmacy, which increases the risk for falls [19, 20]. Also, nearly 50% of geriatric patients suffer from osteoporotic vertebral fractures, a condition associated with an increase in thoracic kyphosis, decrease in gait stability, and increased fall risk [21, 22]. Moreover, up to 30% of geriatric patients above age 60 present with sarcopenia, which is also associated with gait slowing and an increased fall risk [23]. Finally, the prevalence of cognitive impairment ranges from 22-71% in old adults above age 65 [24] and contributes to slow gait, increased gait variability, decreased gait stability, and increased fall risk [25].

Geriatric patients can thus be characterized by a unique set of variables that increases their risk for a fall. Hence, one approach to identify fallers is by grouping fall risk factors into categories, e.g., personal characteristics typically assessed in clinical practice, cognitive function, as well as gait performance, and apply multi-factorial data analysis. Such an approach would allow us to examine the role of each factor in fall risk. Subsequently, it facilitates the development of personalized interventions strategies to modify for example medication [20], cognition [26], and physical activity levels [6]. The present study therefore aims to statistically model categories of fall risk factors that identify geriatric fallers with the highest sensitivity and specificity, with a focus on gait characteristics. To this aim, we pursued two complementary objectives: (1) to identify unique gait properties by extracting the underlying clusters of 11 gait measures and remove redundancies in these measures using factor analysis; and (2) to examine if the sensitivity and specificity of a fall risk model improves when adding first cognitive measures to personal characteristics, and adding thereafter the gait factors identified by factors analysis. We hypothesized that different gait measures sum into the key properties of gait, related to speed and dynamics. With respect to the second aim, we expected an increase in either sensitivity or specificity of fall classification when gait factors are added to the statistical model.

# Materials and methods

## Study population

The present study included 61 patients (41 women and 20 men) of a database of patients that visited the geriatric day clinic of the MC Slotervaart Hospital, Amsterdam between 2011 and 2013 [21, 27, 28]. Patients were admitted to the day clinic based on a medical referral by a general practitioner and underwent extensive screening for physical, psychological, and cognitive functions. Inclusion criteria were: age 70 or older. Exclusion criteria were: (1) Inability to walk for at least three minutes without a walking aid, (2) inability to speak fluently Dutch, and (3) having mobility disability caused by neurological

or orthopedic conditions, limiting function in one or both legs. The Medical Ethical Committee of the MC Slotervaart Hospital approved the study protocol. Written informed consent was obtained from all participants or their legal representatives.

#### Outcome measures

## Determination of fall status

A fall was defined as unintentionally coming to rest on the ground, floor, or other lower level. Patients were interviewed retrospectively about the number of falls over the past year. Also, falls were prospectively registered with a 'fall calendar', for which patients were contacted monthly up to 12 months follow-up, with a minimum of 6 months. For patients with an MMSE-score below 24, fall history was obtained from a caregiver. A patient was classified as 'faller' when one or more falls occurred retrospectively or prospectively.

#### Patient characteristics

Demographic information including age, gender, and body mass index (BMI) were recorded. Maximal grip strength of the dominant hand [29], was quantified with a Jamar hand-held dynamometer (average of 3 trials). The amount of comorbidities was categorized with the Charlson Comorbidity Index (CCI) [30]. Medications were classified according to the Anatomical Therapeutic Chemical (ACT) codes [31] and quantified as the total number of 'Fall Risk Increasing Drugs' (FRIDs), including psychotropic and diuretic drugs [20]. Lateral X-rays of the thoracic spine were analyzed to determine the degree of thoracic kyphosis, indicated by the Cobb angle between the superior endplate of the second thoracic vertebra and the inferior endplate of the twelfth thoracic vertebra [21]. Finally, fall risk was assessed according to the Longitudinal Aging Study Amsterdam (LASA) fall risk profile [32].

#### Cognitive function

Global cognition was assessed with the Mini Mental State Examination (MMSE) with scores below 24 denoting cognitive impairment [33]. The 7-minute screen [34] was administered to assess memory and executive function using the Benton's Temporal Orientation (BTO), the Enhanced Cued Recall (ECR), the animal verbal fluency and the clock drawing test.

#### Gait performance

All patients walked 160 meters at habitual speed on an 80-meter long hallway. A tri-axial accelerometer (87x45x14 mm; sample frequency 100 Hz; Dynaport<sup>®</sup> MiniMod, McRoberts BV, The Hague, the Netherlands) was attached to the lower back at the level of the third lumbar spine segment to measure medio-lateral (ML) and anterior-posterior (AP) trunk accelerations. Acceleration signals were analyzed with custom-made software in MATLAB (version 2014b; The MathWorks, Inc). The signals were corrected for horizontal tilt and low-pass filtered with a 2<sup>nd</sup> order Butterworth filter with a cut-off frequency of 15 Hz. Outliers due to turns were removed from the data using a median filter. Walking speed was calculated by dividing distance walked by the time.

Peak accelerations from AP signals were used to detect time indices of left and right foot contacts. Mean and coefficient of variation (CV) of stride times were computed from the time interval between two consecutive ipsilateral foot contacts. Step consistency was quantified by the standard deviation (SD) of the relative phase between sequential ipsilateral indices of foot contact [35]. Higher SD of the relative phase implies a more inconsistent gait pattern. Long-range correlations between strides were quantified by the scaling exponent  $\alpha$  using detrended fluctuation analysis [7]. A value of  $0.5 \ge \alpha \ge 1$ suggests the presence of long-range correlations and signifies that future fluctuations in strides are more accurately predicted by previous fluctuations.

The Root Mean Square (RMS) of the AP and ML acceleration quantified the variability in the magnitude of the trunk accelerations. The Index of Harmonicity (IH) was computed to examine the smoothness (frequency content) of the signal, using spectral analysis. Perfect smooth trunk accelerations would reveal an IH of 1 [9]. To quantify the degree of predictability of trunk acceleration time series, the Sample Entropy (SEn) was calculated [36]. A complete predictable (periodic) signal will adopt a SEn of 0, with a larger SEn representing a less predictable gait.

### Statistical analysis

Principal Component Analysis (PCA) with a Varimax rotation and Kaiser normalization was performed on the 11 gait variables to determine underlying gait properties, and to reduce the dimensionality of the data to unique factors. The number of extracted principal components (PC's) was determined by analyzing the scree plot which reveals the percentage explained variance by each component. PC's with eigenvalues larger than 1 were considered eligible for inclusion in the final model. The regression coefficients of the extracted PC's were then used for further analyses [13].

To examine the contribution of different fall risk factors, three Partial Least Squares Discriminant Analyses (PLS-DA) were performed using the PLS\_toolbox for MatLab (version 3.7.1; Eigenvector Research Inc.). PLS-DA combines PCA and regression analysis and can handle data consisting of a large number of independent, highly collinear, interrelated variables with relatively few observations (subjects) [37]. In the PLS-DA analyses, patient characteristics, cognitive and gait measures represented the independent variables (X), and fall-status the categorical, dependent variable (Y). The analysis seeks to find underlying latent variables (LV's) to investigate fundamental relations between the matrices X and Y by modelling the covariance structures in these two spaces. All variables were normalized to unit variance. The optimal number of LV's was determined using the scree plot and defined at the level where a plateau phase in the goodness of prediction (Q<sup>2</sup>) was reached [37].

Three models were developed based on: (1) only patient characteristics, (2) patient characteristics and cognitive function, and (3) patient characteristics, cognitive function, and the regression coefficients derived from the factor analysis; the gait factors. Outcome measures of the PLS-DA included scores (individual patients observations) and weights (contribution of fall risk factors to the model), quantifying the relationship between fall risk factors and fall status. The variance explained reflected how variables are clustered within each LV. Classification accuracy of the models was quantified as sensitivity, specificity, and area under the curve (AUC), and visualized with receiving operating characteristic (ROC) curves, with an AUC of 1 representing a perfect fit.

## Results

### Patient characteristics

Fallers (mean age 80.2 ± 4.7) compared to non-fallers (78.8 ± 5.1) presented with a lower handgrip strength (23.7 ± 8.0 versus 27.2 ± 8.8), the same number of FRIDS (1.3 ± 1.2 versus 1.3 ± 1.4), and a comparable CCI (1.6 ± 1.4 versus 1.3 ± 1.2), BMI (27.7 ± 4.2 versus 26.0 ± 3.5), and Cobb angle (52 ± 14 versus 50 ± 13). Fallers scored higher on the LASA risk profile (8.0 ± 1.2 versus 2.4 ± 0.4).

### Falls

Retrospective fall data was registered from all 61 patients during the interview. From six patients, follow-up fall calendar data was obtained for less than 6 months, because patients changed address, or withdrawn from participation and did not want to be

contacted any longer. The mean follow-up duration was 8.6 months. Twenty-five patients were classified as fallers (41%); 18 retrospective fallers, 19 prospective fallers, and 12 patients fell during the last year as well as during follow-up.

### Gait Analysis

Three PC's with eigenvalues >1 and absolute factor loadings >0.4 explained 67.50% of the total variance of the 11 gait measures. PC1 reflected measures related to gait speed, stride times, and the amplitude of trunk accelerations and was labeled 'pace'. PC2 and PC3 represented measures related to gait variability and coordination respectively, and were labeled 'variability' and 'coordination' (Table 7.1). These three identified gait components were then used for the PLS-DA analyses below.

Table 7.1. Loadings of the gait variables	(eigenvalue >1 an	d absolute	loadings > 0.4) as
revealed by PCA with Varimax Rotation.			

Gait measures	Pace	Variability	Coordination
Walking Speed	848		
Root Mean Square AP	844		
Root Mean Square ML	820		
Index of Harmonicity ML	.791		
Stride Time	.748		
CV Stride Time	.583	.435	
Step Consistency		.781	
Long range correlations		774	
Sample Entropy AP		.677	
Sample Entropy ML			.850
Index of Harmonicity AP			.512

CV = Coefficient of Variation; AP = Anterior-Posterior; ML = Medio-Lateral


### The PLS-DA models

Table 7.2 and Fig. 7.1 show the results of the three PLS-DA models. Model 1 and 2 included three LV's, and five LV's were extracted for model 3. Note that in all models, LV1 explains most of the variance in the independent variables (X) and falls (Y), followed by LV2 and by LV3, but based on the Q<sup>2</sup> criteria, five LV's were included. Classification accuracy of the first model with patient characteristics increased from 0.86 to 0.90 (AUC) when cognitive measures were added. Model accuracy further increased from 0.90 to 0.93 (AUC) when the principal gait components derived were subsequently added. In particular specificity increased in the second model from 60% to 72% and reached 80% when gait measures were included.

**Table 7.2.** Characteristics of the three PLS-DA models: Number of latent variables, variance explained in X (fall risk factors) and Y (fall-status), and classification accuracy of fallers and non-fallers

Model	Factors included		nber of LV's	X-block (%)	Y-block (%)	Sensitivity (%)	Specificity (%)	AUC
1	Patient	3	LV1	23.7	32.5	92	60	0.86
	characteristics		LV2	15.0	6.5			
			LV3	15.9	0.7			
			Sum	54.5	39.7			
2	Patient	3	LV1	15.1	34.5	89	72	0.90
	characteristics +		LV2	13.1	9.5			
	cognition		LV3	20.5	2.1			
			Sum	48.7	46.1			
3	Patient	5	LV1	31.8	33.6	92	80	0.93
	characteristics +		LV2	7.8	13.5			
	cognition + gait		LV3	18.4	1.3			
			LV4	7.5	1.4			
			LV5	5.3	0.8			
			Sum	52.4	50.7			

LV = Latent Variable; AUC = Area Under the Curve



Model 1 (light gray) = Patient characteristics;

Model 2 (medium gray) = Patient characteristics + cognitive outcomes;

Model 3 (dark gray) = Patient characteristics + cognitive outcomes + gait outcomes.

Fig 7.1. Receiving Operating Characteristic - curves for the three fall classification models.

Table 7.3 presents the amount of explained variance per independent variable of each included LV of the final model (model 3). The results signify that X-variables are clustered within the LV's. Motor performance and the LASA were mainly presented in LV1, cognitive function in LV2 and LV3, and patient characteristics in LV4 and LV5.

Biplots of the final model provide a graphical representation of the Y-variable (falls) and weights of the X-variables (patient characteristics, cognitive outcomes, and gait outcomes) with respect to the LV's (Fig. 7.2). Fallers and non-fallers present in sharply separated clusters. The coordinates (size) of the weight vectors reflect the importance of the X-variable to the LV's. In this figure, the direction of the vectors reflects how these X-variables relate to fallers or non-fallers. The weights show that LASA, BTO, BMI and gait pace are particularly relevant in the identification of fallers, whereas handgrip, clock drawing, verbal fluency, gait variability, and gait coordination are relevant in the identification of non-fallers.

Independent variable	LV1	LV2	LV3	LV4	LV5	Sum
Gait						
Gait Pace	12.2	0.0	6.0	2.2	1.0	22.2
Gait Variability	0.3	5.9	5.5	7.2	2.1	21.0
Gait Coordination	20.4	13.3	1.3	0.4	3.6	39.0
Cognition						
Mini Mental State Examination (MMSE)	7.7	0.5	58.7	7.5	4.6	86.6
Benton's Temporal Orientation (BTO) test	1.7	0.5	58.7	0.5	1.3	62.7
Enhanced Cued Recall (ECR) test	6.3	5.5	53.4	0.1	4.8	70.0
Clock Drawing test	9.1	12.9	21.7	0.7	8.5	52.0
Verbal Fluency test	10.4	15.5	28.1	16.1	0.1	70.3
Patient characteristics						
Fall Risk Increasing Drugs (FRIDs)	2.8	8.2	2.3	18.4	4.5	36.2
Charlson Comorbidity Index (CCI)	0.2	6.0	9.0	21.1	0.0	36.4
Body Mass Index (BMI)	3.8	8.3	4.1	28.9	26.4	71.5
Longitudinal Aging Study Amsterdam (LASA)	74.4	2.4	0.7	1.4	5.6	84.5
Handgrip	40.9	15.6	8.9	0.2	0.6	66.2
Cobb Angle	2.5	0.8	0.0	0.0	10.6	13.9

**Table 7.3.** Explained variance (%) per independent variable of the 5 extracted Latent Variablesin model 3.

**LV** = Latent Variable






Fig 7.2. Biplots of Latent Variables (LV's) 1 vs. 2 (left) and LV's 1 vs. 3 (right) provide a graphical representation of the response variable fall-status) and weights of the independent variables (patient characteristics, cognitive, and gait factors) with respect to the included LV's. As clearly shown, fallers and non-fallers (dark and light gray respectively) are clustered. Weight vector size reflects the importance of the variable to the model. The direction of the vector refers to whether variables mainly relate to classification of fallers (sensitivity) or non-fallers (specificity).

## Discussion

We applied a factor analysis to speed-related and dynamic gait measures and we then statistically modeled combinations of factors that classified geriatric fallers with the highest sensitivity and specificity. The factor analysis identified pace, variability, and coordination as key properties of gait. A model that included patient characteristics, cognitive function, as well as gait performance produced high classification accuracy (AUC=0.93) and showed an increase in specificity from 60% to 80% compared to a model that only included patient characteristics. We discuss how successful fall risk assessment in the future will most likely include a large array of variables to optimize geriatric patients' fall prediction.

First, PCA applied to 11 gait variables revealed three unique gait properties: pace, variability, and coordination. 'Pace' comprised speed-related measures, namely gait speed, stride time, and the amplitude of AP and ML accelerations (RMS). 'Variability' and 'coordination' are considered as gait properties that reflect the dynamics of gait and were mainly derived from trunk accelerations. The loading structure was consistent, except for the IH in ML direction, which loaded on the pace component (absolute loading: 0.791) while it was expected to load on the coordination component. This might imply that IH ML is related to gait speed. In general, the extracted components were comparable with components identified by previous studies [12–15].

Second, three PLS-DA models were generated and compared (Table 7.2 and Fig 7.1). The first model based on patient characteristics already achieved high classification accuracy (AUC=0.86). LASA clearly outperformed the other variables, as indicated by the size of the weight vectors. LASA provides an extensive screening tool consisting of nine fall-related factors such as dizziness, fear of falling, alcohol intake, fall history, and education level [32]. Although sensitivity of this first model was quite high (80%), specificity remained relatively low (60%). A low specificity (i.e., true negative rate) hampers clinical application because non-fallers will be erroneously identified as fallers and such misclassifications may induce fear of falling and unnecessary interventions.

Adding cognitive measures to the model increased specificity by 12%, reaching a value of 72% (Table 7.2). Age-related decline in gait and cognition co-occurs because brain areas that control gait partly overlap with brain areas that control cognitive function [2]. Gait dysfunction can thus be expected in the presence of cognitive impairment [25, 38] and an impaired gait control in turn increases fall risk. On the other hand, old adults rely on executive functions in daily activities that require divided

Chapter 7

attention (e.g., in traffic and walking while talking). Impairment in executive functions may thus cause dangerous situations and increase fall risk.

Adding gait outcomes to the model further increased the models' specificity by 8%, reaching a value of 80% (Table 7.2). Progressive age-related deterioration in neuromuscular and neurophysiological function engenders decline in sensory systems, sarcopenia, slower movement time and central processing, all linked to deficits in gait and balance [39]. In particular gait components 'variability' and 'coordination' accounted for the increase in specificity, as indicated by the size and direction of the corresponding vectors towards non-fallers (high specificity). These results support the idea that speedrelated measures (captured by the pace domain) may be sufficient for classifying fallers. They do, however, lack specificity that could result in misclassification of non-fallers. Gait speed is widely recognized as an important variable associated with many clinical conditions later in life [4]. The results of the present study show that combining gait speed and speed-related measures with dynamic gait measures will increase specificity and thus classification accuracy. Hence, gait dynamics could easily be added to measures usually addressed in clinical practice. Such gait dynamics can be obtained by clinicians in about 10 minutes. Nowadays, extensive gait analysis is more easily accessible for clinical practice due to the rapid development of off-the-shelf smartphones, iPods and similar smart devices. Equipped with built-in accelerometers and gyroscopes, the devices are light, inexpensive, easy to handle, and thus suitable to analyze gait in a clinic [40].

In conclusion, geriatric patients represent a vulnerable population with an increased risk for falling. Fall risk assessment including modifiable fall risk factors revealed high classification accuracy (AUC = 0.93). Although patient characteristics can accurately identify fallers, the evaluation of executive function and gait dynamics reduced misclassification with an increase in specificity from 60% to 80%. Therefore, we underscore the need for a multifactorial approach in fall risk assessment in geriatric patients, including a comprehensive evaluation of patient characteristics, cognitive function, and gait performance. These fall risk factors should ultimately be targeted by individualized interventions to reduce fall risk.

## References

**1.** Kannus P, Sievänen H, Palvanen M, *et al.* (2005) Prevention of falls and consequent injuries in elderly people. Lancet 366:1885–93.

**2.** Holtzer R, Epstein N, Mahoney JR, *et al.* (2014) Neuroimaging of mobility in aging: A targeted review. Journals Gerontol - Ser A Biol Sci Med Sci 69:1375–1388.

**3.** Ambrose AF, Paul G, Hausdorff JM (2013) Risk factors for falls among older adults: a review of the literature. Maturitas 75:51–61.

**4.** Abellan van Kan G, Rolland Y, Andrieu S, *et al.* (2009) Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people. An International Academy on Nutrition and Aging (IANA) task force. J Nutr Heal Aging 13:881–889.

**5.** Beijersbergen CMI, Granacher U, Vandervoort AA, *et al.* (2013) The biomechanical mechanism of how strength and power training improves walking speed in old adults remains unknown. Ageing Res Rev 12:618–627.

**6.** Hortobágyi T, Lesinski M, Gäbler M, *et al.* (2015) Effects of three types of exercise interventions on healthy old adults' gait speed: A systematic review and meta-analysis. Sport Med 45:1627–1643.

**7.** Hausdorff JM, Purdon PL, Peng CK, *et al.* (1996) Fractal dynamics of human gait: stability of longrange correlations in stride interval fluctuations. J Appl Physiol 80:1448–1457.

**8.** Costa MD, Peng C-K, Goldberger AL, Hausdorff JM (2003) Multiscale entropy analysis of human gait dynamics. Physica A 330:53–60.

**9.** Lamoth CJC, Beek PJ, Meijer OG (2002) Pelvisthorax coordination in the transverse plane during gait. Gait Posture 16:101–14.

**10.** Kaptein RG, Wezenberg D, IJmker T, *et al.* (2014) Shotgun approaches to gait analysis: insights & limitations. J Neuroeng Rehabil 11:120.

**11.** Beauchet O, Annweiler C, Lecordroch Y, *et al.* (2009) Walking speed-related changes in stride time variability: effects of decreased speed. J Neuroeng Rehabil 6:32.

**12.** Lord S, Galna B, Verghese J, *et al.* (2012) Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J Gerontol A Biol Sci Med Sci 68:820–827.

**13.** Riva F, Toebes MJP, Pijnappels M, *et al.* (2013) Estimating fall risk with inertial sensors using gait stability measures that do not require step detection. Gait Posture 38:170–174.

**14.** Hollman JH, McDade EM, Petersen RC (2011) Normative spatiotemporal gait parameters in older adults. Gait Posture 34:111–8.

**15.** Verlinden VJA, van der Geest JN, Hofman A, Ikram MA (2014) Cognition and gait show a distinct pattern of association in the general population. Alzheimer's Dement 10:328–335.

**16.** van Schooten KS, Pijnappels M, Rispens SM, *et al.* (2015) Ambulatory fall-risk assessment: amount and quality of daily-life gait predict falls in older adults. J Gerontol A Biol Sci Med Sci 70:608–615.

**17.** Doi T, Hirata S, Ono R, *et al.* (2013) The harmonic ratio of trunk acceleration predicts falling among older people: results of a 1-year prospective study. J Neuroeng Rehabil 10:7.

**18.** Schwenk M, Howe C, Saleh A, *et al.* (2014) Frailty and technology: a systematic review of gait analysis in those with frailty. Gerontology 60:79– 89.

**19.** Maher RL, Hanlon J, Hajjar ER (2014) Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 13:57–65.

**20.** de Groot MH, van Campen JPCM, Moek MA, *et al.* (2013) The effects of fall-risk-increasing drugs on postural control: a literature review. Drugs Aging 30:901–920.

**21.** de Groot MH, van der Jagt-Willems HC, van Campen JPCM, *et al.* (2014) A flexed posture in elderly patients is associated with impairments in postural control during walking. Gait Posture 39:767–772.

**22.** Miyazaki J, Murata S, Horie J, *et al.* (2013) Lumbar lordosis angle (LLA) and leg strength predict walking ability in elderly males. Arch Gerontol Geriatr 56:141–147.

**23.** Landi F, Liperoti R, Russo A, *et al.* (2012) Sarcopenia as a risk factor for falls in elderly individuals: Results from the ilSIRENTE study. Clin Nutr 31:652–658.

**24.** Ward A, Arrighi HM, Michels S, Cedarbaum JM (2012) Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimer's Dement 8:14–21.

**25.** Kikkert LHJ, Vuillerme N, van Campen JPCM, *et al.* (2016) Walking ability to predict future cognitive decline in old adults: A scoping review. Ageing Res Rev 27:1–14.

**26.** Verghese J, Mahoney J, Ambrose AF, *et al.* (2010) Effect of cognitive remediation on gait in sedentary seniors. J Gerontol A Biol Sci Med Sci 65A:1338–1343.

**27.** de Groot MH, van Campen JPCM, Kosse NM, *et al.* (2016) The association of medication-use and frailty-related factors with gait performance in older patients. PLoS One 11:e0149888.

**28**. van der Jagt-Willems HC, de Groot MH, van Campen JPCM, *et al.* (2015) Associations between vertebral fractures, increased thoracic kyphosis, a flexed posture and falls in older adults: a prospective cohort study. BMC Geriatr 15:34.

**29.** Sallinen J, Stenholm S, Rantanen T, *et al.* (2010) Hand-grip strength cut points to screen older persons at risk for mobility limitation. J Am Geriatr Soc 58:1721–1726.

**30.** Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383.

**31.** WHO Collaborating Centre for Drug Statistics Methodology (2012) Guidelines for ATC classification and DDD assignment 2013. Norwegian Institute of Public Health, Oslo, Norway

**32.** Pluijm SMF, Smit JH, Tromp EAM, *et al.* (2006) A risk profile for identifying community-dwelling elderly with a high risk of recurrent falling: results of a 3-year prospective study. Osteoporos Int 17:417–425.

**33.** Tombaugh TN, McIntyre NJ (1992) The Mini-Mental State Examination: A comprehensive review. J Am Geriatr Soc 40:922–935.

**34.** Solomon PR, Hirschoff A, Kelly B, *et al.* (1998) A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease. Arch Neurol 55:349–355.

**35.** Roerdink M, Lamoth CJC, Kwakkel G, *et al.* (2007) Gait coordination after stroke: benefits of acoustically paced treadmill walking. Phys Ther 87:1009–1022.

**36.** Pincus SM (1991) Approximate entropy as a measure of system complexity. Proc Natl Acad Sci 88:2297–2301.

**37.** Wold S, Sjöström M, Eriksson L (2001) PLSregression: a basic tool of chemometrics. Chemom Intell Lab Syst 58:109–30.

**38.** Morris R, Lord S, Bunce J, *et al.* (2016) Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease. Neurosci Biobehav Rev 64:326–345.

**39.** Papegaaij S, Taube W, Baudry S, *et al.* (2014) Aging causes a reorganization of cortical and spinal control of posture. Front Aging Neurosci 6:28.

**40.** Kosse NM, Caljouw S, Vervoort D, *et al.* (2015) Validity and reliability of gait and postural control analysis using the tri-axial accelerometer of the iPod Touch. Ann Biomed Eng 43:1935–46.



## CHAPTER 8

Conclusions & Future Perspectives

Discussion

## Conclusions and perspectives

The studies described in this thesis investigated the association between common geriatric phenomena (e.g., osteoporosis, medication-use, frailty and cognitive impairment) with postural control during walking in older patients visiting a geriatric outpatient clinic. This provided insight into the interplay between these geriatric phenomena and different properties of the gait pattern. This chapter will discuss the main results and conclusions from this thesis and suggests future perspectives for clinical practice and subsequent research.

## Part I: Osteoporosis-related factors

Osteoporosis is frequently present in older patients [1], and might in time cause vertebral fractures, which could lead to a flexed posture, and consequently to impaired postural control and an increased risk of falling. In the first part of this thesis, this assumption was studied by investigating (1) the relationship between osteoporosis, vertebral fractures, increased thoracic kyphosis and a flexed posture, then (2) the association between these osteoporosis-related factors and postural control, and finally (3) the risk of falling in osteoporotic patients.

# Relationship between osteoporosis, vertebral fractures, increased thoracic kyphosis and flexed posture

Osteoporosis is characterized a by low bone mass leading to enhanced bone fragility and an increased risk of fractures [2, 3]. Fractures of the vertebrae are typical osteoporotic fractures. Thoracic vertebral fractures could increase the kyphotic curvature of the thoracic spine [4], and may therefore cause a flexed posture [5]. In chapter 3 and 4, we screened older patients for vertebral fractures, measured the degree of thoracic kyphosis, and the occiput-to-wall distance (as indicator for a flexed posture) when they visited the geriatric outpatient clinic. Most of these patients had a combination of two or three of these osteoporosis-related factors. Therefore, regression analyses were performed to examine the associations between vertebral fractures, increased thoracic kyphosis and a flexed posture.

A multivariate regression analysis revealed no significant association between an increased thoracic kyphosis and the presence of vertebral fractures (chapter 3). Other studies found similar results: only a third of the individuals with severe thoracic kyphosis have one or more vertebral fractures [6, 7]. The association between vertebral fractures,

Discussion

increased thoracic kyphosis and consequently a flexed posture could probably not be found because there are different causes for an increased thoracic kyphosis and consequently a flexed posture, such as degenerative disc diseases, or muscle weakness [8, 9]. Of these factors, only grip strength, as indicator of overall muscle strength, was assessed in the present studies. However, grip strength was not significantly associated with a flexed posture in the multivariate regression analyses (chapter 3). To obtain more in-depth insight in the relationship between vertebral fractures, increased thoracic kyphosis and consequently a flexed posture, future studies should examine the association between vertebral fractures, increased thoracic kyphosis, and other potential causes for a flexed posture in a longitudinal study design. These insights could subsequently be used to offer and/or improve interventions aimed at correcting patients' posture, such as anti-osteoporotic medications, exercise aimed at trunk stabilization, and manual therapy [10].

### Association between osteoporosis-related factors and postural control

Because vertebral fractures, thoracic kyphosis, and a flexed posture may affect motor function, the association between these osteoporosis-related factors and postural control was investigated in chapter 2 and 3 of this thesis. In the literature study (chapter 2), after reviewing eighteen cross-sectional studies it was concluded that postural control was generally affected in patients with prevalent vertebral fractures, an increased thoracic kyphosis and/or a flexed posture. This was affirmed in the crosssectional study described in chapter 3, where was demonstrated that patients with a flexed posture had overall a more variable and less structured gait pattern, and a more irregular trunk acceleration pattern in the anterior-posterior direction than patients with normal upright posture. This can be explained by the fact that in these patients the body's center of mass is shifted forward [11, 12]. As postural control can be defined as the ability to maintain the center of mass within the support base [13], this would suggest that patients with a forward spinal curvature require correcting responses from dorsal musculature and ligaments to maintain balance. In severe cases of patients with a flexed posture, this is expressed by flexed knees and protrusion of the head [5, 14]. This presumably leads to impairments in postural control mainly in the anteriorposterior direction as was expressed by more postural sway while standing still [15, 16], slower walking speed and smaller step and stride lengths [5, 15]. In addition, arm sway and trunk movements and rotation may be reduced due to the changed flexed posture and altered functioning of muscles and ligaments. Because dynamics of arms, head and

trunk are important mechanisms to maintain balance [17], it is likely that the ability to react to (small) perturbations during walking is diminished in patients with a flexed posture, increasing the risk of falls.

### Risk of falling in osteoporotic patients

Based on the previous described findings, it is suggested that patients with vertebral fractures, increased thoracic kyphosis and/or flexed posture will have an increased risk of falling due to the impairments in postural control. Retrospective studies showed that the presence of both vertebral fractures and an increased thoracic kyphosis are related with increased fall risk [18–20]. In the prospective study presented in chapter 4, we found that older patients with an increased thoracic kyphosis are more likely to fall within the next year.

Since older adults with an increased thoracic kyphosis may thus have an increased fall risk, clinical attention is suggested for these patients, because the consequences of vertebral fractures, increased thoracic kyphosis, flexed posture and falls in the long term may be severe. As concluded in the first part of this thesis, these osteoporosis-related conditions could lead to impaired postural control, and an increased fracture risk. Furthermore, patients with prevalent vertebral fractures, an increased thoracic kyphosis, and/or a flexed posture may experience pain, restrictive respiratory disease, decline in physical functioning, loss of quality of life, and/or mortality [4, 21–24]. Due to the high observed prevalence of vertebral fractures, increased thoracic kyphosis, and flexed posture in the examined older patient population in this thesis, it is recommended to clinicians to screen for these conditions. As part of the comprehensive geriatric assessment, X-rays of the chest are often performed to visualize heart and lungs. These routinely made lateral chest X-rays are reliable to diagnose vertebral fractures [25], and could also be used to measure the degree of thoracic kyphosis by the Cobb angle [15]. A flexed posture can be easily assessed in clinical practice by measuring the occiput-towall distance [5], as done in chapter 3 and 4. When one (or more) of these conditions is prevalent, adequate treatment should be provided. Several studies have shown improvements in the degree of osteoporosis, reduced number of new vertebral fractures and increased thoracic kyphosis by prescribing anti-osteoporotic medications, supplementation of calcium and vitamin D, exercise aimed at trunk stabilization and manual therapy [10, 26]. These interventions might also reduce the risk of falls and resultant fractures in older patients. In order to prevent adverse outcomes associated with the described osteoporosis-related conditions, the aforementioned clinical

examinations could be easily implemented in the screening at the geriatric outpatient clinic, with minimal extra work for both patient and physician.

## Part II: Medication-use

Older patients often have multiple chronic diseases and use consequently multiple medications [27]. Some psychotropic and cardiac medication classes are associated with an increased risk of falls [28–32], and are therefore called fall-risk increasing drugs (FRIDs). Especially psychotropic drugs are known to increase fall risk due to their sedative side-effects, inducing muscle relaxation and decreased grip strength [33], and might therefore impair postural control [13]. In chapter 5, this assumption was confirmed by 71 out of 94 reviewed studies, which found an increase in parameters quantifying body sway, and/or slower walking speed, smaller step length and/or lower cadence after using psychotropic drugs. The effects were more pronounced when people were older, used higher daily dosages of psychotropics, with longer half-lives or for a longer period of time. Importantly, two intervention studies concluded that these effects seem to be reversible when medications are discontinued [34, 35], although it is not clear whether this would also reduce falls [36].

When analyzing the effects of medication-use on fall risk or postural control, it is important to not only investigate the effects of the drug, but also to consider the effects of the underlying disease [37]. For example, antidepressants are known to be associated with an increased risk of falling [28–31] and an impaired postural control (chapter 5). Also depressive symptomatology is a risk factor for falls independent of antidepressant use [38] due to the physical factors, including impaired balance and reduced muscle strength, and cognitive functioning [39, 40]. Studies examining the effects of medication-use on postural control should thus take the underlying illness into account.

In chapter 6, a multifactorial model was therefore created to examine the association between medication-use, the prevalence of several chronic diseases, frailty-related factors and gait performance in older patients. These patients often have multiple diseases simultaneously and consequently chronically use multiple medications. This is in contrast to the reviewed study populations in chapter 5 that consisted of relatively young and healthy adults and tested only single-drug effects. In the examined older patient population of chapter 6, only a moderate association was observed between the use of antiepileptics and antidepressants with impaired gait ability, while hardly any association with other psychotropic drug classes was found, contrary to our expectations based on the literature review described in chapter 5. Interestingly, a strong association was found between frailty-related factors, including unintentional weight loss, selfreported exhaustion, low physical activity, and low grip strength, with impaired gait performance as expressed by lower walking speed, higher mean stride times, increased variability of stride times and less consistent steps. These findings were in line with previous research [41, 42] which suggested that the impaired gait ability that was found might reflect the multisystem reduction in neurophysiological capacity in frailty.

In chapter 6, we also found drugs to be associated with impaired gait ability that were not expected to be. Laxatives, agents acting on sensory organs (e.g., artificial tears), and drugs for peptic ulcer and reflux disease were strongly associated with impaired gait performance. Although these drugs are suggested not to have a direct effect on postural control, they are frequently prescribed in individuals with indicators of frailty, and may therefore act as "frailty markers" [43, 44]. Because the frailty-related factors were stronger associated with impaired gait ability than the use of psychotropic drugs, it was suggested that possibly, at a certain frailty-level, the effect of the deterioration in physical functioning is so large, that the instability provoking sedative side-effects of psychotropic drugs have less impact on gait.

Nevertheless, the findings of the second part of this thesis enhance the necessity for physicians to take the adverse effects of psychotropic drugs on postural control and consequently on fall risk into account when evaluating or prescribing these drugs to older patients. Recent studies found that when a patient presents himself/herself with complaints about dizziness, balance problems or falls to a general practitioner, the adjustment of FRIDs is carried out less often than other management strategies [45, 46]. Evaluation of the use of FRIDs in older patients is therefore recommended. Preferably, psychotropic drugs should only be administered after consideration of other non-pharmacological and/or pharmacological interventions with potentially less effect on postural control. And when psychotropic drugs are administered, then only at the lowest effective dose, with a short half-live, and for limited time [47].

## Part III: Classification of fallers

Based on the previously discussed chapters and other studies [42, 48–51], it is known that multiple, interrelated factors caused by natural age and/or pathology are related to falling and changes in the gait pattern in older patients. The multifactorial nature of falls in this population makes it challenging to predict who will fall, and thus whom to offer preventive intervention. Therefore, in chapter 7 a multi-factorial statistical approach was used to build three models including categories of modifiable fall risk factors among

Discussion

geriatric patients in order to identify fallers with highest accuracy. The first model including patient characteristics, e.g., handgrip strength, medication use, and frailty-related factors, already achieved high classification accuracy (AUC=0.86). Although sensitivity of this first model was quite high (80%), specificity remained relatively low (60%). This could result in misclassification of non-fallers, following unnecessary interventions, and potentially induce a fear of falling which in itself could increase the risk of falling [52, 53].

When cognitive functions and three gait components, namely 'pace', 'variability' and 'coordination' (extracted from eleven gait parameters by factor analysis) were added to the model, it's specificity increased to 80% with an area under the receiver operating curve of 0.93. The results showed that combining gait characteristics derived from instrumented gait analysis, combined with patient characteristics (including the use of FRIDs, the degree of thoracic kyphosis, hand grip strength, the severity of comorbid diseases), and cognitive functioning has high accuracy to identify fallers. This emphasizes the need for the development of a multifactorial fall risk assessment for older patients, including the abovementioned modifiable factors. When any of the identified fall-related factors is prevalent, targeted individualized interventions should be started to reduce the risk of falling. For example, when impairments in gait performance are prevalent, it is recommended to start an individualized preventive multi-component exercise program targeting strength, balance, flexibility, and/or endurance [54, 55]. Osteoporosis, vertebral fractures and increased thoracic kyphosis could be treated with anti-osteoporotic medications, calcium and vitamin D supplementation and/or exercise aimed at trunk stabilization [10, 26]. Medication-use should be evaluated by a patient's physician, for example by using the BEERS or STOPP/START criteria [56, 57], in order to avoid potentially inappropriate medication-use and to decrease adverse drug events in older adults. For cognitive functioning, the effectiveness of therapies, such as cognitive stimulation (or 'mental exercise'), aerobic exercise and/or medications, is not yet clear [58–60].

## Future perspectives for research and clinical geriatric practice

This thesis was able to answer some important questions regarding factors that are associated with postural control and falling in older patients. This group is specifically relevant because falls and their adverse results occur more often when people are older and have more comorbidities [61]. Paradoxically, in the past this frail group was often not included in fall risk studies [62, 63]. Based on the results of this thesis, it was concluded that multiple, interrelated factors are related to falling and changes in the gait pattern in older patients.

### Multifactorial approach for future research in the geriatric population

When investigating gait and/or falls in older patients, it should be taken into account that these patients form a heterogeneous study population with many comorbid factors prevalent. In fact, as many as 400 variables have been suggested to be of interest to investigate in relation to falling [64], and according to chapter 7 and the study of Van Schooten *et al.* [65] multifactorial models including gait parameters showed high classification accuracy. A multifactorial study design is therefore recommended when examining gait and/or falls in older adults.

In these type of studies, methodological difficulties and properties of the data must be considered when choosing statistical methods. In previous studies, logistic regression analyses have often been used [66, 67] to determine the mean effect of a predicting variables, such as gait speed, grip strength, or medical history, on an outcome variable, for example fall incidence in a 1-year follow-up. Consequently, only variables that are important to the entire population are extracted, while variables of importance to a subgroup of the heterogeneous population are difficult to detect [68]. Furthermore, in heterogeneous study populations a large dispersion in predicting and outcome variables is common [69], as was also found in the studies described in this thesis, which makes it more difficult to detect variables of importance to the entire study population.

In addition to the heterogeneity of the study population, another problem is the correlation among variables that are of interest in relation to falls. For example, when analyzing gait, it should be taken into account that gait parameters are not independent, but are both interrelated and complimentary to each other [70–72]. In more conventional regression analyses multicollinearity leads to an increased standard error of regression coefficients [68]. For studies examining gait and/or falls in older adults, it is therefore recommended to use statistical methods where the dependency among variables is taken into account.

Discussion

In chapter 6 and 7 of this thesis, therefore Partial Least Squares (PLS) regression analyses were used to model multiple variables, including patient characteristics, comorbid diseases, medication-use and cognitive functioning, in relation to gait parameters and fall-status, respectively. PLS analyses are not impeded by collinearity among variables [73–75], and they are particularly useful in studies in which a set of dependent variables is predicted from a relatively large set of independent variables in a relatively small study population [76–78]. Therefore, PLS regression analyses might be a useful statistical method to explore the interplay between multiple variables of interest in relation to gait and/or falls in the heterogeneous population of older patients.

### Gait analysis in clinical geriatric practice

In the included studies of the literature reviews described in chapter 2 and 5 of this thesis, postural control during standing or walking was investigated with a large variety of instruments. Functional performance tests are easy-to-use in clinical practice, but seem to be less sensitive than computerized instruments according to the reviewed literature in chapter 2. More objective measures derived from computerized instruments, such as accelerometry as used in the present thesis, are therefore recommended to detect whether patients have impairments in postural control and to obtain more insight into the underlying mechanisms. Recent studies found that smart devices, such as smart phones or the iPod Touch, are valid and reliable to use for such purposes, and that they have the potential to be used for clinical gait assessments since they are light, inexpensive, and easy to handle [79-81]. Easy-to-use applications should be developed to assess postural control during walking in older patients and to monitor interventions targeted at improving postural control. Based on the results of chapter 7 and previous studies [62, 63, 81], it is recommended to include in these applications a combination of gait parameters indicating 'pace' (that is, speed-related gait measures, such as walking speed, stride time, and the amplitude of trunk accelerations), 'variability' and 'coordination' (that are gait properties that reflect the dynamics of gait), since this combination would increase the accuracy to classify (potential) fallers as found in chapter 7.

Because older patients visiting a geriatric outpatient clinic represent a vulnerable population with an increased risk of falling and resultant injuries, the need for a multifactorial approach in fall risk assessment is of great importance. Based on the findings of this thesis, such assessment should include an analysis of the gait pattern combined with a comprehensive evaluation of patient characteristics, osteoporosisrelated factors (such as vertebral fractures, increased thoracic kyphosis and/or a flexed posture), medication-use, frailty-related factors (such as, grip strength and weight loss), and cognitive functioning. Ultimately, these fall risk factors should be targeted by individualized interventions to reduce fall risk, such as exercise targeting strength, balance, flexibility, and/or endurance [54, 55], an evaluation of medication-use for example by using the BEERS or STOPP/START criteria [56, 57], and/or starting osteoporosis-medication and calcium and vitamin D supplementation to reduce the risk of a fracture [26].

## References

**1.** Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285-9.

**2.** Consensus development conference (1993) Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650.

**3.** Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018.

**4.** Kado DM, Miller-Martinez D, Lui L-Y, *et al.* (2014) Hyperkyphosis, kyphosis progression, and risk of non-spine fractures in older community dwelling women: the Study of Osteoporotic Fractures (SOF). J bone Miner Res 29:1–22.

**5.** Balzini L, Vannucchi L, Benvenuti F, *et al.* (2003) Clinical characteristics of flexed posture in elderly women. J Am Geriatr Soc 51:1419–1426.

**6.** Schneider DL, Von Mühlen DG, Barrett-Connor E, Sartoris DJ (2004) Kyphosis does not equal vertebral fractures: The Rancho Bernardo Study. J Rheumatol 31:747–752.

**7.** Kado DM, Browner WS, Palmero L, *et al.* (1999) Vertebral fractures and mortality in older women. A prospective study. Arch Intern Med 159:1215–1220.

**8.** Roghani T, Zavieh MK, Manshadi FD, *et al.* (2016) Age-related hyperkyphosis: update of its potential causes and clinical impacts-narrative review. Aging Clin Exp Res. ePub ahead of print. doi: 10.1007/s40520-016-0617-3

**9.** Katzman WB, Cawthon P, Hicks GE, *et al.* (2011) Association of spinal muscle composition and prevalence of hyperkyphosis in healthy community-dwelling older men and women. Journals Gerontol - Ser A Biol Sci Med Sci 67A:191–195.

**10.** Katzman WB, Wanek L, Shepherd JA, Sellmeyer DE (2010) Age-related hyperkyphosis: its causes, consequences, and management. J Orthop Sports Phys Ther 40:352–60.

**11.** Yuan HA, Brown CW, Phillips FM (2004) Osteoporotic spinal deformity - a biomechanical rationale for the clinical consequences and treatment of vertebral body compression fractures. J Spinal Disord Tech 17:236–42.

**12.** Lyles KW, Gold DT, Shipp KM, *et al.* (1993) Association of osteoporotic vertebral compression fractures with impaired functional status. Am J Med 94:595–601.

**13.** Alexander NB (1994) Postural control in older adults. J Am Geriatr Soc 42:93–108.

**14.** Saha D, Gard SA, Fatone S (2008) The effect of trunk flexion on able-bodied gait. Gait Posture 27:653–60.

**15.** Sinaki M, Brey RH, Hughes CA, *et al.* (2005) Balance disorder and increased risk of falls in osteoporosis and kyphosis: Significance of kyphotic posture and muscle strength. Osteoporos Int 16:1004–1010. **16.** Greig AM, Bennell KL, Briggs AM, *et al.* (2007) Balance impairment is related to vertebral fracture rather than thoracic kyphosis in individuals with osteoporosis. Osteoporos Int 18:543–51.

**17.** Winter D (1995) Human balance and posture control during standing and walking. Gait Posture 3:193–214.

**18.** Kasukawa Y, Miyakoshi N, Hongo M, *et al.* (2010) Relationships between falls, spinal curvature, spinal mobility and back extensor strength in elderly people. J Bone Miner Metab 28:82–87.

**19.** Huang M-H, Barrett-Connor E, Greendale GA, Kado DM (2006) Hyperkyphotic posture and risk of future osteoporotic fractures: the Rancho Bernardo Study. J bone Miner Res 21:419–423.

**20.** Kado DM, Huang M-H, Nguyen CB, *et al.* (2007) Hyperkyphotic posture and risk of injurious falls in older persons: the Rancho Bernardo Study. J Gerontol A Biol Sci Med Sci 62:652–657.

**21.** van der Jagt-Willems HC, Vis M, Tulner CR, *et al.* (2013) Mortality and incident vertebral fractures after 3 years of follow-up among geriatric patients. Osteoporos Int 24:1713–1719.

**22.** Cummings SR, Melton ⊔ (2002) Osteoporosis I: Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767.

**23.** Ross PD (1997) Clinical consequences of vertebral fractures. Am J Med 103:30S–42S; discussion 42S–43S.

**24.** Katzman WB, Huang M-H, Lane NE, *et al.* (2013) Kyphosis and decline in physical function over 15 years in older community-dwelling women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 68:976–983.

**25.** van der Jagt-Willems HC, van Munster BC, Leeflang M, *et al.* (2014) Diagnosis of vertebral fractures on lateral chest X-ray: intraobserver agreement of semi-quantitative vertebral fracture assessment. Eur J Radiol 83:2177–2180.

**26.** Gates BJ, Sonnett TE, DuVall CAK, Dobbins EK (2009) Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother 7:293–323.

**27.** Ziere G, Dieleman JP, Hofman A, *et al.* (2006) Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 61:218– 23.

**28.** Bloch F, Thibaud M, Dugué B, *et al.* (2011) Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 23:329–346.

**29.** Woolcott JC, Richardson KJ, Wiens MO, *et al.* (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960.

**30.** Hartikainen S, Lönnroos E, Louhivuori K (2007) Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 62:1172–1181.

**31.** Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 47:30–39. **32.** Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 47:40–50.

**33.** Huang M-Y, Matsuura N, Kaneko Y, Ichinohe T (2012) Midazolam increases bite force during intravenous sedation. J oral Maxillofac Surg 70:e458-63.

**34.** van der Velde N, Stricker BHC, Pols HAP, van der Cammen TJM (2007) Withdrawal of fall-risk-increasing drugs in older persons: Effect on mobility test outcomes. Drugs Aging 24:691–699.

**35.** Tsunoda K, Uchida H, Suzuki T, *et al.* (2010) Effects of discontinuing benzodiazepinederivative hypnotics on postural sway and cognitive functions in the elderly. Int J Geriatr Psychiatry 25:1259–65.

**36.** Boyé NDA, van der Velde N, de Vries OJ, *et al.* (2016) Effectiveness of medication withdrawal in older fallers: results from the Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) trial. Age Ageing. ePub ahead of print. doi: 10.1093/ageing/afw161

**37.** Leavy B, Michaëlsson K, Åberg AC, *et al.* (2016) The impact of disease and drugs on hip fracture risk. Calcif Tissue Int. ePub ahead of print. doi: 10.1007/s00223-016-0194-7

**38.** Kvelde T, Lord SR, Close JCT, *et al.* (2015) Depressive symptoms increase fall risk in older people, independent of antidepressant use, and reduced executive and physical functioning. Arch Gerontol Geriatr 60:190–95.

**39.** Herrmann LL, Goodwin GM, Ebmeier KP (2007) The cognitive neuropsychology of depression in the elderly. Psychol Med 37:1693–1702.

**40.** Hausdorff JM, Nelson ME, Kaliton D, *et al.* (2001) Etiology and modification of gait instability in older adults: a randomized controlled trial of exercise. J Appl Physiol 90:2117–29.

**41.** Montero-Odasso M, Muir SW, Hall M, *et al.* (2011) Gait variability is associated with frailty in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 66A:568–576.

**42.** Schwenk M, Howe C, Saleh A, *et al.* (2014) Frailty and technology: a systematic review of gait analysis in those with frailty. Gerontology 60:79– 89.

**43.** Teramura-Grönblad M, Hosia-Randell H, Muurinen S, Pitkala K (2010) Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care 28:154–159.

**44.** Askari M, Eslami S, Scheffer AC, *et al.* (2013) Different risk-increasing drugs in recurrent versus single fallers: are recurrent fallers a distinct population? Drugs Aging 30:845–851.

**45.** Stam H, Harting T, Sluijs M van der, *et al.* (2016) Usual care and management of fall risk increasing drugs in older dizzy patients in Dutch general practice. Scand J Prim Health Care 3432:1–7.

**46.** Bell HT, Steinsbekk A, Granas AG (2015) Factors influencing prescribing of fall-riskincreasing drugs to the elderly: A qualitative study. Scand J Prim Health Care 3432:1–8. **47.** Lader M, Tylee A, Donoghue J (2009) Withdrawing benzodiazepines in primary care. CNS Drugs 23:19–34.

**48.** American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons Panel on Falls Prevention (2001) Guideline for the prevention of falls in older persons. J Am Geriatr Soc 49:664–672.

**49.** Sturnieks DL, St George R, Lord SR (2008) Balance disorders in the elderly. Clin Neurophysiol 38:467–478.

**50.** IJmker T, Lamoth CJC (2012) Gait and cognition: the relationship between gait stability and variability with executive function in persons with and without dementia. Gait Posture 35:126–130.

**51.** Lamoth CJC, van Deudekom FJ, van Campen JPCM, *et al.* (2011) Gait stability and variability measures show effects of impaired cognition and dual tasking in frail people. J Neuroeng Rehabil 8:2.

**52.** Li F, Fisher KJ, Harmer P, *et al.* (2003) Fear of falling in elderly persons: association with falls, functional ability, and quality of life. Journals Gerontol Ser B Psychol Sci Soc Sci 58:P283–P290.

**53.** Patil R, Uusi-Rasi K, Kannus P, *et al.* (2013) Concern about falling in older women with a history of falls: Associations with health, functional ability, physical activity and quality of life. Gerontology 60:22–30.

**54.** Gillespie LD, Robertson MC, Gillespie WJ, *et al.* (2012) Interventions for preventing falls in older people living in the community. Cochrane database Syst Rev 9:CD007146.

**55.** Karlsson MK, Magnusson H, von Schewelov T, Rosengren BE (2013) Prevention of falls in the elderly: a review. Osteoporos Int 24:747–762.

**56.** The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60:616–31.

**57.** Gallagher P, Ryan C, Byrne S, *et al.* (2008) STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 46:72–83.

**58.** Woods B, Aguirre E, Ae S, Orrell M (2012) Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane database Syst Rev CD005562.

**59.** Young J, Angevaren M, Rusted J, Tabet N (2015) Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane database Syst Rev CD005381.

**60.** Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane database Syst Rev 1:CD005593.

**61.** Tinetti ME, Speechley M, Ginter SF (1988) Risk factors for falls among elderly persons living in the community. N Engl J Med 319:1701–1707.

**62.** Howcroft J, Kofman J, Lemaire ED (2013) Review of fall risk assessment in geriatric populations using inertial sensors. J Neuroeng Rehabil 10:91. **63.** Hamacher D, Singh NB, Van Dieen JH, *et al.* (2011) Kinematic measures for assessing gait stability in elderly individuals: a systematic review. J R Soc Interface 8:1682–1698.

**64.** Masud T, Morris RO (2001) Epidemiology of falls. Age Ageing 30:3–7.

**65.** van Schooten KS, Pijnappels M, Rispens SM, *et al.* (2015) Ambulatory fall-risk assessment: amount and quality of daily-life gait predict falls in older adults. J Gerontol A Biol Sci Med Sci 70:608–615.

**66.** Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ (2007) Will my patient fall? JAMA 297:77–86.

**67.** Pluijm SMF, Smit JH, Tromp EAM, *et al.* (2006) A risk profile for identifying community-dwelling elderly with a high risk of recurrent falling: results of a 3-year prospective study. Osteoporos Int 17:417–425.

**68.** Eriksson S, Lundquist A, Gustafson Y, Lundin-Olsson L (2009) Comparison of three statistical methods for analysis of fall predictors in people with dementia: negative binomial regression (NBR), regression tree (RT), and partial least squares regression (PLSR). Arch Gerontol Geriatr 49:383–389.

**69.** Robertson MC, Campbell AJ, Herbison P (2005) Statistical analysis of efficacy in falls prevention trials. J Gerontol A Biol Sci Med Sci 60:530–4.

**70.** Beauchet O, Annweiler C, Lecordroch Y, *et al.* (2009) Walking speed-related changes in stride time variability: effects of decreased speed. J Neuroeng Rehabil 6:32.

**71.** Kang HG, Dingwell JB (2008) Separating the effects of age and walking speed on gait variability. Gait Posture 27:572–577.

**72.** Allali G, Ayers EI, Verghese J (2015) Multiple modes of assessment of gait are better than one to predict incident falls. Arch Gerontol Geriatr 60:389–393.

**73.** Wold H (1966) Estimation of principal components and related models by iterative least squares. In: Krishnaiah PR (ed) Multivar. Anal. Academic Press, New York, NY, USA, pp 391–420.

**74.** Haenlein M, Kaplan AM (2004) A beginner's guide to Partial Least Squares Analysis. Underst Stat 3:283–297.

**75.** Boulesteix A-L, Strimmer K (2007) Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform 8:32–44.

**76.** Marzetti E, Lees HA, Manini TM, *et al.* (2012) Skeletal muscle apoptotic signaling predicts thigh muscle volume and gait speed in communitydwelling older persons: an exploratory study. PLoS One 7:e32829.

**77.** Eriksson S, Gustafson Y, Lundin-Olsson L (2008) Risk factors for falls in people with and without a diagnose of dementia living in residential care facilities: a prospective study. Arch Gerontol Geriatr 46:293–306.

**78.** Kosse NM, de Groot MH, Vuillerme N, *et al.* (2015) Factors related to the high fall rate in long-term care residents with dementia. Int Psychogeriatrics 27:803–814.

**79.** Kosse NM, Caljouw S, Vervoort D, *et al.* (2015) Validity and reliability of gait and postural control analysis using the tri-axial accelerometer of the iPod Touch. Ann Biomed Eng 43:1935–46.

**80.** Howcroft J, Lemaire ED, Kofman J (2016) Wearable-sensor-based classification models of faller status in older adults. PLoS One 11:1–16.

**81.** Kosse NM, Vuillerme N, Hortobágyi T, Lamoth CJC (2016) Multiple gait parameters derived from iPod accelerometry predict age-related gait changes. Gait Posture 46:112–117.

# APPENDICES

# APPENDICES

Summary

#### Summary

Falls are a serious problem for older patients visiting a geriatric outpatient clinic: it is the combination of a high fall incidence together with the high susceptibility to injuries that makes a relatively mild fall potentially dangerous to these old persons. Falling is a multifactorial problem, but postural instability during daily activities, such as walking, is suggested to be the most consistent predictor of falls. Age-related physiological changes (i.e., the loss of visual ability, proprioception, vestibular sensitivity, motor and cognitive functions), and a high prevalence of clinical diseases result in a slower and less coordinated gait. These changes can be quantified by a wide variety of gait parameters, each characterizing different aspects of the gait pattern. Several studies among relatively young and healthy older adults have shown that gait characteristics, such as gait speed, stride-to-stride variability, gait asymmetry, harmonic ratios, and sample entropy, can differentiate fallers from non-fallers. However, the results of these studies cannot be extrapolated to geriatric patients, although paradoxically this is the group of older adults that is most vulnerable to falls and resultant injuries. In geriatric patients there are, besides the normal age-related neurophysiological changes, additional comorbid factors present that might affect the walking pattern, and that consequently might increase fall risk.

Therefore, in the present thesis, we examined the association between several phenomena that occur common in geriatric patients, including osteoporosis-related factors, medication-use, and frailty-related factors with postural control during walking in older patients visiting a geriatric outpatient clinic. This provided new insights into the interplay between geriatric phenomena and different properties of the gait pattern. The results could be used for future classification of fallers.

#### Part I: Osteoporosis-related factors

Osteoporosis can cause vertebral fractures, which might lead to a flexed posture, and consequently to impaired postural control and an increased risk of falling. In the first part of this thesis, we investigated these associations. In chapter 2, our literature study among 18 cross-sectional studies revealed that postural control was generally affected in patients with prevalent vertebral fractures, an increased thoracic kyphosis and/or a flexed posture. Impairments in postural control among these patients can be best established when assessed by computerized instruments, such as accelerometry. Unfortunately, in the majority of the reviewed studies the presence and severity of

vertebral fractures, the degree of the thoracic kyphosis, and/or flexed posture were not specified, and the association between these clinical entities in relation to walking remained unclear. Therefore, in chapter 3 we investigated postural control during walking in older patients with a flexed posture, and possible causes for a flexed posture were explored, i.e., the degree of thoracic kyphosis, the presence of vertebral fractures and grip strength as indicator for overall muscle strength. In a study population of 56 older patients, 45% had a flexed posture (occiput-to-wall distance  $\geq$ 5 cm). These patients demonstrated overall a more variable and less structured gait pattern, and a more irregular trunk acceleration pattern than patients with normal posture. Having a flexed posture was significantly associated with an increased thoracic kyphosis (defined as a Cobb angle >50°), but not with other phenomena, such as vertebral fractures and low grip strength.

Based on the results of chapter 2 and 3, we speculated that patients with a flexed posture, increased thoracic kyphosis and/or prevalent vertebral fractures have an increased risk of falling due to their impairments in postural control during walking. However, this hypothesis had not yet been prospectively investigated. Therefore, in chapter 4 we performed a prospective cohort study among 51 older patients to examine the association between vertebral fractures, increased thoracic kyphosis and flexed posture with fall incidents within the next year. In this group, 39% had at least one prevalent vertebral fracture, 55% had an increased thoracic kyphosis, and 44% had a flexed posture. In the presence of an increased thoracic kyphosis, falls were more likely to occur.

Most of the patients that were included in the studies described in chapter 3 and 4 had a combination of two or three of the above-mentioned clinical entities. We suggest that osteoporotic vertebral fractures may contribute to the manifestation of an increased thoracic kyphosis, and in turn to a flexed posture. Due to an increased forward spinal curvature, it is hypothesized that the body's center of mass is shifted forward, causing an increased forward bending moment. This requires correcting responses from dorsal musculature and ligaments, which changes trunk alignment and functioning of muscles and ligaments. Therefore, it is likely that the ability of these older patients to respond on small perturbations during walking is diminished.

Based on this first part of the thesis, we recommend to screen older patients for vertebral fractures, increased thoracic kyphosis and/or a flexed posture, and to assess postural control in these patients, since impairments in postural control are an important risk factor for falls and future fractures in this patient group. Computerized instruments, such as easy-to-use ambulant motion-sensing technology, seem to be most

sensitive to detect these impairments. When impairments in postural control are present in these patients, we recommended to offer them multi-component exercise interventions targeting strength, balance, flexibility, and/or endurance combined with anti-osteoporotic treatment when osteoporosis is diagnosed.

#### Part II: Medication-use

Older patients often have multiple chronic diseases, and therefore often use multiple medications. Meta-analyses showed that psychotropic drugs (antidepressants, neuroleptics, benzodiazepines, antiepileptic drugs) and some cardiac drugs (digoxin, type IA antiarrhythmics, diuretics) are associated with increased fall risk. Because balance and gait disorders are the most consistent predictors of future falls, falls due to these fall-risk-increasing drugs (FRIDs) might be partly caused by impairments of postural control that these drugs can induce. In the second part of this thesis, we therefore examined associations between medication use and postural control. Our literature review in chapter 5 among 94 controlled research articles showed that postural control was impaired when using psychotropic FRIDs. These effects were more pronounced when people were older, used psychotropic drugs at higher daily doses, with longer half-lives, and/or were administered for a longer period of time. The sedative effects of these drugs on postural control are reversible, as was proven in intervention studies where FRIDs were withdrawn. The findings of chapter 5 confirm that the use of psychotropic drugs should be discouraged in the older population, or when usage is necessary, to prescribe these drugs only at the lowest effective dose and for a limited period of time in order to minimize the instability-provoking side-effects.

The current literature on the effects of psychotropics on postural control, as described in chapter 5, only examined acute single-drug effects on postural control during quiet standing in relatively healthy young elderly. Consequently, it was unclear what the impact of the long-term drug use is on gait performance in frail older persons with multiple comorbid diseases and polypharmacy. In chapter 6, we therefore explored the association between the use of psychotropics, multiple other medications, frailty-related parameters and gait performance among 80 older patients. A multivariate Partial Least Squares (PLS) regression analysis revealed that frailty-related parameters were stronger associated with impaired gait performance than the use of psychotropic drugs. It is suggested that the effect of the deterioration in physical functioning in these frail older adults is so large that the instability-provoking side-effects of psychotropic drugs have less impact on gait. This is in accordance to our hypothesis that results from studies

in healthy and relatively young elderly cannot be extrapolated to the frail population, because many complicating factors are present in this older population that might influence postural control. Therefore, it is recommended to future studies among older patients to include frailty-related parameters in their analyses since there are important confounding factors.

### Part III: Classification of fallers

Since falling is a multifactorial problem, and walking is also influenced by many factors that could be simultaneously present in the investigated population, we created in chapter 7 a model of frailty-related parameters supplemented with cognitive functioning and gait performance to discriminate fallers from non-fallers. Because gait parameters are related to each other, first a factor analysis was performed on eleven gait parameters to determine underlying properties of the gait pattern, revealing three latent factors that were labeled 'pace', 'variability', and 'coordination'. Thereafter, Partial Least Squares Discriminant Analyses (PLS-DA) were used to discriminate fallers from non-fallers. The classification accuracy increased when cognitive functioning. The results of this study highlight the need for a multifactorial approach in fall risk assessment, including an analysis of gait performance, frailty-related factors, and specific cognitive functions. Future studies should examine these results more extensively in a prospective design with a larger study population.

#### Conclusions and future perspectives

Based on the studies described in the present thesis, it can be concluded that in older patients visiting a geriatric outpatient clinic impaired postural control during walking is associated with many factors, including osteoporosis-related factors, medication-use, and frailty related factors. In the first part of this thesis, we concluded that patients with a flexed posture, an increased thoracic kyphosis and/or prevalent vertebral fractures have an impaired postural control. This might be the underlying mechanism for the increased fall incidence that was found in patients with an increased thoracic kyphosis. In the second part of this thesis, we described that postural control was impaired in healthy young and older adults when they use psychotropic FRIDs. These effects were not so clearly manifested in older patients, since frailty-related parameters in this population were stronger associated with impaired gait performance than the use of psychotropic medications.

Since impairments in gait and balance are the main risk factors for falls, this emphasizes the need for a multifactorial approach in fall risk assessment as described in the third part of this thesis, including gait analysis, medication review, and screening for frailty- and osteoporosis-related factors, in order to detect patients at risk for falling in an early stage and offer them an individualized intervention tailored to the identified intrinsic and extrinsic fall risk factors.

### APPENDICES

Samenvatting (Summary in Dutch)

Samenvatting

#### Samenvatting

Vallen is een groot probleem bij oudere patiënten die de dagkliniek geriatrie bezoeken. Door het grote aantal valincidenten en het relatief hoge risico op verwondingen, kan een milde val een potentieel gevaar vormen voor deze kwetsbare groep. Een val ontstaat vaak door een combinatie van intrinsieke en extrinsieke factoren; desalniettemin lijkt de beste voorspeller voor vallen een instabiele houding tijdens dagelijkse activiteiten zoals lopen, te zijn. Een langzamer en ongecoördineerder looppatroon kan veroorzaakt worden door allerlei medische aandoeningen, maar kan ook het resultaat zijn van "normale" leeftijdsgerelateerde neurofysiologische veranderingen, zoals een verminderd gezichtsvermogen, een verslechterd gevoel voor evenwicht, en/of verminderde cognitieve en motorische functies. Deze veranderingen in het looppatroon kunnen gemeten worden met een verscheidenheid aan variabelen die ieder een ander aspect van het looppatroon kwantificeren. Diverse studies onder relatief jonge en gezonde ouderen lieten zien dat verschillende loopkarakteristieken, waaronder de loopsnelheid, de variabiliteit in schredetijden, een minder symmetrisch looppatroon, een minder vloeiend lopen en een lagere stabiliteit van het lopen, in staat blijken om vallende en niet-vallende ouderen van elkaar te onderscheiden. De resultaten van deze studies kunnen echter niet (gemakkelijk) geëxtrapoleerd worden naar de populatie van geriatrische patiënten, omdat deze oudere patiënten naast normale leeftijdsgerelateerde neurofysiologische veranderingen vaak ook andere co-morbiditeiten hebben die het looppatroon kunnen beïnvloeden en tevens het risico op een val kunnen verhogen. Dat is opvallend, aangezien deze groep oudere patiënten het grootste risico heeft om te vallen met daarbij een hoog risico op verwondingen gezien hun kwetsbare fysieke staat.

In dit proefschrift is daarom bij patiënten die de dagkliniek geriatrie bezochten het looppatroon onderzocht in relatie tot een groot aantal geriatrische factoren, waaronder osteoporose-gerelateerde factoren, medicatiegebruik en *frailty*-gerelateerde factoren. Dit heeft nieuwe inzichten opgeleverd in de samenhang tussen deze geriatrische fenomenen en verschillende aspecten van het looppatroon. In de toekomst kunnen de resultaten van dit onderzoek gebruikt worden voor het ontwikkelen van een instrument om ouderen met een verhoogd valrisico vroegtijdig te identificeren aan de hand van een analyse van hun looppatroon.

#### Deel I: Osteoporose-gerelateerde factoren

Wervelfracturen ontstaan door osteoporose en kunnen een gekromde houding veroorzaken, wat vervolgens tot een verminderde houdingscontrole en een hoger risico op vallen zou kunnen leiden. Deze hypothese werd in het eerste gedeelte van dit proefschrift onderzocht. Een literatuuronderzoek onder 18 cross-sectionele studies (zie hoofdstuk 2) liet zien dat bij patiënten met prevalente wervelfracturen, een vergrote thoracale kyfose en/of een gekromde houding de houdingscontrole over het algemeen was verminderd. Dit werd het sterkst waargenomen wanneer gecomputeriseerde meetinstrumenten, zoals accelerometrie, werden gebruikt voor het analyseren van de houdingscontrole. Op basis van het literatuuronderzoek kon er echter geen causaal verband vastgesteld worden tussen de aanwezigheid van wervelfracturen, de mate van thoracale kyfose en een gekromde houding, doordat het grootste deel van de geïncludeerde studies slechts één van deze entiteiten onderzocht had in relatie tot de mate van houdingscontrole.

Daarom is in hoofdstuk 3 bij een groep oudere patiënten met een gekromde houding de houdingscontrole tijdens het lopen onderzocht, waarbij tevens de relatie met mogelijke oorzaken voor de gekromde houding werd geanalyseerd, waaronder de mate van thoracale kyfose, de aanwezigheid van wervelfracturen en de mate van handknijpkracht als indicator voor algehele spierkracht. Van de 56 onderzochte ouderen had 45% een gekromde houding (gedefinieerd als een achterhoofd-tot-muur-afstand van meer dan 5 cm). Deze patiënten lieten over het algemeen een variabeler en minder gestructureerd looppatroon zien, en hadden tevens een onregelmatiger patroon van rompversnellingen dan ouderen met een normale, rechtopstaande houding. Het hebben van een gekromde houding was significant geassocieerd met het hebben van een vergrote thoracale kyfose, maar niet met andere onderzochte factoren.

Op basis van de resultaten van hoofdstuk 2 en 3 werd verondersteld dat patiënten met een gekromde houding, een vergrote thoracale kyfose en/of prevalente wervelfracturen een hoger risico om te vallen hadden doordat zij een verminderde houdingscontrole hadden tijdens het lopen. Omdat deze hypothese nog niet eerder prospectief onderzocht was, is in hoofdstuk 4 een cohortstudie onder 51 oudere patiënten beschreven waarbij de aanwezigheid van wervelfracturen, een vergrote thoracale kyfose en een gekromde houding is onderzocht in relatie tot valincidenten die binnen een jaar na bezoek aan de dagkliniek optraden. Binnen deze onderzochte groep patiënten had 39% één of meerdere prevalente wervelfracturen, 55% had een vergrote

Samenvatting

thoracale kyfose, en 44% had een gekromde houding. Wanneer een vergrote thoracale kyfose aanwezig was, bleek de kans op een valincident groter.

De meeste patiënten die geïncludeerd waren in de studies die beschreven staan in hoofdstuk 3 en 4 hadden een combinatie van twee of drie van de eerder genoemde osteoporose-gerelateerde factoren. Er wordt daarom verondersteld dat wervelfracturen die door osteoporose veroorzaakt zijn bijdragen aan het ontwikkelen van een vergrote thoracale kyfose wat vervolgens kan leiden tot een gekromde houding. Door deze voorwaartse kromming van de wervelkolom, verschuift het lichaamszwaartepunt naar voren wat een voorwaarts flexiemoment veroorzaakt. Dit vereist een corrigerende respons van de dorsale rugspieren en -ligamenten, wat de houding van de romp doet veranderen en ook het functioneren van spieren en ligamenten kan beïnvloeden. Het is daarom aannemelijk dat ouderen die een gekromde houding hebben minder goed kunnen reageren op (kleine) balansverstoringen tijdens het lopen, zoals beschreven in hoofdstuk 3, waardoor het risico op een val groter wordt.

Op basis van de resultaten van het eerste gedeelte van dit proefschrift, adviseren we om oudere patiënten te screenen op de aanwezigheid van wervelfracturen, een vergrote thoracale kyfose en/of een gekromde houding. Tevens raden we aan om bij deze patiënten het looppatroon te analyseren, aangezien houdings- en balansproblemen tijdens het lopen belangrijke risicofactoren zijn voor ontstaan van valincidenten en mogelijk daaropvolgende fracturen. Wanneer een patiënt problemen heeft met het handhaven van de balans, wordt het aanbevolen om een gepersonaliseerde interventie aan te bieden die bestaat uit het trainen van de spierkracht, balanshandhaving, flexibiliteit en/of uithoudingsvermogen gecombineerd met een antiosteoporosebehandeling wanneer de botdichtheid ernstig verlaagd is.

#### Deel II: Medicatiegebruik

Oudere patiënten hebben vaak meerdere chronische aandoeningen waarvoor zij vaak meerdere medicijnen gebruiken. Meta-analyses hebben aangetoond dat psychofarmaca (waaronder antidepressiva, neuroleptica, benzodiazepines en anti-epileptica) en een aantal cardiale medicijnen (waaronder digoxine, type IA antiaritmica en diuretica) geassocieerd zijn met een verhoogd valrisico. Aangezien balans- en loopproblemen de meest consistente voorspellers zijn voor toekomstige valproblematiek, werd er beredeneerd dat een medicatie-gerelateerde val mogelijk veroorzaakt wordt door balansproblemen die ontstaan zijn door de bijwerkingen van deze medicijnen. In het tweede gedeelte van dit proefschrift werd daarom de relatie tussen medicatiegebruik

en houdingscontrole onderzocht. Hoofdstuk 5 beschrijft een literatuuronderzoek bij 94 gecontroleerde onderzoeksartikelen waaruit blijkt dat de houdingscontrole verminderd was bij deelnemers die psychofarmaca gebruikten. Deze effecten werden duidelijker waargenomen wanneer participanten ouder waren, een hogere dosis psychofarmaca gebruikten, medicijnen met een langere halfwaardetijd hadden, en/of wanneer medicijnen voor langere tijd gebruikt werden. De sedatieve effecten van deze medicijnen bleken reversibel te zijn, wat aangetoond werd door interventiestudies waarbij het gebruik van valrisicoverhogende medicatie werd afgebouwd. De resultaten van hoofdstuk 5 bevestigen dat het gebruik van psychofarmaca ontmoedigd zou moeten worden bij de oudere patiëntenpopulatie, of wanneer gebruik noodzakelijk is, deze medicijnen alleen worden voorgeschreven in de laagst effectieve dosering en voor een beperkte periode teneinde de balansverstorende bijwerkingen van deze medicijnen tot een minimum te beperken.

De huidige literatuur naar de effecten van psychofarmaca op houdingscontrole, zoals beschreven in hoofdstuk 5, heeft alleen acute effecten van enkelvoudig medicijngebruik op de balanshandhaving tijdens stilstaan onderzocht bij relatief jonge gezonde ouderen. Het bleef dus onduidelijk wat de invloed is van het op lange termijn gebruiken van deze medicijnen op het looppatroon bij oudere fragiele patiënten met meerdere aandoeningen en polyfarmacie. Daarom werd in hoofdstuk 6 de associatie tussen het gebruik van psychofarmaca, verschillende andere medicijnen, frailty-gerelateerde factoren en loopparameters onderzocht bij 80 oudere patiënten. Een multivariate Partial Least Square (PLS) regressieanalyse liet zien dat frailty-gerelateerde factoren sterker geassocieerd waren met een langzamer en onregelmatiger looppatroon dan het gebruik van valrisicoverhogende medicatie. Er wordt gesuggereerd dat de achteruitgang in fysiek functioneren bij deze fragiele ouderen zo sterk was, dat de sedatieve bijwerkingen van de psychofarmaca minder invloed hadden op het looppatroon. Dit kwam overeen met de stelling dat resultaten van studies bij gezonde, relatief jonge ouderen niet gemakkelijk extrapoleerbaar zijn naar de fragiele oudere populatie, omdat in deze oudere patiëntenpopulatie veel complicerende factoren aanwezig zijn die de houdingscontrole kunnen beïnvloeden. Voor toekomstig onderzoek naar vallen en lopen bij kwetsbare ouderen wordt daarom aangeraden om frailty-gerelateerde factoren mee te nemen in analyses omdat dit belangrijke beïnvloeders van de resultaten kunnen zijn.

#### Deel III: Classificatie van vallers

Aangezien vallen een multifactorieel probleem is, en lopen ook beïnvloed wordt door diverse factoren die tegelijkertijd aanwezig kunnen zijn, werd in hoofdstuk 7 een model gecreëerd van frailty-gerelateerde factoren aangevuld met indicatoren voor het cognitief functioneren en loopparameters met als doel om vallers van niet-vallers te onderscheiden. Aangezien loopparameters gerelateerd zijn aan elkaar, werd eerst een factoranalyse uitgevoerd met elf loopparameters om de onderliggende eigenschappen van het looppatroon te bepalen. Uit deze analyse kwamen drie latente factoren naar voren die we gelabeld hebben als "tred", "variabiliteit" en "coördinatie". Vervolgens is een Partial Least Square Discriminant Analyse (PLS-DA) uitgevoerd om vallers van nietvallers te onderscheiden. De nauwkeurigheid van de classificatie werd hoger toen cognitieve factoren en de drie loopcomponenten werden toegevoegd aan een model van frailty-gerelateerde factoren. De resultaten van dit hoofdstuk lieten zien dat een multifactoriële benadering voor het schatten van het valrisico gewenst is, waarbij met name een analyse van het looppatroon, het onderzoeken van frailty-gerelateerde factoren, en een beoordeling van specifieke cognitieve functies aan bod zouden moeten komen. Toekomstige studies zouden de resultaten van het uitgevoerde onderzoek nog uitvoeriger kunnen onderzoeken in een prospectief design met een grotere onderzoekspopulatie.

#### Conclusies en toekomstperspectief

Op basis van dit promotieonderzoek kan geconcludeerd worden dat bij ouderen die de dagkliniek geriatrie bezoeken een verminderde houdingscontrole tijdens het lopen gerelateerd is met vele factoren, waaronder osteoporose-gerelateerde factoren, medicatiegebruik, en frailty-gerelateerde factoren. In het eerste gedeelte van deze thesis werd geconcludeerd dat patiënten met een gekromde houding, een vergrote thoracale kyfose en/of prevalente wervelfracturen een verminderde houdingscontrole hebben. Dit is mogelijk de onderliggende oorzaak van de hogere valincidentie die bij deze patiënten gevonden werd. In het tweede deel van dit proefschrift is beschreven dat de houdingscontrole was verminderd bij zowel oudere als jongere proefpersonen wanneer zij valrisicoverhogende psychofarmaca gebruikten. Deze effecten waren echter minder duidelijk bij de onderzochte oudere patiënten, omdat frailty-gerelateerde factoren in deze populatie sterker gerelateerd waren met een aangedaan looppatroon dan het gebruik van psychofarmaca.

Aangezien houdings- en balansproblemen de belangrijkste risicofactoren zijn voor een val, is het van groot belang om het risico op een val te bepalen op basis van een analyse van het looppatroon, aangevuld met een medicatie-review en het screenen op frailty- en osteoporose-gerelateerde factoren. Door tijdige identificatie van ouderen met een risico om te vallen, kan in een vroeg stadium een gepersonaliseerde interventie aangeboden worden gericht op het verbeteren van de geïdentificeerde intrinsieke en extrinsieke valrisicoverhogende factoren.

# APPENDICES

Dankwoord (Acknowledgements in Dutch)

Dankwoord

#### Dankwoord

Tot slot wil ik nog een aantal mensen persoonlijk bedanken die betrokken zijn geweest bij dit proefschrift en mij geholpen, gemotiveerd en gesteund hebben bij de totstandkoming ervan.

Allereerst wil ik alle deelnemers aan de verschillende onderzoeken bedanken: zonder uw deelneming had dit onderzoek niet uitgevoerd kunnen worden. Bedankt dat u ondanks de vele testen en onderzoeken die u al had op de dagkliniek, ook nog voor mij hebt willen lopen met dat "rare kastje" op de rug. En sorry voor de maandelijks terugkerende telefoontjes met de vraag of u gevallen was in de voorgaande maand. Ik hoop dat het u allen goed gaat!

Zonder deelnemers geen onderzoek... maar ook zonder begeleiding geen onderzoek! Wat ooit begon met een literatuuronderzoek voor de Master Bewegingswetenschappen, heeft uiteindelijk geleid tot dit proefschrift. Dat was nooit gelukt zonder het enthousiasme en de begeleiding van mijn promotor prof. dr. J.H. Beijnen, copromotor dr. C.J.C. Lamoth, en drs. J.P.C.M. van Campen voor de dagelijkse begeleiding.

Beste Claudine: jij bent van begin tot eind bij dit onderzoek betrokken geweest. Dankjewel voor alle hulp die je mij hebt gegeven. De laatste loodjes waren het zwaarst, maar ik heb de afgelopen jaren enorm veel geleerd van jouw ideeën en theorieën, je specifieke feedback die mij uitdaagde me verder in de materie te verdiepen, en je doorzettingsvermogen. Je hebt mij gestimuleerd en gemotiveerd om dit proefschrift af te maken, en zonder jou was dat nooit gelukt. Dankjewel voor alles!

Beste Jos (van Campen): bedankt voor je positieve en stimulerende houding! Je ideeën en plannetjes werken erg aanstekelijk en hebben mede geleid tot dit proefschrift. Ik heb veel van je geleerd over de geriatrische patiënt, en onze besprekingen hebben mij enorm geholpen in het schrijfproces. Door hardop alle punten te bespreken, kwam er lijn in mijn gedachten, en daardoor ook in de artikelen :-) Dankjewel voor alle hulp, feedback en ideeën, en ook voor je interesse in mijn andere bezigheden. Veel dank!

Beste Jos (Beijnen): heel erg bedankt voor het mogelijk maken van dit onderzoek en de vrijheid die u mij gegeven heeft om dit onderzoek uit te voeren. Het waren rare tijden voor het Slotervaartziekenhuis, daarom ben ik des te meer dankbaar dat het onderzoek door heeft kunnen gaan, en ik ben onder de indruk hoe u mijn abstracts en manuscripten – ondanks alles – toch altijd zo snel van commentaar wist te voorzien. Bedankt! Tevens wil ik graag de mijn mede-auteurs van de artikelen in dit boekje bedanken.

Allereerst Hanna: samen met jou onderzoek doen was geweldig! Ik heb enorm veel van je geleerd: over de geriatrische patiënt, over osteoporose, wervelfracturen, kyfose, en alles wat daarbij komt kijken. Dankjewel voor de fijne samenwerking, je peptalks, de kopjes koffie en je positief kritische blik. En wat fijn dat je mijn paranimf wilt zijn! Bedankt! En laten we nog meer onderzoeksplannetjes uitwerken!

Dan Nienke: dankjewel voor je positieve feedback en je ideeën voor de PLS-artikelen! Ik vond het leuk om samen met jou en Claudine de PLS-analyses te doorgronden en het heeft geresulteerd in twee mooie gezamenlijke artikelen. En bedankt voor je gezelligheid tijdens de congressen die we bezocht hebben! Ik denk met veel plezier daaraan terug.

En Lisette: jij bent verder gegaan met het artikel over de classificatie van vallers toen ik er helemaal mee vast liep. Dankjewel voor je verfrissende blik en ideeën voor het artikel! Het heeft een mooi stuk opgeleverd, en ik vind het leuk dat jij het (bewegingswetenschappelijk) onderzoek in het Slotervaartziekenhuis voortzet.

Ook wil ik graag de andere co-auteurs bedanken voor hun tips, ideeën en feedback: Tibor Hortobágyi, Willem Lems, Marije Moek, Linda Tulner, Oscar de Vries, Nicolas Vuillerme. Thank you for your contributions to the papers of this thesis!

Verder wil ik alle medewerkers van de dagkliniek Geriatrie bedanken voor hun belangstelling en medewerking aan dit onderzoek. Geriaters: bedankt voor jullie goede tips en inhoudelijke aanvullingen om het onderzoek te laten slagen. Alle arts-assistenten (aio's, agnio's, haio's, en co's): het duurde even voor ik doorhad wie wie was, wie wat deed en wie waarvoor wel of niet in opleiding was ;-) maar ik dank jullie voor je interesse, tips en aanvullingen!

Dan mijn kamergenoten in het Slotervaartziekenhuis, Suzanne, Hanna, Mieke, Marije, Hans, en Roos: wat was het leuk om met jullie een kamer te delen!! Dank jullie wel voor alle gezelligheid naast en tijdens het werken, en de vele kopjes koffie en thee. Ik denk met veel plezier terug aan alle gesprekken en discussies die we gevoerd hebben: zowel werk- als onderzoekgerelateerd, maar ook alles daarbuiten: van de maandagochtend-Boer-zoekt-Vrouw-bespreking tot vakantieplannen, en van politiekmaatschappelijke discussies tot taal- en grammatica-probleempjes. Dank jullie wel, en hopelijk tot snel weer ziens!

Ook wil ik mijn nieuwe (en inmiddels soms alweer oude) collega's bij Saxion en de Haagse Hogeschool bedanken voor hun betrokkenheid en interesse in het onderzoek. Maar bovenal bedankt voor de leuke nieuwe werkplek! Ik heb het heel erg naar mijn zin in het onderwijs, en dat komt mede door jullie! Dan, lieve (schoon)familie, vrienden, vrienden-van-vrienden, en andere kennissen: dank voor jullie interesse in het onderzoek! En sorry dat we elkaar de afgelopen paar jaar niet zo vaak gezien hebben; ik hoop dat dat in de toekomst beter wordt! Ook wil ik al mijn volleybalteamgenoten bedanken voor de gezelligheid en sportieve in- en ontspanning op en naast het veld: een welkome afwisseling van al het zittende denk- en typewerk.

In het bijzonder wil ik nog een paar mensen persoonlijk bedanken. Lieve Karin, Jan, Frea en Wendy: vanaf de middelbare school zijn we al vriend(inn)en. Bedankt dat jullie er altijd voor me zijn! En bedankt ook voor alle dagjes weg, avonden thee/wijn/bier drinken, en voor de heerlijke fietsvakanties. Ook al zien we elkaar niet meer elke dag (zoals vroegâh), lief en leed blijf ik met jullie delen. Laten we snel weer afspreken!

Lieve Dieuwke, mijn BW-vriendinnetje: samen hebben we de wondere wereld van de bewegingswetenschappen ontdekt, en zijn we allebei na onze Master begonnen aan een promotietraject. Het is altijd fijn om met jou af te spreken en alle promotie- en nietpromotie gerelateerde successen en frustraties te delen. Dankjewel voor alle gezelligheid! En dat ik mezelf altijd bij jou in Groningen mag uitnodigen :-)

Lieve Willemijn, mijn favoriete (inmiddels ex-) huisgenootje: wat een geluk dat wij bij elkaar kwamen wonen aan de ASW! Eerst moesten we ons huis nog delen met anderen, maar hoe fijn was het om samen een "oefenhuwelijk" aan te gaan in de Marnixlaan!? Dankjewel voor al je gezelligheid, voor het koken als ik laat thuis was, voor onze vrouwenavondjes en fietsweekendjes, en voor het feit dat je mij aan het opruimen en schoonmaken hebt gekregen (alhoewel ik soms nog terugval in oude gewoontes...). En bedankt dat je mijn paranimf wilt zijn! Het was heerlijk om samen met jou in een huis te wonen, en ik hoop dat we elkaar nog vaak blijven zien, ondanks dat we nu "gescheiden" door het leven gaan.

Lieve broertjes, Lourens (en Lotti!) en Paul: ondanks dat we ver uit elkaar wonen en allemaal met verschillende dingen bezig zijn, houden we contact d.m.v. onze onvolprezen familie-app. Onze humor is (soms) smakeloos, (vaak) hopeloos, maar (altijd) grandioos (AAA-rijmschema!), en ik hoop dat de stroom aan (on)zin over de app eindeloos (nog een A!) blijft.

Lieve ouders: van jullie heb ik het werken bij de gezondheidszorg (en alles wat daarmee samenhangt) al van jongs af aan meegekregen: toen ik nog klein was gingen we "kijken bij de baby'tjes" als we mama ophaalden van haar werk, en later deed ik vakantiewerk bij jullie in het brandwondencentrum en de huisartsenpraktijk. Bedankt dat jullie me altijd de vrijheid hebben gegeven om mijn eigen keuzes te maken, en voor jullie vertrouwen daarin. Nog meer dank voor jullie interesse in al mijn bezigheden en voor jullie support daarbij!

Dan tot slot, mijn lieve Jeroen: dankjewel dat je er altijd voor me bent. Je hebt mij gesupport als ik weer 's avonds of in het weekend achter mijn laptop zat te typen. Maar je hebt mij ook achter dat ding weggehaald als het nodig was ;-) Samen naar de film gaan of een biertje drinken in de stad deden mij goed! Ik kijk uit naar de toekomst, als we allebei klaar zijn met onze boekjes: naar de zeeën van vrije tijd die ons wachten en alle plannetjes die we daar al voor hebben. Maar nu eerst: vakantie!

Maartje

# APPENDICES

Curriculum Vitae

Curriculum Vitae

#### **Curriculum Vitae**

Maartje de Groot werd geboren op 20 november 1986 in Aduard en groeide op in Roden. In Juli 2005 behaalde zij in Leek aan RSG de Borgen haar VWO-diploma, waarna zij startte met de Bachelor Bewegingswetenschappen aan de Rijksuniversiteit Groningen. Deze opleiding werd in Maart 2010 afgerond. Ondertussen begon zij in September 2008 alvast met de Master Human Movement Sciences (HMS), eveneens aan de Rijksuniversiteit Groningen. Tijdens de Master rondde zij aan de



Vrije Universiteit in Amsterdam aan de Faculteit der Bewegingswetenschappen de opleiding tot HBO-docent af.

In september 2010 startte Maartje met haar afstudeerproject van de Master HMS, waarvoor zij begon met een onderzoeksstage bij de Dagkliniek Geriatrie in het Slotervaartziekenhuis in Amsterdam, onder supervisie van Claudine Lamoth, Jos van Campen en Hanna Willems. In augustus 2010 rondde zij haar afstudeerproject af met de afstudeerscriptie "The influence of vertebral fractures and thoracic kyphosis on variability and stability of walking among geriatric patients", waarmee zij haar diploma voor de Master HMS behaalde. Na haar afstuderen kreeg zij de mogelijkheid om in het Slotervaartziekenhuis haar afstudeeronderzoek uit te breiden tot een promotie-onderzoek. Het resultaat hiervan ligt nu voor u.

In november 2014 begon Maartje aan een (tijdelijke) baan als docent bij de opleiding Podotherapie van Saxion Hogescholen in Enschede. Inmiddels werkt zij sinds juni 2015 met veel plezier als docent bij de opleiding Voeding & Diëtetiek aan de Haagse Hogeschool.

# APPENDICES

**Publications & Presentations** 

#### Publications

- <u>M.H. de Groot</u>, J.P.C.M. van Campen, N.M. Kosse, O.J. de Vries, J.H. Beijnen, C.J.C. Lamoth. The association of medication-use and frailty-related factors with gait performance in older patients. *PLoS ONE* 2016; 11 (2): e0149888.
- N.M. Kosse, <u>M.H. de Groot</u>, N. Vuillerme, T. Hortobágyi, C.J.C. Lamoth. Factors related to the high fall rate in long-term care residents with dementia. *International Psychogeriatrics* 2015; 27 (5): 803-814.
- H.C. van der Jagt-Willems, <u>M.H. de Groot</u>, J.P.C.M. van Campen, C.J.C. Lamoth, W.F. Lems. Associations between vertebral fractures, increased thoracic kyphosis, a flexed posture and falls in older adults: a prospective cohort study. *BMC Geriatrics* 2015; 15: 34.
- <u>M.H. de Groot</u>, H.C. van der Jagt-Willems, J.P.C.M. van Campen, W.F. Lems, J.H. Beijnen, C.J.C. Lamoth. A flexed posture in elderly patients is associated with impairments in postural control during walking. *Gait & Posture* 2014; 39 (2): 767-772.
- <u>M.H. de Groot</u>, J.P.C.M. van Campen, M.A. Moek, L.R. Tulner, J.H. Beijnen, C.J.C. Lamoth. Authors' reply to Toda: "The effects of fall-risk-increasing drugs on postural control: A literature review". *Drugs & Aging* 2013; 30 (12): 1041-1042.
- <u>M.H. de Groot</u>, J.P.C.M. van Campen, M.A. Moek, L.R. Tulner, J.H. Beijnen, C.J.C. Lamoth. The effects of fall-risk-increasing drugs on postural control: A literature review. *Drugs* & Aging 2013; 30 (11): 901-920.
- <u>M.H. de Groot</u>, H.C. van der Jagt-Willems, J.P.C.M. van Campen, W.F. Lems, C.J.C. Lamoth. Testing postural control among various osteoporotic patient groups. A literature review. *Geriatrics & Gerontology International* 2012; 12 (4): 573-585.

#### Presentations

#### International congress presentations

- Oral presentation "Can gait variability measures predict falls in geriatric outpatients? A prospective validation study" at the symposium "Instrumented analysis of gait variability as diagnostic instrument in geriatric medicine" at the 10<sup>th</sup> International Congress of the EUGMS (abstract nr. SS4.04). 17-19 September 2014, Rotterdam. Abstract published in: *European Geriatric Medicine* 2014; 5 (Suppl. 1): S29-S30.
- Oral presentation "The relationship between medication-use and gait variability in frail elderly: from FRIDs to frail" at the 10<sup>th</sup> International Congress of the EUGMS (abstract nr. 01.13). 17-19 September 2014, Rotterdam. Abstract published in: *European Geriatric Medicine* 2014; 5 (Suppl. 1): S49.
- Poster presentation "The effect of fall-risk-increasing drugs (FRIDs) on gait variability in frail elderly" at the ISPGR World Congress (abstract nr. P1-H-32). 29 June–3 July 2014, Vancouver, BC, Canada.
- Oral presentation "Do patients with vertebral fractures and/or increased thoracic kyphosis fall more often? Preliminary results of a study among geriatric patients about the relation between falling and gait variability and stability" at the 1<sup>st</sup> Joint World Congress of ISPGR and Gait & Mental Function (abstract nr. 0.15.3). 24-28 June 2012, Trondheim, Norway.
- Poster presentation "The influence of vertebral fractures and thoracic kyphosis on variability and stability of walking among geriatric patients" at the "2011 Alliance for Healthy Aging Symposium on Frailty and Healthspan" (p. 88). 20-22 October 2011, Groningen.

#### National congres presentations (in Dutch)

- Onderzoekspitch in het kader van de Stimuleringsprijs Geriatrie van de Nederlandse Vereniging voor Klinische Geriatrie (NVKG) tijdens de Geriatriedag. 13 februari 2014, 's-Hertogenbosch.
- Mondelinge presentatie "Het effect van medicatie op het looppatroon bij oudere patiënten met polyfarmacie en co-morbiditeit: van FRIDs naar FRAIL" tijdens de Wetenschapsmiddag. 20 november 2013, Slotervaartziekenhuis, Amsterdam. *Prijs voor "Beste Voordracht"*.
- Posterpresentatie "Kan het effect van psychofarmaca op balans geobjectiveerd worden? Een literatuurreview" tijdens de Geriatriedagen (p. 125). 6-8 februari 2013, 's-Hertogenbosch.
- Posterpresentatie "Vallen patiënten met wervelfracturen en/of thoracale kyfose vaker? Een onderzoek naar de relatie tussen het looppatroon en vallen bij geriatrische patiënten" tijdens de Geriatriedagen (pp. 129-130). 8-10 februari 2012, 's-Hertogenbosch.
- Posterpresentatie "De balanshandhaving van osteoporosepatiënten (met en zonder wervelfracturen) is verminderd: een literatuuronderzoek" tijdens de Geriatriedagen (p. 120), 3-4 februari 2011, 's-Hertogenbosch.